# AUTHOR INDEX*

## Volume 61


A

Aalfs, K. K., 1013
Aaltonen, L. A., 4541, 4545, 5718, 6991
Aas, T., 2505
Abarca-Quinones, J., 2843
Abbadie, C., 2656
Abbolito, M. R., 2523
Abbruzzese, J. L., 71, 4143
Abdalla, A. M., 1406
Abdel-Hady, E-S., 192
Abecassis, J., 4122
Abel, J., 4398
Abele, R., 8647
Abendroth, K., 3535
Abernathy, K., 7792
Abken, H., 1976
Aboagye, E. O., 2935, 4937
Abraham, S., 6945
Abramovitch, R., 4873
Abrams, M. T., 8758
Aburatani, H., 889
Achanta, G., 8723
Achanzar, W. E., 455
Achary, M., 8022
Achilles, E. G., 7298
Ackermann, D., 4514
Ackermann, R., 4214
Ackerstaff, E., 3599
Acs, G., 3561
Acs, P., 3561
Adachi, M., 7009
Adachi, S., 1178, 7675
Adachi, Y., 2015, 7882
Adam, B-L., 6029
Adam, C., 2804
Adam, L., 81, 400
Adams, G. P., 4750
Adams, J., 3071, 3535
Adde, M. A., 5028
Adeyinka, A., 2071
Adler, G., 3508, 4222, 4526
Adrian, T. E., 4923
Aebersold, D. M., 2911
Afar, D. E. H., 1686
Affleck, K., 7196
Afshari, C. A., 1392
Agathanggelou, A., 7277
Aguado, M., 6555
Ahangari, F., 4561
Ahmad, S. A., 1255
Ahmadi, T., 2080
Ahmadian, M. R., 4916
Ahmed, A., 7240
Ahn, B., 8357
Ahnen, D. J., 1541
Ahrendt, S. A., 1309, 2092, 8113
Ahrens, W., 778
Ahuja, N., 3573
Aihara, T., 14
Aikou, T., 6328
Ailawadi, M., 7264
Airoldi, I., 1285
Aittomäki, K., 5718
Aizawa, M., 5132
Akada, M., 7900
Akakura, N., 6548
Akalin, A., 4791
Akasaka, T., 7363
Akedo, H., 4885
Akerman, G. S., 3837
Akewanlop, C., 4061
Akhtar, M., 2399
Akhurst, T., 2983
Akita, K., 7675
Akita, R. W., 4467
Akiyama, S. K., 2445
Akiyama, S-i., 469
Akiyama, Y., 5570
Akram, M., 6892
Akslen, L. A., 2505
Aktas, H., 6213
Al-Ahdal, M. N., 3627
Alani, R. M., 6008
Alas, S., 5137
Alavanja, M. C. R., 4350
Alawi, E. A., 2092
Alazzouzi, H., 7727
Albanell, J., 4744, 6500
Albanese, C., 1983
Albelda, S. M., 6201
Alberti, L., 3096
Alberts, D. S., 4306
Albini, A., 5441, 8171
Albrecht, J. H., 8564
Aldape, K., 1122, 3949
Aldape, K. D., 4956, 6674
Aldaz., C. M., 8068
Alder, H., 1578, 2870, 6640
Alder, J. D., 1486
Alder, L., 1486
Aldridge, J., 5461
Alemany, R., 6377
Alers, J. C., 3164
Alexander, F. E., 2542
Alexander, H. R., 8751
Alexander, J., 5010, 8689
Alexander-Lister, L. D., 6264
Ali, A. A., 7179
Aliaga, C., 8683
Alila, H. W., 3961
Alitalo, K., 1786, 6511
Allameh, A., 3119
Allander, S. V., 8624
Allemand, E., 6876
Alligood, K. J., 7196
Allred, C. D., 5045
Allred, D. C., 3578
Allred, E. N., 7669
Allred, K. F., 5045
Alm, K., 7754
Al-Mehdi, A. B., 333
Alnemri, E., 2713
Alnemri, E. S., 5796
Aloe, S., 2523
Aloisi, A., 4666
Alon, U., 3124
Alonso, M., 2124
Alpaugh, M. L., 5231
Alpaugh, R. K., 4750
Al-Refaie, W., 6805
Alt, A., 4591
Altomare, D. A., 589
Altucci, L., 6360
Alund, G., 4514
Alvarado-Moreno, J. A., 6281
Alvarez, H., 3795
Alvarez, R. D., 6313
Alves, V. A. F., 7375
Amacker, M., 7594
Amaker, B. A., 4791
Amano, J., 2226
Amara, N., 4660
Amarnani, S. N., 8787
Ambros, P. F., 5992
Ambrosone, C. B., 7130
Amelung, F., 3712
Amin, K. M., 6201
Amin, P., 517, 6428
Amlot, P. L., 5145
Ammanamanchi, S., 6239
Amorosi, A., 5415
Amos, C. I., 1269, 1354
Amstad, P., 6350
An, W. G., 1671
Anabitarte, M., 4514
Anastassiou, G., 3439
Andersen, L. D., 2492
Andersen, M. E., 1879
Andersen, M. H., 493, 869, 5964
Andersen, R. J., 6788
Anderson, D. M., 2572
Anderson, E., 6739
Anderson, G. R., 8274
Anderson, K., 126
Anderson, K. C., 3071
Anderson, K. S., 8366
Anderson, R. L., 3182
Andersson, S., 608
Ando, M., 2395
Ando', S., 6747
André, A., 3518
Andreassen, A., 8689
Andreassen, P. R., 7660
Andreú, T., 6925
Andriani, F., 1699
Angevin, E., 3240, 6838
Angibaud, P., 131
Anichini, A., 318, 8218
Anido, J., 6500
Anjo, A., 1996
Ansardi, D. C., 8470
Anthuber, M., 5575
Antonescu, C. R., 3171
Antony, C., 4398
Anver, M. R., 7449
Anzano, M., 6665
Aoyagi, Y., 7950
Aozasa, K., 1382
Apak, T. I., 3925
Aplan, P. D., 6382
Apostolidis, C., 2804
Appella, E., 4773
Applegate, T. L., 131
Apricena, F., 5824
Aquino-Parsons, C., 8924
Arakawa, F., 370
Arakawa, H., 2827, 8256
Araki, N., 3969
Araki, T., 5692
Aramandla, R., 5389
Arango, D., 4910
Arap, W., 8110
Arbuckle, M. I., 8385
Archer, K. J., 7233
Arcinas, M., 5202
Arena, G., 8171
Argani, P., 4320
Arguello, M., 1733
Arii, S., 7840
Arlen, P., 3725, 7568
Arlinghaus, R. B., 138
Arlt, M., 1272
Armengol, M., 7727
Armstrong, L., 2232
Arnett-Mansfield, R. L., 4576
Arnold, D. R., 3200
Arnold, J. T., 5038
Arnould, L., 7955
Arock, M., 5289
Arola, J., 2813
Arribas, J., 4744
Arrigoni, C., 1983
Arteaga, C. L., 6583, 8887
Artemov, D., 3039
Arutunyan, A., 4024
Arvand, A., 5311
Aryee, D. N. T., 5992
Asada, R., 445
Asahara, T., 23, 6656
Asaka, M., 6548
Asamoto, M., 4693
Asano, T., 1276, 3294
Asch, H., 5402
Asgari, K., 8611
Ash, C., 6131
Asher, A., 8058
Ashfaq, R., 3581
Ashkenazi, A., 2759
Ashkenazi, E., 4612
Ashktorab, H., 2399
Ashley, R., 8459
Ashok, T. D. S., 612
Asimacopoulos, P. J., 538
Aslam, F., 570, 3465
Asosingh, K., 2862
Assaf, N., 5242
Asselin, E., 1862
Assimakopoulou, M., 4287
Astuti, D., 7277
Athanasiou, A., 538
Attanucci, J., 2625
Attema, J., 1839
Au, J. L-S., 6145
Auersperg, M., 4266
Augenlicht, L. H., 565, 570, 3465, 4910, 6297, 8931
Auguste, P., 1717
Aukerman, L., 2062
Aulitzky, W. E., 7635
Auner, H. W., 2335
Autio, V., 6038
Avadhani, A., 6467
Avdievich, E., 7934
Averbook, B. J., 2031
Averbuch, S. D., 7184
Avezaat, C. J., 8743
Avula, R., 4258, 5895
Awata, N., 3969
Ayotte, P., 5869
Ayres, M., 5474
Aytac, U., 7204
Aznavoorian, S., 6264
Azuma, A., 1065
Azzarone, B., 3240

B

Ba, Y., 6805, 8498
Baak, J. P. A., 4311
Babbin, B. A., 6290
Bachelder, R. E., 5736
Bacher, G., 392


* For title of article and coauthors, see listing in Contents of Volume 61 beginning on page 9015 at the end of this index issue.

# AUTHOR INDEX*

## Volume 61


A

Aalfs, K. K., 1013
Aaltonen, L. A., 4541, 4545, 5718, 6991
Aas, T., 2505
Abarca-Quinones, J., 2843
Abbadie, C., 2656
Abbolito, M. R., 2523
Abbruzzese, J. L., 71, 4143
Abdalla, A. M., 1406
Abdel-Hady, E-S., 192
Abecassis, J., 4122
Abel, J., 4398
Abele, R., 8647
Abendroth, K., 3535
Abernathy, K., 7792
Abken, H., 1976
Aboagye, E. O., 2935, 4937
Abraham, S., 6945
Abramovitch, R., 4873
Abrams, M. T., 8758
Aburatani, H., 889
Achanta, G., 8723
Achanzar, W. E., 455
Achary, M., 8022
Achilles, E. G., 7298
Ackermann, D., 4514
Ackermann, R., 4214
Ackerstaff, E., 3599
Acs, G., 3561
Acs, P., 3561
Adachi, M., 7009
Adachi, S., 1178, 7675
Adachi, Y., 2015, 7882
Adam, B-L., 6029
Adam, C., 2804
Adam, L., 81, 400
Adams, G. P., 4750
Adams, J., 3071, 3535
Adde, M. A., 5028
Adeyinka, A., 2071
Adler, G., 3508, 4222, 4526
Adrian, T. E., 4923
Aebersold, D. M., 2911
Afar, D. E. H., 1686
Affleck, K., 7196
Afshari, C. A., 1392
Agathanggelou, A., 7277
Aguado, M., 6555
Ahangari, F., 4561
Ahmad, S. A., 1255
Ahmadi, T., 2080
Ahmadian, M. R., 4916
Ahmed, A., 7240
Ahn, B., 8357
Ahnen, D. J., 1541
Ahrendt, S. A., 1309, 2092, 8113
Ahrens, W., 778
Ahuja, N., 3573
Aihara, T., 14
Aikou, T., 6328
Ailawadi, M., 7264
Airoldi, I., 1285
Aittomäki, K., 5718
Aizawa, M., 5132
Akada, M., 7900
Akakura, N., 6548
Akalin, A., 4791
Akasaka, T., 7363
Akedo, H., 4885
Akerman, G. S., 3837
Akewanlop, C., 4061
Akhtar, M., 2399
Akhurst, T., 2983
Akita, K., 7675
Akita, R. W., 4467
Akiyama, S. K., 2445
Akiyama, S-i., 469
Akiyama, Y., 5570
Akram, M., 6892
Akslen, L. A., 2505
Aktas, H., 6213
Al-Ahdal, M. N., 3627
Alani, R. M., 6008
Alas, S., 5137
Alavanja, M. C. R., 4350
Alawi, E. A., 2092
Alazzouzi, H., 7727
Albanell, J., 4744, 6500
Albanese, C., 1983
Albelda, S. M., 6201
Alberti, L., 3096
Alberts, D. S., 4306
Albini, A., 5441, 8171
Albrecht, J. H., 8564
Aldape, K., 1122, 3949
Aldape, K. D., 4956, 6674
Aldaz., C. M., 8068
Alder, H., 1578, 2870, 6640
Alder, J. D., 1486
Alder, L., 1486
Aldridge, J., 5461
Alemany, R., 6377
Alers, J. C., 3164
Alexander, F. E., 2542
Alexander, H. R., 8751
Alexander, J., 5010, 8689
Alexander-Lister, L. D., 6264
Ali, A. A., 7179
Aliaga, C., 8683
Alila, H. W., 3961
Alitalo, K., 1786, 6511
Allameh, A., 3119
Allander, S. V., 8624
Allemand, E., 6876
Alligood, K. J., 7196
Allred, C. D., 5045
Allred, D. C., 3578
Allred, E. N., 7669
Allred, K. F., 5045
Alm, K., 7754
Al-Mehdi, A. B., 333
Alnemri, E., 2713
Alnemri, E. S., 5796
Aloe, S., 2523
Aloisi, A., 4666
Alon, U., 3124
Alonso, M., 2124
Alpaugh, M. L., 5231
Alpaugh, R. K., 4750
Al-Refaie, W., 6805
Alt, A., 4591
Altomare, D. A., 589
Altucci, L., 6360
Alund, G., 4514
Alvarado-Moreno, J. A., 6281
Alvarez, H., 3795
Alvarez, R. D., 6313
Alves, V. A. F., 7375
Amacker, M., 7594
Amaker, B. A., 4791
Amano, J., 2226
Amara, N., 4660
Amarnani, S. N., 8787
Ambros, P. F., 5992
Ambrosone, C. B., 7130
Amelung, F., 3712
Amin, K. M., 6201
Amin, P., 517, 6428
Amlot, P. L., 5145
Ammanamanchi, S., 6239
Amorosi, A., 5415
Amos, C. I., 1269, 1354
Amstad, P., 6350
An, W. G., 1671
Anabitarte, M., 4514
Anastassiou, G., 3439
Andersen, L. D., 2492
Andersen, M. E., 1879
Andersen, M. H., 493, 869, 5964
Andersen, R. J., 6788
Anderson, D. M., 2572
Anderson, E., 6739
Anderson, G. R., 8274
Anderson, K., 126
Anderson, K. C., 3071
Anderson, K. S., 8366
Anderson, R. L., 3182
Andersson, S., 608
Ando, M., 2395
Ando', S., 6747
André, A., 3518
Andreassen, A., 8689
Andreassen, P. R., 7660
Andreú, T., 6925
Andriani, F., 1699
Angevin, E., 3240, 6838
Angibaud, P., 131
Anichini, A., 318, 8218
Anido, J., 6500
Anjo, A., 1996
Ansardi, D. C., 8470
Anthuber, M., 5575
Antonescu, C. R., 3171
Antony, C., 4398
Anver, M. R., 7449
Anzano, M., 6665
Aoyagi, Y., 7950
Aozasa, K., 1382
Apak, T. I., 3925
Aplan, P. D., 6382
Apostolidis, C., 2804
Appella, E., 4773
Applegate, T. L., 131
Apricena, F., 5824
Aquino-Parsons, C., 8924
Arakawa, F., 370
Arakawa, H., 2827, 8256
Araki, N., 3969
Araki, T., 5692
Aramandla, R., 5389
Arango, D., 4910
Arap, W., 8110
Arbuckle, M. I., 8385
Archer, K. J., 7233
Arcinas, M., 5202
Arena, G., 8171
Argani, P., 4320
Arguello, M., 1733
Arii, S., 7840
Arlen, P., 3725, 7568
Arlinghaus, R. B., 138
Arlt, M., 1272
Armengol, M., 7727
Armstrong, L., 2232
Arnett-Mansfield, R. L., 4576
Arnold, D. R., 3200
Arnold, J. T., 5038
Arnould, L., 7955
Arock, M., 5289
Arola, J., 2813
Arribas, J., 4744
Arrigoni, C., 1983
Arteaga, C. L., 6583, 8887
Artemov, D., 3039
Arutunyan, A., 4024
Arvand, A., 5311
Aryee, D. N. T., 5992
Asada, R., 445
Asahara, T., 23, 6656
Asaka, M., 6548
Asamoto, M., 4693
Asano, T., 1276, 3294
Asch, H., 5402
Asgari, K., 8611
Ash, C., 6131
Asher, A., 8058
Ashfaq, R., 3581
Ashkenazi, A., 2759
Ashkenazi, E., 4612
Ashktorab, H., 2399
Ashley, R., 8459
Ashok, T. D. S., 612
Asimacopoulos, P. J., 538
Aslam, F., 570, 3465
Asosingh, K., 2862
Assaf, N., 5242
Asselin, E., 1862
Assimakopoulou, M., 4287
Astuti, D., 7277
Athanasiou, A., 538
Attanucci, J., 2625
Attema, J., 1839
Au, J. L-S., 6145
Auersperg, M., 4266
Augenlicht, L. H., 565, 570, 3465, 4910, 6297, 8931
Auguste, P., 1717
Aukerman, L., 2062
Aulitzky, W. E., 7635
Auner, H. W., 2335
Autio, V., 6038
Avadhani, A., 6467
Avdievich, E., 7934
Averbook, B. J., 2031
Averbuch, S. D., 7184
Avezaat, C. J., 8743
Avula, R., 4258, 5895
Awata, N., 3969
Ayotte, P., 5869
Ayres, M., 5474
Aytac, U., 7204
Aznavoorian, S., 6264
Azuma, A., 1065
Azzarone, B., 3240

B

Ba, Y., 6805, 8498
Baak, J. P. A., 4311
Babbin, B. A., 6290
Bachelder, R. E., 5736
Bacher, G., 392


* For title of article and coauthors, see listing in Contents of Volume 61 beginning on page 9015 at the end of this index issue.

Back, T. C., 6255
Backlund, D. C., 6577
Backlund, M. G., 6577
Backsch, C., 7118
Backus, H. H. J., 3675
Badache, A., 383
Badaró, R., 1563
Bader, E., 7616
Baek, M. J., 36
Baens, M., 4916
Baer, M. R., 1747
Baer, R., 7943
Baer, S. C., 4306
Baffa, R., 1578, 4827
Bagnato, A., 8340
Baguley, B. C., 1517, 2935
Bähr, M., 2759, 5833
Bai, M., 3735
Bai, X-f., 1107, 6860
Bailey, D., 5486
Bailly, C., 504, 6876
Bair, E. L., 3308
Baish, J. W., 8348
Bakanauskas, V. J., 4278
Baker, A. F., 2766
Baker, S. J., 4569
Bala, S., 6042
Balansky, R. M., 2472
Balatoni, J., 2983
Balatsos, V., 8381
Balbin, M., 7091
Baldassarre, G., 4583, 4827
Baldet, P., 2537
Baldetorp, B., 1214
Balduf, C., 8534
Baldus, C., 7233
Baldwin, A. S., Jr., 3535
Baldwin, S. W., 110
Bales, E., 8074
Bali, J-P., 1415
Balkwill, F. R., 4961
Ball, D. W., 3200
Ballangrud, A. M., 2008
Ballard, L., 1000
Ballesteros, P., 6524
Ballinger, J. R., 3348
Balmain, A., 1305
Balzi, M., 8803
Bamford, T. L., 3182
Banchereau, J., 6451
Bancroft, C. C., 5911
Band, V., 8014
Bander, N. H., 2008
Bandyopadhyay, D., 8074
Bandyopadhyay, S. K., 2261
Banerjee, D., 4599
Banerji, L., 8005
Banfalvi, G., 88
Bang, Y-J., 4628
Banham, A. H., 8820
Bani, M. R., 309
Banks, E. P., 4325
Bansal, N., 2002
Banyard, J., 7298
Bao, C., 3682
Bao, R., 1291
Barber, P. R., 6413
Baria, K., 5948
Barker, E. A., 6025
Barker, F. G., II, 1122
Barker, J. E., 3182
Barker, N., 278
Barksdale, E. M., Jr., 363
Bärlund, M., 8235
Barna, B. P., 5796
Barnard, G. F., 2145, 5714
Barnes, C. M., 7298
Barnes, D., 1171
Baron, A., 285
Barone, M. V., 2267
Barouki, R., 3942
Barraclough, R., 5619
Barrett, J. C., 1367, 1392
Barrette, T. R., 7585
Barrientos, J. C., 4497
Barrios, R. J., 2736
Barsky, S. H., 5231
Barsoum, J., 6201
Bartek, J., 4990
Barth, R. F., 8179
Barth, R. J., Jr., 641
Barth, S., 8737
Barthmaier, P., 4175
Bartholdi, M. F., 5168
Bartkova, J., 4990
Bartlett, D. L., 8751
Bartos, J. D., 8274
Bartsch, D., 5905
Bartsch, H., 2788
Bartucci, M., 6747
Bartz-Schmidt, K. U., 3439
Barzilai, A., 1849
Basaraba, A., 3837
Baselga, J., 4744, 6500
Baserga, R., 8930
Bashambu, M., 4820
Basik, M., 8274
Basila, D., 2105
Basset, P., 2189
Basso, A., 7184
Bast, R. C., Jr., 5895
Bastert, G., 3712
Bastian, B. C., 7642
Batard, P., 5850
Bateman, A. C., 1296
Bates, R. C., 5275
Bates, S., 6328
Bates, S. E., 6635
Batistoni, D., 8775
Batra, R., 6406
Battista, S., 4583
Baudin, E., 6762
Baudouin-Legros, M., 1693
Bauer, M., 2138
Bauerfeind, P., 7616
Baum, C., 5116
Baum, M., 1457
Baumann, H., 1747
Baumann, R. P., 7770
Baurain, J-F., 3718, 4078
Baurain, R., 2843
Baxter, A., 8480
Baylin, S. B., 2816, 3200, 3225, 4689
Bayon, Y., 8504
Bazarov, A. V., 1178
Bazzoni, F., 1050
Beà, S., 2409
Beach, J. B., 6367
Beal, M. D., 1327
Bean, J., 1457
Beasley, N., 8820
Beasley, N. J. P., 5262
Beattie, B., 2983
Beauchamp, R. D., 5389
Beaudry, C., 4190
Beauheim, C., 5168
Beauregard, D. A., 6811
Becciolini, A., 8803
Bech-Otschir, D., 8416
Becker, C. M., 7298, 7669
Becker, I., 1903, 2804
Becker, J. C., 493, 869, 5964
Becker, K-F., 2804
Beckers, T., 392
Becknell, B., 7233
Beckwith, S. M., 3561
Bedi, A., 3276
Bednarek, A. K., 8068
Bedor, M. M., 8366
Beecken, W-D., 2207
Beer, D., 7908
Beer, K., 7118
Beer, K. T., 2911
Beerman, T. A., 3787
Beesley, C., 4357
Begent, R. H. J., 3653, 4716
Beggiolin, G., 6034
Begue, A., 2656
Beguinot, F., 1162
Behrens, J., 7039
Beissert, S., 3619
Belanger, A., 4591
Belcourt, M. F., 7770
Beleño, N., 2119
Belinsky, M. G., 3339, 7225
Bell, D. A., 4169
Bell, D. W., 8062
Bellan, C., 462
Belldegrun, A., 7925
Bello, L., 7501, 8730
Bellocq, J-P., 2189
Bellone, G., 2200
Belov, L., 4483
Beltrán, L., 6971
Belur, L. R., 1522
Belzacq, A-S., 1260
Bemmels, N. A., 6660
Benatti, P., 896, 7798
Benavidez, M., 1855
Bendix, R., 7608
Benhamou, S., 2480
Bénistant, C., 1415
Bennett, W. P., 4350
Bennicelli, C., 2472
Benoît, G., 700
Ben-Senior, L., 4561
Benson, D. A., 2833
Bentzen, L., 5318
Bentzien, F., 7356
Benveniste, E. N., 3084
Beranger, S., 2386
Beravs, K., 4266
Berdel, W. E., 647
Berens, M. E., 4190
Berg, P. E., 1073
Berg, R. J. W., 977
Bergelson, J. M., 2953, 6592
Berger, I., 5215
Berger, M. S., 1122, 1957, 4956, 5843, 6674
Berger, N., 2267
Berger, S., 303
Bergh, J., 2256, 8317
Bergman, W., 5303
Bergmann, M., 8188
Bergsagel, P. L., 8068
Berking, C., 8306
Berkowitz, R. S., 4169, 7264
Berlingieri, M. T., 4583
Berman, E., 7536
Bernabei, P., 3518
Bernard, D., 2656
Bernardini, R., 3002
Bernet, V., 6105
Bernhard, E. J., 333, 2289, 4278
Bernock, L. J., 1113
Bernstein, I. D., 5126
Bernstein, L., 3410
Berry, S. E., 8290
Bersani, I., 318
Bert, T., 5905
Bertagna, X., 6762
Bertagnolli, M. M., 118, 2547
Bertherat, J., 6762
Berthold, F., 7039
Berthon, P., 1919
Bertino, J. R., 1941, 2579, 4599
Bertolini, F., 4341
Bertrand, M., 5544
Berzofsky, J. A., 6868
Bessho, M., 8371
Betensky, R. A., 6713
Bethune, C. R., 3669
Betta, E. D., 896
Betti, C. J., 4550
Bettinotti, M. P., 5511
Beverloo, H. B., 5374
Beyer, C., 2311
Bhakta, S., 3406
Bhalla, K., 1799
Bhalla, K. N., 759
Bhardwaj, B., 632
Bhardwaj, N., 6451
Bhat, K. P. L., 6137, 7456
Bhimnathwala, H. G., 8758
Bhujwalla, Z. M., 3039, 3599
Bhushan, A., 8851
Biaglow, J. E., 5630
Bian, Y., 8351
Bianchi, A., 3002
Bianchini, A., 2
Bianco, R., 8887
Biankin, A. V., 8830
Biankin, S. A., 8830
Bible, K. C., 739, 4258
Bièche, I., 1652, 1919
Bielawska, A., 1233
Bigg, D. C. H., 2961
Bigg, H. F., 3610
Bigler, J., 3566
Bigner, D. D., 3556
Bikfalvi, A., 1717, 7501, 8730
Bilban, M., 6322
Bilinski, R. T., 2547
Biliran, H., Jr., 8676
Billiar, T. R., 1138
Biondi, A., 2542, 4666
Bioulac-Sage, P., 45
Biramijamal, F., 3119
Birch, L., 6089
Birchmeier, W., 7039
Bird, J., 8480
Bird, R. P., 7699
Birke, M., 6480
Birner, P., 5703
Birrell, G. W., 145
Birrer, M. J., 4382, 4450
Bisgaard, M. L., 1619
Bisgaard, M-L., 7798
Bissada, N. K., 4112
Bissery, M. C., 1996
Bittner, M. L., 4683
Bittorf, T., 2453
Bjerkvig, R., 6830
Black, A. R., 7754
Black, K. L., 842, 5601


** For title of article and coauthors, see listing in Contents of Volume 61 beginning on page 9015 at the end of this index issue.*

Black, M. E., 3022
Black, P. M., 8730
Black, P. McL., 7501
Blackwell, J. L., 8361
Blackwood, M., 6112
Blagosklonny, M. V., 4301
Blaivas, M., 2162, 6885
Blake, M. E., 5486
Blancato, J., 7978
Blancher, C., 7349
Blanco, J. G., 5810
Blandamura, S., 1830
Blank, E., 2996
Blankenstein, T., 1095
Blasberg, R. G., 2983
Blasco, M. A., 912, 5580
Blaser, M. J., 1406
Blass, M., 4612
Blaumann, H., 8638
Blay, J. Y., 3096
Blessing, M., 2311
Block, E., 2923
Blömeke, B., 4350
Blomqvist, C., 5718
Blons, H., 8595
Bloomfield, C. D., 59, 7233
Blount, P. L., 8284
Blum, H. E., 2609
Blum, W. F., 8601
Blumberg, P. M., 943, 4612
Blute, M. L., 6494
Blutt, S. E., 4294
Bobek, M. P., 2162, 6885
Bock, M., 8647
Böcker, W., 355
Boddapati, M., 4985
Bode, A., 5749
Bode, A. M., 850, 1604, 3908, 4084
Boden, R., 4716
Bodis, S., 732, 8203
Boeck, W., 4222
Boeddinghaus, I., 8452
Boeglin, W. E., 497
Boelk-Galvan, D., 1522
Boerner, S. A., 739
Boersma, A. W. M., 6982
Boffetta, P., 778
Boggio, K., 2809
Bogoyevitch, M. A., 3610
Bohlen, P., 39, 5090, 6624, 7002
Böhm, B. O., 4526
Bohr, V. A., 5378
Boilly, B., 76, 4337
Bok, D., 2774
Bok, R. A., 2533
Boland, C. R., 2676, 7444
Boldog, F., 3131
Boler, A. M., 5028
Bollen, A., 7683
Bolon, I., 970
Bolt, H-M., 4398
Boman, B. M., 8408, 8664
Bonavida, B., 5137
Bond, J. P., 4092
Bondy, M. L., 8465
Bonham-Carter, O., 8408
Bonilla, F., 8595
Bonnesen, C., 6120
Bonura, C., 7803
Bonvini, P., 1671
Booher, R. N., 8211
Boon, T., 3718, 5544
Boothman, D. A., 5193, 8290
Bootle, D., 749
Bordenave, J., 5289
Bordonaro, M., 3465
Borello, U., 1247
Borg, A., 5979
Borges, M. W., 3200
Borghi, F., 896
Borgo, S., 3285, 8381
Borkowski, A., 1227
Bornfeld, N., 3439
Bornhauser, M., 3524
Borrelli, M. J., 1113
Børresen-Dale, A-L., 2505
Borsetto, L., 7495
Bos, N. A., 7654
Bosco, O., 2200
Bosken, C. H., 1445
Bostick, P. J., 8845
Bostick, R. M., 3566
Boswell, C. B., 6563
Bottazzoli, F., 5517
Bottero, L., 6532
Bottero, V., 7785
Bottorff, D. A., 943
Boucher, Y., 39, 8079
Boudouresque, F., 1196
Boudreau, M. D., 1386
Bouffler, S. D., 912
Boulay, A., 2189
Bouras, T., 903
Bourgaux, J-F., 1415
Boushey, R. P., 687
Bout, A., 8743
Bouvet, M., 6805
Bova, G. S., 6372
Bowcock, A. M., 7943
Bowden, C., 131
Bowden, G. T., 3308, 4329
Bowen, C., 5611
Bowman, E. D., 6367, 7430
Bown, N., 8
Boxer, G. M., 3653, 4716
Boxer, L. M., 5202
Boyd, D., 400
Boyd, J., 908
Boyd, J. T., 3339
Boyer, J. C., 8405
Bozik, M. E., 2625
Brabletz, T., 8089
Bradbury, C. M., 3486, 7689
Bradley, G., 2371
Bradlow, H. L., 2547
Brady, F., 2935
Brand, R., 4923
Branda, J., 8811
Brandalise, S., 2542
Brandenburg, S. A., 4947
Brandsma, J. A., 6982
Brandts, C. H., 2105
Brash, A. R., 497
Brattain, M. G., 6239
Braun, R. D., 3027
Braun, S., 1890
Braun, T. M., 8513
Braunstein, I., 5529
Bravman, J., 1791
Breakefield, X. O., 2983
Breau, R., 2376
Brechbiel, M. W., 4474, 4966
Bréchot, C., 7803
Bredehorst, R., 2968
Bredesen, D. E., 5741
Brekken, R. A., 8569
Bremer, M., 7608
Brémond, A., 5024
Brennan, M. F., 3171
Brenner, A. J., 8068
Brenner, B. M., 8274
Brenner, C., 1260
Brenner, D. J., 5710
Brenner, P. C., 423, 5331
Brentnall, T. A., 3573
Bresciani, F., 6360
Bressette, D. S., 7978
Breuhahn, K., 2311
Brichory, F., 7908
Briehl, M. M., 2766
Brignetti, D., 5453
Brignola, P. S., 7196
Brindle, K. M., 6811
Brinker, M. G. L., 4105
Brinkmann, A. O., 3937
Briskin, K., 1457
Brissette-Storkus, C., 2625
Brisson, J., 5869
Brix, G., 2513
Broadwater, G., 2917
Bröcker, E-B., 5964
Brockmann, M. A., 6624
Brockmöller, J., 5051
Bröde, P., 4398
Brodeur, G. M., 679, 1314
Brodie, C., 4612
Brodsky, R. A., 654
Brogan, I. J., 3937
Broggini, M., 935, 1991
Brognard, J., 3986
Broker, T. R., 4858
Broman, K. W., 8866
Bromley, M., 2907
Bronner, M. P., 3573
Bronte, V., 859
Brooks, M. W., 8366, 8838
Brossart, P., 6846
Brouillard, F., 1693
Brousseau, R., 6281
Brouwer, J., 6982
Brown, A. M. C., 7934
Brown, G. D., 2935
Brown, J. M., 145, 5425
Brown, K., 3443, 8385
Brown, K. L., 3837
Brown, M., 3858, 5420
Broxterman, H. J., 2552
Brück, J., 8643
Brucker, M. J., 8758
Bruderer, J., 4514
Brugger, W., 6846
Brunelle, J. K., 8274
Bruner, J. M., 4375
Brunet, J-S., 5420
Brüning, T., 4398
Brünner, N., 532
Bruske-Hohlfeld, I., 778
Bryant, H. U., 8412
Bryant, P. E., 912
Bryce, L. A., 27
Bryington, M., 6290
Bucana, C. D., 1255, 1464, 7048
Bucci, F., 7189
Buchdunger, E., 2929, 5778
Buchegger, F., 7971
Büchler, M. W., 4655
Buchwald, D., 2517
Buckhaults, P., 6996
Budhjara, V., 1825
Budrow, J., 1013
Buffa, V., 1247
Bühring, H-J., 6846
Bui, T-A., 270
Buller, R. E., 4371
Bullock, B., 4325
Bullock, H. A., 2220
Bullrich, F., 2870, 6640
Bulun, S. E., 2250, 2328
Buluwela, L., 921, 2782
Bumgarner, R., 1611
Bundred, N. J., 6739
Bunni, M. A., 3675
Burch, H., 6105
Burd, R., 5630
Burdick, A. D., 3314
Burg, G., 452
Bürger, H., 355, 6982
Burger, R. A., 3045, 5083
Burgess, A. W., 4474, 5355
Burgess, C., 3131
Burkeholder, S., 6451
Burlini, A., 4341
Burman, K. D., 6105
Burnham, J., 7404
Burns, D. J., 1486
Burns, D. K., 5552
Burns, G. F., 5275
Burns, S., 27
Burns, T. C., 6467
Burnstein, K. L., 4294
Burri, P., 2911
Burris, L. L., 8412
Burton, D. W., 2282
Busam, K., 7642
Busam, K. J., 6008
Buser, C. A., 8758
Busse, D., 6583
Bussolati, G., 4393
Busuttil, V., 7785
Butcher, L. L., 5741
Butkiewicz, D., 7430
Butler, B. R., 348
Butler, G. S., 3610
Butler, L. M., 3591
Butler, M. O., 8366
Butterfield, L. H., 8782, 8787
Bützow, R., 2813
Buurman, W. A., 5523
Buys, C. H. C. M., 4105
Byers, S. W., 7978
Bykovskaia, S., 363
Byth, K., 4576
Byun, D-S., 6688, 7034

## C

Cabanillas, F., 7204
Cabot, M. C., 5102
Cabrera, M-E., 2542
Caceres-Cortes, J. R., 6281
Cadoret, A., 3245
Caignard, A., 3240, 6838
Cairncross, J. G., 4155, 6713
Cairns, R. A., 8903
Cairo, G., 8422
Cajal, S. R., 5784
Calabresi, P., 6816
Calberg-Bacq, C-M., 3450
Caldwell, C. W., 8375
Caldwell, L. E., 616
Calhoun, E., 5895
Califano, J., 939
Caligiuri, M. A., 59, 7233
Calilliw, R., 7925
Calin, G., 2870, 6640
Callen, D. F., 1171

** For title of article and coauthors, see listing in Contents of Volume 61 beginning on page 9015 at the end of this index issue.*

Callister, M. D., 7417
Calogero, R. A., 3518
Calvin, J., 3902
Calvisi, D. F., 2085
Calzetta, O., 8638
Cama, A., 5415
Camalier, C. E., 4160
Camandona, M., 2200
Camargo, A., 7375
Cameron, J. L., 4320
Camitta, B. M., 7333
Campbell, D., 6730
Campbell, I. G., 7426
Campbell-Thompson, M., 632
Campelli, F., 8171
Camphausen, K., 2207
Campion, J-P., 45
Campo, E., 2409, 8820
Campos, I., 1269
Cancemi, M., 6360
Candido, K. A., 228
Cannavo', E., 7719
Cantacuzène, D., 950
Cantarella, G., 3002
Cao, D., 6899
Cao, M., 8135
Cao, T., 7978
Cao, X., 3735
Cao, Y., 5441, 8429
Cao, Z., 1517
Capella, G., 2816, 4689
Capeller, B., 5964
Capocasa, F., 7189
Capolongo, L., 1983
Caporali, S., 6360
Caporaso, N. E., 5636
Capparelli, C., 4432
Caprioli, R. M., 2239
Caputi, M., 462
Carbajal, S., 6971
Carbone, A., 2200
Carbone, D. P., 2015
Carboni, F., 2523
Carceller, F., 1717
Cardiff, R. D., 261, 1816, 3480, 8298, 8811
Carducci, M. A., 1477, 7464
Carè, A., 6532
Carenini, N., 6034, 7189
Carethers, J. M., 2676
Carey, D. E., 813
Caristi, S., 6360
Carles-Kinch, K., 3250
Carling, T., 8094
Carlini, S., 2523
Carlson, B. D., 7233
Carlson, E. J., 3472
Carlson, J. W., 4382
Carlton, P. S., 6112
Carmeliet, P., 532, 2404
Carminati, P., 6034, 7189
Carone, M. D., 2523
Carosella, E. D., 6838
Carothers, A. M., 118, 2547
Carpenter, P., 6958
Carpten, J., 8624
Carr, B. I., 7211
Carrabba, G., 7501, 8730
Carreira, C. M., 2404, 8079
Carrier, J., 6912
Carroll, A. J., 7233
Carroll, R. S., 7501, 8730
Carrozzino, F., 5441
Carsana, M., 318
Carson, D. A., 7248
Carson, J. P., 2713
Carson-Walter, E. B., 6649
Cartee, L., 2583
Carter, J. H., 4679
Carter, J. J., 1934
Carter, M. C., 7196
Cartmel, B., 1457
Cartwright, I. L., 5885
Caruso, M., 1983
Casalbore, P., 4272
Casciano, C. N., 7525
Cascorbi, I., 5051
Case, T., 497, 2239
Casero, R. A., Jr., 5370
Cass, C. E., 7217
Cassard, L., 2189
Cassetti, M. C., 7861
Cassidy, J., 5505
Cassoni, P., 4393
Castelli, C., 222
Castillo, E., 3285
Castranova, V., 8051
Castrén, K., 4350
Castrop, F., 2138
Catalano, P. J., 4910
Catalona, W. J., 4982, 5692
Catimel, B., 4474
Caulee, K., 4122
Cavallo, F., 2809, 3518
Cavenee, W. K., 5349, 5355, 8569
Cavin, C., 3299
Caylor, J., 3750
Cazares, L. H., 6029
Cazzaniga, G., 4666
Çeliker, M. Y., 2365
Celis, E., 4773, 7577
Cemazar, M., 4266, 4784, 6413
Cepeda, M., 7978
Cerdán, S., 6524
Cerhan, J. R., 6494
Ceriani, R., 2996
Cernaianu, G., 5575
Cerniglia, G. J., 4278
Cerottini, J-C., 509, 2047, 5153, 5850
Cerutti, F., 7501
Chabot, G. G., 700
Chacko, V. P., 5016
Chadwick, R. B., 1619
Chae, K-S., 7034
Chai, C-Y., 1080, 3698
Chai, H., 4030
Chaib, H., 2390
Chakraborty, M., 7255
Chakrani, F., 4827
Chambaz, C., 509
Chamberlain, J. S., 2062
Chambers, K., 2031
Chambers, T. C., 4450
Chambers, W. H., 2625
Champlin, R., 138, 3355
Chan, A. D., 8845
Chan, A. M-L., 4985
Chan, A. S-C., 3877
Chan, K., 6971
Chan, L. C., 2542
Chan, S. Y-Y., 3877
Chanas, S. A., 3299
Chandra, S., 8179
Chandrasekhar, S., 5447
Chang, A., 3425, 7811
Chang, A. E., 8513
Chang, B-D., 7754
Chang, C. L., 7444
Chang, C-I., 1100
Chang, C-Y., 8712
Chang, F., 6276
Chang, K-H., 3110
Chang, S., 1122
Chang, S-G., 6688
Chang, Y., 3450
ChangLai, S-P., 1412
Chansky, H. A., 3586
Chanturita, T. I., 4797
Chaplin, D. J., 4716, 6413, 6811
Chapman, A. L. N., 6219
Chappuis, P. O., 4092
Chapuis, H., 1415
Chapuis, Y., 6762
Charlton, D. E., 2008
Charlton, P., 749
Chatterjee, A., 2119
Chatterjee, D., 1964, 7148
Chaudhary, M. A., 3627
Chaudhuri, G., 4701
Chauhan, D., 3071
Chaurand, P., 2239
Chehab, N. H., 7030
Chekmareva, M. A., 2833
Chellappan, S. P., 2583
Chen, A., 8127
Chen, C-J., 8118
Chen, C-M., 8375
Chen, C-Y., 2799
Chen, D., 4879
Chen, E., 1686
Chen, E. Y., 2429
Chen, G-q., 4723
Chen, G-W., 8873
Chen, H., 4357, 8651
Chen, J., 2434, 6548, 7383
Chen, J. J., 1013
Chen, J. J. W., 5223
Chen, J-T., 2799
Chen, L., 4345
Chen, N., 717, 3908, 7473, 8274
Chen, N-Y., 1604
Chen, P., 1122, 3949, 4561, 6185
Chen, Q., 778, 2381
Chen, R., 654
Chen, R-H., 4445
Chen, S., 1338
Chen, S-Y., 197, 3704
Chen, T., 4679, 7792
Chen, T-C., 4238
Chen, W. R., 459
Chen, Yi, 6020
Chen, Yia., 4112
Chen, Yid., 4683, 5979, 8624
Chen, Yin., 6437, 7754
Chen, Yix., 2434
Chen, Yu, 517, 5453, 6428, 7464, 7763
Chen, Y. Q., 4283
Chen, Y-H., 7413
Chen, Y-T., 2055, 4671
Chen, Z., 2542, 3339, 4797, 5911
Chen, Z-S., 7225
Chenard, M-P., 2189
Cheng, J., 5875
Cheng, J. Q., 5985
Cheng, J-L., 5223
Cheng, P., 2015
Cheng, S-Y., 8569
Cheng, W-F., 1080, 3698
Cheng, Y., 2399, 4278
Cheng, Y-W., 2799
Cherbonnel-Lasserre, C. L., 1129
Chervinsky, D. S., 6382
Chester, K. A., 3653
Chetcuti, A., 6331
Cheung, A. N. Y., 5998
Cheung, I., 6892
Cheung, K-J., Jr., 4974
Cheung, N-K. V., 4048, 6892
Chi, S., 6892
Chi, S-G., 6688, 7034
Chiang, C-S., 8859
Chiarenza, A., 3002
Chiari, R., 3718
Chiba, H., 1896
Chieco-Bianchi, L., 5441
Children's Cancer Group, 7404
Chilkoti, A., 7163
Chilkoti., A., 1548
Chin, K., 1250, 8527
Chin, L., 8150
Ching, L-M., 1517, 1948
Chini, B., 4393
Chinnaiyan, A. M., 7585
Chinol, M., 4393
Chin-Yee, I., 4155
Chiocca, E. A., 864, 2983, 5336
Chiou, H-L., 2799
Chiou, W. J., 1486
Chiquet-Ehrismann, R., 8586
Chiu, A., 339
Chiu, P. M., 5998
Chiu, R. K., 145
Cho, K. R., 3869, 8247
Cho, S., 6708
Cho, Y-M., 4693
Choi, C., 3084
Choi, H. H., 4628
Choi, I., 6089
Choi, M., 6912
Choi, Y. R., 36
Chokkalingam, A. P., 4333
Chomez, P., 5544
Chong, W., 7383
Chott, A., 1629
Chouaib, S., 3240, 4078, 6838
Chow, K-C., 2727
Chow, L. S-N., 3877
Chow, L. T., 4858
Chrest, F. J., 1493
Christen, R. D., 1508
Christensen, E., 6494
Christensen, I. J., 532
Christensen, J., 2183
Christiani, D. C., 612, 3419, 8718
Christopherson, R. I., 4483
Christov, K., 7456
Chu, C. S., 4766
Chu, J., 5491
Chuang, Y., 7325
Chubb, L. S., 1879
Chun, Y-J., 8164
Chung, D. C., 6050, 7325
Chung, H-J., 8347
Chung, H-W., 8347
Chung, J., 5736
Chung, J-G., 8873
Chung, L. W. K., 6012, 7310
Chyzak, G., 2961
Ciafrè, S. A., 1555
Cicatiello, L., 6360
Cifaldi, L., 2809, 3518
Cimino, G., 2542
Cin, P. D., 5778
Cinar, B., 7310
Cinti, C., 5952


** For title of article and coauthors, see listing in Contents of Volume 61 beginning on page 9015 at the end of this index issue.*

Ciolino, H. P., 3919
Ciomei, M., 1983
Ciotti, M. T., 4272
Ciupitu, A-M. T., 222
Claas, A., 5179
Clair, T., 6938
Clare, S. E., 2320
Claret, F-X., 7204
Clark, A. S., 3986, 4892
Clark, G., 2320
Clark, S. J., 6331
Clarke, A. R., 7060
Clarke, C. L., 4576
Clarke, K., 4474
Clarke, M. L., 7217
Clarke, P. A., 4003
Classen, M., 1903
Claudio, P. P., 462, 5952
Clavien, P-A., 1233
Cleary, M. L., 7363
Clément, B., 45
Clement, R. P., 7525
Clements, E., 3561
Clements, M. A., 6029
Cleton-Jansen, A-M., 1171
Clevers, H., 278
Cliby, W., 5895
Clohisy, D. R., 4038
Cockerill, S. G., 7196
Coderre, J. A., 8179
Codony-Servat, J., 4744, 6500
Cody, S. H., 4474
Coetzee, G. A., 785, 848
Coffey, D. C., 3591
Cohen, D., 7015, 7623
Cohen, J. S., 4971, 7536
Cohen, L. A., 8683
Cohen, L. S., 6851
Cohen-Barak, O., 5529
Cohen-Gould, L., 1941
Cohen-Jonathan, E., 2289
Coker, A. L., 3837
Colau, D., 3718
Colburn, N. H., 4160
Colditz, G. A., 3955
Cole, K. J., 6708
Cole, P. D., 4599
Coleman, D. M., 3388
Coleman, R. E., 110
Coles, B. F., 7130
Coles, J. A., 6524
Colige, A., 3450
Colitti, C., 7264
Colligan, B., 4679
Collins, C. C., 1250
Collins, M. H., 2953
Collins, S. J., 6002
Colombatti, A., 339
Colombo, B. M., 2386
Colombo, M. P., 6532
Colomer, D., 2409
Coltrini, D., 309
Colvin, O. M., 864
Comhair, S. A. A., 8578
Comijn, L., 3675
Comiskey, M., 6912
Comoglio, P. M., 5861
Condorelli, G., 1162
Cone, R. D., 1432
Conney, A. H., 3847, 5002
Connolly, D. C., 1291
Connor, C. E., 2917
Conolly, R. B., 1879
Conroy, J. M., 8274
Conseiller, E., 5833
Consogno, G., 3092
Constantinescu, V., 778
Conte, D., 4675
Conze, D., 8851
Cooke, S. P., 3653
Cooma, I., 3647
Cooney, K. A., 8651
Coons, S. W., 4190
Cooper, A. G., 582
Cooper, D., 1457
Cooper, J. A., 2429
Cooper, R. A., 2907
Cooper, R. S., 2307
Coppola, D., 1280, 5985
Coquery, S., 6451
Coralli, C., 4784
Corbacho, C., 5784
Corbitt, G., 192
Corcione, A., 1285
Corcos, L., 1645
Cordell, J. L., 8820
Cordoba, J-C., 2542
Cordon-Cardo, C., 1220, 2816, 3171, 6892, 7642
Corn, P. G., 2816, 3225, 5636
Cornblatt, B. S., 8611
Cornelisse, C. J., 1171
Corner, G., 6297
Corner, G. A., 4910
Coronelia, J. A., 7889
Corpuz, R. T., 4197
Corry, P. M., 1113
Cortessis, V., 2381
Corti, A., 5517
Corti, L., 1830
Cosimelli, M., 2523
Cossu, G., 1247
Costa, M., 8051
Costantini, R. M., 5415
Coste, J., 6762
Couch, F. J., 4951, 5895
Coukos, G., 4766
Coulet, F., 8595
Coulie, P. G., 3718, 4078
Coumoul, X., 3942
Counter, C. M., 3556
Couse, J. F., 6089
Couto, J., 4175
Cox, G. J., 5262
Cox, R., 1820
Cox, S., 2885
Cozma, D., 8866
Crago, A., 5736
Crankshaw, D. L., 5757
Crawford, H. C., 2097
Crawford, J., 1171
Crean, C. D., 7878
Credo, B., 1486, 5480
Creek, K. E., 3837
Cress, A. E., 3308
Cressman, V. L., 6577
Creswell, K., 2434
Crijns, A. P. G., 1291
Cripe, T. P., 2953
Crittenden, M. R., 7240
Croce, C. M., 1578, 2870, 4827, 6640
Crocker, J., 6219
Crombet, T., 5090
Crosby, R. M., 7196
Cross, S., 4561
Crothers, B., 4382
Croul, S., 4287
Crowley, C. W., 4197
Crum, C. P., 2356
Crystal, R., 4405
Crystal, R. G., 7530
Cuello, M., 4892
Cuevas, P., 1717
Cui, B., 4030
Cui, H., 4947
Cui, T. Y., 4842
Cull, V. S., 2453
Culley, L. L., 59
Cummings, O. W., 7878
Cunha, G. R., 3844, 6064, 8135, 8143
Cunha, T. J., 6064
Cunningham, J. M., 6494
Cunningham, V. J., 4937
Cuomo, C., 7623
Curiel, D. T., 813, 2953, 6313, 6377, 7882, 8361
Curley, S. A., 3330
Curran, E. M., 5771
Curran, J. A., 6730
Curran, T., 513
Currie, M. J., 3206
Currier, M. A., 2953
Curtin, K., 126
Cusack, J. C., Jr., 3535
Cushing-Haugen, K. L., 1934
Cussenot, O., 1919
Cuthbert, A., 912
Cuthbert, A. P., 7594
Cutts, S. M., 8194
Cykert, D. M., 1367
Czerniak, B., 8659

**D**

Dachs, G. U., 4784
Daemen, T., 7305
da Gloria da Costa Carvalho, M., 939
Dagna, L., 3092
D'Agostini, F., 2472, 8171
Dagrosa, A., 8775
Dahiya, R., 97, 3262, 6064, 7101
Dahm, P., 3388
Dahmen, R. P., 7039
Dai, J., 3294
Dai, Q., 7136
Dai, Y., 5106
Daigle, J. L., 8859
Daily, D., 1849
D'Alessandro, R., 2523
Daling, J. R., 1934, 8459
Dallal, R. M., 884
Dallman, M. J., 153
Dalmasso, E. A., 6029
Dalton, W. S., 3276
Daly, M. B., 5420
D'Amato, R., 7669
Damia, G., 1991
D'Amico, C., 5415
Dammann, R., 3105
Dang, N. H., 7204
Dangerfield, W., 749
Dangsupa, A., 6290
Daniel, R. L., 5552, 8068
Daniel, T., 2015
Daniotti, M., 4666
Danks, M. K., 3045, 5078, 5083
Dannenberg, A. J., 118
Danø, K., 7091
Darbyshire, P. J., 8547
Daris, J-P., 8703
Darnowski, J. W., 6816
Daschbach, E. M., 6868
D'Atri, S., 7719
Datta, K., 1768, 6952
Datta, N. S., 6487
D'Attino, R. M., 1996
Dauer, M., 6445
Daugaard, P., 5318
Dave, K. B., 8429
David, K., 2968
Davide, J. P., 8758
Davidson, N. E., 7025
Davidson, S. E., 6394
Davie, J. R., 1362
Davis, A., 1013, 7943
Davis, D. W., 1464
Davis, J. W., 6029
Davis, J. W., II, 3314
Davis, R. L., 3949
Davis, W., Jr., 3339
Dawling, S., 6716
Dawsey, S. M., 4098
Dawson, M. I., 4723
Day, I., 1296
Day, M. L., 489, 2390
Dayton, B. D., 1486
Dean, M., 6635
Dean, N. M., 2105
Deane, N. G., 5389
Dearling, J., 4716
Deavers, M., 7264
De Backer, O., 5544
Debies, M. T., 8866
Debinski, W., 5660
de Bont, E. S. J. M., 7654
Debus, J., 8441
Decarli, A., 5415
de Ceballos, M. L., 5784
De Cesare, M., 6034, 7189
Decker, P. A., 2092
Decker, R. H., 2583
Deckert-Schlüter, M., 5242
Declerck, P. J., 5587
DeClerck, Y. A., 5587
De Clercq, E., 5057
Décorps, M., 5595
Dedhar, S., 6788
Deed, R. W., 8803
Deen, D. F., 6674
deFazio, A., 4576
De Fazio, P., 462
De Flora, S., 2472, 8171
Deftos, L. J., 2282
DeGrado, T. R., 110
Degreef, H., 4916
DeGregori, J., 2953
de Gruijl, F. R., 977
Deguchi, M., 7101
Dehner, B., 4679
Deininger, M. W. N., 8005
De Isabella, P., 6034
Deisseroth, A., 4405
de Jong, F. H., 3937
de Jong, M. C., 2552
de Jong, R., 1398, 7464
de Kernion, J., 7925
de Klein, A., 5374
de Koning, J. P., 1305
de la Chapelle, A., 6991
Delahoussaye, Y. M., 145
Delahunt, B., 4815
de Lange, P., 3937
De Larco, J. E., 2857

** For title of article and coauthors, see listing in Contents of Volume 61 beginning on page 9015 at the end of this index issue.*

De Latour, M., 2294
de la Vega, O., 4483
Del Campo, J. M., 6500
de Leij, L. F. M. H., 4105
de Leon, M. P., 896
Delius, H., 608
Dell'Agnola, C., 4341
Della Torre, P., 1983
Delohery, T., 439, 725
De Los Reyes, A., 3632
Deloughery, T. G., 7868
Delprado, W., 423, 5331
de Lumen, B. O., 7473
Del Valle, L., 4287
DeMarini, D. M., 6679
De Marzo, A. M., 103, 7464, 8611, 8617
DeMeester, S. R., 3410
DeMeester, T. R., 3410
Demers, A., 5869
Demetri, G. D., 8118
Demeure, M. J., 2092
Demidem, A., 2294
Demtröder, K., 2492
Demunter, A., 4916
Denda, A., 1451
den Dulk, H., 6982
Deng, J., 3406, 4333
de Nigris, F., 2267
Denkert, C., 303
Denkhaus, D., 7039
Denko, N. C., 795
Denner, L., 186, 1699
Denning, M. F., 4591
Dennis, P. A., 3986, 4892
Denny, C. T., 5311
Denny, W. A., 2935
Dent, P., 2583, 5106
Dentice, M., 4583
de Oliveira, M. P., 2542
DePinho, R. A., 8150
De Plaen, E., 5544
De Pol, A., 896
De Raeve, H., 2862
Deroanne, C. F., 3450
DeRoock, I. B., 3308
de Rooij, D. G., 3267
Dervieux, T., 5810
Desai, S., 2562
Desai, S. D., 5926
de Sauvage, F. J., 7291
Descamps, S., 4337
Desmond, R. A., 6377
deSolms, S. J., 8758
de Souza-Pinto, N. C., 5378
De Stasio, G., 4272
Detorie, N., 7464
De Tribolet, N., 7971
Deutsch, T. F., 4490
Deutscher, S. L., 4851
Deutzmann, R., 339
Devaraj, S., 5552
Devaux, B., 4197
Devereux, W., 5370
Devevey, L., 5289
Devine, A., 131
De Vivo, I., 3955
DeVries, A. F., 2513
de Vries, E. G. E., 7305
Devy, L., 3450
Dewailly, E., 5869
DeWeese, T., 5453
DeWeese, T. L., 7464, 8611
Dewhirst, M. W., 428, 1548, 2917, 3027, 3281, 6413, 7964
De Wolf-Peeters, C., 4916
Dhar, S., 8014
Dharap, S., 7792
Dharia, A., 97, 3262
Dhillon, S., 1296
Dhodapkar, M., 6451
Diah, S. K., 5461
Diamandis, E. P., 3425, 7811
Diamandis, M., 7811
Diamond, A. M., 2307
Diaz, M. O., 4550
DiBiase, S. J., 270
Di Carlo, E., 2809, 3518
Di Castro, V., 8340
Diccianni, M. B., 7333
Dichgans, J., 2744
Diederichs, S., 647
Diegelman, P., 6437, 7754
Diehl, A. M., 5016
Diehl, L., 5389
Diehl, V., 2080
Diep, A., 2381
Diers, M. D., 1522
Dietrich, P-Y., 2047, 5850
Dietze, E. C., 616
DiGiovanni, J., 6971
Dijk, N. J., 278
Dijke, P., 2112
Dikov, M. M., 2015
Dill, P., 6846
Dillehay, D. L., 6723
Dilley, J., 517, 5453
Dilling, M. B., 3373
di Loreto, C., 7375
Dimanche-Boitrel, M-T., 1645
Dimitrov, P., 7388
Dimovski, A. J., 8351
Dimri, G., 8014
Ding, H., 3826
Ding, I., 526
Ding, Y., 7142
Dinkelberg, R., 2552
Dinsmore, C. J., 8758
DiPietro, L. V., 1013
Dirsch, V. M., 5817
Diry, M., 3942
Di Santo, J. P., 1717
Disis, M. L., 5161
Dissette, V. B., 8782, 8787
DiStefano, F., 4003
di Tomaso, E., 8079
Divan, A., 3157
Diwan, B. A., 455
Dixon, M., 6739, 8452
Djonov, V., 2911
Dmitriev, I., 6377
Doan, T. P., 7713, 8429
Dobbelstein, M., 5941
Dobbie, Z., 7616
Dockhorn-Dworniczak, B., 355, 647
Doffek, K., 8113
Doffek, K. M., 2092
Doki, Y., 3188, 5570
Dokter, W. H. A., 4105
Dolan, M. E., 2307
Doll, J., 3712
Dolman, C. S., 6178, 8498
Dolmans, D. E. J. G. J., 2404
Dolzan, M., 4520
Domingo, D., 439
Donaher, J. L., 3858
Donahue, H. J., 1765
Donald, S. P., 1810
Donaldson, E. E., 5757
Donat, S., 4398
Donawho, C. K., 215
Dong, G., 4797, 5911
Dong, Q., 6331
Dong, Y., 333, 2923
Dong, Z., 850, 1382, 1604, 3908, 4084, 5749
Donnelly, E., 2413
Dorey, F., 4660
Dorie, M. J., 145
Dörk, T., 7608
Dörrie, J., 4731
Dosaka-Akita, H., 2500
dos Remedios, C. G., 4483
Dou, Q. P., 1280
Dougherty, T. J., 991
Douglas, J. T., 813
Dowdy, S. F., 474
Dowsett, M., 6739, 8452
Doxsey, S. J., 2212
Drach, J., 1629
Drake, J. L., 3604
Dralle, H., 4526
Dranoff, G., 162
Drazan, K. E., 1464
Drebin, J. A., 6563
Dreckschmidt, N. E., 808
Drenning, S. D., 5919
Drew, R., 7464
Drexler, I., 8647
Driggers, L. J., 1541
Drobetsky, E. A., 3781
Drouin, R., 3781
Druck, T., 4827
Drucker, D. J., 687
Du, F., 7943
Du, M-Q., 1629
Du, Y., 8094
Dubauskas, Z., 2833
Dubey, P., 3256
Dubiel, W., 8416
Dubinett, S. M., 6406
DuBois, R. N., 497, 2670
Dubois, V., 2843
Dubrovin, M., 2983
Duclos, J-M., 6762
Ducrest, A-L., 7594
Dudas, M. E., 3171
Duensing, A., 2356, 8118
Duensing, S., 2356
Duffel, M. W., 3925
Duggan, D. J., 4683
Duggan-Keen, M., 192
Dugger, D. L., 4197
DuHadaway, J. B., 3151
du Manoir, S., 4122
Dumanski, J. P., 5778
Dummer, R., 452, 823
Dumon, K. R., 1578, 4827
Dumontet, C., 5024
Dumrese, T., 4072
Dunach, M., 1671
Dunklee, B., 3775
Dunlop, M. G., 7060
Dunn, S. E., 1367
Dunphy, E. J., 2953
Dunsmore, I. R., 3157
Dunstan, C. R., 4432
Dupertuis, Y. M., 7971
Dupouy, M., 5289
Duquette, M., 7830
Durden, D. L., 5587
Durell, B., 641
Duriez, C., 486
During, M. J., 4827
Dürst, M., 7118
Duszyk, M., 376
Dutoit, V., 509, 2047, 5153, 5850
Duvvuri, U., 7747

## E

Eads, C. A., 3410
Eapen, A., 3145
Earle-Hughes, J., 7792
Eastman, A., 1533
Ebara, M., 5382
Ebara, S., 3882, 4386
Ebbs, S., 8452
Ebensperger, C., 6925
Eberhard, D. A., 4197
Eberhart, D. E., 513
Ebert, B., 991
Echchakir, H., 4078
Echtenacher, B., 5523
Eck, S. C., 3077
Eckardt, K-U., 5215
Eckert, C., 2517
Economou, J. S., 8782, 8787
Edamatsu, H., 4701
Edelman, A., 1693
Edelmann, W., 565, 6297, 7934, 8520
Edler, L., 608
Edlund, M., 7310
Edmonson, S., 4520
Edwards, B., 2015
Edwards, N. S., 5275
Edwards, S., 126
Eerola, H., 5718
Efferth, T., 7731
Efremov, G. D., 8351
Egawa, M., 6012
Egawa, S., 884
Egeblad, M., 1786
Eggert, A., 1314
Eggleston, I. M., 6120
Ehara, T., 7627
Ehrig, T., 5692
Ehrlich, M., 6931
Ehrlich, S. M., 8664
Eiben, G. L., 7861
Eicher, S. A., 3321
Eichhorst, S. T., 243
Eide, L., 5378
Eigler, A., 6445
Einhorn, L. H., 2220
Einsiedel, H. G., 3570
Eklin, K., 4545
Eklund, C., 5718
Eksborg, S., 6423
Elashoff, R., 8917
El-Bayoumy, K., 3647, 7479
El-Deiry, W., 6467
El-Deiry, W. S., 1334
El Etreby, M. F., 7179
El Fahime, M., 2189
El-Gamil, M., 1089
Elgavish, A., 6777
Elhosseiny, A., 8381
Eliaz, R. E., 2592
Elkahloun, A. G., 2320, 8624
Elkin, M., 4253
Elkins, D. A., 6494
Elledge, S. J., 5362
Ellenrieder, V., 4222
Ellenson, L. H., 4569

* For title of article and coauthors, see listing in Contents of Volume 61 beginning on page 9015 at the end of this index issue.

Ellerbroek, S. M., 1855, 3194
Ellies, L. G., 8298
Elliott, P. J., 3071, 3535
Ellis, L. M., 1255, 1464, 7048
Ellis-Hutchings, M. S., 8758
Elmishad, A. G., 7861
Elmore, L. W., 4791
El-Naggar, A., 837
El-Tanani, M., 5619
Eltoum, I-E., 6777
Eltze, E., 355
Emanuelli, G., 2200
Embry, M., 517
Emens, L. A., 880, 3689
Emig, P., 392
Emiliusen, L. M., 7240
Emmert-Buck, M. R., 4098
Emrich, T., 3053
Enam, S., 4287
End, D. W., 131
Endo, T., 3640
Endoh, T., 1451
Endres, S., 6445
Enewold, L., 6367
Eng, C., 4311
Engert, A., 8737
Engin, T. S. W., 3837
Engler, S., 2968
Engler., J. A., 6264
Englisch, S., 1659
Engstrand, L., 2684
Enomoto, S., 5065
Enroth, H., 2684
Entschladen, F., 2866
Epstein, C. J., 3472
Ercolini, A. M., 880, 3689
Erdreich-Epstein, A., 5587
Eriksson, I., 2684
Erlichman, C., 739
Erzurum, S. C., 8578
Eshleman, J. R., 654
Eskenazi, A. E., 1073
Eslahi, N. K., 859
Espín, E., 7727
Essand, M., 8122
Esteller, M., 2092, 2816, 3225, 4689, 7015
Estrov, Z., 138
Ethier, S. P., 5168
Eto, I., 3961
Etoh, T., 2145
Ettenberg, S. A., 4892
Ettinger, S. N., 7964
Euhus, D. M., 4556
Evans, C. L., 6958
Evans, D. G. R., 5948
Evans, J. F., 1733, 6131
Evans, J. W., 145
Evans, M. K., 1493
Evans, S. M., 2289, 2974
Even, J., 7568
Evine, K., 5707
Evron, E., 921, 2782, 8014
Ewert, D. L., 3151
Ewing, C. M., 4683, 5969, 8617
Ewing, P. J., 1486

F

Fabbro, D., 732, 8203
Fabian, R. L., 4490
Fabre, M., 3245
Fabris, C., 7495
Fabris, V., 293
Facchetti, P., 1285
Fackelmayer, F. O., 1659
Facompré, M., 6876
Factor, V. M., 2085, 6665
Fadl-Elmula, I., 8241
Faibel, M., 4971
Fairchild, C. R., 7507
Faith, D. A., 8617
Falchetti, M., 5415
Falck, J., 4990
Falconi, M., 285
Falcovitz, A., 88
Falk, W., 5575
Fallik, D., 6555
Fallon, B. G., 1457
Fan, F., 1255
Fan, J., 2579
Fan, K., 7934
Fan, L., 1073
Fan, M., 4450
Fan, R., 8718
Fan, S., 8022
Faneyte, I. F., 3458
Fang, B., 186, 3330
Fang, J., 5731
Fang, W., 8094
Fang, Y., 3806
Fangmeier, J., 864
Fannon, M., 7669
Fanslow, W., 7556
Farace, M. G., 1555
Faraoni, P., 8803
Farber, J. L., 2459
Farber, R. A., 8405
Fares, M. Y., 7130
Fargnoli, J., 8480
Farhadi, M., 6830
Farías, S., 8775
Farinas, A., 5727
Farinas, A. J., 8659
Farion, R., 6524
Farnell, D. R., 3961
Farnsworth, J., 764
Farver, C., 8578
Faull, K. F., 5741
Fausto, N., 594
Fay, J., 6451
Fazi, F., 2, 1247
Fazio, V. M., 1555, 7015, 7623
Fearon, E. R., 8247
Fedele, M., 4583
Feger, F., 5289
Fehr, J. L., 4514
Fei, D. T., 2533
Feigelson, H. S., 785, 848
Feinberg, A. P., 4947
Feith, D. J., 6073
Feldkamp, M. M., 4425
Feldman, D., 2852
Feldman, M., 7747
Feldman, M. D., 2974
Feldman, R. I., 5985
Felicetti, F., 6532
Fellows, W. K., 2625
Feng, G., 7999
Feng, K-C., 4723
Feng, L., 7233, 8723
Feng, Z., 7110
Fenton, B., 526
Fenzi, G., 1426
Ferguson, A. T., 7025
Ferguson, C., 1611
Fernandes, E., 3131
Fernandez, A-M., 2843
Fernández, P. L., 2409, 8820
Fernö, M., 5979
Feroze, F., 4283
Ferrara, F. F., 2
Ferrara, J. L. M., 162
Ferrari, A. C., 7544
Ferrari, N., 8171
Ferrarini, M., 3092
Ferri, C., 309
Ferrone, S., 4642, 8647
Ferry-Dumazet, H., 5289
Festinesi, A., 4272
Fetter, J. R., 3961
Feuerstein, M. P. B. G., 7683
Fiala, E. S., 8435
Fidler, C., 8820
Field, J. K., 538, 1624
Fields, J. Z., 8408, 8664
Fields., A. P., 1375
Figlin, R., 7925
Fijan, A., 4514
Filho, A. M., 1563
Filippova, G. N., 6002
Filipski, E., 1996
Fillbrandt, R., 6624
Filmus, J., 4837
Finch, R. A., 1469, 3033
Finerty, J., 4642
Finette, B. A., 3432
Finger, D. N., 842
Fink, S. P., 256
Finkelstein, S. D., 7404
Finlay, J. L., 7404
Finn, O. J., 4756
Finn, R., 2983
Fiorentini, F., 1983
Firozi, P. F., 1445
Fischbach, K., 3578
Fischel, J-L., 7785
Fischer, H-P., 4398
Fischer, K., 2804
Fischer, S. M., 4879
Fishel, R., 7369
Fisher, D. E., 5275
Fisher, D. R., 5126
Fishman, D. A., 3194
Fitzgibbons, E. D., 8459
Fizazi, K., 5652
Flanagan, W. M., 6583
Flanders, K., 6665
Flavell, R. A., 3908
Fleischhacker, R., 8188
Fleming, J., 7479
Flesken-Nikitin, A., 3110
Fletcher, C. D. M., 8118
Fletcher, J. A., 8118
Flexor, M. A., 700
Flintoff, W., 1941
Fliss, M., 7623
Flores, J. M., 6234
Fluge, O., 2505
Fluharty, A. L., 5741
Flury, R., 4514
Flynn, A. A., 4716
Flynn, E., 7669
Fodde, R., 7020
Foekens, J. A., 1421, 5407
Foernzler, D., 7616
Fogler, W. E., 7669
Foidart, J-M., 3450
Fojo, T., 6328
Folkman, J., 2207, 7298, 7669
Fong, E. M., 2602
Fong, K. M., 249, 3581
Fong, S. E., 4197
Fonong, T., 7488
Fontana, J. A., 4723
Foraker, A. B., 6660
Ford, O. H., 4315
Forest, V-I., 5869
Fornace, A. J., Jr., 2487
Forni, G., 2809, 3518
Foroni, L., 5145
Foroni, M., 896
Förster, K., 2968
Forsythe, H. L., 4791
Fortes, C., 778
Fosdick, L., 3566
Foshag, L. J., 5723
Foss, F., 5933
Foster, B. A., 2562
Foster, C. S., 4357
Foster, R. S., 2220
Foti, M., 8930
Foukas, P., 538
Foulkes, W. D., 4092
Fox, J. N., 6739
Fox, S. B., 3206
Fracchioli, S., 7811
Fraig, M. M., 4112
Frame, M. C., 8385
Francesco, M., 4175
Franco, N., 7955
Frandsen, T. L., 532
Franke, G., 4605
Frankel, A., 4837
Frankenne, F., 3450
Frankfater, A., 3493
Frankl, H., 2381
Frants, R. R., 5303
Frantz, C. N., 1073
Frantz, G. D., 4197
Fraumeni, J. F., Jr, 4333
Fraumeni, J. F., Jr., 3406, 5415
Frazier, M. L., 1269
Frederiksen, C. M., 2492
Freeman, J. W., 6239
Frei, U., 5215
French, F. S., 2892, 4315
Frenkel, E. P., 4017
Freud, A. G., 59
Frick, K. K., 1073
Fried, L. M., 2649
Friedberg, E. C., 5552
Friedman, C., 1457
Friedman, S. L., 7675
Frierson, H. F., Jr., 5974, 7388
Friesen, M. D., 33
Friess, H., 4655
Fritsch, M. K., 7268
Froberg, M. K., 771
Froelich, C. J., 348
Frost, D., 5480
Fu, L., 7383
Fuery, C. J., 131
Fueyo, J., 6693
Fujie, H., 4365
Fujii, H., 2870, 4357, 6640
Fujii, K., 2022
Fujii, T., 4405
Fujii-Kuriyama, Y., 5707
Fujikawa, K., 8697
Fujiki, H., 1896, 6356
Fujimori, M., 6656
Fujimoto, I., 1666
Fujimoto, S., 3262
Fujimoto, S-i., 97
Fujimoto, T., 3770

** For title of article and coauthors, see listing in Contents of Volume 61 beginning on page 9015 at the end of this index issue.*

Fujimura, S., 1896
Fujino, M. A., 8256
Fujita, M., 6345, 7722
Fujita, Ta., 7913
Fujita, To., 7900
Fujiwara, H., 3399
Fujiwara, T., 7855
Fujiwara, Y., 3188, 5570, 5723
Fukao, K., 7950
Fukuda, M., 2226
Fukuda, T., 23
Fukuda, Y., 2361, 8527
Fukumoto, S., 4244
Fukumura, D., 2404, 6020
Fukunishi, Y., 1144
Fukushima, H., 3139
Fukushima, S., 6964
Fukushima, T., 172
Fukuyama, Y., 5727
Fuller, J. A., 228
Funabashi, H., 2395
Fung, K-M., 1527
Furcht, L. T., 2857
Furlanetto, T., 7616
Furmanski, P., 2996
Furui, J., 2732
Furukawa, K., 4244
Furukawa, Y., 2129, 3544, 4414, 6345, 6474, 7722
Furumai, R., 4459
Furumoto, K., 7840
Furuya, F., 3640
Furuyama, J-i., 1029
Fusaro, G., 2583
Fusco, A., 1426, 2267, 4583
Füzesi, L., 7731
Fyles, A., 6400

G

Gaarde, W. A., 7079
Gabig, T. G., 7878
Gabra, H., 6977
Gabrielson, E., 7623
Gabrilovich, D. I., 2015
Gadd, M., 8811
Gadner, H., 5992
Gage, W. R., 8611, 8617
Galambos, P., 6445
Galendo, D., 8158
Galera, J. L., 6360
Galipeau, P. C., 8284
Gallick, G. E., 7048
Galliera, E., 935
Gallinger, S., 6131
Gallo, J. M., 5491
Galloway, D. A., 1934, 8459
Galve-Roperh, I., 5784
Galvez, A. F., 7473
Gamage, S. A., 2935
Gambacorti-Passerini, C., 5468
Gambarotta, G., 5861
Gambotto, A., 2625
Gandhi, V., 5474
Gangi, L., 4797
Gänsbacher, B., 1272
Ganther, H., 3062, 7171
Gao, D-Q., 3212
Gao, F., 1022, 5207
Gao, G-P., 6201
Gao, J., 5038
Gao, J-X., 6860
Gao, L., 2371
Gao, P., 3399
Gao, W., 6679
Gao, W-Q., 7291
Gao, X., 1619
Gao, Y-T., 3406, 4333, 7136
Gao, Zhe., 8664
Gao, Zhi., 8664
Garavaglia, R., 8775
Garber, J. E., 5420, 8062
Garbisa, S., 7495
Garcia, S., 1941
García-Cuéllar, M-P., 6480
Garcia de Herreros, A., 1671
García-Martín, M-L., 6524
García-Palencia, P., 6234
Garcia-Pardo, A., 8586
García-Sastre, A., 8188
Gardner, L. M. G., 3250, 6322
Gardner, T. A., 6012
Garfield, S. H., 943
Garnett, M., 8909
Gartsbein, M., 4591
Gasche, C., 7444
Gasior, C. L., 6958
Gaskin, A. A., 7964
Gaspard, J. P., 6050
Gaspard, R., 7792
Gasser, T., 4514
Gaston, V., 6762
Gatalica, Z., 1375
Gatfield, J., 5941
Gati, A., 3240
Gatter, K., 5262, 8820
Gatter, K. C., 1830, 7992
Gau, C-L., 4701
Gauny, S. S., 1129
Gay, C., 7792
Gazdar, A. F., 249, 3581, 3795, 4556, 5727, 7943, 8659
Geddes, J. F., 4287
Gee, J. M. W., 6739
Gee, M. S., 2974, 7747
Geelen, E., 3164
Geertsen, R., 823
Geiger, J. D., 8513
Geisler, S., 2505
Geissler, E. K., 5575
Geissler, M., 2609
Gelder, M. E. M-v., 5407
Gelman, I. H., 5644
Gelmann, E. P., 5611
Gelmetti, V., 2
Gemma, A., 8527
Geng, L., 2413
Genini, D., 7248
Gentile, A., 5861
Gentzschein, E., 3326
Geoerger, B., 1527
George, M. D., 2445
George, S. L., 7233
Geradts, J., 249, 3581
Gerald, W. L., 6892
Gerauer, H., 4731
Gerhard, D. S., 4982
Gerhard, M., 1903
Germano, I. M., 5796
German Pediatric Germ Cell Tumor Study Group, 7268
Geroni, C., 1983, 1991
Gershenson, D. M., 7264
Gerweck, L. E., 4740
Gescher, A., 1058
Geurts-Moespot, A., 5407
Geyer, R. J., 3669
Ghadimi, B. M., 8143
Ghamande, S., 7556
Ghiotto, F., 1285
Ghiringhello, B., 7811
Gho, Y. S., 4253
Ghose, A., 7479
Ghosh, D., 7585
Giaccia, A. J., 795, 2429
Giannini, C., 7803
Giardina, G., 7811
Giatromanolaki, A., 1830, 7992
Giavazzi, R., 309
Gibson, G. R., 641
Gicquel, C., 6762
Giedlin, M., 2062, 2618
Giercksky, K-E., 5824
Giese, A., 4190
Giezeman-Smits, K. M., 2625
Giglia-Mari, G., 2480
Giguère, V., 6755
Giguère, Y., 5869
Gilbert, B., 4272
Gilbert, C., 486, 2961
Gilcrease, M., 4556, 5727
Gill, K., 1910
Gillenwater, J. Y., 6012
Gillespie, A. M., 3472
Gillespie, G. Y., 2154, 3084, 8470
Gillessen, S., 162
Gillies, S. D., 1500, 6178, 8498
Gilmour, L. M. R., 2169
Gioffre, C., 1964
Giordano, A., 462, 4651, 5952
Giordano, G. G., 462
Giordano, T., 7908
Giralt, J., 6500
Giron-Michel, J., 3240
Gitlitz, B., 7925
Giudici, G., 4666
Giuliani, R., 309
Giuliano, A. E., 8845
Giulotto, E., 4520
Gius, D., 3486, 7689
Giussani, C., 7501, 8730
Gladyshev, V. N., 2307
Glanzmann, C., 732, 8203
Glasebrook, A. L., 8412
Glaspy, J. A., 8782, 8787
Glass, T. L., 6693
Glatting, G., 3853
Glazer, P. M., 3775
Glazer, R. I., 7647
Glick, R. D., 3591
Glickson, J. D., 7747
Glinskii, O. V., 4851
Glinsky, G. V., 4851
Glinsky, V. V., 4851
Gneiting, T., 2513
Go, M., 8381
Gobbi, A., 4341
Göbel, U., 7268
Godal, A., 5824
Godfrey, T., 1122
Godfrey, V., 6577
Godoi, P. H. C., 7375
Godwin, A. K., 5420, 8062
Goel, A., 7444
Goemann, M., 7464
Goetz, A. W., 7635
Goffinet, C., 3718
Goggins, M., 4320, 8540
Gogineni, S. K., 4506
Gohongi, T., 6020
Going, J. J., 27
Gökmen-Polar, Y., 1375
Gola, E., 5441
Goldberg, G. S., 1334
Goldberg, I. D., 2365, 8022
Goldberg, L., 4306
Goldberg, R. J., 1541
Goldberger, N., 8624
Goldfinger, N., 88
Goldman, J. M., 8005
Goldman, R., 6367
Goldsmith, M. E., 6328
Goldup, S., 1171
Goletz, T. J., 4766, 6868
Golovsky, D., 423, 5331
Goltsov, A., 3882
Gomer, C. J., 6185
Gomez-Manzano, C., 6693
Gondo, T., 1776
Gong, J., 3176
Gong, Y., 5168
Gonzales, M., 4329
Gonzalez, F. J., 8435
Gonzalez-Gomez, I., 1398
González-Suárez, E., 5580
Gooch, B. D., 2713
Goodman, G., 2420
Goodman, J. E., 7488
Goodman, S. L., 1781
Goodman, S. N., 818
Goodwin, M. E., 4450
Goodwin, W. J., Jr., 1457
Gordon, J., 4287, 8547
Gorelik, E., 478, 1707
Gores, G. J., 6388
Gorgoulis, V. G., 538
Gorlick, R., 4599
Gorospe, M., 1493
Gosney, J. R., 1624
Goto, H., 469
Goto, Y., 1896, 4620
Gottardis, M. M., 2917, 8703
Göttlicher, M., 8534
Gottschalk, A. R., 2105
Gough, M. J., 7240
Gould, H. J., 5517
Goulette, F. A., 6816
Gourdeau, H., 7217
Goyal, J., 8014
Grady, W. M., 900
Graeven, U., 7282
Graff, J. R., 4679
Graff, L., 2138
Grafström, R. H., 2885
Graham, S. L., 8758
Gramigni, C., 2200
Granda, T. G., 1996
Grandis, J. R., 5919
Grant, S., 2583, 5106
Granville, D. J., 1260
Gratzl, M., 2138
Gray, C. P., 7339
Gray, J. W., 1250
Gray, S. G., 5950
Graziano, F., 2523
Greaves, M. F., 2542
Grebe, S. K. G., 4815
Grebenchtchikov, N., 5407
Green, C. J., 2696
Green, D. W., 6563
Green, E., 5307
Green, J. E., 7449
Green, S. J., 1022
Greenberg, A. H., 6669
Greenberg, N., 2562
Greenberg, N. M., 2736, 6777

** For title of article and coauthors, see listing in Contents of Volume 61 beginning on page 9015 at the end of this index issue.*

Greenblatt, M. S., 4092
Gregorio, C. D., 896
Gregory, C. W., 2892, 4315
Greil, J., 6480
Greiner, J. W., 206, 2523, 5517
Greiner, R. H., 2911
Gresh, W. E., Jr., 3961
Gress, T. M., 4222
Greten, F. R., 3853
Gretschel, S., 4605
Gribben, J. G., 4761
Gribi, R., 7333
Gricks, C. S., 5145
Griebel, J., 2513
Griend, D. J. V., 2833
Grignet-Debrus, C., 3450
Grigolato, P., 285
Grijalva, R., 1727
Grimaldi, J. C., 4197
Groen, H. J. M., 1585
Groene, H-J., 3119
Groffen, J., 1398
Grönberg, H., 1619
Gröne, H-J., 5215, 8880
Groopman, J. D., 33, 103
Grosenbach, D. W., 4497
Groshen, S., 8654
Gross, K. W., 6382
Grosse-Hovest, L., 1846
Grossfeld, G. D., 8135, 8143
Grossman, L., 7430
Grotzer, M. A., 1314
Grove, L., 6487
Grubbs, C. J., 2472, 3961
Grube, B., 1338
Gruber, G., 5215
Grubissich, L. M., 6213
Gruis, N. A., 5303
Grundy, S., 5552
Grünebach, F., 6846
Gruvberger, S., 5979
Gruys, M. E., 6255
Grygiel, J. J., 423, 5331
Gu, J., 1741, 3330, 4723, 6703
Gu, J-r., 7383
Gu, L-J., 2542
Gu, X., 1269
Gu, Z., 4660
Guadagni, F., 2523
Guan, J., 8554
Guan, X-Y., 3806
Guanti, G., 7020
Guba, M., 5575
Gückel, B., 4072
Gudas, L. J., 2774
Guenette, R. S., 2602
Guengerich, F. P., 8164
Guerra, N., 3240, 6838
Gugger, M., 4636
Guglielmino, R., 1285
Guha, A., 3826, 4425
Gui, G., 8452
Guichard, S. M., 5083
Guida, E., 3182
Guikema, J. E. J., 7654
Guillaume, P., 509, 2047, 5153, 5850
Guillemard, V., 694
Guillosson, J-J., 5289
Guilloux, Y., 1107
Gujral, A., 2282
Guler, R. L., 5771
Gulley, J., 3725, 7568
Gullick, W. J., 2169
Gultekin, S. H., 4048
Gum, J. R., Jr., 3472
Gump, J., 3863
Gunawan, B., 7731
Gunnarsson, C., 8448
Gunningham, S. P., 3206
Günthert, U., 2862
Guntrip, S. B., 7196
Guo, C., 3556
Guo, F., 5562
Guo, H. F., 4048
Guo, J., 7383
Guo, J. Q., 138
Guo, P., 8569
Guo, W-J., 4098
Guo, X., 2774, 5950, 5950
Guo, Z., 1354, 8395
Gupta, A., 6112, 6805
Gupta, A. K., 4278
Gupta, E., 8480
Gupta, R. A., 497
Gurates, B., 2328
Güre, A. O., 2055
Gurley, K. E., 327
Gürsel, D. B., 1717
Gussio, R., 7248
Gustafsson, J. A., 2537
Gustafsson, J-A., 5331
Gutierrez-Roelens, I., 3718
Gutkind, J. S., 2641
Gutmann, D. H., 3826
Gutterman, J. U., 5486
Guzmán, M., 5784
Gyllensten, U. B., 2684

**H**

Ha, H-Y., 984
Haas-Kogan, D. A., 2105
Haba, A., 7846
Habeler, W., 5441
Haber, D. A., 8062
Haber, M., 5803
Haberer, B., 4982
Haberkorn, U., 3712
Habgood, G. J., 1013
Hacker, A., 5370
Hackett, N., 439
Hadani, M., 4971
Hadari-Naor, I., 1439
Haensch, W., 3932, 4605
Haensch, W. E., 991
Häffner, A. C., 452
Hafner, M., 5523
Hager, B. W., 1477
Hahm, K-B., 6665
Hahn, W. C., 8366, 8838
Hail, N., Jr., 6698
Haile, R., 2381
Haiman, C. A., 3955
Hainaut, P., 6679
Haines, D. C., 2487, 6665
Hait, W. N., 4010
Hajitou, A., 3450
Halabi, S., 2533
Halazonetis, T. D., 7030
Halbleib, J. M., 1855
Halgren, R. G., 5474
Hall, C., 4474
Hall, E. J., 5710
Hallahan, D. E., 2413
Hallgren, C. G., 739
Hallit, S. L., 6264
Halperin, J. A., 6213
Halwachs-Baumann, G., 2335
Hamacher, K. A., 2008
Hamada, H., 673, 7009
Hamada, J-i., 6248
Hamaguchi, M., 2361
Haman, A., 6281
Hamaoka, T., 3399
Hamatsu, T., 1005
Hambek, M., 1045
Hamblin, M. R., 4490, 7155
Hamel, N., 4092
Hamelin, R., 2124
Hamilton, A. D., 1280
Hamilton, R. L., 7404
Hamilton, T. C., 1291
Hammann, A., 1645
Hammer, R. E., 5552
Hamper, U., 7464
Hampson, I. N., 192
Hampton, G. M., 5974, 7388
Han, C., 3206
Han, E. K-H., 1486, 5480
Han, J. Y., 4942
Han, Q., 4017
Han, S., 3998
Han, S. K., 6163
Han, W. F., 1493
Han, Z., 1022, 3176, 5207
Hanada, K-i., 5511
Hanai, N., 4474
Hanash, S., 7908
Hanash, S. M., 2162, 6885
Hancock, B., 6131
Handelsman, D. J., 6331
Handke, T., 991
Hankinson, S. E., 3955
Hanley, N. M., 6679
Hanna, E., 2376
Hannan, M. A., 3627
Hannun, Y. A., 1233
Hanrahan, C. F., 2736
Hansson, L-E., 2684
Hantash, F. M., 6569
Hanzely, Z., 1406
Hao, C., 1162
Hao, X. P., 419, 8085
Hara, A., 7699
Hara, Y., 2827
Harada, K., 8659
Harada, M., 1089
Haraguchi, K., 3640
Harashima, N., 2038
Harbeck, N., 1272
Hardman, R. A., 1392
Hardmeier, T., 4514
Hardt, D., 1659
Haridas, V., 5486
Harig, S., 4761
Harkes, I. C., 278
Harkins, L., 2154
Härkönen, P. L., 4229
Harley, C. B., 3053
Harlow, E., 8062
Harmsen, M. C., 4105
Harnden, P., 1678
Harper-Wynne, C., 8452
Harris, A. L., 1830, 3206, 5262, 6394, 6669, 7349, 7992
Harris, C. C., 4350, 5636, 6350, 6660, 7430
Harris, L. C., 3045, 5078, 5083
Harris, R., 7196
Harris, W. H., 1171
Harrison, P. R., 7479
Harth, V., 4398
Hartigan-O'Connor, D., 2062, 8794
Hartman, G. D., 8758
Hartmann, L. C., 4258, 5895
Hartmann, M., 4214
Hartsough, M. T., 2320
Hartwick, W. J., 7811
Haruki, N., 5362
Harvey, S., 5168
Hasan, I., 3285
Hasan, T., 717, 4490, 7155
Hasebe, T., 2177
Hasegawa, F., 2751
Hasegawa, H., 1005
Hashimoto, H., 6335
Hashimoto, S., 7627
Hashimoto-Tamaoki, T., 1029
Hashio, M., 3969
Hasler, B. P., 7868
Hassan, K., 837
Hassan, K. A., 7959
Hatano, T., 2177
Hatfield, D. L., 2307
Hatta, N., 7422
Hattinger, C., 5992
Haubner, R., 1781
Hauck, C. R., 7079
Haudenschild, C. C., 6906
Haugen, A., 6350
Haugen, D. F., 2505
Haughney, P. C., 6064
Haugland, H. K., 7394
Haulk, T., 7464
Hauptmann, S., 303
Hauser, H., 2609
Havenga, M., 8743
Haviv, Y. S., 8361
Hawk, N., 138
Hay, K., 6131
Hayakawa, M., 1276, 3294
Hayakawa, T., 2361, 7913
Hayasawa, H., 4414
Hayashi, H., 4459
Hayashi, K., 2361, 3016, 4779
Hayashi, N., 7563
Hayashi, R., 2751
Hayashizaki, Y., 1144
Hayes, D. F., 2533, 4061
Hayes, J. D., 3299, 6120
Hayes, S. A., 2112
Hayre, N., 6105
Hays, S., 7889
Hayward, N. K., 1154
Hayward, S. W., 6064, 8135, 8143
Hazan, C., 7642
He, B., 4315
He, C., 3330
He, L., 1080, 3698, 3735, 5803
He, M., 7383
He, P., 7488
He, Q., 6918
He, W., 7435
He, Y., 7383
Head, D. R., 423, 5331, 8830
Heaney, A., 5307
Hebbar, M., 4337
Hebert, J. R., 7136
Heckman, C. A., 5202
Hector, A., 7608
Hedayati, M., 7430
Hedley, D., 6400
Hedley, D. W., 7394
Hedlund, T. E., 7122
Hedrich, H. J., 8263

* *For title of article and coauthors, see listing in Contents of Volume 61 beginning on page 9015 at the end of this index issue.*

Hegamyer, G. A., 4160
Hegde, P., 7792
Hegge, L. F., 3480
Hegyi, I., 732
Hehlgans, T., 5523
Heicappell, R., 5580
Heike, Y., 445
Heilman, D. K., 3369
Heilmann, L., 7697
Heim, S., 8241
Heimann, P., 4130
Heimbrook, D. C., 8758
Heindel, C. C., 666
Heinimann, K., 7616
Heiser, A., 3388
Heisterkamp, N., 1398
Heitz, P. U., 5186
Held, M., 2684
Held, W. A., 1144
Heldin, C-H., 2929, 5778
Helenius, M. A., 5340
Helguero, L. A., 293
Heller, G., 3591
Heller, J. B., 8782
Heller, J. D., 5499
Hellström, I., 2420
Hellström, K. E., 2420
Helman, L., 3750
Helman, L. J., 6868
Helmke, B., 8880
Helou, K., 8263
Hemler, M. E., 2276
Hemmeryckx, B., 1398
Hemmings, B., 8203
Hemminki, A., 6377
Hempen, P. M., 1299
Henderson, A. J., 8480
Henderson, B. E., 785, 848, 3326, 8393
Henderson, C. J., 3299
Henderson, D. R., 517, 5453, 6428, 7464
Hendler, S. F., 4222
Hendrix, M. J. C., 3250, 4371, 6322
Henriksson, R., 2256
Henry, W. M., 8274
Henshall, S. M., 423, 5331, 8830
Hentze, H., 1659
Henze, G., 2517, 3570
Henze, M., 3712
Herberhold, C., 4398
Herbertz, S., 8880
Hergenhahn, M., 8158
Hérigault, G., 6524
Hering, F., 4514
Herlyn, M., 3819, 4642, 7318, 8306
Herman, J. G., 2092, 2816, 3225, 4689, 5636, 7025
Hernandez, J. M., 7925
Hernández, L., 2409
Hernández, S., 2409
Herrington, C. S., 4858
Herrlich, P., 1569
Herrlinger, U., 2983
Hersey, P., 7339
Hertle, L., 355
Herva, R., 4541
Hesch, R-D., 1659
Hesketh, R., 482
Hess, A. R., 3250
Hester, J., 197, 3704
Heumos, I., 1890
Heuser, C., 1976
Hewer, A., 6350
Hibbard, M. K., 8118
Hicklin, D., 5090
Hicklin, D. J., 39
Hicks, C., 1825
Hicks, J. W., 3472
Hickstein, D. D., 3586
Hideshima, T., 3071
Higgins, T., 7861
Hill, G. R., 162
Hill, R., 6400
Hill, R. P., 8903
Hill, S. A., 4716, 6811
Hillman, M. J., 6918
Hills, M., 8452
Hines, J., 6082
Hinson, S., 4951
Hippo, Y., 889
Hiraga, A., 4966
Hiraga, T., 4418
Hirai, F., 5382
Hirakawa, H., 1776
Hirakawa, K., 889, 2676
Hirano, N., 3969
Hirao, T., 612
Hirata, K., 6474
Hiratsuka, S., 1207
Hirayama, Y., 2632
Hirohashi, K., 1843
Hirohashi, S., 2751
Hirohata, S., 5796
Hirono, S., 3016, 4779
Hirose, Y., 370, 1874, 1927, 1957, 4956, 5843, 7699
Hirsch, B., 5268
Hirsch, K. G., 2583
Hirtreiter, C., 5523
Hisatake, J., 3361, 5307
Hisatake, Y., 3361
Hishita, T., 2878
Hlubek, F., 8089
Hmelnitsky, I., 8194
Ho, A., 474
Ho, C-T., 5749
Ho, H-C., 2727, 8873
Ho, H-N., 237
Ho, J. C-m., 8578
Ho, L., 7204
Ho, R., 1314
Ho, R. J. Y., 3669
Ho, S-M., 6768
Ho, S-T., 1412
Ho, Y-J., 1412
Hoang, T., 6281
Hoang-Vu, C., 4526
Hoar, K. M., 8366
Hoare, S. F., 27
Hobbs, P. D., 4723
Hobom, U., 5941
Hochberg, F. H., 864
Hochman, A., 1849
Hochman, J., 5242
Hochster, H., 2996
Hockfield, S., 7056
Hodge, J. W., 4497
Hodnick, W. F., 7770
Hoeflich, A., 8601
Hoelzinger, D. B., 4190
Hoesel, W., 957
Hoess, R. H., 2885
Hoffman, R. M., 4017, 6805
Hoffmann, J. J., 5486
Höfler, H., 2138
Hofmann, M., 1569, 8534
Hofmann, W., 5179, 5307
Hofseth, L., 6350
Hogarty, M. D., 679
Hogg, D., 2371
Höglund, M., 8241
Hogue, B. A., 5378
Hohenkirk, L. F., 8513
Hojo, H., 8401
Hokaiwado, N., 4693
Holland, J. F., 1754
Hollander, M. C., 2487
Holle, E., 6783
Hollema, H., 4105, 7305
Hollestelle, A., 278
Hollingshead, M. G., 4030
Hollingshead, P. G., 4197
Hollingsworth, M. A., 1833, 4923
Hollister, T , 439
Hollstein, M., 3119, 8158
Holm, P. S., 3053
Holmberg, L., 2256, 8317
Holmes, E. J., 7404
Holmes, R., 4371
Holmskov, U., 8880
Holst-Hansen, C., 532
Holt, G. E., 5857
Holt, P. R., 725, 1406, 6297
Holt, S. E., 4791
Holtick, U., 2080
Holtrup, M., 7731
Holub, A. D., 2953
Hom, Y. K., 8135
Hombach, A., 1976
Hommel, G., 7697
Hommura, F., 2500
Hondermarck, H., 76, 4337
Hong, J-H., 8859
Hong, S., 2434
Hong, T-M., 5223
Hong, W. K., 556, 837, 1445, 7959
Honjo, Y., 6635
Honma, Y., 178
Honore, P., 4038
Honorio, S., 7277
Honsawek, S., 3660
Hood, L., 1611
Hoon, D. S. B., 4773, 5723, 8845
Hoos, A., 3171
Hop, W. C. J., 3164
Horak, E. M., 4750
Horev, J., 4873
Hori, M., 7563
Hori, O., 4206
Hori, S., 5432
Hori, T., 3016, 4779
Horie, T., 4365
Hörig, H., 8520
Horiguchi, M., 3913
Horikoshi, N., 7689
Horinouchi, S., 4459
Horiuchi, I., 6548
Hornez, L., 4337
Horsfall, D. J., 926
Horsman, D. E., 3439
Horsman, M. R., 5318
Horsthemke, B., 3439
Horvath, L. G., 5331
Horwitz, S. B., 5803
Hoser, G., 2194, 6517
Hoshizima, N., 4345
Hosoi, H., 3373
Hosokawa, M., 2424, 6548
Hosoya, Y., 8527
Hostein, I., 4003
Hostetter, G., 8624
Hou, M., 706
Hough, C. D., 3869
Houghten, R. A., 5153
Houghton, A., 7642
Houghton, P. J., 3373
Houghton, R. L., 1563
Housni, H. E., 4130
Houston, M., 3535, 6297
Howard, C. M., 462
Howell, S. B., 1508, 7603
Howell, W. M., 1296
Howells, L., 1058
Hruban, R., 4923
Hruban, R. H., 1299, 1833, 4320, 8540
Hrycyna, C. A., 6635
Hsia, D. A., 7079
Hsieh, C-L., 6012
Hsieh, J-T., 6592
Hsieh, L-L., 2799
Hsieh, S-Y., 4238
Hsing, A. W., 3406, 4333
Hsu, C., 7920
Hsu, J-Y., 2852
Hsu, K-F., 1080, 3698
Hsu, L-C., 7713
Hsu, N-Y., 2727, 8873
Hsu, S-M., 237
Hsu, T-C., 4160
Hsu, Y., 6708
Hu, C-A. A., 1810
Hu, F., 6679
Hu, G., 3176
Hu, J., 7268
Hu, K., 428, 3281
Hu, M., 3586, 5652, 6693
Hu, N., 4098
Hu, X., 6290
Hu, Y., 8751
Hu, Y. C., 8113
Hu, Y. J., 2307, 6002
Hua, X. H., 7248
Huang, C., 8051
Huang, D. P., 3877
Huang, E. L., 3682
Huang, H., 4258
Huang, H-J. S., 5349, 5355, 8569
Huang, J., 1619
Huang, M., 3276, 6406
Huang, M-T., 5002
Huang, N., 478
Huang, P., 1065, 8723
Huang, Q., 428
Huang, R. C. C., 5499
Huang, S., 1796, 3373, 8094
Huang, S-C., 237
Huang, T. H-M., 8375
Huang, W., 8586
Huang, X., 478, 1707, 3704, 8416
Huang, Y., 6918
Hubbard, A. K., 1791
Huber, C., 1095, 8647
Huber, P. E., 8441
Huber, R., 2804
Huber, W., 7731
Hubert, R. S., 1686
Hudson, L. G., 1855, 3314
Huebner, K., 1578, 4827
Huffman, J. W., 5784
Huflejt, M. E., 4851
Hugh, T. B., 8830
Hughes-Davies, L., 482
Hugo, P., 6281
Huhn, M., 8737

** For title of article and coauthors, see listing in Contents of Volume 61 beginning on page 9015 at the end of this index issue.*

Hui, A. B-Y., 3877
Hui, L., 3176
Hukku, B., 5969
Hulbert, M., 1624
Huls, G., 4055
Humphrey, P. A., 5692
Hung, C-F., 1080, 3698
Hung, M-C., 2838, 3394, 7142, 7413, 8390
Hunt, C., 3486
Hunt, J. D., 1386
Hunter, D. J., 3955
Hunter, K. W., 8866
Hunter, R. D., 6394
Huo, K-K., 3806
Hurks, H. M. H., 5303
Hurst, B., 4679
Husøy, T., 5010
Huss, W. J., 2736
Hussain, S. P., 6350
Hussein, H., 2542
Hussell, S., 5126
Huszthy, P. C., 6830
Hutchins, L. F., 7130
Hutchinson, R. J., 8513
Hutter, L. K., 5486
Huynh, N. T., 2696
Hwang, D. H., 1386
Hwang, H-S., 5193, 8290
Hwang, J., 5016
Hwang, J. D., 5919
Hwu, P., 7920
Hylander, B. L., 7556
Hynes, N. E., 383
Hynes, R. O., 5255

## I

Iannone, M., 4010
Ibrahim, E. C., 6838
Ichijo, H., 5432
Ichikawa, H., 1334
Ichikawa, T., 864, 2833, 5336
Ichikawa, Y., 2833
Ichimura, S., 5885
Ido, A., 3016, 4779
Idos, G., 647
Idres, N., 700
Igawa, M., 7101
Ihara-Watanabe, M., 1637
Iijima, T., 7950
Ijiri, R., 8401
Ikeda, M., 4414
Ikeda, S., 3770, 6656
Ikeda, T., 2665, 8697
Ikeda, Y., 4693
Ikegaki, N., 1073, 1314
Ikehata, H., 3913
Ikenaka, K., 1666, 4809
Ikezoe, T., 5307
Ikonen, T., 6038
Ikonomopoulos, J., 538
Iliakis, G., 270, 5425, 8554
Illei, P., 6892
Im, Y-H., 6665
Imai, K., 2751, 3139, 4365, 7009
Imai, M., 6360
Imaida, K., 4693
Imamura, M., 6629, 7840
Imamura, T., 1592
Imboden, M., 1500
Imoto, I., 6629
Inazawa, J., 6629
Incardona, F., 842
Ince, T. A., 4311
Indraccolo, S., 5441
Indranie, C., 1927
Ingle, J. N., 4951
Ingley, E., 2453
Inomata, M., 445
Inoue, H., 2145, 4329, 4628, 5714, 7379
Inoue, M., 950, 1843, 3188, 5570, 5796
Inoue, R., 4414
Inoue, T., 8803
Inui, H., 23
Inui, K., 1666
Ionescu-Tiba, V., 8811
Ip, C., 2923
Ireson, C., 1058
Irizarry, A. R., 2301
Isaacs, J. T., 5038, 6372
Isaacs, W. B., 103, 4683, 5969, 8617
Isaksson, M., 5374
Ischiropoulos, H., 778
Ise, T., 1592
Isenmann, S., 2759
Ishibashi, K., 4365
Ishibashi, T., 6151
Ishida, E., 6335
Ishida, N., 4620
Ishida, T., 7009
Ishiguro, H., 6345
Ishii, E., 2542
Ishii, H., 1578, 4827
Ishii, M., 889
Ishii, Y., 178
Ishimori, T., 4966
Ishizaka, Y., 4414
Isobe, N., 7840
Isogai, C., 5587
Isola, J., 1214, 5345
Isozaki, H., 4345, 7743
Israel, M. A., 1122, 1805, 2162
Issa, J-P., 8274
Issa, J-P. J., 3573, 8540
Itakura, J., 5562
Ito, K., 7900
Ito, M., 2038
Itoh, F., 3139
Itoh, H., 8486
Itoh, K., 2038, 3299, 6459
Itoh, M., 1144
Itoh, T., 1338, 4414
Itoiz, M. E., 8638, 8775
Ittmann, M., 3882
Iturria, S., 5895
Itzchak, Y., 4873
Iughetti, P., 7375
Ivanusa, T., 4266
Iwadate, M., 8256
Iwadate, Y., 8769
Iwahashi, M., 6158
Iwanaga, T., 445
Iwasaki, M., 3399
Iwasaki, T., 4885
Iwata, R., 5707
Iwata, S., 2395
Iwaya, K., 5707
Iyengar, R. V., 3045
Iyer, J., 1073
Izumi, H., 1592
Izzotti, A., 2472

## J

Jäättelä, M., 1786
Jablons, D. M., 5959, 8527
Jack, G. S., 497
Jackman, A. L., 3675
Jackson, C. A., 8470
Jackson, P. E., 33
Jacob, S., 6555
Jacobs, A., 2983
Jacobs, Y., 7363
Jacobsen, S. J., 6494
Jacotot, E., 1260
Jae, H-S., 5480
Jaeger, U., 1629
Jaffee, E., 4923
Jaffee, E. M., 880, 3689, 4320
Jaffrézou, J-P., 2558
Jäger, D., 2055
Jäger, E., 2055
Jager, M. J., 5303
Jäger, P., 4514
Jahnukainen, K., 706, 6423
Jahnukainen, T., 6423
Jahr, S., 1659
Jahreis, G. P., 8274
Jain, A., 4175
Jain, R. K., 39, 2404, 6020, 8079, 8348, 8930
Jaiswal, M., 6388
Jakesz, R., 8188
Jakobovits, A., 1686
Jakse, G., 7731
Jamal, N., 5652
James, C. D., 739, 5895
Jang, J-H., 3541
Jang, J-J., 6665
Jang, S. J., 7959
Jänicke, F., 6682
Janknecht, R., 2690
Jankova, R., 8351
Jansen, A. P., 808
Jansen, G., 3675
Jansen, L., 7118
Janss, A. J., 1527
Janssen, W. E., 6290
Jaramillo, E., 2676
Jarnagin, K., 4175
Jarrett, C. R., 7978
Jarrett, R. F., 6219
Järvinen, H., 4545
Järvinen, H. J., 1619
Järvinen, P., 5345
Jasar, D., 8351
Jasin, M., 4842
Jass, J., 7743
Jass, J. R., 827
Jauch, K-W., 5575
Jaworski, R. C., 4576
Jayatilake, G. S., 5486
Jeffers, M., 3131
Jefferson, W. N., 4325
Jeggo, P. A., 3886
Jen, J., 939, 1309
Jenkins, W. T., 2974
Jenne, J. W., 8441
Jeronimo, C., 7015
Jesnowski, R., 550
Jett, J. R., 5636
Ji, X-D., 5349
Ji, Y., 3176
Jia, S-F., 3394, 4066
Jialal, I., 5552
Jiang, C., 3062, 7171
Jiang, G., 6931
Jiang, G-L., 1796
Jiang, W., 4197
Jiang, Y., 2365
Jimenez, X., 7002
Jin, C., 5295
Jin, F., 7136
Jin, Y., 3176
Jin, Z., 1334
Jing, C., 4357
Jinushi, M., 7563
Jiricny, J., 2813, 7719
Jo, H., 3084
Job, D., 5024
Jochemsen, A. G., 1839
Joel, D. D., 8179
Johannes, W. U., 7122
Johansson, B., 5374
John, S. K., 8668
Johns, T. G., 5349, 5355
Johnsen, H., 2505
Johnson, C. K., 1619
Johnson, D. R., 1469
Johnson, G. M., 659
Johnson, P., 8851
Johnson, P. H., 5168
Johnson, P. J., 3877
Johnson, P. M., 6025
Johnson, R. T., 4315
Johnson, R. T., Jr., 2892
Johnson, W. W., 7525
Jolivet, J., 7217
Jonak, Z. L., 884
Jonas, T., 4971
Jones, D. A., 433
Jones, D. J. L., 1058
Jones, G., 4978, 5688
Jones, J., 1833
Jones, J. B., 1299
Jones, M., 8820
Jones, P. A., 5875
Jones, T. R., 81
Jong, H-S., 4628
Jorczak, M. M., 8062
Jordan, R. C. K., 2371, 7015
Jordan, V. C., 3632, 5683, 6619
Jori, G., 7495
Joseph, S. O., 8298
Joshi, B. H., 5661, 6194, 8058
Joshi, R., 2983
Josifovski, T., 8351
Jost, M., 7282
Jothy, S., 5090
Jounaidi, Y., 4437
Jove, R., 3276
Jowett, A., 7196
Ju, D. W., 3735
Ju, G., 8051
Ju, Y. H., 5045
Juan, G., 1220, 6892
Judmaier, W., 2513
Jug, G., 5992
Juhl, H., 2968
Jukes, R., 1058
Julin, C. M., 1805
June, C. H., 4766
Jung, A., 8089
Jung, G., 1846
Jung, H-Y., 2847
Jung, K., 3425
Jung, S. S., 4942
Jung, Y. D., 1255, 7048
Jungbluth, A., 4671
Jungbluth, A. A., 5349
Junghans, R. P., 7889
Junkermann, H., 3712
Jurasz, P., 376
Jure-Kunkel, M., 8480

** For title of article and coauthors, see listing in Contents of Volume 61 beginning on page 9015 at the end of this index issue.*

Jürgensen, J. S., 5215

K

Kaartinen, V., 1398
Kacinski, B., 4405
Kaczmarek, E., 4190
Kaczmarek, M., 6906
Kadambi, A., 2404
Kadlubar, F. F., 7130
Kado, S., 2395
Kadwell, S. H., 7196
Kadomatsu, K., 8486
Kaelin, C. M., 5697
Kagan, V. E., 7777
Kagawa, S., 186, 3330
Kahlenberg, M. S., 8274
Kahn, A., 3245
Kahn, C. R., 2071
Kahn, D., 8520
Kai, Y., 6248
Kaibori, M., 950
Kaina, B., 7399
Kaiser, L. R., 4766, 6201
Kaji, A., 4084
Kakehi, Y., 5432
Kakinuma, S., 5382
Kakizuka, A., 5432
Kakudo, K., 6060
Kalli, K., 4258, 5895
Kalliomaki, T., 8903
Kallioniemi, A., 8235
Kallioniemi, O-P., 6038
Kalmes, H. A., 3595
Kalos, M., 1563
Kamada, M., 4184
Kamada, N., 23
Kamarashev, J., 452, 823
Kamath, L., 5933
Kambara, T., 7743
Kamel, A. M., 2542
Kamen, B. A., 4599
Kameta, A., 5707
Kamidono, S., 6012
Kamijo, T., 2177
Kamiyama, Y., 950
Kampinga, H. H., 1585
Kamps, W. A., 7654
Kamsler, A., 1849
Kan, M., 5295
Kaneda, Y., 14, 5570
Kaneko, K., 5570
Kanematsu, T., 2732
Kang, G. H., 2847
Kang, H., 36
Kang, Y. J., 3382
Kanke, Y., 3913
Kannagi, R., 4620
Kanno, Y., 3925
Kanomata, N., 2177
Kantarjian, H., 2343
Kanthou, C., 4784
Kanto, T., 7563
Kantoff, P., 2533
Kantoff, P. W., 5420
Kantor, J., 2523
Kanwar, J. R., 1948
Kanwar, R. K., 1948
Kanyama, H., 14
Kanz, L., 6846
Kanzawa, T., 5796
Kao, C., 6012
Kao, C-H., 1412
Kao, G., 333
Kar, S., 7211
Karanikas, V., 3718, 4078
Karaskova, J., 3826
Karbach, J., 2055
Kärf, G., 8317
Kargman, S., 1733, 6131
Karimpour, S., 3486
Karkkainen, M. J., 1786
Karner, B., 5703
Karpanen, T., 1786
Karpenko, M. J., 8274
Karpf, D. B., 5453
Karpinski, S., 7282
Karrison, T., 2833
Karsan, A., 6788
Karsenty, G., 5652
Karsten, U., 4605
Karstens, J. H., 7608
Karumanchi, S. A., 1768
Karvinen, P., 5718
Kasahara, A., 7563
Kasahara, T., 4414
Kashmiri, S. V. S., 2523
Kasper, S., 2239
Kass, E., 206
Kast, W. M., 5499, 5857, 7861
Kastrinakis, N., 538
Kasumi, F., 445
Katakura, H., 4809
Kataoka, T., 23
Katayama, M., 1874
Kato, H., 1776, 5382
Kato, J., 8697
Kato, K., 445, 1592, 8401
Kato, T., 2129, 4459
Kato, Y., 4184
Katoh, H., 2500
Katsaros, D., 3425, 7811
Katsetos, C. D., 4287
Katsuda, K., 7855
Katsuki, M., 7627
Katsuoka, Y., 6060
Katula, K., 6487
Katzenellenbogen, B., 6089
Kaufman, H. L., 8520
Kaufmann, S. H., 739, 4258
Kaul, S., 3712
Kauraniemi, P., 8235
Kavallaris, M., 5803
Kawabata, Y., 725
Kawaguchi, H., 4244
Kawai, H., 1741, 6703
Kawai, J., 1144
Kawakami, K., 6194
Kawakami, M., 6194
Kawakami, Y., 2500, 7900
Kawakita, M., 4620
Kawamoto, S., 4966
Kawamura, K., 5366
Kawamura, K-i., 6548
Kawanishi, S., 2878
Kawano, K., 6459
Kawano, S., 5307
Kawano, Y., 1666, 4809
Kay, G., 4561
Kay, R., 8909
Kayano, H., 8371
Kayser, S., 4072
Kazim, L., 1747
Kazimirsky, G., 4612
Ke, Y., 4357
Keane, M. M., 4892
Kearney, L., 4666
Keating, M. J., 6640
Keck-Waggoner, C. L., 8068
Kedra, D., 5950
Keel, S., 4490
Keeney, G., 5895
Keeney, M., 4155
Kees, U. R., 59
Keiditsch, E., 1903
Keith, B. R., 7196
Keith, W. N., 27
Kelleher, D. K., 1358
Kelley, M. R., 2220, 5116
Kelloff, G., 7449
Kelloff, G. J., 2472
Kelly, G. M., 7056
Kelsey, K. T., 612, 3419, 3949
Kemmner, W., 4605
Kemp, C. J., 327
Kemp, P. R., 482
Kempinga, C., 7305
Kench, J. G., 8830
Kennedy, W. J., 1678
Kennett, R. H., 1073
Kenney, P. J., 5757
Kensler, T. W., 33, 103
Kenward, E., 8909
Keohavong, P., 6679
Kerbel, R., 462
Kerbel, R. S., 4837, 5090
Kern, S., 4923
Kern, S. E., 1833, 4320
Kern, S. G., 5974, 7388
Kern., S. E., 1299
Kerr, K., 1527
Kershaw, M. H., 7920
Kersting, M., 5905
Keshelava, N., 6185
Keshmeshian, M., 3212
Keski-Oja, J., 6511
Keskitalo, J. J., 4229
Kesler-Diaz, A., 3949
Kessler, H., 1781, 4526
Kesterson, N. K., 4982
Kew, M., 7803
Khalili, K., 4287
Khan, J., 3750
Khan, M. A., 4350, 5636
Khan, M. K., 2207
Khan, S. G., 3321
Khan, T., 2562
Khanna, C., 3750
Khare, P. D., 370
Khodjakov, A., 1038
Khokha, R., 1707
Kidd, L. C. R., 103
Kiefer, J., 1045
Kiefer, M., 6201
Kiess, W., 8601
Kiessling, R., 222
Kiewlich, D., 3660
Kiguchi, K., 6971, 8068
Kihara, C., 3544, 6474
Kim, D., 8164, 8787
Kim, D-H., 3419
Kim, H., 36, 4942
Kim, H. L., 2833
Kim, H. S., 4942
Kim, H. T., 931, 6665
Kim, H-Y., 6688
Kim, I. Y., 6665
Kim, J. A., 2031
Kim, J. I., 6688
Kim, J. S., 2838
Kim, J. W., 931
Kim, K. E., 2487
Kim, K-W., 3290
Kim, M., 813, 2124
Kim, M. S., 2261, 3290
Kim, N. K., 36, 4628
Kim, N-G., 36
Kim, P. N., 4253
Kim, S., 8164
Kim, S. H., 8062
Kim, S. U., 4809
Kim, S. Y., 4942
Kim, S-H., 7709
Kim, S-J., 931, 6665
Kim, T-Y., 6163
Kim, W. H., 2847
Kim, Y. H., 36
Kim, Y. S., 3472
Kim, Y. W., 6163
Kim, Y-I., 6912
Kim, Y-J., 3290
Kim, Y-S., 6938
Kimmelman, A. C., 4985
Kimsely, P., 526
Kimura, F., 2665
Kimura, H., 5366
Kimura, K., 5611
Kimura, S., 4365
Kinch, M. S., 2301, 3250
King, C. R., 7978
King, P. H., 2154
Kinghorn, A. D., 4030
Kingsbury, G. A., 7889
Kiningham, K. K., 6082
Kiniwa, Y., 7900
Kinnunen, P. K. J., 3978
Kinoshita, H., 1843
Kinsella, T. J., 5193, 8290
Kinsey, B., 1699
Kinzler, K. W., 256, 818, 3801, 6649, 6996, 7798
Kipps, T. J., 2870, 6640, 7248
Kirchgessner, C. U., 2649
Kirchhoff, S., 7148
Kirchmayr, R., 7118
Kirchner, T., 8089
Kiriyama, Y., 6755
Kirk, C. J., 2062, 8794
Kirkels, W. J., 1265
Kirley, S. D., 7325
Kirma, N., 1910
Kisby, G. E., 5552
Kish, P. E., 2162
Kishi, K., 3188
Kishi, Y., 1013
Kishida, T., 7277
Kisker, O., 7298, 7669
Kita, D., 7985
Kitagawa, N., 8401
Kitahara, O., 2129, 3544, 6474
Kitajima, S., 7044
Kitano, S., 2145
Kitao, Y., 4206
Kitayama, W., 1451
Kitazono, M., 6328
Kitchener, H. C., 192
Kittas, C., 538
Kittrell, F. S., 6945
Kiyatkin, N., 8127
Kiyomiya, K-i., 2467
Kjaergaard, J., 2031
Klaar, S., 2256, 8317
Klar, U., 5790
Klatzmann, D., 2386
Kleeff, J., 4655, 5562
Kleihues, P., 2759

* *For title of article and coauthors, see listing in Contents of Volume 61 beginning on page 9015 at the end of this index issue.*

Kleinerman, E. S., 3394, 4066
Kleinman, H. K., 4253
Klein-Szanto, A. J., 3961
Klenner, T., 392, 6925
Klenova, E. M., 6002
Kletsas, D., 538
Klijn, J. G. M., 278, 1421
Klimek, F., 608
Klimp, A. H., 7305
Kline, K., 6569
Klinken, S. P., 2453
Klitzman, B., 7964
Klivényi, G., 3712
Klöpper, K., 7608
Klungland, A., 5378
Kluth, M., 550
Knaus, R., 6925
Kneba, M., 1629
Knecht, R., 1045
Knight, W. B., 7196
Knippers, R., 1659
Knönagel, H., 4514
Knop, J., 8643
Knudsen, S., 2492
Knudson, C. M., 659
Knuth, A., 2055
Ko, Y., 4398
Kobayashi, H., 2788, 4773, 4966, 7577
Kobayashi, M., 6548
Kobayashi, Y., 8401
Köbel, M., 303
Kobune, M., 5116, 8697
Koch, A., 7039
Koch, C. J., 2289
Koch, D., 1976
Koch, P., 3330, 5941
Koch, W., 939
Koch, W. M., 7015
Kodama, S., 5396
Kodama, T., 889
Koeffler, H. P., 647, 3361, 3770, 5307, 8917
Koehl, G., 5575
Koeneman, K. S., 7310
Koeppen, H., 7291
Koga, K., 6248
Koga, M., 6459
Koga, S., 5796
Kogan, S. C., 3472
Koh, J., 3863
Koh, N., 1843
Kohl, N. E., 8758
Köhler, T., 8005
Kohlhagen, G., 504, 1964
Kohn, L. D., 6105
Kohno, H., 2424
Kohno, K., 469, 1592
Koike, K., 3361, 4365
Koivisto, P. A., 6038
Koivunen, E., 3978
Koizumi, K., 2676, 8527
Kojima, S., 7675
Kokkinakis, D. M., 4017
Kokoris, M. S., 3022
Kokotas, S., 538
Kolachana, P., 8351
Kolb, H. J., 8601
Koliopanos, A., 4655
Kolitz, J. E., 7233
Kollender, G., 8880
Koller, B. H., 6577
Kolluri, S. K., 4723, 8534
Kolodner, R. D., 7934
Kolonel, L. N., 785, 848, 3326, 8393
Komata, T., 5796
Komatani, H., 2827
Komatsu, S., 1144
Komatsu, Y., 4459
Komiyama, A., 3361
Komiyama, T., 7298
Komminoth, P., 5186
Kondo, A., 1508, 7603
Kondo, S., 5796
Kondo, Y., 5796
Kong, G., 3027
Kong, G. A., 1548
Kong, S., 1269
Konishi, F., 445
Konishi, J., 4966
Konishi, N., 6335
Konishi., Y., 1451
Konopka, T. E., 3182
Kool, M., 2552
Koomagi, R., 3119, 8158
Kooner, R., 5331
Koper, J. W., 3937
Kopitz, C., 1272
Korach, K. S., 6089
Korc, M., 5562
Korch, C., 6340
Koren, R., 1439
Korgaonkar, C., 3145
Kornblau, S. M., 3355
Körner, G., 2517
Korotkov, K. V., 2307
Korourian, S., 7130
Korsmeyer, S. J., 659
Korz, D., 921, 2782
Koshikawa, N., 6322
Kosmehl, H., 711
Kostenuik, P. J., 4432
Kotani, H., 2827
Kotcherguina, L., 3262
Kotera, Y., 8105
Kotsinas, A., 538
Kotzor, N., 8089
Koukourakis, M. I., 1830, 7992
Koul, D., 6693
Koul, S., 2119
Kovacs, G. R., 7861
Kovalsky, O., 2487
Kovar, H., 5992
Kovatich, A., 462
Kowalski, D., 3787
Kozin, S. V., 39, 4740
Krackhardt, A. M., 4761
Kraemer, K. H., 3321
Kraker, A., 8211
Kral, A. M., 8758
Kramer, A., 1227
Kramer, D. L., 6437, 7754
Kramer, E., 2996
Kramer, K., 4048
Kramer, R. A., 7507, 8480
Krammer, P. H., 243, 1846, 7148
Krasnykh, V., 2953
Krebs, I., 8880
Kreczy, A., 2513
Kreimann, E. L., 8638, 8775
Kreitman, R. J., 5070
Kremmer, E., 2804
Kremsdorf, D., 7803
Kremser, C., 2513
Kresty, L. A., 6112
Krett, N. L., 5474
Kreuzer, K-A., 2517
Kreye, E., 6098
Kripke, M. L., 215
Krishnan, S. S., 6367
Krissansen, G. W., 1948
Kristo, P., 4545
Krithivas, K., 5420
Krivak, T. C., 4382
Kroemer, G., 1260
Kroesen, B-J., 4105
Kröger, A., 2609
Krogh, T. N., 957
Krohne, T. U., 2609
Kronenberg, A., 1129
Kronfeld, I., 4612
Krop, I. E., 5697
Krueger, A., 7148
Krüger, A., 1272
Kruh, G. D., 7225
Kruhøffer, M., 2492
Krull, E. J., 3045, 5083
Kruszewski, M. P., 1477
Krynetski, E. Y., 5810
Krystal, G., 2453
Krystal, G. W., 3660
Krzic, M., 4266
Kuba, K., 7518
Kubo, H., 1786
Kubo, S., 1843
Kubota, S., 8486
Kubota, T., 3770
Kucherlapati, R., 565, 6297, 7934, 8520
Kudo, Y., 7044
Kudoh, S., 8527
Kuehl, P. M., 6046
Kuemmerle, N. B., 764
Kufe, D. W., 4061
Kügler, K., 647
Kügler, S., 5833
Kühne, M., 3886
Kuick, R., 6885
Kuismanen, S., 7798
Kuismanen, S. A., 1619, 2813
Kulesz-Martin, M. F., 5402
Kulik, G., 2713
Kuliopulos, A., 5933
Kumagai, M., 5028
Kumamoto, K., 4620
Kumar, A., 6958, 7552, 8611
Kumar, C. C., 2232
Kumar, M. V., 7179
Kumar, R., 81, 400
Kumaravel, T. S., 1493
Kumon, H., 4671
Kung, J. W., 943
Kunhi, M., 3627
Kunkel, P., 6624
Kunkel, R., 228
Kuno, T., 1874
Kunugi, S., 8527
Kunwar, S., 7683
Kunz, D. P., 1747
Kuo, C. B., 6098
Kuo, C. T., 8845
Kuo, J., 1686, 5499
Kuo, L., 1100
Kupper, T. S., 3619
Kuraguchi, M., 3465, 7934
Kuramoto, H., 3741
Kurashige, T., 4671
Kurebe, M., 2467
Kurihara, N., 8381
Kurimoto, F., 8527
Kuriyama, H., 1805
Kuriyama, N., 1805
Kurnit, D. M., 2162, 6885
Kuroda, M., 5707
Kuroda, M. J., 8366
Kuroiwa, G., 8697
Kuroki, Ma., 370
Kuroki, Mo., 370
Kuroki, T., 4591
Kurumboor, S. K., 3410
Kurusu, M., 6356
Kurzrock, R., 2343
Kusama, T., 4885
Kusec, R., 1629
Kushnir, T., 4873
Kust, G. A., 4311
Kustin, E. M., 6723
Kusunoki, M., 1029
Kutko, M. C., 3591
Kuwada, N., 2665
Kuwano, M., 469
Kuzmenko, A. I., 7777
Kuznetsov, G., 1013
Kuzushita, N., 7563
Kwon, C-H., 4569
Kwon, E. D., 5857
Kwong, E., 1733, 6131
Kwong, J., 3877
Kyo, S., 5796
Kyprianou, N., 1227
Kyriakopoulou, L. G., 7811
Kytölä, S., 1214

## L

Laakkonen, L. J., 3978
Labra, S., 2542
Lacey, D. L., 4432
Lackey, K., 7196
Laco, G., 504
Laco, G. S., 1964
Lacombe, M-J. T., 6838
Lacour, S., 1645
Lacroix, F. B., 7660
Ladanyi, M., 6892
Laderoute, K. R., 2696
LaFace, D., 8227
Lafanechère, L., 5024
Laflamme, N., 5869
Lafleur, E. A., 4066
Laflin, K. J., 8068
Lafrenière, R. G., 7217
Laghi, L., 2676
Lahm, H., 8601
Laiho, P., 4545
Laird, P. W., 3410, 5875
Laissue, J., 2911
Lakhter, A. J., 5601
Lakkakorpi, P. T., 4229
Lakshmanan, R. R., 1327
Lal, G., 6131
Lam, D. H., 6382
Lam, E. W-F., 8005
Lam, K. S., 3308
Lam, S., 3581
Lamartiniere, C. A., 6777
Lamb, C. A., 293
Lambert, L. A., 641
Lamberts, S. W. J., 3937
Lamborn, K. R., 1122, 1805, 7683
Lamparelli, M. G., 1983
Lampe, J. W., 3566
Lamph, W. W., 5919
Lamszus, K., 6624
Lan, F., 7383

** For title of article and coauthors, see listing in Contents of Volume 61 beginning on page 9015 at the end of this index issue.*

Lanari, C., 293
Lander, A. D., 5562
Landesman-Bollag, E., 3810
Landi, S., 6679
Landis, D. M., 666
Landré, J., 7501
Lane, M. E., 6170
Lang, F. F., 4375
Langdon, S. P., 2169
Lange, C. W., 4723
Langenberg, P., 6046
Lango, M. N., 5919
Lanotte, M., 700
Lantvit, D., 4030, 7456
Lantz, J., 1477
Lapcevich, R. K., 1022
Lapointe, P., 8703
Lapointe, R., 7920
Lapp, H., 7388
La Quaglia, M. P., 3591
Larocca, L. M., 4272
LaRochelle, W. J., 3131
Larsen, A. K., 2961
Larson, R. A., 7233
Larson, S. M., 2983
La Russa, V. F., 6931
LaRusso, N. F., 6388
Lass, U., 2517
Latella, L., 4990
Latif, F., 7277
Latil, A., 1919
Lau, A. W. S., 1598
Lau, N., 3826, 4425
Laucirica, R., 261
Lauer, F. T., 3314
Lauer, S., 7268
Laug, W. E., 5587
Launonen, V., 4545
Laurent, E., 2343
Laurent, G., 2558
Laurent-Puig, P., 8595
Laus, C., 7830
Laus, R., 3760
Lavergne, O., 2961
Laverty, F. S., 6730
Lavigne, J. A., 7488
Lavin, M. F., 4561
Lawler, J., 7830
Lawler, P., 7830
Lawrence, L., 3653
Lawrence, T., 8211
Lawrence, T. S., 7585
Lawry, J., 3157
Lawson, S., 8547
Laxmi, Y. R. S., 3925
Lazarovici, P., 3002
Lazo, J. S., 7211
Lazzari, M., 1555
Le, T., 1629
Le, X., 71, 4143
Leach, J. K., 3894
Leach, S. D., 4320
Leavitt, J., 4405
LeBaron, R. G., 926
Lebel, M., 1816
LeBien, T. W., 5268
Le Bouc, Y., 6762
Le Bourhis, X., 76
Lechevallier, E., 1196
Lechner, K., 1629
Leclere, A., 303
Le Dai, J., 5558
Leder, P., 1816
Le Doussal, V., 1652
Lee, A., 333
Lee, A. J., 5764
Lee, A. V., 5771
Lee, B., 5070, 8122
Lee, B. I., 931
Lee, C. S., 423
Lee, C-H., 6688
Lee, C-S., 1280, 5331, 7110, 8830
Lee, C-T., 6163
Lee, E., 2381
Lee, E-S., 3632
Lee, F. S., 4136
Lee, F. Y. F., 7507
Lee, F-T., 4474
Lee, H., 2799, 4467
Lee, H-P., 3326
Lee, H-Y., 6693
Lee, I., 5630
Lee, J., 5453, 5895, 8751
Lee, J. C., 2974
Lee, J. H., 4942
Lee, J. I., 837
Lee, J. Y., 4942
Lee, J-H., 8322
Lee, J-K., 6255
Lee, J-N., 8390
Lee, J-W., 984
Lee, K. Y., 6755
Lee, K-K., 984
Lee, M. V., 2602
Lee, M-G., 6688, 7034
Lee, M-S., 3290
Lee, N., 7217
Lee, N. H., 7792
Lee, P. K., 842
Lee, S. B., 8062
Lee, S. H., 4942
Lee, S. J., 3084
Lee, S. K., 4942
Lee, S. N., 4942
Lee, S. P., 6219
Lee, S. W., 1386
Lee, S-J., 6688
Lee, S-K., 8164
Lee, S-W., 3290
Lee, T-H., 984
Lee, W. M. F., 2974, 7747
Lee, W-C., 4238
Lee, W-H., 3110, 7878
Lee, W-J., 5389
Lee, Y. K., 4258
Leek, R., 5262
Leeper, D. B., 5630
Leet, C., 7426
Leggett, B. A., 827, 6046
Lei, L., 1354, 7825
Lei, R. Y., 880, 3689
Lei, X., 8361
Leid, M., 4723
Leigh, J. S., 7747
Leino, R. L., 771
Leitner, W. W., 8100
Leland, P., 8058
Lele, S., 7556
Lemière, S., 1717
Lemoine, J., 76
Lemonnier, L. A., 6723
Lempereur, L., 3002
Le Naour, F., 7908
Lenferink, A. E. G., 6583
Lengauer, C., 818
Lennerstrand, J., 2256
Lenz, H-J., 8654
Lenz, J., 8643
Lenz-Stöppler, C., 5941
Leon, J., 6002
Leon, L., 3171
Leonard, S. S., 8051
Leoncini, L., 462
Leong, K. G., 6788
Leoni, L. M., 7248
Leopold, W. R., 8211
Leppert, M., 1000
Lerman, M. I., 8924
Lesueur-Ginot, L., 2961
Letvin, N. L., 8366
Leung, K. M., 1598
Leung, T. W., 5998
Levan, G., 8263
Levenson, A. S., 6619
Lévi, F., 1996
Levin, W., 6400
Levine, A. J., 3124
Levine, B., 3443
Levine, D. A., 908
Levine, J. E., 8513
Le Voyer, T., 8866
Levy, D., 2381
Levy, R., 7363
Lewalle, J-M., 3450
Lewin, A. C., 8480
Lewis, J. J., 3171
Lewis, R. W., 7179
Li, B., 1280, 8014
Li, C., 4561, 8150
Li, C-Q., 778
Li, C-Y., 428, 3281
Li, D., 1445, 8465
Li, F. P., 8062
Li, G., 3819, 4098, 4974, 7318
Li, H., 3450, 4723, 8361
Li, H-C., 4253
Li, Jia., 1138
Li, Jing., 8051
Li, Jinj., 7383
Li, Ju., 8211
Li, J-N., 1493
Li, L., 2390, 3882, 4386, 4591, 6783, 6977, 7417
Li, M., 478, 1666
Li, S., 2376, 5491, 7464
Li, S-F., 1178
Li, T-K., 5926
Li, W. W., 2579
Li, X., 186, 6679
Li, X. Y., 1699
Li, X-C., 4143
Li, Y., 517, 3281, 5453, 6428, 6592, 6906
Li, Y. F., 1089
Li, Y-Q., 3348
Li, Y-X., 1065
Li, Z., 1765
Li, Z-Y., 5911
Liang, C., 3660, 6170
Liang, G., 5875
Liang, R., 6945
Liang, X. H., 3443
Liang, Y., 7179
Liao, J. C., 1100
Liao, Q., 4655
Liao, Q. Y., 6569
Liao, S-Y., 8924
Liaw, Y-F., 4238
Libbrecht, L., 4916
Liberman, U. A., 1439
Libutti, S. K., 8751
Lichenstein, H. S., 3131
Lichtlen, P., 2696
Lichtner, R. B., 5790
Lidar, Z., 4971
Liddle, C., 749
Lidereau, R., 1652, 1919
Liebes, L., 2996
Liekens, S., 5057
Lien, H-C., 237
Liénard, D., 509, 2047, 5850
Lillehaug, J. R., 2505
Lillie, J., 5895
Liloglou, T., 538, 1624
Lim, C-K., 1058
Lim, E., 4030
Lin, A., 2833
Lin, B., 1611
Lin, C-H., 4238
Lin, D., 3272
Lin, H., 138
Lin, H. Z., 5016
Lin, J., 4982
Lin, P., 4974
Lin, P. C., 2413
Lin, P-S., 3894
Lin, R-H., 237
Lin, S-H., 138
Lin, S-M., 6082
Lin, T-Y., 2727
Lin, X., 1508, 7603, 8611
Lin, Y., 659, 4010, 5002, 6406
Lin, Y-M., 6345
Lin, Z. P., 1469
Linardakis, E., 7240
Lindahl, T., 2256
Lindblom, A., 1619, 7798
Linderholm, B. K., 2256
Linehan, W. M., 8143
Ling, M., 1080, 3698
Ling, N., 1432
Lingner, J., 7594
Linja, M. J., 3550, 5340
Linkesch, W., 2335
Linnekin, D., 2453
Linton, H. J., 6958
Liotta, L., 2212
Liotta, L. A., 5636, 6938
Lipkin, M., 565, 7934, 8381
Lipkin, S. M., 7020
Lipkowitz, S., 4892
Lippman, M. E., 5284
Lippman, S. M., 2720, 4306, 4879, 6307
Lippolis, J. D., 873
Lipsky, P. E., 602
Lipson, K. E., 3660, 6170
Lisk, D., 2923
Liskay, R. M., 3775
Lissandrini, D., 285
Litman, T., 6635
Little, J. B., 428
Littlefield, B. A., 1013
Litwack, G., 8930
Liu, B., 1754, 6377, 7020
Liu, D., 837, 8758
Liu, E. T., 4797
Liu, G., 5749, 8718
Liu, H., 459, 3632, 6619
Liu, H-L., 5168
Liu, J., 138, 455, 2183, 3949, 6860, 6906
Liu, L., 3961
Liu, L. F., 5926
Liu, L. N., 3373
Liu, M., 2232


** For title of article and coauthors, see listing in Contents of Volume 61 beginning on page 9015 at the end of this index issue.*

Liu, N., 1022, 2434, 5207
Liu, R., 3535
Liu, T., 1619, 7798
Liu, T-J., 1412, 6693
Liu, V. W. S., 5998
Liu, W., 1255, 1464
Liu, W. M., 526
Liu, W-C., 1129
Liu, X., 348, 1107, 3009
Liu, Y., 1107, 3194, 5402, 6795, 6860
Liu, Y. E., 2365
Liu, Z., 4474
Lizard-Nacol, S., 7955
Ljubimov, A. V., 5601
Ljubimova, J. Y., 5601
Llansa, N., 2720
Lo, D. Y., 3281
Lo, K-W., 3877
Lobanenkov, V. V., 4947, 6002
Lobell, R. B., 8758
Löber, C., 5941
Løberg, E. M., 5010
Lobl, T. J., 2843
Löbrich, M., 3886
Lo Celso, C., 5861
Locher, A., 7616
Locke, J. E., 3486
Lo Coco, F., 2
Lode, H. N., 6178
Loeb, D. M., 921, 2782
Loeb, L. A., 666, 3230
Loftus, J. C., 7079
Logothetis, C. J., 5652
Logue, J. P., 6394
Lohez, O. D., 7660
Lohmann, D. R., 3439
Lohr, F., 3281
Löhr, M., 550
Lohuizen, M., 2409
Loi, R., 2085
Loignon, M., 3781
Lokeshwar, B. L., 4294
Loksh, A., 5601
Loktionova, N. A., 53
Lollini, P. L., 2809
Lombardo, C., 4675
Loncaster, J. A., 2907, 6394
Long, H., 7878
Long, L., 8520
Long, M. W., 6487
Long, S., 1820
Long, T. I., 3410
Longhino, J., 8638
Longton, G., 8284
Löning, S. A., 5215
Löning, T., 6682
Lønning, P. E., 2505
Lönnroth, C., 4707
Look, M. P., 1421, 5407
López, J. M., 7091
Lopez-Hernandez, F. J., 8504
López-Otín, C., 7091
Loponen, N. T., 4229
Lord, R. V., 3410
Lorenz, M., 3053
Lorenzi, M. V., 8703
Lorenzo, P. S., 943, 4612
Lorimer, D., 6276
Losi, L., 896
Lossos, I. S., 7363
Lotan, R., 556, 4306, 4879, 6698, 7999
Lotrian, D., 45
Lotze, M. T., 363, 884, 2625
Lou, G., 3735
Lou, Y-R., 5002
Loubat, A., 7785
Louis, D. N., 6713
Louis, H., 76
Loukinov, D. I., 6002
Loukinova, E., 4797
Loukola, A., 4541, 4545
Louvel, A., 6762
Lo Vullo, S., 4675
Lowenstein, C. J., 3682
Lu, D., 6755, 7002
Lu, H., 3450
Lu, J., 3062, 6112, 7171, 7577
Lu, K., 5895
Lu, P., 33
Lu, S-I., 4561
Lu, Y., 5486
Lu, Y. Y., 5985
Lu, Y-P., 5002
Luan, J., 8150
Lubet, R., 7449
Lubet, R. A., 2472
Lubomierski, N., 5905
Lucas, S., 5544
Lucini, V., 7501, 8730
Lücke, C. D., 482
Ludeman, S. M., 864
Ludwig, A., 3053
Ludwig, L., 4526
Luger, N. M., 4038
Luk, P., 1733
Lukas, C., 4990
Lukas, J., 3212, 4990
Lukas, P., 2513
Luke, A., 2307
Luker, K. E., 6540
Lukes, L., 8866
Lumma, W. C., 8758
Luna, M. C., 6185
Lund, L. R., 7091
Lundholm, K., 4707
Lunec, J., 8
Luo, J., 4683
Luo, J-L., 1058, 8158
Luo, W., 138
Lurkin, I., 1265
Luthra, R., 1269
Luthra, S. K., 2935
Lüthy, I., 293
Luton, J-P., 6762
Lutterbaugh, J. D., 256, 900
Lutz, M. P., 3508
Luwor, R. B., 5349, 5355
Lux, M. L., 8118
Lynch, H. T., 5420, 7020
Lynch, I. J., 632
Lynch, M., 7507
Lynch, P. M., 1269
Lynch, T. J., 8718

## M

Ma, D., 2008
Ma, J., 5491, 6708
Ma, K-N., 126
Ma, W-Y., 850, 1604, 3908, 4084, 5749
Mabuchi, H., 2870, 6640
Macasieb, J., 7473
MacDermed, D., 145
Macdiarmid, J., 6730
MacDonald, C. J., 3919
Mach, D. B., 4038
Mach, J-P., 7971
Mach, N., 162
Machado, J., Jr., 4978, 5688
Machida, E., 2226
Machida, K., 2361
Machiels, J-P. H., 880, 3689
Machluf, M., 8730
Machotka, S. V., 8758
Mackey, J. R., 7217
MacKoul, P. J., 4382
MacLeod, C. L., 8298
Macleod, K. G., 2169
Macoska, J. A., 2390
MacPhail, S. H., 8924
Madeleine, M. M., 1934, 8459
Madelmont, J. C., 2294
Madrigal, J. A., 5145
Madsen, J., 8880
Maecker, B., 8366
Maeda, H., 5432
Maehara, N., 7518
Maestre, N., 2558
Magalhães, I. Q., 2542
Magdolen, V., 1272
Magee, J. A., 5692
Magener, A., 3712
Magill, E., 4599
Magklara, A., 3425
Maglione, J. E., 8298
Magné, N., 7785
Magno, R. M., 2399
Magnusson, P. K. E., 2684
Magrath, I. T., 5028
Magro, G., 339
Maher, E. R., 5215, 7277
Maher, G. W., 8624
Mahler, Y. Y., 2953
Mahmoud, N. N., 2547
Mahon, F-X., 8005
Mai, J. C., 7709
Maier, S. E., 4971
Maihle, N. J., 4467
Mailand, N., 4990
Mailliard, R. B., 884
Mair, M., 2320
Maitra, A., 3581, 3795, 7943
Majewski, M., 2194
Majima, H., 6082
Majima, H. J., 5382
Mak, T., 6131
Mak, T. W., 8395
Makarov, V., 1406
Mäkelä, S., 2537, 5331
Makino, K., 2838, 7413
Makishima, K., 1592
Makuuchi, M., 6805
Malcolm, A. J., 8
Malhotra, R., 2212
Maliepaard, M., 739, 3458
Malikzay, A., 7030
Malins, D. C., 6025
Malkowski, M., 2232
Mall, J., 8416
Maloney, M., 641
Maloney, P., 1624
Mami-Chouaib, F., 4078
Manchul, L., 6400
Mancini, M., 2
Mancuso, P., 4341
Mandahl, N., 8241
Mandava, U., 1910
Mandil, R., 4612
Manfredi, A. A., 3092
Mang, C., 1781
Manika, Z., 8381
Manivel, J. C., 2857
Mann, A., 2311
Mann, J. R., 8547
Mann, S., 6331
Manne, V., 7507
Männel, D. N., 5523
Manner, C. K., 8298
Mannhalter, C., 1629
Manning, S., 497
Mannucci, R., 1699
Manos, E. J., 433
Manova, K., 1941
Mantyh, P. W., 4038
Manusukhani, M., 2119
Manzi, A., 5741
Mao, J-H., 1305
Mao, L., 837, 7417, 7959
Marabese, M., 935
Marani, M., 186, 1699
Marcelli, M., 186, 1699
Marchesi, E., 5468
Marchini, S., 935, 1983, 1991
Marcucci, G., 59
Marculescu, R., 1629
Marcus, A., 8520
Mardor, Y., 4971, 7536
Margan, S. H., 6331
Margolis, R. L., 7660
Margolis, R-L., 5024
Mariadason, J., 6297
Mariadason, J. M., 3465
Mariani, L., 4190, 4675
Mariatos, G., 538
Marincola, F. M., 6868
Marini, F. C., III, 3355
Marinier, A., 8703
Maris, J. M., 679
Mark, E. J., 612, 3419
Marker, K. M., 6958
Markl, I. D. C., 5875
Markovina, S., 7689
Markowitz, S., 256
Markowitz, S. D., 900, 3801
Markowski, M., 5611
Marks, A. F., 6494
Marks, D. L., 1432
Marks, J., 2782
Marks, J. D., 4750
Marks, J. R., 5697
Marks, P. A., 3591, 8492
Maron, A., 3450
Marongiu, A., 608
Marra, G., 7616, 7719
Marsh, S., 5505
Marsiglio, A., 1991
Martial, J., 7356
Martin, E. W., Jr., 6991
Martin, M. D., 3578
Martin, P. J., 5126
Martin, P-M., 1196, 1421
Martín-Caballero, J., 6234
Martinelli, G., 4341
Martinez, A., 7277
Martinez, L. A., 5652
Martin-Hirsch, P., 192
Martini, J-F., 7356
Martone, T., 2200
Martuza, R. L., 153, 3009
Maru, Y., 1207
Maruyama, H., 5562
Maruyama, R., 5727, 8659
Masada, I., 5741

** For title of article and coauthors, see listing in Contents of Volume 61 beginning on page 9015 at the end of this index issue.*

Masala, G., 5415
Mason, D. Y., 8820
Mass, M. J., 6679
Massagué, J., 256
Massobrio, M., 7811
Masson, R., 2189
Masuda, A., 5362, 8331
Masuda, T., 7379
Masumori, N., 2239
Masumura, K-i., 3913
Masunaga, Y., 7913
Masur, K., 2866
Matar, M., 859
Matarese, F., 6360
Mateyak, M. K., 1178
Mathew, C. G., 1171
Mathew, J., 565
Mathieu, Y. D., 7594
Matias-Guiu, X., 2816
Matikainen, M. P., 6038
Matin, S. F., 2261
Matrisian, L. M., 2097, 3844
Matsubara, N., 4345, 7743
Matsubara, S., 6012, 7882
Matsuda, A., 178, 8371
Matsuda, K., 5562, 8256, 8527
Matsuda, M. M., 5289
Matsuda, S., 2361
Matsumoto, K., 7518
Matsumoto, M., 2827
Matsumoto, T., 6459, 6971
Matsumoto, Y., 4885, 5562
Matsumura, T., 2665
Matsunaga, K., 1874
Matsunaga, T., 7009
Matsuno, F., 7846
Matsuo, S., 2467, 8486
Matsuoka, S., 5362
Matsuoka, Y., 2395
Matsura, T., 7777
Matsushima-Nishiu, M., 3741
Matsushima-Nishiwaki, R., 7675
Matsuura, I., 6158
Matsuyama, A., 5714, 7379
Matsuyama, S., 1896
Matsuzuka, F., 1382
Matter, C., 5186
Matthews, D. C., 5126
Matthey, B., 8737
Matusik, R. J., 497, 2239, 6795
Matzner, I., 5179
Maurer, B. J., 5102
Maurer, R., 4514
Maurice, M. A., 3388
Mauro, L., 6747
Maxwell, P. H., 5215
Maxwell, R. J., 5318
Maya, R., 7635
Mayer, C., 3619
Mayers, I., 376
Mayne, K., 926
Mayne, S. T., 1457
Mayo, J. G., 4030
Maytin, E. V., 7155
Mayumi, T., 7913
Mazumdar, A., 81, 400
Mazumder, A., 3009
Mazure, N. M., 2429
Mazzara, G., 206
Mazzarelli, P., 7015, 7623
Mazzocchi, A., 222
McBride, W. H., 8782, 8787, 8859
McBroom, J. W., 4382
McCaig, A., 2169
McCall, A. M., 4750
McCallum, B., 1171
McCart, J. A., 8751
McCarthy, D. J., 2453
McCarthy, M., 1820
McClure, G. Y., 7130
McCollum, E. D., 4791
McConkey, D. J., 1464, 7048
McConville, C. M., 8547
McCormick, F., 854, 4445, 5959
McDevitt, M. R., 2008
McDonnell, D. P., 2917, 8712
McDonnell, S. K., 6494
McDonnell, T. J., 6693
McDonough, W. S., 4190
McDougal, A., 3902
McDougall, J. K., 1934
McElhiney, S., 7861
McGlynn, K. A., 4333
McHardy, L. M., 6788
McHowat, J., 4024
McIlrath, J., 912
McInistry, R., 5106
McIvor, R. S., 1522
McKean-Cowdin, R., 785, 848, 8393
McKeehan, W. L., 5295
McKenna, E. A., 8513
McKenna, W. G., 2289, 4278
McLaughlin, J. C., 228
McLaughlin, P. M. J., 4105
McLean, G. W., 8385
McLellan, L. I., 3299
McLendon, R. E., 3556
McLeod, H. L., 5505
McMahill, M., 439
McMahon, G., 1464, 2413, 3660, 6170, 7048
McMahon, M., 3299, 4956
McMarlin, A., 6938
McMenamin, M. G., 5636
McNeal, J. E., 2852
McNeel, D. G., 5161
Meccia, E., 6532
Meck, M. M., 5083
Mecklin, J-P., 1619, 4545
Medico, E., 5861
Medina, D., 261, 6945
Medina, O. P., 3978
Medina-Pérez, W. Y., 6635
Medof, M. E., 654
Medrano, E. E., 8074
Meehan, K. R., 3009
Meek, J. E., 1619
Meeuwsen, T., 7654
Mega, T., 2267
Mege, F., 7955
Megyesi, J. F., 6713
Mehew, J. W., 5202
Mehta, R., 2307
Mehta, R. G., 7456
Mei, J. M., 1810
Meier, R., 7616
Meijer-van Gelder, M. E., 5407
Meira, L. B., 5552
Melana, S. M., 1754
Melcher, A. A., 7240
Melese, T., 4175
Melillo, R. M., 1426
Melman, M. P., 6382
Melo, J. V., 8005
Meloen, R. H., 2552
Meltzer, P., 3750
Meltzer, P. S., 5979, 6322, 8624
Meltzer, S. J., 2399, 2816, 6046
Melzer, K., 7642
Memin, E., 6055
Mendelsohn, J., 6500
Mendez, R., 5558
Mendiratta, S. K., 859
Menetrier-Caux, C., 3096
Meng, L., 2250
Meng, W. S., 8782, 8787
Meng, X., 3267
Menigatti, M., 896
Menke, A., 3508, 4222
Menna, P., 8422
Menoyo, A., 7727
Menrad, A., 5790
Menter, D. G., 2720
Mentor-Marcel, R., 6777
Merani, S., 293
Mercurio, A. M., 5736
Mercurio, F., 3810
Merlini, L., 7189
Merlo, A., 4978, 5688
Mermelstein, S. J., 474
Mernaugh, R. L., 6716
Merrill, A. H., Jr., 6723
Mesri, E. A., 2641
Metcalf, J., 4112
Metcalfe, J. C., 482
Metzelaar-Blok, J. A. W., 5303
Metzger, R., 647
Meydani, A., 5933
Meyer, D. E., 1548
Meyers, C., 4858
Meyers, M., 5193
Mi, Q., 4030
Mi, Z., 7709
Mialhe, A., 5024
Miao, W-M., 7830
Micheli, P., 462
Michigami, T., 1637
Miederer, M., 2804
Mihatsch, M. J., 4514
Mihich, E., 2788
Miike, R., 3949
Mikami, T., 19
Mikhak, B., 7464
Miki, H., 5570
Miki, K., 6805
Miki, T., 673
Mikkelsen, R. B., 3894
Mikolajczyk, S. D., 6958
Milano, G., 7785
Milbrandt, J., 5692
Milchgrub, S., 3581
Millar, D. S., 6331
Millar, L. S., 6958
Miller, C. W., 3770, 5307
Miller, D. C., 2124
Miller, D. P., 8718
Miller, E. P., 6977
Miller, G. J., 6340, 7122
Miller, J. L., 7155
Miller, K. D., 3369
Miller, L., 5644
Milliken, D., 4961
Millis, R., 1171
Mills, G. B., 1862, 5486, 5529, 5895, 7204, 7825
Mills, L. H., 5764
Milosevic, M., 6400
Milowsky, M. I., 3294
Milyavsky, M., 88
Mimari, D., 6239
Mimori, K., 1578, 7379
Mimura, J., 5707
Min, H-Q., 5950
Min, J. S., 36
Min, W., 526
Minagawa, R., 1005
Minaguchi, T., 3741
Minami, S., 2732
Minami, T., 1305
Minami, Y., 7950
Minchenko, D. A., 2459
Miner, J. H., 5601
Minghelli, S., 5441
Minimo, C., 462
Minna, J. D., 249, 3581, 4556, 5727, 7819, 7943, 8659
Minotti, G., 8422
Minucci, S., 2
Miotto, G., 7495
Miranda, C., 376
Miranda, G. A., 8782, 8787
Mirbod, P., 3119
Misek, D. E., 2162, 6885
Mishima, K., 5349
Mishima, M., 1508, 7603
Mishima, Y., 4414
Mishina, T., 2500
Misko, I., 4561
Missiaglia, E., 285
Mistro, D., 1260
Mistry, P., 749
Mita, K., 5885
Mitchell, D., 4974
Mitchell, F., 3675
Mitelman, F., 8241
Mitlianga, P., 6693
Mitsiades, C., 2704
Mitsiades, N., 577, 2704, 4864
Mitsuuchi, Y., 589
Mitterbauer, G., 1629
Miura, Y., 2878, 6987
Miwa, N., 6345
Miyagawa, K., 23
Miyagi, T., 7563
Miyahara, R., 1666
Miyake, T., 8401
Miyamori, H., 8896
Miyata, H., 3188
Miyatake, S-I., 3969
Miyauchi, M., 7044
Miyazaki, A., 3640
Miyazaki, J-i., 1005
Miyazawa, T., 4365
Miyoshi, H., 4365
Miyoshi, Y., 14
Mizuguchi, H., 7913
Mizumoto, K., 7518
Mizutani, S., 2542
Moan, J., 5824
Moasser, M. M., 2945, 7184
Moch, H., 4514, 7277
Mochimaru, H., 8527
Mochizuki, M., 2632, 7739
Modak, S., 4048
Modestou, M., 3145
Mody, R., 1941
Moerland, E. W., 1171
Moesta, K. T., 991
Moffatt, K. A., 7122
Moghaddam, M., 4190
Moghanaki, D., 8298
Mogk, D. W., 4272
Mohapatra, G., 7683
Mohla, S., 3844, 4642
Mohler, J. L., 2892, 4315

** For title of article and coauthors, see listing in Contents of Volume 61 beginning on page 9015 at the end of this index issue.*

Mohr, L., 2609
Mohrenweiser, H., 1354
Mohsin, S. K., 3578
Moisio, A-L., 2813
Mok, S. C., 4169, 6768, 7264
Molina, C. A., 6055
Molina, M. A., 4744
Molinolo, A. A., 293
Mollenhauer, J., 8880
Mologni, L., 5468
Momburg, F., 1095
Monaco, C., 1426
Mondello, C., 4520
Monden, M., 14, 3188, 5570
Mondesire, W., 7920
Monestiroli, S., 4341
Moneta, D., 1983
Monia, B. P., 7079
Monni, O., 8235
Mononen, N., 6038
Monroe, K., 3326
Monroy-Garcia, A., 6281
Montaner, S., 2641
Monticello, T., 7507
Montmain, G., 3096
Monzo, M., 1309
Moon, E-J., 3290
Moon, H-B., 984
Moon, R. C., 7449, 7456
Mooney, D. J., 2183
Mooney, L. V. A., 6708
Moore, B. A., 6264
Moore, J. V., 192
Moore, J. W., 7349
Moore, P. S., 285
Moossa, A. R., 6805
Mora, J., 6892
Moreira, E. S., 7375
Moreira-Filho, C. A., 7375
Morelli, C., 6747
Moreno, V., 4589
Moretta, A., 3240
Morey, A. L., 8830
Morgan, C., 6112
Morgan, N. V., 1171, 5215, 7277
Morgans, D., 4175
Mori, A., 7840
Mori, H., 1874, 7699
Mori, I., 6060
Mori, K., 7913
Mori, M., 1578, 2145, 4414, 5714, 7379
Mori, Y., 6046
Morice, R. C., 7959
Morimoto, C., 7204
Morimura, K., 6964
Morin, P. J., 3869
Morini, M., 5441, 8171
Morioka, M., 6248
Moris, A., 4072
Morishita, Y., 7950
Moriuchi, A., 3016, 4779
Moriwaki, H., 7675
Moriya, K., 4365
Morkowski, S., 3760
Morony, S., 4432
Morotomi, M., 2395
Morrione, A., 2194
Morris, A. P., 2899
Morris, C., 6739
Morris, J. S., 4879
Morris, S. W., 2194, 6517
Morrisett, J. D., 3882
Morrison, A. J., 7394
Morrison, C. J., 3610
Morrison, K., 8909
Morrissey, C., 7277
Morrissey, M., 5895
Morrow, C. D., 8470
Morrow, C. S., 5461
Morse, H. C., III, 6002
Morse, M. A., 1233, 6112
Mortarini, R., 8218
Mortensen, R. M., 6213
Morton, C. L., 5078
Morton, D. L., 5723
Morvan, D., 2294
Moscinski, L. C., 6290
Moser, A. R., 3480
Moses, M. A., 2207, 5731
Moskal, J. R., 6822
Moskaluk, C. A., 5974, 7388
Mosnier, L. O., 977
Moss, B., 8751
Moss, P. A. H., 8547
Moss, S. F., 725, 1406
Mossalayi, M. D., 5289
Mossman, B. T., 1791
Mostofi, F. K., 4333
Mote, P. A., 4576
Motoori, S., 5382
Motoyoshi, K., 2665
Mottet, N., 1415
Moulder, S. L., 8887
Mouly, H., 7803
Mourateva, E., 3837
Mowles, D., 7217
Moyano, J. V., 8586
Moyer, J. D., 8683
Moyers, J. S., 2071
Moynahan, M. E., 4842
Moyret-Lalle, C., 486
Mrózek, K., 59, 616, 7233
Mucci, N. R., 2390
Mueller, S., 5284
Muench, K., 5905
Müerköster, S., 243
Mujoo, K., 5486
Mukai, K., 5707
Mukai, M., 4885
Mukai, T., 3399
Mukaida, N., 673
Mukeria, A., 778
Mukhopadhyay, D., 1768, 6952
Muldoon, L. L., 7868
Mulé, J. J., 228, 2062, 2618, 8105, 8513, 8794
Mullen, J. T., 5447
Muller, D., 4122
Müller, H., 7616
Müller, M., 5580
Müller, P., 550, 6925
Müller-Tidow, C., 647
Mulligan, S. P., 4483
Mullin, R. J., 7196
Mumford, J. L., 6679
Münchenhagen, P. M., 5215
Mundy, G. R., 2572, 4418
Münger, K., 2356
Munishkin, A., 5168
Munshi, N., 4583
Münster, P. N., 2945, 8492
Muracciole, X., 1196
Murai(Hata), N., 1733
Murakami, A., 1776, 2424
Muramatsu, M., 1144
Muramatsu, T., 7882, 8486
Murata, T., 7840
Murata-Collins, J. L., 831
Murillo, H., 7408
Murmann, O. V., 823
Murohashi, I., 8371
Murone, C., 5355
Murono, S., 7875
Murphy, B. J., 2696
Murphy, K. R., 1500
Murray, D. M., 7196
Murray, N. R., 1375
Murty, V., 725
Murty, V. V. V. S., 2119
Murugesan, S. R., 4320
Muschel, R. J., 333, 2289, 4278
Müschen, M., 2080
Musiani, P., 2809, 3518
Musso, O., 45
Muster, T., 8188
Muthuswamy, S. K., 8887
Muto, M. G., 7264
Mutter, G. L., 4311
Myers, R., 2935
Myers, S. R., 2472

## N

Nabholz, M., 7594
Nabors, L. B., 2154
Nacca, A., 4393
Nadaf, S., 2015
Nadal-Desbarats, L., 7747
Nadel, B., 1629
Nadler, L. M., 8366
Nafziger, J., 5289
Nagahara, N., 8401
Nagai, K., 2177
Nagane, M., 8569
Nagano, T., 5382
Nagao, M., 2632
Nagasaka, T., 4345, 7743
Nagase, H., 1305
Nagashima, F., 50
Nagashima, S., 1776
Nagata, K., 3016, 4779
Nagata, S., 1382, 5070
Nagata, Y., 2395, 4671
Nagatani, G., 1592
Nagley, P., 5998
Naglich, J. G., 8480
Naguibneva, I., 2961
Nagura, H., 5132
Nagy, A., 3826
Nair, R., 4160
Naishiro, Y., 2751
Naito, A., 1334
Naito, Y., 5132
Najfeld, V., 1754
Nakabeppu, Y., 6388
Nakachi, K., 8917
Nakada, H., 950
Nakada, M., 7985, 8896
Nakagawa, H., 6991, 7743
Nakagawa, K., 4365
Nakagawa, R., 2827
Nakagawa, S., 7913
Nakagawa, T., 1666, 5362
Nakahira, K., 4809
Nakajima, C., 3399
Nakajima, M., 7855
Nakamori, M., 6158
Nakamura, H., 3139, 4885, 5447
Nakamura, K., 370, 5969
Nakamura, M., 2759, 6060, 6158, 6335
Nakamura, M. C., 8629
Nakamura, T., 7518, 8697
Nakamura, Y., 2129, 2665, 3544, 3741, 6060, 6345, 6474, 7722, 8256
Nakanishi, O., 931
Nakano, O., 5132
Nakao, T., 7840
Nakase, H., 6335
Nakatani, Y., 8401
Nakayama, E., 4671
Nakayama, J., 1666, 2226
Nakazawa, K., 8486
Nam, M-S., 984
Nam, S., 1280
Nam, S. W., 6938
Namork, E., 5010
Nan, B., 186
Nanda, A., 6649
Nanda, D., 8743
Nanney, L. B., 5389
Nanus, D. M., 2774, 3294
Naomoto, Y., 4345, 7855
Nara, K-i., 50
Narayanan, L., 3775
Narod, S. A., 5420
Nascimbeni, R., 896
Nass, D., 4971
Nasser, S., 5697
Nasser, S. M., 8079
Nasu, Y., 4386
Natali, P. G., 8340
Nau, M. M., 4892
Naumann, M., 8416
Naumann, U., 5833
Navarro, D., 3294
Navone, N. M., 5652
Nawata, S., 1776
Neal, Z. C., 1500
Nechuta, T., 2232
Neckers, L. M., 1671
Negrini, M., 2870, 6640
Neiman, P. E., 6002
Nelkin, B. D., 3200, 6977
Nelsen, C. J., 8564
Nelson, C. P., 103
Nelson, H. H., 612, 3419
Nelson, J., 5644
Nelson, J. B., 3599
Nelson, P. S., 1611, 4791
Nelson, W. G., 103, 7025, 7464, 8611, 8617
Nenoi, M., 5885
Neri, D., 711
Nervi, C., 2, 1247
Nesland, J. M., 5824
Nestl, A., 1569
Neuhausen, S. L., 5420
Neumaier, B., 3853
Neustadt, B., 2232
Neuwelt, E. A., 7868
Nevanlinna, H., 5718
Newbold, R. F., 912, 7594
Newbold, R. R., 4325
Newcomb, E. W., 2124
Newman, R. A., 5474
Nexo, E., 6227
Neyts, J., 5057
Ng, B., 2996, 7709
Ng, S-C., 5480
Ngan, H. Y. S., 5998
Ngo, T. T., 602
Nguyen, A., 4175
Nguyen, C., 2562

** For title of article and coauthors, see listing in Contents of Volume 61 beginning on page 9015 at the end of this index issue.*

Nguyen, D., 759, 7925
Nguyen, H., 4175
Nguyen, L., 4982
Nguyen, L. D., 5161
Nguyen, N., 517, 6428
Nguyen, N. T., 1727
Nguyen, P., 1671, 3750
Nguyen, T., 7339
Ni, Y., 3986
Nice, E. C., 4474
Nicholas, C., 6297
Nichols, A., 970
Nichols, K. E., 8062
Nicholson, B., 8298
Nicholson, R. I., 6500, 6739
Nicholson, S. A., 5636
Nicke, M., 7608
Nickel, B., 392
Nickerson, T., 6276
Nicklee, T., 7394
Nickoloff, B. J., 228, 2062
Nicol, T., 7015, 7623
Nicoletti, I., 1699
Nicosia, S. V., 5985
Nie, L., 6703
Nieborowska-Skorska, M., 2194, 6517
Niedner, H., 7603
Nielsen, B. S., 532, 7091
Nielsen, F. U., 5318
Nielsen, P. E., 5468
Niemitz, E. L., 4947
Niethammer, A. G., 6178, 8498
Niggemann, B., 2866
Nigro, J., 1122
Niitsu, N., 178
Niitsu, Y., 8697
Niizeki, H., 6548
Nikas, D., 8730
Nikitin, A. Y., 3110
Nikolic, Z., 8811
Nikula, T. K., 2804
Nilsson, F., 711
Nimmanapalli, R., 759, 1799
Nimura, Y., 2361
Niranjan, B., 921, 2782
Nishida, M., 3741
Nishiguchi, S., 1843
Nishihara, T., 2878
Nishikawa, M., 1843
Nishimura, H., 1896
Nishimura, N., 673
Nishimura, S., 2827, 7009
Nishino, N., 4459
Nishio, M., 6151
Nishioka, N., 6388
Nishitoh, H., 5432
Nishizuka, S., 4536
Nita, M. E., 3544
Nitiss, J. L., 53
Niu, G., 3276
Niu, Y., 2071
Nizze, H., 550
Noda, M., 1029
Noda, T., 1207
Noël, A., 3450
Noelle, R. J., 641
Noguchi, M., 3969, 7950
Noguchi, Y., 4671
Nohmi, T., 3913
Nokihara, H., 673
Nolasco, M., 1563
Nolte, D., 991
Nomoto, M., 1592
Nomoto, S., 7015
Nomura, M., 3908, 4084
Nonet, G. H., 1250
Noonan, D. M., 5441, 8171
Nooter, K., 6982
Nör, J. E., 2183
Norberg, T., 8317
Nordal, R. A., 3348
Nordgren, H., 8317
Nordquist, R. E., 459
Norris, J. D., 2917
Norris, M. D., 5803
Norton, J. D., 8803
Notohara, K., 7743, 8401
Notterman, D. A., 3124
Notterpek, L., 5741
Nourigat, C., 5126
Novick, A. C., 2261
Nowak, C., 991
Nowak, N. J., 8274
Noya, F., 4858
Nozaki, S., 3369
Nudelman, A., 8194
Numa, F., 1776
Nunez, G., 2713
Nuovo, G. J., 6991
Nupponen, N. N., 8624
Nurcombe, V., 76
Nusgens, B. V., 3450
Nussler, A. K., 5289
Nutt, C. L., 4155, 7056
Nwokekeh, N. U., 7792
Nyati, M. K., 7585
Nyberg, F., 778
Nyengaard, J. R., 532
Nyrén, O., 2684
Nyström-Lahti, M., 2813

O

Oberhuber, G., 5703
Oberley, L. W., 5537
Oberley, T. D., 808, 6082, 7071
Obermair, A., 5703
O'Brien, K. P., 5778
O'Bryan, E., 759, 1799
Ochi, M., 2038
Ochiai, A., 2177, 7950
Ochieng, J., 1869
Ockert, D., 3524
O'Connell, P., 3578
Oda, T., 7950
Odaka, M., 6201
O'Donnell, F. T., 1269
Odwin, S., 7488
Oehler, C., 732
Oesterreich, S., 5771
Offer, H., 88
Offit, K., 8351
Oflazoglu, E., 7556
Öfner, D., 2513
Ogawa, I., 7044
Ogawa, M., 7722
Ogawa, O., 5432
Ogawa, S., 4206
Ogawa, Y., 2177
Ogur, G., 4130
Ogura, S., 2500
Ogura, Y., 1464
Oh, B. R., 97
Oh, J., 517
Oh, J. D., 5741
Oh, J. S., 1367
Oh, J-W., 3084
Ohba, M., 4591
Ohbayashi, T., 5707
Ohgaki, H., 2759
Ohkawa, T., 7855
Ohki, M., 1334, 6629
Ohmori, H., 5366
Ohnmacht, G. A., 5511
Ohno, H., 7363
Ohnuma, K., 7204
Ohshima, H., 8357
Ohshima., H., 778
Ohta, K., 3640
Ohta, T., 1347
Ohtani, H., 5132
Ohtani, N., 1187
Ohtani, S., 7855
Ohue, M., 14
Ohwaki, M., 2395
Oikawa, K., 5707
Okabe, H., 2129
Okabe, S., 6356
Okada, A., 1207
Okada, H., 2625
Okada, N., 7913
Okada, Y., 7913
Okajima, M., 6656
Okamura, A., 6248
Okan, N. A., 8074
Okayasu, I., 19
Okayasu, R., 1820
Okazaki, Y., 1144
Okby, N. T., 5636
Okegawa, T., 6592
Okiji, S., 749
Okochi, E., 2632, 7739
Okoye, F. I., 880, 3689
Oku, N., 5065
Okubo, T., 1338
Okuda, H., 4184
Okumura, A., 2424
Okumura, T., 950
Okunieff, P., 526
Okuno, M., 7675
Old, L. J., 2055, 4474, 4671, 5349, 5355, 6851
Olden, K., 2445
Oliff, A. I., 8758
Oliva, G., 7375
Olive, M., 5652
Olive, P. L., 8924
Olivi, M., 1652
Olivier, M., 6679
Oliyai, C., 2843
Olsen, B. R., 6830
Olson, K. L., 7435
Olson, T., 7268
Olsson, B. M., 8448
Omer, C. A., 8758
Onaga, M., 3016, 4779
Onaga, Y., 3016, 4779
Onda, M., 5070
O'Neill, D. P., 5028
O'Neill, G., 5331
O'Neill, J. P., 3432
Ong, D. E., 7065
Ongkeko, W. M., 1598
Onizuka, S., 7298
Ono, K., 3544, 3741, 6345, 6474
Ono, M., 469
Ono, S., 3399
Ono, T., 3913, 4671
Onodera, H., 7840
Onoue, M., 2395
Onyango, P., 4947
Opitz, O. G., 6467
Oppelaar, H., 1970
O'Reilly, M. S., 2207, 7298
Oren, M., 7635
Orend, G., 8586
Orenstein, A., 4971
Orikasa, S., 5132
Orlando, M., 759
Ørntoft, T. F., 2492, 6227
Orr, M. D., 110
Orr, S., 1058
Ortel, B., 717, 7155
Ortiz, B. H., 7264
Ortiz, M. A., 8504
Ortiz-Pallardo, M. E., 4398
Ortmann, D., 2609
Osada, H., 8331
Osakada, M., 3969
Osborne, C. K., 2320, 3578, 5771
Oseth, L. A., 5268
Oshima, M., 1733
Oshinka, H., 2413
Osman, I., 7642
Osman, S., 2935, 4937
Ossowski, L., 7544
Östman, A., 2929, 5778
Otake, Y., 1666
Otevrel, T., 8664
Otte, M., 6682
Otterson, G. A., 1327
Ottini, L., 5415
Otto, H. F., 8880
Ou, Y. C., 1879
Ouafik, L. H., 1196
Ouellet, F., 7217
Ovejero, C., 3245
Overall, C. M., 3610
Overgaard, J., 5318
Overman, K., 2713
Overwijk, W. W., 7920
Oviedo, A., 6822
O-Wang, J., 5366
Owens, D. M., 5248
Owen-Schaub, L. B., 4066
Owolabi, O., 4375
Oyajobi, B. O., 2572
Oyama, T., 2015
Oyanagi, H., 1666
Ozawa, K., 4206, 4414
Ozawa, T., 4956, 5382, 6674
Özbek, S., 2311
Ozono, K., 1637

P

Pace, S., 7189
Paciga, J. E., 5985
Pack, J., 7642
Paczesny, S., 2386
Padera, T. P., 2404, 8079
Padilla-Nash, H., 8143
Padula, F., 2
Paganelli, G., 4393, 5517
Pagano, E., 293
Pagano, J. S., 7875
Page, M., 7196
Pagel, M. A., 7868
Paggi, M. G., 4651, 5952
Paglin, S., 439
Paik, S., 7925
Pairolero, P. C., 5636
Pal, S., 6952
Palakurthi, S. S., 6213
Palapattu, G. S., 4660


** For title of article and coauthors, see listing in Contents of Volume 61 beginning on page 9015 at the end of this index issue.*

Palese, P., 8188
Palkowitz, A. D., 8412
Palli, D., 5415
Pallini, R., 4272
Palmantier, R., 2445
Palme, M. H., 1013
Palmer, G. A., 2453
Palmirotta, R., 5415
Palombella, V. J., 3071
Palucka, A. K., 6451
Palumbo, L., 570
Palumbo, M., 6034
Pamukcu, R., 3961
Pan, L., 162
Pan, S., 8569
Pan, T., 8127
Pan, W., 2885
Panageas, K. S., 2008
Panagopoulos, I., 5374
Panavally, S., 5979
Pandey, R. K., 991
Pandey, S., 1948
Pandit, S., 7623
Pandita, A., 5895
Panh, M-H., 5024
Panicali, D., 3725
Panicali, D. L., 206
Panovski, M., 8351
Pant, A. C., 7763
Pantazis, P., 1964, 7148
Pantel, K., 1890, 6682
Pantuck, A., 7925
Pao, A. Y., 2838
Papay, R., 2031
Papon, J., 2294
Parada, Y., 8005
Parajuli, P., 8227
Pardee, A. B., 4301
Pardoll, D. A., 3682
Parekh, H. K., 7552
Parenza, M., 6532
Parfait, B., 1652
Parhar, P., 2124
Parikh, A., 6372
Park, B-K., 7647
Park, D. J., 8654
Park, H., 3084
Park, J. Y., 4942
Park, J-G., 3541
Park, K., 8322
Park, K-H., 6163
Park, M-S., 6012
Park, S. H., 931
Park, S-Y., 1138
Park, W. S., 4942
Park, Y. K., 8322
Parker, L. L., 7920
Parker, M., 616
Parker, M. A., 5389
Parl, F. F., 6716
Parlow, A. F., 5764
Parmiani, G., 222, 8218
Parmigiani, G., 1299
Parney, I. F., 1162
Parrella, P., 1555, 7015, 7623
Parsons, M. A., 3157
Pasche, B., 8351
Pascolo, S., 4072
Pasqualini, R., 8110
Pass, H. I., 5727
Passaniti, A., 4994
Passioukov, A., 2843
Passos-Bueno, M. R., 7375
Pastan, I., 5070, 8122
Pastorek, J., 5262, 6394, 7992
Patel, C. B., 921
Patel, D., 7318
Paterlini-Bréchot, P., 7803
Paterson, C., 4561
Patheal, S. L., 2542
Patil, S., 5692
Pattengale, P. K., 1398
Patterson, A. D., 2487
Paul, M., 2239
Paul, P., 6838
Pauley, R. J., 1320
Paulsen, J. E., 5010, 8689
Paulson, T. G., 8284
Pavlovich, C., 8143
Pawlik, C. A., 3045
Pawlik, T. M., 5447
Pawlowski, V., 4337
Payan, R., 5024
Payne, C. M., 2766
Payne, J. K., 6958
Pearce, H. L., 8412
Pearson, A. D. J., 8
Pease, K. M., 6619
Pece, S., 2641
Pechan, P. A., 2983
Peck, K., 5223
Pecker, I., 4655
Pedersen, L. O., 493, 869, 5964
Pederzoli, P., 285
Pediatric Oncology Group, 7268
Pedley, R. B., 3653, 4716
Pedroni, M., 896, 7798
Peehl, D. M., 2112, 2852
Peer, C., 8412
Pe'er, J., 5242
Pegg, A. E., 53, 6073
Pehamberger, H., 8188
Peinado, M. A., 2816, 4689
Pekarsky, Y., 6640
Peleg, S., 5652
Pelicano, H., 8723
Pelicci, P. G., 2, 1247
Pelisson, I., 1754
Pellizzari, E., 6367
Peloux, N., 5024
Pelroy, R., 4642
Peltenburg, L. T. C., 1839
Peltomäki, P., 1619, 2813, 6042, 7798
Pemberton, J., 4679
Penco, S., 7189
Pendleton, C. D., 6868
Peng, Q., 5824
Peng, X. Y., 4405
Peng, Z., 4143
Penketh, P. G., 3033
Pennathur-Das, R., 5453
Pennella, G., 1991
Pennica, D., 4197
Pennington, M. E., 3308
Percesepe, A., 896, 7798
Perego, P., 6034, 7189
Perera, F. P., 6708
Perez-Perez, G. I., 1406
Perfetti, P., 4272
Pericle, F., 859
Perilla, A., 2119
Perkins, C. L., 759
Perkins, E., 4175
Perlman, E. J., 7268
Perrault, A. R., 8554
Perrera, C., 7719
Perret, C., 3245
Perret, D., 4272
Perri, P., 2523
Perricaudet, M., 3450
Perrin, G., 2047
Perris, R., 339
Perry, A., 1825
Perry-Lalley, D. M., 5511
Pertl, U., 8498
Perucho, M., 3139
Pervin, S., 4701
Pesce, C., 8171
Peschle, C., 6532
Pesci, A., 285
Pestell, R. G., 6170
Peter, J., 957
Peter, M. E., 7148
Peters, G., 8005
Peters, G. J., 1585, 3675
Peters, H. A., 5407
Peters, J. H., 3410
Peters, K. B., 5425
Peters, M., 2183
Petersen, C., 706
Peterson, B. J., 6494
Peterson, C., 5979
Peterson, L. A., 5757
Peterson, V. J., 4723
Petrelli, N. J., 8274
Petridou, E., 2542
Petros, W. P., 864
Petruk, K. C., 1162
Petty, E. M., 4130
Peyrat, J-P., 76, 4337
Peyron, J-F., 7785
Peyton, M., 7943
Pezullo, J. R., 8143
Pezzoni, G., 6034
Pezzuto, J. M., 4030, 6137, 7456
Pfahl, M., 8504
Pfarr, C. M., 916
Pfeffer, R., 4971
Pfeifer, G. P., 3105, 7110, 8158
Pfeiffer, K-P., 2513
Pflug, B. R., 3599
Pham, T., 4197
Phang, J. M., 1810
Phelps, D. A., 3045
Philippi, C., 3508
Philippou, S., 7282
Phillips, D. H., 6350, 6708
Phillips, D. L., 7025
Phillips, D. R., 8194
Phillips, J. L., 8143
Phillips, P. C., 1527
Phillips, W. A., 7426
Philp, A. J., 7426
Philpott, A., 482
Piantadosi, S., 1309, 7464, 8611
Piao, Z., 8094
Piazza, G. A., 3961
Piazza, M., 1830
Pica, C. M., 6540
Picard, S-F., 7955
Pichard, C., 7971
Pichlmeier, U., 6682
Pickering, R. M., 1296
Piedrafita, F. J., 8504
Pieper, R. O., 1957, 4956, 5843, 6674
Pierantoni, G. M., 4583
Pierce, R. H., 594
Pierotti, M. A., 4675
Pietenpol, J. A., 5480
Pietra, G., 8218
Pietras, K., 2929, 5778
Pietsch, T., 7039
Pignatelli, B., 778
Pihan, G. A., 2212
Pihlajaniemi, T., 45, 6511
Pijnenborg, A. C. L. M., 3458
Pike, M. C., 848, 8393
Pikkarainen, T., 8385
Pilch, B., 6876
Pili, R., 1477
Pimentel, F., 3795
Pimkhaokham, A., 6629
Pineiro, L., 6451
Pinilla, C., 5153
Pinski, J., 6372
Pintilie, M., 6400
Pinto, J. T., 725
Pinyol, M., 2409
Pippin, J. A., 6563
Pirie-Shepherd, S. R., 7298, 7669
Pirisi, L., 3837
Pisano, C., 6034, 7189
Pisarev, V., 8227
Pisc, C., 8811
Pisters, P. W., 1727
Pistoia, V., 1285
Pitot, H. C., 1879
Pittman, B., 8683
Pitts, R. L., 3561
Piwnica-Worms, D., 6540
Pizer, E. S., 1493
Pizzorno, G., 4405, 6899
Planas-Silva, M. D., 3858
Platten, M., 2759
Plautz, G. E., 5661
Plisov, S. Y., 2961
Plouin, P-F., 6762
Pluderi, M., 7501, 8730
Plum, S. M., 1022
Plumb, J. A., 749
Plummer, S., 1058
Plunkett, W., 1065, 8723
Pluth, J. M., 2649
Poellmann, C. C., 7964
Pogliani, E., 4666
Pogo, B. G-T., 1754
Pogue, B. W., 717
Pogue-Geile, K., 2625
Pohar, K. S., 2816
Pohl, C., 1976
Poignée, M., 7118
Poignet, H., 131
Polakis, P., 4197
Polascik, T. J., 110
Polek, T. C., 4294
Polissar, N. L., 6025
Polk, D. B., 963, 8668
Pollack, I. F., 2625, 7404
Pollak, M., 4333, 6276
Pollmann, C., 8416
Pollock, P. M., 1154
Pollock, R. E., 1727
Polsky, D., 6008, 7642
Polverini, P. J., 2183
Polyak, K., 5697
Pommier, Y., 53, 504, 1964
Pong, R-C., 6592
Ponnazhagan, S., 6313
Ponz de Leon, M., 7798
Poon, R. Y. C., 1598
Popescu, N., 8838
Poptani, H., 2002, 7747
Porteous, D. J., 6977
Porter, C. W., 6437, 7754

** For title of article and coauthors, see listing in Contents of Volume 61 beginning on page 9015 at the end of this index issue.*

Porter, D. A., 5697
Porter, D. C., 8470
Porter, P., 1934
Porwancher, K., 2124
Posner, R. H., 4892
Posso, H., 2119
Pott, C., 1629
Potten, C. S., 8803
Potter, J. D., 126, 1000, 3566, 7136
Potter, P. M., 3045, 5078, 5083
Poulaki, V., 577, 2704, 4864
Poulsen, S. S., 6227
Poulson, J. M., 7964
Pourquier, P., 53, 1964
Poustka, A., 7731, 8880
Powell, B., 1527
Powell, J. A., 1171
Powell, S. M., 7388
Powell, S. N., 270
Powis, G., 2766
Pöyhönen, M., 4541
Prados, M., 1122
Prat, J., 2816
Pratesi, G., 6034, 7189
Prayaga, S., 3131
Prayson, R. A., 8058
Praz, F., 6555
Prehn, J., 3750
Prendergast, G. C., 3151
Prescher, G., 3439
Prescott, S. M., 8429
Press, M. F., 3212, 8393
Presta, M., 309, 2232, 5057
Pretlow, T. G., 419, 8085
Pretlow, T. P., 419, 7699, 8085
Prevention, H. R., 2537
Prevention, J. G. M. K., 5407
Prevention, S. W. B., 3314
Prevention, T. O., 3640
Prevention, W. G. H., 5045
Prevo, L. J., 8284
Prewitt, T. E., 2307
Price, D. T., 110
Price, J., 497
Price, P. M., 2935, 4937
Pride, M. W., 215
Priest, D. G., 3675
Prime, J. E., 8820
Prins, G. S., 6089, 7310
Prins, R. M., 842
Prinz, C., 1903
Prise, V. E., 6413
Prochownik, E. V., 6487
Prox, D., 7669
Pruneri, G., 4341
Pruschy, M., 732, 8203
Przepiorka, D., 3355
Pugacheva, E. M., 6002
Puig, X., 2409
Puig-Antich, V., 3145
Puijk, W. C., 2552
Puisieux, A., 486
Pulfer, S., 5491
Pulgar, T. G., 5784
Pulido, H. A., 2119
Pullen, J. D., 7333
Pullman, J., 2420
Puri, R. K., 5661, 6194, 8058
Purohit, A., 2212
Putnam, J. B., 7417
Pützer, B. M., 7052
Putzi, M. J., 8611, 8617

## Q

Qi, R., 7792
Qian, C-N., 4143
Qian, G-S., 33
Qiao, Y., 3321
Qin, W., 270
Qiu, S. G., 7255
Quackenbush, J., 7792
Quader, S. T., 455
Quaglino, E., 2809, 3518
Quaranta, V., 6322
Quatannens, B., 2656
Quealy, J. A., 4084
Quelle, D. E., 3145
Quincy, D. A., 1013
Quinn, D. I., 423, 5331
Quinn, T. P., 4851, 8629
Quiqueres, A-L., 5850
Quiquerez, A-L., 2047

## R

Raab-Traub, N., 7875
Rabiasz, G. J., 6977
Rabitti, C., 7623
Rabizadeh, S., 5741
Rabkin, S. D., 153, 3009
Rackley, R. R., 2261
Rad, R., 1903
Rademaker, A., 8351
Raderer, M., 1629
Rades, D., 7608
Radomski, M. W., 376
Radvanyi, F., 1265
Radzyminski, J., 5453
Raghunath, P. N., 6517
Rago, C., 6996
Rahmatpanah, F., 8375
Raitano, A. B., 1686
Raja, K., 6350
Rajput, A., 900
Rak, J., 462, 5090
Rakhmilevich, A. L., 1500
Raleigh, J. A., 8924
Ram, Z., 4971
Ramamurthi, K., 1508
Raman, V., 2782
Ramer, K., 8629
Ramesh, N., 5453
Rammensee, H-G., 1846, 4072
Ramos, Y. F. M., 1839
Ramsdell, W. M., 4306
Rando, R. R., 2774
Rands, E., 8758
Rangel-Corona, R., 6281
Rangnekar, V. M., 7255
Rank, F., 7091
Rao, C. V., 1927, 3647
Rao, J. S., 419, 8085
Rao, P. H., 4506
Rapp, D. G., 5663
Rapp, U. R., 3595
Rascher, G., 5833
Rashid, A., 3406, 6046
Rashid, M. G., 489
Rasko, J. E. J., 6002
Raspall, G., 6500
Rassenti, L., 2870, 6640
Rastelli, L., 4197
Rastert, R., 8441
Ratanatharathorn, V., 2376
Ratcliffe, P., 5262
Ratcliffe, P. J., 6394, 6669
Ratovitski, E. A., 3682
Raucher, D., 7163
Rauscher, F. J., III, 1
Ravel, Y., 5529
Ravenel, J. D., 4947
Ravi, R., 3276
Ravi, R. K., 3200
Ravid, A., 1439
Ravid-Megido, M., 4873
Ravindernath, A., 3925
Rawlings, E., 5145
Ray, E. C., 1541
Raymond, A. K., 5652
Rayter, Z., 6739
Razavi, R., 6055
Re, D., 2080
Rea, P. A., 7225
Read, T-A., 6830
Reali, E., 5517
Rebbeck, T. R., 5420
Rebel, H., 977
Rebuzzini, P., 4520
Reddi, E., 7495
Reddy, B. S., 1927, 3647
Reddy, R., 7747
Redman, B. G., 228
Redmond, R. W., 717
Redon, R., 4122
Redston, M., 6131
Reed, J. A., 8074
Reed, J. C., 1260, 6640
Reed, K., 5491
Reed, R. K., 2929
Reed, S. G., 1563
Reep, B. R., 7196
Regalia, E., 1050
Regen, P. S., 8851
Regezi, J. A., 2371
Reha'k, M., 88
Rehn, M., 45, 6511
Reich, J., 8351
Reichert, A., 1398
Reid, B. J., 8284
Reid, S., 6912
Reiffers, J., 5289
Reilly, R. T., 880, 3689
Reimers, D., 1717
Reinmuth, N., 1255, 1464
Reis, A., 3570
Reisfeld, R. A., 1500, 6178, 8498
Reisinger, R., 8601
Reiter, R. E., 3256, 4320, 4660
Relling, M. V., 5810
Remotti, H., 2547
Rémy, C., 5595, 6524
Ren, C., 4386
Rene, L. M., 3486, 7689
Rennstam, K., 1214
Repasky, E. A., 7556
Rephaeli, A., 8194
Report, S. S. M., 2782
Requeijo, S. P., 8435
Resch, H., 732
Reske, S. N., 3853
Resta, D., 3092
Restifo, N. P., 7920, 8100
Reubi, J. C., 4636
Révillion, F., 76, 4337
Rexer, B. N., 7065
Reynoids, C. P., 679, 5102, 6185
Reynolds, P. N., 7882
Rezai-Zadeh, N., 6290
Rha, S-J., 3330
Rhee, S. H., 1386
Rhees, J., 7444
Rhijn, B. W. G., 1265
Rhim, J. S., 2390, 5969
Rhyu, M-G., 2847
Ria, F., 1555
Riabowol, K., 4345
Ribas, A., 8782, 8787
Ribatti, D., 5057
Ribeiro-Filho, L., 7101
Ricciardelli, C., 926
Rice, A., 6170
Rice, P. L., 1541
Rich, J. N., 3556
Rich, K. M., 1825
Richard, A., 7217
Richards, E. C., 6851
Richards, F. M., 7277
Richards, S. K., 1619
Richardson, P., 3071
Riches, A. C., 912
Richiardi, G., 7811
Richmond, A., 4901, 8150
Richon, V. M., 3591, 8492
Richter, J., 4514
Rickheim, D. G., 8564
Rickinson, A. B., 6219
Rickman, D. S., 2162, 6885
Riddle, D. S., 7240
Rieber, E. P., 3524
Ried, T., 8143
Rieder, H., 3439
Riedinger, M. S., 842, 5601
Riegman, P. H. J., 3164
Riethdorf, L., 1890, 6682
Riethmüller, G., 1890
Rifkind, R., 8492
Rifkind, R. A., 3591
Rigas, B., 3285, 8381
Rigaud, G., 285
Riggins, G., 5697
Rigopoulos, A., 4474
Rikimaru, T., 1005
Rimner, A., 2744
Rimoldi, D., 509, 5850
Rinaldi, M., 1555, 7623
Rincón, M., 8851
Rindi, G., 285
Rinelli, A., 4272
Ringel, I., 7536
Ringel, J., 550
Ringel, M. D., 6105
Ringert, R-H., 7731
Ringnér, M., 5979, 8624
Rini, F., 222
Rinker-Schaeffer, C. W., 2833
Rinneberg, H., 991
Rio, M-C., 1652, 2189
Rios-Doria, J., 489
Riou, J-F., 6876
Ripamonti, M., 1983, 1991
Risques, R-A., 4689
Rist, M., 4514
Rittenhouse, H. G., 6958
Rittenhouse-Olson, K., 4851
Ritter, G., 4474, 4671, 5355, 6851
Rittman, B., 3131
Ritz, U., 8647
Rius, J. L., 3472
Rivera, A., 8143
Rivlin, R. S., 725
Rivoltini, L., 222
Rizvi, I., 7155
Rizzo, C., 8703
Ro, J. Y., 2847

** For title of article and coauthors, see listing in Contents of Volume 61 beginning on page 9015 at the end of this index issue.*

Roa, W. H., 1162
Robbins, M. E. C., 5537
Robbins, P., 8306
Robbins, P. D., 7709
Robbins, P. F., 1089, 8100
Roberge, M., 6788
Robert, J., 5869
Roberts, D. W., 7488
Roberts, J. D., 2445
Roberts, P. C., 6723
Roberts, S. A., 5948
Robertson, C. N., 110
Robertson, D., 4003
Robertson, J. F., 6739
Robertson, K. A., 2220
Robertson, N., 7349
Robey, R. W., 6635
Robillot, C., 3942
Robinson, A. F., 6002
Robinson, B. A., 3206
Robinson, G., 5736
Robles, A. I., 6660
Rocchi, P., 1196
Rocha, S., 732, 8203
Rocha-Zavaleta, L., 6281
Roche, P., 5895
Roche, P. C., 4951
Roche, S., 1415
Rockman, S. P., 7426
Rockwell, S., 7770
Rodeck, U., 2200, 7282
Rödicker, F., 7052
Rodriguez, J. G., 3647
Rodriguez, R., 7464
Rodriguez-Bauman, A., 5926
Rodriguez-Bigas, M. A., 8274
Rodriquez, C. R., 2533
Röefzaad, C., 3932
Roffler, S. R., 5223
Roger, P., 2537
Rogers, J., 6331
Rogers, S. D., 4038
Roh, H., 6563
Roigas, J., 5215
Rojo, F., 4744, 6500
Rökman, A., 6038
Rokstad, A. M., 6830
Rolland, A., 6451
Roller, M., 1045
Rollins, L., 197
Romagnolo, B., 3245
Romain, S., 1421
Romanenko, A., 6964
Romans, K. E., 6996
Romero, M. E., 4864
Romero, P., 509, 2047, 5153, 5850
Romieu-Mourez, R., 3810
Romirer, I., 8188
Ron, R., 4873
Ronai, Z., 4642
Roncari, L., 3826, 4425
Ronchi, R., 8422
Roncucci, L., 896
Rong, R., 6918
Roninson, I. B., 7754
Roodi, N., 6716
Roop, B. C., 6679
Roots, I., 5051
Roques, C. N., 8405
Rosanò, L., 8340
Rosas, S. L. B., 939
Rosato, E. F., 4827
Rösch, T., 1903
Rose, A., 4214
Rose, G. S., 4382
Rose, W. C., 7507
Rose-John, S., 2311
Rosell, R., 1309
Roselli, M., 2523
Roselló, J., 6500
Rosen, E. M., 8022
Rosen, J. M., 261
Rosen, K., 4837
Rosen, M. A., 6064
Rosen, N., 2945, 7184, 8492
Rosen, S. T., 5474
Rosenau, A., 2311
Rosenbaum, J. S., 8569
Rosenberg, E., 764
Rosenberg, S., 3212
Rosenberg, S. A., 1089, 8100
Rosenberg, S. H., 5480
Rosenthal, G., 4612
Rosi, G., 4272
Rosi, K. S., 7211
Roskelley, C. D., 6788
Rosolen, A., 1671
Ross, D. A., 2162
Ross, D. D., 739
Ross, S., 7291
Rossi, G., 896
Rossi, R., 1983
Rossiter, H., 3619
Rossow, K. L., 2690
Rostom, A., 3627
Rosty, C., 4320
Rotem, C., 1439
Roth, J., 5186, 5941
Roth, J. A., 186, 3330
Roth, M. J., 4098
Roth, W., 2759
Roth, Y., 4971
Rothchild, K., 2031
Rothkamm, K., 3886
Rotimi, C. N., 2307
Rotman, G., 1849
Rotter, V., 88
Rouse, J., 8866
Rousseau, F., 5869
Roussel, M. F., 5810
Rovere, P., 3092
Rowlinson-Busza, G., 2935
Royds, J. A., 3157
Roz, L., 4675
Ruan, Y., 5741
Rubin, B. P., 8118
Rubin, E. H., 5926
Rubin, H., 799
Rubin, K., 2929
Rubin, M. A., 489, 2390, 2833, 8651
Rubin, S. C., 4766
Rubinfeld, B., 4197
Rubio, C., 2676
Rubio-Godoy, V., 509, 5153, 5850
Ruchatz, A. N., 7240
Rüdiger, H. A., 1233
Rudland, P. S., 4357, 5619
Rueda, D., 5784
Ruehlmann, J. M., 6178, 8498
Ruffino, L., 6971
Ruffner, K. L., 5126
Rugarli, C., 3092
Ruhland, C., 4222
Ruiters, M. H. J., 4105
Ruiz, A., 2774
Ruiz, R., 8118
Runquist, O. A., 8408
Ruohola, J. K., 4229
Ruoslahti, E., 8385
Rusin, M., 7430
Rusnak, D. W., 7196
Russell, P., 6331
Russell, R., 6899
Russo, A., 5415
Rustgi, A. K., 6467
Rutherford, T., 4405
Rybak, S. M., 8737
Ryberg, D., 6350
Ryoo, Z-Y., 984
Ryu, B., 1833, 4320
Ryu, B-G., 7034

## S

Saadi-Kheddouci, S., 3245
Saal, L. H., 5979
Saarma, M., 3267
Sabichi, A. L., 2720
Sabino, M. A. C., 4038
Sabo, P., 3022
Sachet, M., 8188
Sachinidis, A., 4398
Sachsinger, J., 5580
Sacks, N., 8452
Sacks, P. G., 4506
Sadhukhan, P. C., 2261
Saedi, M. S., 6958
Saeed, A. I., 7792
Saegusa, M., 19
Safaei, R., 7603
Safah, H., 6931
Safe, S., 3902
Saffran, D. C., 1686
Saga, T., 4966
Sagalowsky, A., 8659
Sagalowsky, A. I., 6592
Sagiya, Y., 8256
Saglio, G., 1555
Saha, S., 6996
Sahin, A., 5558
Sahla, M. E., 2537
Said, J., 4660
Saida, T., 7900
Saieva, C., 5415
Saika, T., 4671
Saini, A., 2953
Saisho, H., 5382
Sait, S., 8274
Saito, J., 6105
Saito, K., 2676
Saito, N., 2038
Saito, S., 1187
Saito, T., 6822, 7913, 8331
Saji, M., 6105
Sakai, T., 1187
Sakaki, T., 6335
Sakamoto, Y., 6987
Sakamuro, D., 3151
Sakata, K., 1874
Sakita, I., 14
Sakiyama, S., 5366, 8769
Sakko, A. J., 926
Sala, E., 896
Salani, D., 8340
Saleem, A., 4937
Salerni, B., 896
Säll, T., 8241
Salmi, T. T., 6423
Salovaara, R., 2813, 4545, 6991
Salter, J., 8452
Salvador, J. M., 2487
Salvato, K. A., 1013
Salvatore, D., 1426
Salvatorelli, E., 8422
Salvucci, O., 318
Salzler, R. R., 1747
Salzmann, J-L., 2386
Samowitz, W., 1000
Samowitz, W. S., 126
Sampath, D., 1065
Samper, E., 912, 5580
Samuel, S. K., 1362
Sánchez, C., 5784
Sánchez-Alcázar, J. A., 1038
Sanchez-Cespedes, M., 1309, 2092, 7015, 7623
Sanchez-Sweatman, O., 1707
Sanda, M. G., 489
Sanders, B. G., 6569
Sanfiz, A., 4985
Sang, Q. X. A., 2365
Sang, S., 5749
Sanità, F., 4272
Sanjuan, N., 293
Sankala, H. M., 2583
Sano, T., 7675
Sansom, O. J., 7060
Santa, T., 4365
Santi, L., 5441
Santner, S. J., 1320
Santoro, M., 1426, 2267, 4583
Sanz, G., 131
Sanzo, J. F., 2974
Sapi, E., 4405
Sapinoso, L. M., 5974, 7388
Saragovi, H. U., 694
Saramäki, O. R., 3550, 5340
Sarasin, A., 2480
Saremaslani, P., 5186
Saretzki, G., 3053
Saria, E. A., 8617
Sariola, H., 3267
Sarna, M. K., 2453
Sarosi, I., 4432
Sartorelli, A. C., 1469, 3033, 7770
Sarvazyan, N., 4024
Sasaki, F., 8401
Sasaki, H., 445, 6713
Sasaki, M., 97, 3262, 4809
Sasaki, S., 3139
Sasaki, Y., 1451, 3969, 7563
Sasano, H., 2250
Sasse, S., 8737
Sathyanarayana, U. G., 4556
Sato, E., 1843
Sato, H., 984, 7985, 8896
Sato, K., 2665, 7204
Sato, M., 1896, 5132
Sato, N., 4966
Sato, S., 4244, 4459, 7044
Sato, Yasuh., 8697
Sato, Yasuo, 8769
Satoh, S., 2129, 6345
Satoh, T., 3741, 3882, 4386
Satyamoorthy, K., 3819, 7318, 8306
Sauleda, S., 6500
Saunders, H. M., 2974
Saunders, M. M., 1765
Saunier, B., 6105
Sausville, E. A., 931
Sauter, G., 4514
Sautès-Fridman, C., 2189
Sauvageot, J., 103, 4683, 8617
Savelyeva, L., 5179
Savinainen, K. J., 3550

** For title of article and coauthors, see listing in Contents of Volume 61 beginning on page 9015 at the end of this index issue.*

Savopoulos, R., 8480
Sawicka, J., 376
Sawicki, G., 376
Sawyer, M., 6350
Sawyers, C. L., 6276
Scaglione, F., 7501
Scanlan, M. J., 2055
Scarpa, A., 285
Scarselli, A., 896
Scatena, C. D., 5480
Schaer, J-C., 4636
Schäfer, B. W., 823
Schafer, J. M. G., 6619
Schäfer, K-L., 355
Schaffer, D., 126, 1000
Schaffner, W., 2696
Schaid, D. J., 6494
Schaider, H., 8306
Schaller, G., 1890
Schammann, T., 6846
Scheffer, G. L., 739, 2552, 3458, 6034
Scheffzek, K., 4916
Scheidweiler, A. F., 5186
Scheinberg, D. A., 2008
Schell, T. D., 873
Schellens, J. H. M., 3458
Schellhammer, P. F., 6029
Schenk, P. W., 6982
Scheper, R. J., 2552, 3458
Schepp, W., 1903
Scherneck, S., 5179
Scherpen, F., 7654
Schier, R., 4750
Schiffmann, E., 6938
Schilling, H., 3439
Schindl, M., 5703
Schinkel, A. H., 3458
Schinköthe, T., 8737
Schiripo, T. A., 8062
Schirle, M., 4072
Schirmacher, P., 2311
Schlaepfer, D. D., 7079
Schlaeppi, J. M., 5090
Schlag, P., 5179
Schlag, P. M., 991, 3932, 4605
Schleutker, J., 6038
Schlienger, K., 4766
Schlimok, G., 1890
Schlom, J., 206, 2523, 3725, 4497, 5517, 7568
Schlosshauer, P. W., 4569
Schlotter, F., 6055
Schlumberger, M., 6762
Schmandt, R., 5895
Schmelz, E. M., 6723
Schmid, R. M., 3853, 4526
Schmid, U., 4514
Schmidt, B. A., 4214
Schmidt, C., 550
Schmidt, C-A., 2517
Schmidt, E. V., 8811
Schmidt, L., 6255
Schmidt, L. J., 7408
Schmidt-Ullrich, R., 3894
Schmiegel, W., 7282
Schmielau, J., 4756
Schmitt, L., 8880
Schmitt, M., 1272
Schmitz, I., 7148
Schmitz, M., 3524
Schneider, A., 6846, 7118
Schneider, C., 497, 1976
Schneider, D. T., 7268
Schneider, E., 1038, 5461
Schneider, F., 4605
Schneider, G. B., 3250
Schneider, M. R., 5790
Schneider, P. M., 647
Schneider-Mergener, J., 2453
Schnipper, D. R., 8366
Schnuerch, H-G., 1045
Schnuriger, V., 5850
Schnurr, M., 6445
Schober, M., 4283
Schoenberg, M., 7015
Schoenherr, D. M., 1113
Schold, S. C., 4017
Scholl, F. A., 823
Scholz, C., 6445
Schön, M. P., 3619
Schönenberger, A., 4514
Schöniger, M., 1903
Schoppmann, S. F., 5703
Schrage, M., 4660
Schrama, D., 493
Schraml, P., 4514, 7277
Schreiber, R. D., 6540
Schreiner, S., 6480
Schrøder, L., 493
Schroeder, T., 4990
Schroeijers, A. B., 2552
Schubiger, P. A., 8203
Schuermann, M., 5905
Schuhmacher, C., 2804
Schuhmacher, J., 3712
Schultz, P. G., 7388
Schultze, J. L., 4761, 8366
Schulz, J. B., 5833
Schumacher, K., 3932
Schupp, J. E., 8290
Schuppert, F., 6105
Schuster, A. E., 7268
Schut, H. A. J., 8689
Schutte, M., 278
Schwab, M., 5179
Schwaiger, M., 1781, 2804
Schwall, R. H., 4197
Schwartz, D. R., 3869
Schwartz, G. G., 4294
Schwartz, P., 4405
Schwartz, S., Jr., 7727
Schwartz, S. M., 1934, 8459
Schwarze, S. R., 474
Schwei, M. J., 4038
Schweinfest, C. W., 4112
Schweizer, P., 2813
Schwiertz, A., 5215
Schwint, A. E., 8638, 8775
Sciarretta, F., 2523
Sciorati, C., 3092
Scorilas, A., 7811
Scott, A. M., 4474, 5349, 5355
Scott, D., 5948
Scott, P. A. E., 3206
Scott, S., 5453
Scotton, C. J., 4961
Sebastian, S., 2328
Sebti, S. M., 1280
Sedivy, J. M., 1178
Sedwick, W. D., 8290
Seeber, S., 392
Seeberg, E., 5378
Seed, B., 6020
Seeger, K., 2517, 3570
Seeger, R. C., 679
Seewaldt, V. L., 616
Seftor, E. A., 3250, 6322
Seftor, R. E. B., 3250, 6322
Segawa, N., 6060
Segeren, C. M., 3937
Sehested, M., 4990
Sehgal, C. M., 2974
Sei, S., 5028
Seidel, B., 3508
Seidl, C., 2804
Seidman, J., 4382
Seike, M., 8527
Seiki, M., 984, 1207
Seiler, R. W., 4190
Seitz, U., 3853
Seker, H., 7430
Sekikawa, K., 4620
Sekimoto, M., 14
Selby, P. J., 1678
Seldin, D. C., 3810
Seletsky, B. M., 1013
Seliger, B., 1095, 1976, 8647
Sellar, G. C., 6977
Sellin, J. H., 2899
Selner, M., 7217
Selvakumaran, M., 1291
Selzner, M., 1233
Semenza, G. L., 2911
Semjonow, A., 355
Sen, A., 5895
Senekowitsch-Schmidtke, R., 1781, 2804
Seng, W. L., 7830
Sennino, B., 309
Sent, D., 1976
Senter, P. D., 14
Sentjurc, M., 4266
Seol, D-W., 1138
Seol, J. Y., 6163
Seol, M-H., 1138
Seon, B. K., 7846
Seow, A., 3326
Seow, H. A., 7770
Sepetavec, T., 2015
Seppänen, J. A., 4229
Seraj, M. J., 1765
Serra, A., 1555
Serrano, M., 6234
Serroni, A., 2459
Sersa, G., 4266
Sertié, A. L., 7375
Serve, H., 647
Seshadri, R., 1171
Sesterhenn, I. A., 4333
Setchell, B., 706
Settasatian, C., 1171
Seufferlein, T., 4222
Sgouros, G., 2008
Sgroi, D., 2320, 5697
Sgroi, D. C., 8062
Shachaf, C., 5529
Shackleford, G. M., 8811
Shah, J. P., 4506
Shah, N., 5268
Shah, S. A., 6912
Shaha, A. R., 4506
Shaharabany, M., 4873
Shaheen, R. M., 1255, 1464
Shahlavi, T., 3321
Shahnavaz, S. A., 2371
Shain, K. H., 3276
Sham, H., 5480
Sham, J. S. T., 3806
Shan, B., 3110
Shan, S., 6413
Shandra, A., 392
Shang, Y., 3858
Shannon, K. M., 8062
Shannon, P., 3826
Shannon, W. D., 1825
Shantz, L. M., 6073
Shao, J., 2670
Shao, L-e., 7333
Shao, R., 7142, 7413
Shao-Xi, L., 370
Shapero, M. H., 3760
Shappell, S. B., 497, 2239
Shariat, S. F., 2562
Sharma, M., 2112
Sharma, P. M., 921
Sharma, S., 6406
Sharma, T., 81
Sharov, V., 7792
Sharp, G. B., 7743
Shaw, D. R., 6313
Shaw, L. M., 5736
Shaw, R. J., 7196
Shay, J. W., 5796
Shé, M. N., 6708
She, Q-B., 1604, 3908
Sheen, I-S., 4238
Sheikh, M. S., 6918
Shekhar, M. P. V., 1320
Shelley, S. A., 5985
Shen, H., 3321, 8465
Shen, J., 3369, 6971
Shen, M-C., 3406
Shen, R., 3294
Sheng, H., 2670
Sheng, J. J., 3925
Sheng, S., 8676
Shepard, S. B., 582
Sher, Y-P., 5223
Shera, K., 1934
Sherman, D. H., 7770
Shete, S., 1354
Sheu, B-C., 237
Sheu, G-T., 2799
Sheu, J-C., 8094
Shi, H., 8375
Shi, H. H., 5998
Shi, H. Y., 6945
Shi, L., 3465
Shi, Q., 71, 4143
Shi, X., 4655, 8051
Shi, Y. E., 2365
Shi, Z., 1065
Shibata, D., 4541, 5875
Shibata, E., 7449
Shibata, K., 1144
Shibata, M-A., 7449
Shibuki, H., 7627
Shibuta, K., 5714
Shibutani, S., 3925
Shibuya, M., 1207
Shichijo, S., 2038
Shields, P. G., 6350, 6367
Shientag, L., 333
Shigematsu, H., 7627
Shigeno, K., 7101
Shih, C-S., 2727
Shih, H., 7248
Shih, I-M., 818
Shih, J-Y., 5223
Shih, W. J., 4010, 5002
Shiina, H., 7101
Shikata, T., 3373
Shiloh, Y., 1849, 4561
Shim, Y-H., 2847
Shim, Y-S., 6163


* *For title of article and coauthors, see listing in Contents of Volume 61 beginning on page 9015 at the end of this index issue.*

Shimada, H., 5587
Shimada, K., 6335
Shimada, M., 1005
Shimada, Y., 2632, 6629
Shimizu, A., 5778
Shimizu, K., 228, 2618, 4809, 7743, 8105
Shimizu, M., 1874, 2500
Shimizu, N., 6987
Shimizu, Y., 6656
Shimkets, J., 3131
Shimkets, R., 3131
Shimura, H., 3640
Shin, K-H., 3541
Shin, M. S., 4942
Shing, Y., 5731
Shinohara, T., 673
Shintaku, I., 5132
Shintaku, P. I., 7925
Shintani, Y., 4365
Shinya, H., 8381
Shiohara, M., 3361
Shiomi, S., 1843
Shiotani, H., 1451
Shiozaki, H., 3188, 5570
Shirabe, K., 1005
Shirai, T., 4693
Shirakawa, K., 445
Shirakawa, Y., 4345
Shirasaki, F., 7422
Shirin, H., 725
Shito, K., 7020
Shivapurkar, N., 5727
Shkarin, P., 4740
Shochat, D., 2843
Shoemaker, J. S., 7964
Shofuda, T., 7900
Shogan, J., 363
Shono, T., 4375
Shor-Posner, G., 1457
Shou, J., 7291
Showe, L., 8306
Shows, T. B., 8274
Shridhar, V., 4258, 5895
Shrieve, D. C., 2376
Shrubsole, M. J., 7136
Shu, S., 2031
Shu, X-O., 7136
Shuin, T., 4184
Shukla, A., 1791
Shuman, M. A., 2533
Shureiqi, I., 4879, 6307
Shurin, G. V., 363
Shurin, M. R., 363
Shvedova, A. A., 7777
Shyam, K., 3033
Shyr, Y., 5389
Shyu, W-C., 4238
Sibona, N., 2200
Siccardi, A. G., 5517
Siddiqui, Y., 3627
Sidell, N., 3998
Sidransky, D., 939, 1309, 2092, 7015, 7623, 8113
Sieg, D. J., 7079
Siegal, G. P., 6313
Siegert, A., 303
Siegmund, K., 2381
Sierk, A. J., 3124
Sierra-Rivera, E., 2413
Signori, E., 1555
Sikes, C. R., 5652
Sill, H., 2335
Silva, E. G., 7264
Silva, G. L., 4030
Silva, J. M., 8595
Silver, A., 1820
Silverman, G. A., 1776
Sim, B. K. L., 7669
Simi, B., 3647
Simiantonakis, I., 8441
Simmons, H. H., 4750
Simmons, M. L., 1122
Simms, L., 6046
Simon, B., 5905
Simon, R., 355, 4514, 5153
Simon, S. M., 7763
Simons, J. W., 2736, 7464
Simons, L. A., 6619
Simpson, A., 7375
Simpson, J. F., 8887
Sinclair, C., 4951
Sindram, D., 1233
Singal, R., 4820
Singer, F. R., 2602
Singer, L. A., 1013
Singer, S., 8118
Singh, B., 4061, 4506
Singh, J. S., 4197
Singh, R., 4701, 8227
Singh, V., 5106
Singhal, A. K., 459
Singletary, S. E., 8465
Sinn, H-P., 8441
Sissons, S. E., 3369
Sivridis, E., 7992
Sizeland, A., 6665
Sjöblom, T., 5778
Sjöquist, M., 2929
Skarlatos, J., 1830
Skawran, B., 7608
Skinner, H., 8540
Skinner, H. G., 4320
Skinner, K. A., 3410
Skorecki, K. L., 5529
Skorski, T., 2194, 6517
Skowronski, E., 5741
Skrzat, S., 131
Slack, R., 5284
Sladek, T. L., 348
Slager, S. L., 6494
Slany, R. K., 6480
Slater, R., 5374
Slattery, M. L., 126, 1000
Slawin, K. M., 2562, 6795
Sledge, G. W., Jr., 3369
Sleeman, J. P., 1569
Slezak, P., 2676
Slijepcevic, P., 912
Sliwkowski, M. X., 4467
Slootstra, J. W., 2552
Slosman, D. O., 7971
Slovak, M. L., 831
Slupianek, A., 2194, 6517
Slupsky, J. R., 3595
Small, E. J., 2533
Smeekens, S. P., 6276
Smets, G., 131
Smid, K., 1585, 3675
Smilenov, L. B., 5710
Smirne, C., 2200
Smit, V. T. B. H. M., 1171
Smith, A. K., 4599
Smith, A. M., 625
Smith, B. A., 1678
Smith, D. I., 4258, 5895
Smith, D. R., 8179
Smith, E., 6906
Smith, E. M., 2232
Smith, H. J., 3604
Smith, I., 8452
Smith, K. J., 7196
Smith, L. E., 7110
Smith, L. R., 7861
Smith, P. H., 4357
Smitherman, P. K., 5461
Smitt, P. S., 8743
Smoot, D. T., 2399
Smorodinsky, N. I., 4561
Smyth, F. E., 4474
Smyth, J. F., 2169, 6977
Snell, V., 3355
Snow, G. B., 1970
Snyder, J. D., 2953
So, B-J., 984
So, T., 2022
Soares, F., 7375
Sobol, R. W., 7399
Söder, O., 706, 6423
Söderlund, T., 3978
Sodhi, A., 2641
Soeltl, R., 1272
Soh, J-W., 725
Sohn, K. H., 1386
Sohn, K-J., 6912
Sohn, O. S., 8435
Soifer, S. J., 8629
Sokoloff, M. H., 2833
Solaiyappan, M., 3039
Solary, E., 1645
Solbach, C., 1045
Solorzano, C. C., 7048
Soloway, P. D., 3610
Sommer, A., 5790
Son, Y-I., 884
Sondel, P. M., 1500
Sone, S., 469, 673
Sonenshein, G. E., 3810
Song, C., 3272
Song, J. I., 5919
Song, J. J., 1299
Song, M. S., 8322
Song, S., 2162
Song, S. H., 4628, 6145
Song, W., 2562, 6783, 7530
Song, Y., 4773
Soni, S., 8520
Sonneveld, P., 3937
Sonoda, Y., 4956, 6674
Sood, A. K., 4371
Sopov, I., 1272
Soprano, D. R., 7552
Sordillo, E. M., 1406
Sørensen, B. S., 6227
Sörensen, N., 7039
Sorensen, P. H. B., 8909
Soret, J., 6876
Sorger, K., 8880
Soria, C., 3450
Soria, J-C., 837, 7959
Sorokin, L. M., 5601
Souil, E., 3245
Soukos, N. S., 4490
Sounni, N-E., 3450
Soussan, P., 7803
Southeast Sweden Breast Cancer Group, 8448
Southern, S. A., 4858
Southey, M. C., 903
Southgate, J., 1678
Southwick, E. C., 7211
Sowter, H. M., 6669
Sozzi, G., 1578, 4675
Spadaro, M., 2809
Spagnoli, G. C., 197
Spahn, L., 5992
Spatz, A., 2480
Speel, E. J. M., 5186
Speiser, D., 5850
Spence, A. M., 3669
Spencer, D. I. R., 3653
Spencer, D. M., 2562, 6795
Spencer, M., 7623
Spencer, V. A., 1362
Sperling, K., 3570
Spessotto, P., 339
Sphicas, E., 439
Spieker, R., 739
Spila, A., 2523
Spinella, F., 8340
Spiroski, M., 8351
Spitz, D. R., 3486, 5537
Spitz, M. R., 1354, 1445, 3321, 7819, 7825, 8465
Spohn, B., 7142
Sporn, M. B., 8412
Sposto, R., 7404
Spring, K., 4561
Spurgers, K. B., 6693
Squire, J. A., 3826
Sreekumar, A., 7585
Srethapakdi, M., 2945
Sridhar, S., 7179
Srinivasula, S., 2713
Srinivasula, S. M., 5796
Sriuranpong, V., 3200
Sroka, T. C., 3308
St. Clair, D., 6082
St. Croix, B., 6649, 6996
Stables, J., 7196
Stack, M. S., 1855, 3194
Stad, R., 1839
Stadheim, T. A., 1533
Stadler, W. M., 2833
Stahel, R. A., 4761
Stål, O., 8448
Stamenkovic, I., 577
Stamp, G., 4961
Stampfer, M., 6708
Stampfer, M. R., 1250
Stanbridge, E. J., 4536, 7118, 8924
Stanczyk, F. Z., 3326
Stankovic, T., 8547
Stanley, M. W., 8564
Stanyon, R., 6255
Staratschek-Jox, A., 2080
Stark, L. A., 7060
Starkov, A., 771
Starling, J. J., 8412
Starr, J. R., 8459
Stas, M., 4916
Staub, J., 4258, 5895
Stavridi, E. S., 7030
Stavrou, D., 6624
Steeg, P. S., 2320
Stefanovska, A-M., 8351
Steffel, A., 8227
Steffensen, I-L., 5010, 8689
Stegmueller, M., 1045
Steinbauer, M., 5575
Steinberg, S. M., 2523
Steinhoff, C., 4214
Steinman, R., 6451
Steinmann, D., 7608
Steitz, J., 8643
Stella, A., 7020

* *For title of article and coauthors, see listing in Contents of Volume 61 beginning on page 9015 at the end of this index issue.*

Stephans, K. F., 8366
Stephens, J., 5453
Stephens, L. C., 3330, 3355
Sterin, M., 7536
Sterman, D. H., 6201
Stern, D. M., 4206
Stern, N., 1849
Stern, P. L., 192
Sterner, R. E., 8127
Sterner-Kock, A., 1045
Stetler-Stevenson, W. G., 6322
Stevanovic, S., 4072
Stevens, M. W., 1619
Stevnsner, T., 5378
Steward, W. P., 1058
Stewart, A. F., 6925
Stewart, A. G., 3182
Stewart, A. J., 749
Stewart, D. M., 8022
Stewart, J. C., 2301
Stewart, L. M. V., 4294
Stewart, S. K., 5028
Stewart, T. M., 5370
Stiegler, P., 462
Stiewe, T., 7052
Stigter, M., 1970
Stine, O. C., 6046
Stins, M. F., 5587
Stiouf, I., 3355
Stock, W., 2307
Stockert, E., 2055, 4671, 5349
Stødkilde-Jørgensen, H., 5318
Stoehlmacher, J., 8654
Stoffel, A., 4506
Stokoe, D., 2105
Stoler, D. L., 8274
Stolina, M., 6406
Stolk, J. A., 1563
Stone, A., 7130
Stone, J. C., 943
Stoner, G. D., 6112
Stoppacciaro, A., 309, 6532
Störkel, S., 4815
Storz, M., 452
Stoter, G., 6982
Stracke, M. L., 6938
Stram, D. O., 785
Straten, Pt., 493
Stratford, I. J., 6394
Stricker, P. D., 423, 5331
Strickfaden, S., 8290
Strieter, R., 6406
Strieter, R. M., 2183
Stringer, B. K., 582
Strittmatter, H-J., 8441
Strohmeyer, T., 4214
Strom, S. S., 3321
Stronach, E. A., 6977
Strout, M. P., 59
Struman, I., 7356
Stubberfield, C., 7196
Stuhrmann, M., 7608
Stumm, S., 4072
Stuppner, H., 5817
Sturgis, E. M., 3321
Su, A. I., 5974, 7388
Su, J-M., 2799
Su, L., 8718
Su, L-K., 2838
Su, Z-F., 3348
Suarez, B. K., 4982
Subbarayan, V., 2720
Subleski, J., 6255
Sublet, J., 8227
Suda, T., 6248
Sudilovsky, D., 6064, 8135
Suen, J., 2376
Sueoka, E., 1896
Sueoka, N., 1896, 6356
Suganuma, M., 6356
Sugaya, M., 2022
Sugenoya, Y., 3969
Sugimachi, K., 1005, 5714
Sugimoto, Y., 7563
Sugimura, M., 1451
Sugimura, T., 2632, 7739
Sugiyama, M., 8331
Suh, N., 8412
Suit, H. D., 39
Sukumar, S., 921, 8014
Suliman, Y., 6467
Sullards, M. C., 6723
Sumerel, L. A., 813
Suminami, Y., 1776
Sumitomo, M., 3294
Sumiyoshi, H., 5796
Sumiyoshi, T., 23
Sun, B., 6931
Sun, D., 4175
Sun, J., 1280, 2276
Sun, J. Z., 526
Sun, L., 3660, 4994, 6170
Sun, M., 5985
Sun, S., 327
Sun, T., 138
Sun, X., 3382, 5771
Sun, X-Y., 1810
Sun, Y., 8211
Sun, Z., 2112
Sundberg, C., 1768
Sung, T., 2124
Surh, Y-J., 850
Surmacz, E., 6747
Sutherland, R. L., 423, 5331, 8830
Sutter, G., 8647
Sutton, L. N., 1527
Suvarna, P., 5349
Suzuki, A., 6548
Suzuki, H., 3640
Suzuki, K., 4184, 5132, 5396
Suzuki, M., 3925
Suzuki, N., 3925
Suzuki, O., 7375
Suzuki, S., 1276
Suzuki, T., 2250
Suzuki, Y., 5132, 7900
Svanberg, E., 4707
Svechnikov, K., 6423
Swartz, G., 1022
Swartz, H. M., 4266
Swede, H., 8274
Sweeley, C., 6822
Sweeney, C., 7130
Sweeney, C. J., 3369
Sweep, C. G. J. F., 5407
Swift, L. M., 4024
Swinler, S. E., 256
Syed, V., 6768
Szeto, W., 4197
Szoka, F. C., Jr., 2592
Szpaderska, A. M., 3493
Szpirer, C., 8263
Szumiel, I., 912

**T**

Taback, B., 5723, 8845
Taccioli, G. E., 4520
Tada, Y., 5366
Tadakuma, T., 1276
Tada-Oikawa, S., 2878
Tafani, M., 2459
Tagawa, M., 5366, 8769
Taguchi, H., 5307
Tahara, Y., 4779
Taher, M. M., 764
Tahir, S. A., 3882, 4386
Tahir, S. K., 1486, 5480
Tait, A. S., 5803
Tait, L., 1320
Takada, K., 8697
Takagi, T., 3544, 6474
Takahashi, K., 2015, 3969, 7627
Takahashi, M., 23, 1122, 3949, 8697
Takahashi, N., 7846
Takahashi, S., 950, 1187, 2632, 4693
Takahashi, T., 2015, 5362, 7985, 8331, 8896
Takakura, M., 5796
Takakura, N., 6248
Takakuwa, T., 1382
Takano, H., 1592
Takaoka, A. S., 2751
Takaoka, M., 7855
Takashima, S., 2424
Takata, M., 7422
Takata, T., 7044
Takata, Y., 7855
Takayama, H., 1382
Takayama, K., 7882
Takayama, T., 8697
Takebayashi, Y., 504, 1964
Takeda, A., 5065
Takeda, T., 1843
Takehara, K., 7422
Takehara, T., 7563
Takei, Y., 8486
Takemoto, H., 3188
Takemoto, R., 8306
Takemura, H., 172
Takenaka, K., 8527
Takenoshita, S., 4620
Takenoyama, M., 2022
Takeoka, M., 7627
Taketo, M. M., 1733
Takeuchi, S., 3770
Takimoto, R., 8697
Takino, T., 7985, 8896
Talamini, G., 285
Talanian, R. V., 1138
Talbott, R., 8480
Talmadge, J. E., 8227
Talpaz, M., 138, 2343
Tamaki, Y., 14
Tamano, H., 5065
Tamanoi, F., 4701
Tamaoki, T., 3016
Tammela, T. L. J., 3550, 5340, 6038
Tamminen, A., 5718
Tamori, A., 1843
Tampé, R., 8647
Tamura, M., 2022
Tan, W., 3272
Tan, Y., 4017, 6805
Tanabe, K. K., 5447
Tanabe, T., 4628
Tanaka, F., 1666
Tanaka, M., 4414, 7518
Tanaka, N., 4345, 7743, 7855
Tanaka, S., 1005, 2145, 8527
Tanaka, T., 2424, 3544, 3741, 6345, 6474, 7333, 7722
Tanaka, Y., 97, 2022, 5714, 8401
Tang, C., 5284, 6170
Tang, C-B., 1527
Tang, D., 6708
Tang, H., 4143
Tang, L., 5106
Tang, M., 3795
Tang, M-s., 7110
Tang, Q., 4329
Tang, T. C-M., 3806
Tang, X., 837
Tanghetti, E., 2232
Taniguchi, H., 889
Taniguchi, M., 5570
Taniguchi, S., 7627
Tanimura, H., 6158
Taniwaki, M., 8371
Tanner, M., 1214, 5345
Tanno, Sac., 589
Tanno, Sat., 589
Tao, Q., 3735
Taquet, N., 6451
Taquet, S., 6451
Tartaglia, L., 6034
Tatematsu, Y., 8331
Tateno, M., 1144
Tatsumi, T., 7563
Tatsuta, M., 3969, 4885
Taube, T., 2517
Tavana, H., 4175
Tavecchio, L., 4675
Taverna, D., 5255
Tawatao, R., 7248
Taylor, A. M. R., 8547
Taylor, J., 6885
Taylor, J. M. G., 2390
Taylor, P. R., 4098
Tazelaar, H. D., 5636
Tazi, J., 6876
Tcheurekdjian, L., 831
Teh, B. T., 5950
TehraniYazdi, A. R., 6713
Teitell, M. A., 5311
Tekmal, R. R., 1910
Telleman, P., 7889
Tempero, M. A., 4923
Templeton, D., 749
Tendler, D. S., 3682
Tennenbaum, T., 4591
Tenzer, A., 8203
Teo, P. M. L., 3877
Terada, M., 445
Terasawa, H., 3725
Terashima, I., 3925
Terashima, M., 7101
Terheyden, P., 493
Terhorst, C., 6912
Terkeltaub, R., 2282
Terpe, H-J., 355
Terui, Y., 4414
Teshima, T., 162
Testa, J. R., 589
Teti, D., 6360
Tetsu, O., 854
Tevethia, S. S., 873
Tew, K. D., 3339
Thai, G., 859
Thakker, N., 2371
Thanos, D., 4583
Theaker, J. M., 1296
Theil, K. S., 59

** For title of article and coauthors, see listing in Contents of Volume 61 beginning on page 9015 at the end of this index issue.*

Thein, M., 3009
Then, F., 6445
Théret, N., 45
Therrien, J-P., 3781
Thews, O., 1358
Thiagalingam, S., 256
Thibodeau, S. N., 6494
Thiel, C., 2968
Thier, R., 4398
Thies, W-G., 1569
Thode, S., 4175
Thøgersen, V. B., 6227
Thomachot, M. C., 3096
Thomas, E. K., 228, 2618, 6868
Thomas, G. V., 4660
Thomas, M., 647
Thomas, P., 2822
Thomas, R. J. S., 7426
Thomas, R. S., 1879
Thomas, T. Z., 2239
Thomas, W. A., 6219
Thompson, A., 912, 7616
Thompson, A. M., 482
Thompson, P. A., 7130
Thompson, P. M., 679
Thompson, R. C., 842
Thompson, T. C., 3882, 4386
Thompson, W. J., 3961
Thomson, N. M., 5757
Thonnard, J., 3718
Thor, A. D., 348
Thorgeirsson, S. S., 2085, 6665
Thorpe, P. E., 8569
thor Straten, P., 493, 869, 5964
Thull, N. M., 859
Thurston, S. W., 8718
Thust, R., 7399
Thybo, T., 5378
Thykjaer, T., 2492
Tian, D., 6679
Tibaudi, D., 2200
Tice, D. A., 4197
Tiemann, F., 3053
Tilanus, H. W., 3164
Tilbrook, P. A., 2453
Tilley, W. D., 926
Timblin, C. R., 1791
Timchenko, N. A., 8564
Timme, T. L., 3882, 4386
Tinchon, C., 2335
Tindall, D. J., 7408
Tinelli, S., 7189
Tisdale, M. J., 3604
Tjuvajev, J. G., 2983
To, K-F., 3877
Todaka, T., 6248
Todd, A. V., 131
Todo, T., 153
Todoroki, T., 4365
Tofilon, P. J., 4375
Togashi, K., 4966
Tognon, C., 8909
Toh, H. C., 3704
Tohyama, K., 2878
Tohyama, Y., 2878
Tolkacheva, T., 4985
Tolleson, W. H., 3837
Tolnay, M., 5688
Tomarev, S. I., 8079
Tome, M. E., 2766
Tomei, G., 7501, 8730
Tomicic, M. T., 7399
Tomioka, D., 7518
Tomita, N., 14
Tomita, Y., 370
Tomizaki, K-y., 4459
Tomizawa, Y., 7943
Tomizuka, H., 4414
Tomlinson, G., 7943
Tomlinson, G. E., 7819
Tomlinson, J. S., 5231
Tommasino, M., 608
Tomonaga, M., 3770
Tomura, M., 3399
Tondelier, D., 1693
Tondravi, M., 6906
Tong, W-M., 8158
Tong, Y., 7530
Tonn, J. C., 7039
Topley, P., 7196
Torres, J. V., 1367
Tort, F., 2409
Tosatti, M. P. M., 309
Tosi, G. M., 462
Tosi, S., 4666
Touloukian, C. E., 8100
Towle, M. J., 1013
Townsend, A. J., 5461
Toyooka, K. O., 4556, 5727, 8659
Toyooka, S., 4556, 5727, 8659
Toyota, M., 3573, 4689, 8540
Tozer, G. M., 4784, 6413
Traganos, F., 3285
Tragni, G., 318
Traianedes, K., 2572
Trail, P. A., 8480
Traish, A. M., 3810
Tran, H., 5268
Trapasso, F., 1578, 4827
Trastek, V., 5636
Trasti, S. L., 6577
Travis, W. D., 5636
Trefzer, U., 303
Treilleux, I., 5024
Trejdosiewicz, L. K., 1678
Trencia, A., 1162
Trent, J. M., 4683
Trepel, J., 1671, 3750
Trepel, J. B., 931
Trepel, M., 8110
Treseler, P. A., 3472
Triche, T. J., 6185
Trinchieri, G., 2974
Triplett, J., 4679
Trippett, T. M., 1941
Tritt, R., 2220
Tritton, T. R., 2558
Trojan, A., 4761
Troncoso, P., 3795
Troso-Sandoval, T., 8492
Trott, D. A., 7594
Trouet, A., 2843
Trougouboff, P., 8820
Troussard, A., 6788
True, L., 5692
True, L. D., 1611
Truini, M., 1285
Truninger, K., 2813
Truong, T. D., 7889
Truong, T. K., 1338
Trusolino, L., 5861
Tsai, C-M., 2727
Tsai, E. M., 7413
Tsai, E-M., 8390
Tsai, S-C., 1412
Tsai, W-Y., 6708
Tsang, B. K., 1862
Tsang, K. Y., 3725, 7568
Tsao, C., 8118
Tsao, J-L., 4541
Tsao-Wei, D., 3212
Tsao-Wei, D. D., 8654
Tsarfaty, G., 4873
Tsarfaty, I., 4873
Tsavaler, L., 3760
Tschachler, E., 3619
Tschentscher, F., 3439
Tseng, W. W., 1464
Tseng, Y-H., 2071
Tso, C-L., 7925
Tsokos, M., 577, 2704, 4864
Tsubouchi, H., 3016, 4779
Tsuchida, K., 4985
Tsuda, H., 445, 1334, 6629
Tsuda, N., 2038
Tsujii, H., 5382
Tsujimoto, H., 4536
Tsujimura, T., 3399
Tsujinaka, T., 5570
Tsukada, Y., 7913
Tsukamoto, M., 4459
Tsukamoto, T., 2239
Tsukamoto, Y., 4206
Tsukasaki, K., 3770
Tsunoda, T., 2129, 3544, 3741, 6345, 6474, 7722
Tsuruo, T., 4459
Tsushima, T., 4671
Tsutsui, K., 6987
Tsutsumi, M., 1451
Tsutsumi, S., 889
Tsutsumi, T., 4365
Tsutsumi, Y., 5070
Tu, H., 7803
Tugendreich, S., 4175
Tulac, S., 4175
Tulsian, P., 4160
Tuominen, E. K. J., 3978
Tur, M. K., 8737
Turka, L. A., 3077
Turley, H., 5262
Turlin, B., 45
Turnbull, L., 1624
Turner, K., 3206
Turner, S., 3863
Turner, S. J., 1296
Turner, W. R., 4112
Tüting, T., 8643
Tuveson, D. A., 8118
Tweddle, D. A., 8
Tyagi, R., 2162
Tykocinski, M. L., 8127
Tyurina, Y. Y., 7777
Tzukerman, M., 5529

## U

Uchida, H., 7009
Uchida, K., 2395
Uchida, Y., 8371
Uchiyama, T., 2878
Ueda, K., 6158
Ueda, M., 4414
Ueda, R., 4244
Ueda, T., 172
Ueki, T., 8540
Uekusa, Y., 3399
Uematsu, K., 5959, 8527
Ulbricht, U., 6624
Ulbright, T. M., 2220
Ulinski, G., 6768
Ullrich, R. L., 1820
Ulmer, J., 6002
Umansky, F., 4612
Umar, S., 2899
Umbricht, C. B., 2782
Underhill, C. B., 1022, 2434, 5207
Unger, P., 5644
Uno, F., 7855
Unoki, M., 3741
Unverzagt, C., 957
Urakami, S., 7101
Urasaki, Y., 53, 172, 504, 1964
Urdiales-Ramos, J., 6281
Ursin, G., 3326
Ushijima, T., 2632, 7739
Ushio, Y., 6248
Uskokovic, M., 3361
Uto, H., 3016, 4779
Uwai, M., 4414

## V

Vacek, P. M., 3432
Vähäkangas, K. H., 4350
Vahteristo, P., 5718
Vaidya, B., 7318
Vail, M. E., 594
Vajkoczy, P., 6830
Vakar-Lopez, F., 8659
Valduga, G., 7495
Vale, T., 602
Valerie, K., 764
Valle, D., 1810
Vallorosi, C. J., 489
Vallyathan, V., 8051
Valmori, D., 509, 2047, 5153, 5850
Valve, E. M., 4229
van Beerendonk, H., 1171
van Bokhoven, A., 6340
Van Camp, B., 2862
van Dekken, H., 3164
van de Laar, A., 6635
van den Broeke, L. T., 6868
Vandenbunder, B., 2656
van den Oord, J. J., 4916
van der Bruggen, P., 197
van der Eb, A. J., 1839
van der Heyden, M., 278
Vanderkerken, K., 2862
van der Kuip, H., 7635
van der Kwast, T. H., 1265, 5407
van der Molen, H., 4105
van der Poel, H., 7464
Van derpoorten, K., 2843
van der Velden, P. A., 5303
van der Wilt, C. L., 3675
van der Zee, A. G. J., 27, 7305
van de Vijver, M. J., 3458
van de Wetering, M., 278
van de Winkel, J. G. J., 4055
van Dongen, G. A. M. S., 1970
van Drunen, E., 5374
van Egmond, M., 4055
van Garderen, E., 4055
van Gastelen, M. A., 3458
Vanhoefer, U., 392
Vanin, E. F., 5810
Van Kerckhove, J., 486
van Kranen, H. J., 977
Van Meir, E. G., 1162
van Putten, J. W. G., 1585
Van Riet, I., 2862
Van Schaftingen, E., 3718
van Spriel, A. B., 4055
van Steeg, H., 977

** For title of article and coauthors, see listing in Contents of Volume 61 beginning on page 9015 at the end of this index issue.*

Van Tuyle, G., 3894
Van Waes, C., 4797, 5911
van Wering, E., 5374
van Wert, J., 4820
van Wijk, A., 1398
Varakis, J. N., 4287
Varambally, S., 7585
Vardiman, J. W., 7233
Varella-Garcia, M., 6340
Varley, J. M., 5948, 8062
Varmi, M., 8340
Varner, J., 2232
Varney, M., 8227
Varon, R., 3570
Varricchio, F., 8058
Varsanyi-Nagy, M., 5741
Vasi, N. H., 2953
Vasile, S., 3660
Vassalli, J-D., 970
Vassart, G., 4130
Vasselli, J., 8143
Vasudevan, K. M., 7255
Vatolin, S., 6002
Vaughan, A. T. M., 4550
Vaupel, P., 1358
Vazquez, M., 7971
Vecchio, G., 1426
Vecchione, A., 1578, 4827
Veerman, G., 3675
Veigl, M. L., 8290
Veikkola, T., 6511
Velasco, G., 5784
Velasco, M. A., 1375
Velcich, A., 565, 570, 3465, 6297
Velders, M. P., 5857, 7861
Velickovic, M., 4815
Vellagas, R., 1464
Vellenga, E., 7654
Venet, M., 131
Venkatasubbarao, K., 6239
Venter, D. J., 903
Venzon, D., 4382
Venzon, D. J., 5028
Verbeken, E., 5057
Vercoutter-Edouart, A-S., 76
Verde, P., 2267
Vergnon, I., 4078
Verma, A., 3561
Verma, A. K., 808
Vermeulen, H., 4055
Verschoyle, R., 1058
Verwiebe, E. G., 808
Vesci, L., 7189
Vespignani, I., 1555
Vesprini, D., 5420
Vessella, R., 1611
Vessella, R. L., 3550
Vetter, H., 4398
Vicent, D., 2071
Vichier-Guerre, S., 950
Vidaud, D., 1919
Vidaud, M., 1652, 1919
Vieira, H. L. A., 1260
Vieira, S. A. D., 8005
Vierimaa, O., 4541
Vierumäki, R., 2813
Vieweg, J., 3388
Viglietto, G., 2267, 4583
Viitanen, T. P., 4229
Vikhanskaya, F., 935
Vile, R. G., 7240
Vilkki, S., 4541
Villalobos, M. J., 4550
Villani, R., 7501
Villani, R. M., 8730
Viloria-Petit, A., 5090
Vincan, E., 7426
Vincent, J. J., 5070
Vinson, M. A., 6025
Virant, S. M., 5045
Virgin, J., 4283
Virmani, A. K., 249, 3581, 4556, 8659
Visakorpi, T., 3550, 5340
Visconti, R., 1426
Visser, G. W. M., 1970
Vissers, K. J., 3164
Vitolo, M., 4994
Vivanco, I., 1686
Vivat-Hannah, V., 8703
Vizoso, F., 7091
Vlodavsky, I., 4655
Vogelmann, R., 3508
Vogels, R., 8743
Vogelstein, B., 33, 256, 818, 3801, 6649, 6996, 7719, 7798
Vogelzang, N. J., 2533
Vogg, A. T., 3853
Voglino, G., 608
Vojnovic, B., 6413
Vokes, E. E., 2307
Voland, J. R., 5349
Volk, E. L., 5461
Vollmar, A. M., 5817
Vomastek, T., 2713
von Bergwelt-Baildon, M. S., 8366
Vonderheide, R. H., 4761, 8366
von Fournier, D., 8441
von Heydebreck, A., 7731
von Kienlin, M., 5595
von Lindern, R., 7413
von Melchner, H., 6925
Von Stein, O. D., 1569
von Tempelhoff, G-F., 7697
von Zglinicki, T., 3053
Voorn, D. A., 3675
Vorm, O., 957
Vozianov, A., 6964
Vries, A. W-d., 977
Vrignaud, P., 1996
Vrouenraets, M. B., 1970
Vujcic, S., 6437
Vukovic, V., 7394
Vulevic, B., 3339

## W

Waalkes, M. P., 455
Wachsberger, P. R., 5630
Wächter, G. A., 5486
Wachter, Y., 4731
Wada, H., 1666
Wada, R. K., 1073, 3998
Wada, Y., 6012
Wadler, S., 4910, 6170
Waga, K., 6281
Wagenaar, R. A., 2097
Wagenbach, N., 7118
Wagenpfeil, S., 1903
Waghray, A., 4283
Wagner, A., 7020
Wagner, L. M., 5083
Wagner, M., 3853, 4526
Wagner, M. W., 5193, 8290
Wagner, T., 6783
Wagner, U., 4514
Wahl, M. L., 5630
Wahrer, D. C. R., 8062
Waidyaratne, S. N., 6185
Wain, G. V., 4576
Wain, J. C., 612, 3419, 8718
Wainstein, A., 8520
Wakao, D., 8371
Wakasugi, H., 445
Wakatsuki, Y., 6356
Wakeling, A. E., 6739
Wakimoto, N., 2665
Wakita, K., 854
Waksman, G., 474
Walentinsson, A., 8263
Walker, A. M., 6098
Walker, M., 4061
Walker, P. R., 2047
Wallace, J., 2212
Wallace, K. B., 771
Wallenius, V., 8263
Wallwiener, D., 4072
Walsh, B. J., 5803
Walsh, C., 6145
Walsh, E. S., 3339
Walsh, G. L., 7959
Walsh, M. D., 827
Walshaw, M. J., 1624
Walter, K., 7616
Walter, K. M., 8540
Walther, P. J., 8712
Waltman, J. L., 53
Wan, D., 7383
Wan, H., 556
Wang, B., 71, 4143, 7142
Wang, B-S., 3406
Wang, C-Q., 3647
Wang, C-X., 8683
Wang, E-j., 7525
Wang, F., 5295
Wang, G., 7920
Wang, He., 8917
Wang, Hongt., 5102
Wang, Hongy., 5425, 8554
Wang, Hu., 270, 8554
Wang, H-J., 5723, 8787, 8845
Wang, Jians., 4112
Wang, Jianx., 4386
Wang, Jingl., 145
Wang, Jingx., 6548
Wang, J-B., 33
Wang, J-J., 1412
Wang, K. Z. Q., 478
Wang, Lia., 6494
Wang, Lin., 3908
Wang, Lu., 7417, 7959
Wang, L. G., 7544
Wang, L-E., 1354, 1445, 8465
Wang, L-S., 2727
Wang, Me., 7211
Wang, Mingh., 7882, 8361
Wang, Mings., 2365
Wang, Q., 486
Wang, Q-c., 5070
Wang, Q-H., 4098
Wang, R-F., 7920
Wang, Sha., 3176
Wang, Shun., 1611
Wang, Shuy., 110
Wang, S-C., 2838, 8390
Wang, Tia., 3682
Wang, Tim., 8811
Wang, V. W., 4169
Wang, Wei., 5505
Wang, Wen., 4707
Wang, Xia., 6716
Wang, Xin, 7417
Wang, Xinr., 3321
Wang, X. Q., 1598
Wang, X-F., 3556
Wang, X-J., 7435
Wang, X-Y., 739
Wang, Ya, 8554
Wang, Yan, 138
Wang, Yang., 3787
Wang, Yanl., 5370
Wang, Yanp., 3176
Wang, Yi., 5420
Wang, Yo., 8412
Wang, Yua., 1013
Wang, Yue, 1754
Wang, Yul., 8211
Wang, Yun., 1354
Wang, Yuz., 6064, 8135, 8143
Wang, Za., 3062, 7171
Wang, Zhl., 2583, 5106
Wang, Zhip., 3610
Wang, Zi., 7211
Wang, Z-Q., 8158
Wang-Rodriguez, J., 5974
Wanherdrick, K., 4122
Wani, A. A., 64
Wani, G., 64
Wani, M. A., 64
Wannenmacher, M. F., 8441
Ward, J. M., 6255, 8751
Ward, M. D., 6002
Ware, J. L., 4791
Waring, P., 4561
Warloe, T., 5824
Warmka, J. K., 1855
Warren, C., 5948
Warren, P., 6783
Waser, B., 4636
Washington, M. K., 5389
Wasik, M. A., 2194, 6517
Wasserheit, C., 2996
Watanabe, M., 4061, 5396, 6255
Watanabe, N., 2632, 7739
Watatani, M., 23
Watkins, D. N., 2816, 6649
Watson, D. K., 4112
Watson, M. A., 1825, 5692
Watson, P., 6669, 7020
Watson, P. H., 2071, 5262
Watson, R., 4716
Watson, S. A., 625
Watt, F. M., 5248
Watt, K. P., 6977
Wattenberg, E. V., 1855
Watters, D., 4561
Waxman, D. J., 4437
Wazer, D. E., 8014
Weaver, D., 8851
Webber, M. M., 455
Weber, B., 5179
Weber, B. L., 5420
Weber, C. K., 3595
Weber, M. J., 2713
Weber, M. M., 8601
Weber, W. A., 1781
Webster, A., 6739
Webster, L., 5168
Wedlich, D., 3508
Weeks, B. H., 7435
Weeks, J. K., 5078
Wehland, J., 5024
Wei, K., 7413
Wei, L., 2439
Wei, L. L., 5284
Wei, Q., 1354, 1445, 3272, 3321,

** For title of article and coauthors, see listing in Contents of Volume 61 beginning on page 9015 at the end of this index issue.*

8465
Wei, S., 1178
Wei, S. H., 8375
Wei, S. J., 3486, 7689
Wei, Y., 6783
Weigand, M. A., 243
Weigel, N. L., 4294
Weil, M. M., 1820
Weinberg, R. A., 3858, 8838
Weiner, L. M., 4750
Weiner, R., 7356
Weinstein, I. B., 725, 3188
Weinstein, J. K., 1291
Weintraub, D., 880, 3689
Weisburger, J. H., 8435
Weise, S., 7608
Weiss, L., 8851
Weissman, B. E., 7943
Weiss-Steider, B., 6281
Weisz, A., 6360
Weitzman, S. A., 921, 2782
Welch, D. R., 1765, 8866
Welch, J., 1154
Welford, S. M., 5311
Weller, M., 2744, 2759, 5833
Wels, B. F., 1013
Welsh, J. A., 4350, 5636
Welsh, J. B., 5974, 7388
Welsh, S., 1013
Welshons, W. V., 5771
Welt, S., 4474, 6851
Welzel, N., 1629
Wen, J., 6860
Wen, W-H., 3212
Wen, Y., 7142
Wendt, M. A., 5736
Werdell, J., 1320
West, C. M. L., 2907, 5948, 6394
West, D. C., 4357
Wester, H-J., 1781
Westerdahl, K., 3267
Westhof, A., 6925
Weston, V. J., 8547
Westphal, E-M., 6925
Westphal, M., 6624
Westra, W., 939
Westra, W. H., 1309, 2092
Weterman, M. A. J., 4130
Wetmore, C., 513
Wetzler, M., 1747
Weyant, M. J., 118, 2547
Weynants, P., 3718
Wheeler, C. J., 842
Wheeler, D. L., 808
Wheeler, T. M., 497, 6025
Whitaker, G. B., 8569
White, A., 3937
White, J. T., 1611
White, M. A., 602
White, P. S., 679
White, R. L., 7713
White, S. B., 4136
White, V. A., 3439
Whitehall, V. L. J., 827
Whitehead, C. M., 3961
Whitehead, R., 497
Whitehead, R. H., 7426
Whitehouse, A. S., 3604
Whitman, S. P., 59, 7233
Whitton, J., 3566
Wick, J. B., 4017
Wick, W., 2744, 2759, 5833
Wickenhauser, C., 2080
Wickham, T. J., 2953
Wickramasinghe, K., 3410
Wickström, S. A., 6511
Wieczorek, A. A., 1464
Wiederschain, D., 1741
Wiemann, S., 8880
Wiemels, J. L., 2542
Wiemer, E., 3937
Wiencke, J. K., 612, 3419, 3949
Wienrich, B. G., 3619
Wientjes, M. G., 6145
Wierdl, M., 5078, 5083
Wiese, C., 1129
Wiesener, M. S., 5215
Wiestler, O. D., 5242, 7039
Wiewrodt, B. R., 1314
Wiewrodt, R., 6201
Wigginton, J. M., 6255
Wilander, E., 608
Wilber, K., 4514
Wilcox, C. S., 7211
Wild-Bode, C., 2744
Wilentz, R. E., 4320
Wilhelmi, A., 2311
Wilkinson, M. C., 5619
Wilks, D. P., 2907
Williams, C., 8412
Williams, C., Jr., 6851
Williams, D. A., 5116
Williams, D. E., 6788
Williams, J. H., 2453
Williams, J. L., 3285
Williams, L. T., 8629
Williams, M., 1058
Williams, N. N., 4827
Williams, P. J., 2572, 4418
Williams, T. A., 5861
Williams, T. M., 8758
Williamson, E. A., 5307
Wills, R., 8480
Willson, J. K. V., 256, 3801
Willson, T. M., 2917
Wilson, E. M., 2892, 4315
Wilson, J., 6413
Wilson, J. B., 6730
Wilson, J. L., 4961
Wilson, J. M., 6201
Wilson, J. W., 8803
Wilson, K. T., 2399
Wilson, M., 1255, 3326
Wiltrout, R., 1707
Wiltrout, R. H., 6255
Wiltrout, T. A., 6255
Windsor, L. J., 6264
Winter, C. R., 1765
Winter, P. M., 2002
Winter, R. N., 1227
Wipf, G. C., 1934
Wirths, S., 6846
Wisman, G. B. A., 27
Wisniewski, N. A., 7964
Wistuba, I. I., 3795
Witte, L., 7002
Witte, O. N., 3256
Wittkowski, K. M., 6451
Witzens, M., 4761
Wodarz, D., 3501
Wohlwend, A., 970
Wojcik, A., 912
Wojno, K. J., 8651
Wolber, F. M., 2445
Wolburg, H., 5833
Wolf, A., 7616
Wolf, C. R., 3299
Wolf, E., 8601
Wolf, H., 2492, 6227
Wolf, J., 2080
Wolf, J. E., 4306
Wolf, P., 8113
Wolf, S., 2809
Wolff, K., 8188
Wolfgang, C. D., 8122
Wollscheid, U., 1095
Won, J. H., 4405
Wong, A., 1113
Wong, C. S., 3348
Wong, C. W., 333
Wong, D. J., 8284
Wong, D. T., 6467
Wong, E., 7934
Wong, K., 3561
Wong, L. C., 5998
Wong, M., 2105
Wong, M. K. K., 478
Wong, T. A., 4197
Wong, W. Y. L., 4306
Woo, E. Y., 4766
Wood, C. G., 5652
Wood, E. R., 7196
Wood, K., 8820
Wood, L. V., 5028
Woodruff, J. M., 3171
Workman, C., 2492
Workman, P., 4003
Worley, B. S., 6868
Wormke, M., 3902
Worth, L. L., 4066
Woster, P. M., 5370
Wotawa, A., 1645
Wouters, B. G., 145
Wouters, D., 3675
Wouters, W., 131
Wrensch, M., 3949
Wright, F. A., 1619
Wright, G. L., Jr., 6029
Wright, M. J., 2453
Wu, A., 3009
Wu, C-L., 7325
Wu, C-W., 5223
Wu, D. S., 6064
Wu, G-j., 4951
Wu, H., 3256
Wu, J. M., 2289
Wu, L., 939, 1309
Wu, L. C., 7943
Wu, M., 7383
Wu, R., 5223, 8247
Wu, S-L., 8873
Wu, T. C., 5499
Wu, T-C., 1080, 3698
Wu, X., 1354, 3176, 3826, 5295, 7819, 7825
Wu, Y., 33, 138, 7002
Wu, Y-Q., 8651
Wucherpfennig, K. W., 8366
Wuertz, B. R. K., 2857
Wulbrand, U., 5905
Wu-Wong, J. R., 1486, 5480
Wyche, J. H., 7148
Wycoff, C. C., 6394
Wyke, A. W., 8385
Wykoff, C. C., 5262, 7992
Wypych, J., 5453

## X

Xia, F., 270
Xia, W., 5644
Xia, X., 2376
Xia, Z., 1747, 8366
Xiang, R., 1500, 6178, 8498
Xiao, G-H., 589
Xiao, H., 1533, 7325
Xiao, J., 2899
Xiao, S., 8118
Xiao, Y., 7015, 7623
Xiao, Z., 6029
Xie, D., 8917
Xie, K., 71, 4143, 7142
Xie, X., 6795
Xie, Z., 1260
Xinarianos, G., 1624
Xing, D., 3272
Xiong, P., 8465
Xiong, Q., 71, 4143
Xiong, S., 1727
Xiong, Y., 1347
Xu, B., 7383
Xu, G. W., 4155
Xu, J., 1563
Xu, L., 3176, 6020, 8569
Xu, L-L., 8718
Xu, M., 4017, 6805
Xu, W., 8074
Xu, X., 2434, 3084, 4879, 5207, 6098
Xu, X. L., 7943
Xu, X. S., 3775
Xu, X-C., 4306, 7999
Xu, Y., 1879, 2220, 3321, 5116
Xue, L., 2194, 6517
Xue, Y., 6082

## Y

Yagasaki, F., 8371
Yager, J. D., 7488
Yahalom, J., 439
Yakes, F. M., 6583, 8887
Yalon-Hacohen, M., 5529
Yalowich, J. C., 7777
Yamada, A., 6459, 8896
Yamada, M., 4414
Yamada, T., 1666, 2751
Yamada, Y., 1874, 7699
Yamaguchi, C., 5382
Yamaguchi, N., 3399
Yamaguchi, T., 8256
Yamamoto, Akif., 7900
Yamamoto, Akir., 7913
Yamamoto, H., 3139, 3188, 6822, 7727
Yamamoto, K., 1451
Yamamoto, M., 3299, 7882
Yamamoto, T., 2361
Yamamura, H., 3969
Yamamura, T., 1029
Yamana, H., 6474
Yamano, T., 14, 5570
Yamaoka, Y., 2129
Yamashina, I., 950
Yamashita, J., 7985, 8896
Yamashita, K., 7379
Yamashita, T., 2665
Yamashita, Y-i., 1005
Yamaue, H., 6158
Yamaura, A., 8769
Yamazaki, M., 1637
Yamini, P., 7608
Yamori, T., 4459
Yan, D-H., 7142
Yan, F., 963, 8668
Yan, H., 7719, 7798

** For title of article and coauthors, see listing in Contents of Volume 61 beginning on page 9015 at the end of this index issue.*

Yan, L., 5731
Yan, P. S., 8375
Yan, Q-W., 6635
Yan, T., 8290
Yanagawa, R., 2129, 3544, 6474
Yanagi, H., 1029, 4206
Yanagihara, K., 1666, 2632
Yanagisawa, K., 8331
Yanagisawa, N., 19
Yancey, D. R., 3388
Yang, C., 8811
Yang, C. S., 5002
Yang, C-T., 5959
Yang, D., 5857
Yang, F., 2112
Yang, G., 3105, 3882, 4386
Yang, J., 4010, 4901, 5652, 8150
Yang, J. C., 5511, 7920
Yang, J-M., 3806, 4010
Yang, K., 565, 7934
Yang, K-C., 6345
Yang, L., 3586
Yang, M., 3131
Yang, N., 7383
Yang, P-C., 5223
Yang, Q., 8158
Yang, Q-e., 5028
Yang, R. S. H., 1879
Yang, S., 2328
Yang, S. C., 1309
Yang, S. Q., 5016
Yang, S-C., 5223
Yang, S-T., 8569
Yang, W., 7840, 8179
Yang, W. C., 565, 6297
Yang, W-H., 2008
Yang, X., 2833, 5284, 7025
Yang, X-H., 348
Yang, Y., 2420, 2439, 3735
Yang, Z-Q., 6629
Yanik, G. A., 8513
Yano, M., 3188, 5570
Yano, S., 6248
Yanovsky, M., 2696
Yansura, D. G., 4197
Yao, F., 4283
Yao, M., 7277
Yaremko, B., 2232
Yashiro, M., 889, 2676
Yasuda, M., 2022
Yasuda, T., 3188
Yasui, A., 50
Yasumoto, K., 2022
Yasunaga, Y., 5969
Yasutomi, M., 23
Yaswen, P., 1250
Yates, A. J., 7404
Yazgan, O., 916
Ye, C., 478
Ye, S., 1296
Ye, Y., 7383
Yeatman, T. J., 7792
Yeh, C-C., 5959
Yeh, E., 4175
Yeh, G. C., 3919
Yeh, H., 4766
Yeh, K-T., 8873
Yeh, N. T., 5911
Yeh, P., 3450
Yeh, Y-W., 8873
Yehia, G., 6055
Yen, H-C., 6082
Yeo, C. J., 4320, 8540
Yeung, C., 3750
Yeung, K., 7148
Yikang, S., 8395
Yin, J., 6046
Yin, X-Y., 6487
Yin, Z., 339, 2232
Ying, H., 842
Yiu, G. K., 6768
Ylä-Herttuala, S., 1786
Yoden, T., 3969
Yokose, T., 2177, 7950
Yokoyama, Y., 8371
Yoneda, T., 2572, 4418, 7101
Yong, V. W., 1162
Yong, W. H., 842, 5601
Yonou, H., 2177
Yoo, C-G., 6163
Yoo, N. J., 4942
Yoon, J-H., 7110, 8158
Yoon, S. S., 5447
Yoshida, A., 172
Yoshida, B. A., 2833
Yoshida, H., 8395
Yoshida, J., 6151
Yoshida, M., 4459, 6356
Yoshida, M. C., 2632
Yoshida, S., 4244
Yoshida, Y., 2878
Yoshikawa, R., 1029
Yoshimatsu, K., 1013
Yoshimi, N., 1874, 6971
Yoshimine, T., 4809
Yoshimoto, M., 445
Yoshimura, A., 8527
Yoshimura, N., 7627
Yoshinaga, K., 7379
Yoshino, T., 4345, 7743
Yoshioka, M., 3432
Yoshitani, S-i., 2424
You, D., 8703
You, L., 5959
You, M., 4030
You, Z., 197, 3704
Young, A. Z., 6008
Young, J., 827, 6046
Young, J. D., 7217
Young, L. J. T., 8298
Young, M. R., 4160
Young, P. E., 7978
Yousef, G. M., 3425, 7811
Youssef, E. M., 6698, 7999
Yu, A. L., 7333
Yu, B., 1338, 6170
Yu, Chund., 5295
Yu, Chunr., 5106
Yu, D., 1727
Yu, D. C., 7464
Yu, D-C., 517, 5453, 6428
Yu, D-Y., 984
Yu, F., 4136
Yu, H., 3276
Yu, J., 186, 333, 1810, 3443, 3801, 7333
Yu, J. S., 842
Yu, L., 8683
Yu, M. C., 3326
Yu, M. J., 1013
Yu, Q., 2439
Yu, W., 6569
Yu, W-h., 577
Yu, X., 6783, 8611
Yu, Y., 1820, 8150
Yuan, F., 3281
Yuan, R-q., 8022
Yuan, Y., 5558
Yuan, Z-M., 6703
Yuan, Z-q., 5985
Yuan., Z-M., 1741
Yuen, P., 2542
Yukawa, O., 5885
Yun, C-o., 2404
Yung, W. K. A., 6693
Yuspa, S. H., 4591
Yusta, B., 687


## Z


Zabriskie, R., 1820
Zacharatos, P., 538
Zacksenhaus, E., 8395
Zafrakas, M., 6682
Zaharoff, D. A., 3281
Zahnow, C. A., 261
Zajchowski, D. A., 5168
Zalutsky, M. R., 1548
Zamboni, G., 285
Zamora, A. J., 1196
Zanker, K. S., 2866
Zantek, N. D., 2301
Zapf, J. W., 3632, 6619
Zardi, L., 711
Zarghooni, M., 7811
Zarnegar, M., 2112
Zasloff, E. J., 1563
Zatloukal, K., 1569
Zatyka, M., 7277
Zaugg, K., 732
Zawatzky, R., 5523
Zaydan, M-A. A., 6931
Zehbe, I., 608
Zeiss, C. J., 1469
Zeitoun, K. M., 2250
Zeleznik-Le, N. J., 59
Zelinski, D. P., 2301
Zelterman, D., 4405
Zeltzer, P. M., 842
Zembutsu, H., 6474
Zeng, H., 7225
Zeng, Q., 5919
Zeng, X., 7647
Zeng, Z-C., 270
Zepter, K., 452
Zerillo, C. A., 7056
Zervos, E. E., 6991
Zeschnigk, M., 3439
Zha, S., 8617
Zhai, Y., 8247
Zhan, P., 2833
Zhan, X., 6906
Zhang, B., 6064, 8135
Zhang, D., 6899
Zhang, F. F., 831
Zhang, H., 517, 1964, 6428, 7002, 7819
Zhang, J., 6795, 8730
Zhang, L., 428, 1022, 1727, 2434, 3801, 5207, 6996, 7383
Zhang, M., 6945
Zhang, P., 5771
Zhang, P. J., 8127
Zhang, Q., 6517
Zhang, T., 8664
Zhang, W., 428, 842, 6945, 8654
Zhang, X., 1563, 3281, 6050
Zhang, X. D., 7339
Zhang, X. Y., 7339
Zhang, X-k., 4723
Zhang, Y., 4723, 5453, 6201
Zhang, Y-Z., 4098
Zhang, Z., 8051
Zhao, H., 7819
Zhao, J., 1338, 2562, 5186
Zhao, Q., 478, 1707, 4136
Zhao, R., 7383
Zhao, W., 5537
Zhao, X., 6795, 7383
Zhao, Y., 3281, 5153, 6082
Zhau, H. E., 6012, 7310
Zheng, G., 8127
Zheng, P., 1107, 6860
Zheng, S., 3419, 8578
Zheng, T., 1457
Zheng, W., 1013, 7136
Zheng, W. L., 7065
Zhong, L-t., 5741
Zhong, S., 4084
Zhong, W., 7071
Zhou, D., 1338
Zhou, H-M., 970
Zhou, J., 2250, 2328
Zhou, N., 2381
Zhou, S., 771
Zhou, W., 818, 8718
Zhou, X-P., 4311
Zhou, Z., 1765, 3382, 3394, 4066
Zhu, B. T., 5764
Zhu, J., 2071
Zhu, L., 6406
Zhu, M. Z., 3725, 7568
Zhu, Q., 64
Zhu, Q-s., 2381
Zhu, S., 1073
Zhu, W-G., 1327
Zhu, W-Q., 1869
Zhu, X., 4569
Zhu, X-X., 2162
Zhu, Y., 7825
Zhu, Y-R., 33
Zhu, Z., 478, 1707, 7002
Ziegler, A., 5595, 6524
Ziegler, S. I., 1781
Zilles, O., 6480
Zimmer, R., 2822
Zimmerman, C. L., 1522
Zimmerman, E., 2220
Zimmermann, A., 4655
Zimmermann, S., 7052
Zimonjic, D., 8838
Zingg, D., 8203
Zisman, A., 7925
Zlatescu, M. C., 4155, 6713
Zoberi, I., 7689
Zöchbauer-Müller, S., 249, 3581, 8659
Zografski, G., 8351
Zonderman, A. B., 3869
Zorick, T., 7375
Zou, Y., 7142
Zoubek, A., 5992
Zoumpourlis, V., 538
Zuck, E., 1439
Zuckerman, K. S., 6290
Zukerberg, L. R., 7325
Zunino, F., 6034, 7189
Zunino, S. J., 4731
Zuo, J. J., 6185
Zurer, I., 88
Zusi, F. C., 8703
Zuzak, T. J., 1314
Zwarthoff, E. C., 1265
Zwerski, S. L., 5028
Zyzak, L. L., 3837


** For title of article and coauthors, see listing in Contents of Volume 61 beginning on page 9015 at the end of this index issue.*

# SUBJECT INDEX

## Volume 61


A

**A33**
anti-huAb A33 Ig responses, colon cancer, 6851
**A-105972**
identification and characterization, 1486
**A-204197**
antimitotic activity, 5480
**Aberrant crypt foci**
β-catenin expression, 8085
dysplastic
and tumorigenesis, *Min*/+ mouse, 5010
inhibition by PPAR ligands, 2424
iNOS expression, 419
***ABL* gene promoter**
methylation, chronic myeloid leukemia, 6931
***Acacia victoriae* (Bentham)**
triterpenoid saponins
tumor cell proliferation inhibition, 5486
**4-(Acetoxymethylnitrosamino)-1-(3-pyridyl)-1-butanone**
AGT activity reduction, 5757
***N*-Acetylcysteine**
chemoprotection against bone marrow toxicity, 7868
growth inhibition, Kaposi's sarcoma, 8171
***N*-Acetylgalactosaminyltransferase-3**
MUC2 *O*-glycosylation, colonic adenocarcinoma, 950
***N*-Acetyltransferase**
*NAT1*
polymorphisms, and bladder cancer, 5051
*NAT2*
mutations, age-associated cancer risk, 1265
polymorphisms, and bladder cancer, 5051
**Acidic vesicles**
radiation response, cancer cells, 439
**Acidosis**
VEGF regulation, brain tumors, 6020
**Actin**
assembly promotion by VHL, 4184
***α-Actinin-4***
point mutated peptide-reactive CTLs, non-small cell lung cancer, 4078
**Activated in prostate cancer *AIPC* gene**
expression, prostate cancer, 2390
**Activating protein kinase C-ε**
$\beta_1$ integrin-mediated collagen IV adhesion PKC role, breast cancer, 2445
**Activating protein kinase C-μ**
$\beta_1$ integrin-mediated collagen IV adhesion PKC role, breast cancer, 2445
**Activator protein 1**
activity, oxidative stress-resistant cells, 3486
inhibition by [6]-gingerol, 850
inhibition by noni glycosides, 5749
TPA-induced, 4084
vinblastine-induced apoptosis, 4450
**6-[3-(1-Adamantyl)-4-hydroxyphenyl]-2-naphthalenecarboxylic acid analogue MM1143**
apoptosis induction, 4723
**Adefovir**
growth inhibition, nasopharyngeal carcinoma, 7875
**Adenine nucleotide translocator**
apoptosis induction by verteporfin, 1260
**Adeno-associated virus**
gene therapy, cancer, 6313
**Adenocarcinoma**
colonic
clustered carbohydrate antigen expression, 950
fatty acid CoA ligase 4 upregulation, 8429
MUC2 *O*-glycosylation by *N*-acetylgalactosaminyltransferase-3, 950
TCR$\beta^{-/-}$ p53$^{-/-}$ mice, 2390
colorectal
gene expression profiles, 3124
Id helix-loop-helix protein expression, 8803
endometrial
resveratrol properties, 6137
ErbB-2 transgenic mice, 6971
esophageal
epigenetic patterns, 3410
hypermethylation, 3410
FGF-5 overexpression, 5511
gastric
*RASSF1A* inactivation, 7034
lung
core 2 β1,6-*N*-acetylglucosaminyltransferase expression, 2226
growth inhibition by CEP1612, nude mice, 1280
loss of heterozygosity, 7950
tyrosine kinases and tumor cell anoikis resistance, 2439
mammary
docetaxel and doxorubicin chemotherapy, mouse, 1996
*MT1-MMP* overexpression, transgenic mice, 984
MHC class I expression
and immunocytokine therapy, 1500
ovarian endometrioid
β-catenin deregulation, 8247
pancreatic
interferon β therapy, NOS II gene and, 71
Sp1 activity and angiogenesis, 4143
VEGF expression, 4143
pancreatic ductal
microsatellite instability, features, 3139
prostatic
endostatin polymorphism and, 7375
LPB-*Tag* transgenic mice, 2239
transgenic mouse
genes overexpressed in prostate cancer, identification, 5857
uterine
genistein-induced, mice, 4325
**Adenoma**
colorectal
gene expression profiles, 3124
mEH and, 2381
risk factors, 2381
gallbladder
β-catenin exon 3 mutations, 19
progression
hypergastrinemia and, APC$^{Min-/+}$ mouse model, 625
**Adenomatous polyposis coli**
*Apc(B1822V)*
and dietary fat intake, 1000
*Apc*$^{\Delta}$*716* mouse
chemoprevention by rofecoxib, 1733
*Apc* gene
mutations
germline, familial adenomatous polyposis, 7616
mammalian two-hybrid system, colon cancer, 854
*MSH* mutant *Apc*$^{1638N}$ mice, 7934
tumors
genetic/dietary modulation, 565
*APC2* gene
localization and allelic imbalance, 7978
*Apc*$^{Min}$/+ mice
intestinal polyposis inhibition by iNOS-selective inhibitors inhibitors, 8357
mammary neoplasia susceptibility, 3480
*Apc*$^{Min-/+}$ mouse
hypergastrinemia and adenoma progression, 625
*Apc*$^{1638N}$ mice
*MSH* mutant
tumorigenesis and *Apc* mutations, 7934
**Adenosine 5′-triphosphate-binding cassette sub-family A transporter 2**
cloning and characterization, 3339
**Adenovirus**
Arg-Gly-Asp fiber-mutant Ad vector-transduced dendritic cells
vaccine efficacy, 7913
Bax overexpression, prostate cancer, 186
Bcl2/adenovirus E1B 19kD-interacting protein 3
expression, tumors, 6669
caspase-8 gene transfer
anoikis induction, gastric cancer, 7009
coxsackievirus and Ad receptor deficiency and replicating adenovirus potency, 813
CV787
synergy with paclitaxel and docetaxel, 517
*FHIT* transduction, esophageal cancer, 1578
gene expression
l-plastin, ovarian and bladder cancer, 4405
heat-activated transgene expression, prostate cancer, 1113
midkine promoter-based replicative, 7882
mutant p27, antitumor effects, 6163
oncolytic
EGFR-targeted, 6377
rhabdomyosarcoma, 2953
oncolytic CV706
PSA-selective, prostate cancer trial, 7464
plasmid prime-boost
vaccination, hepatocellular carcinoma, 8782
protease-enhanced gene therapy, glioblastoma, 1805
rAdMET-SeMET gene therapy, 6805
replicative
Ad-OC-E1a, prostate cancer bone metastasis therapy, 6012
CAR deficiency and, 813
HSV1-tk, malignant glioma treatment, 8743
midkine promoter-based, pediatric solid tumor treatment and bone marrow tumor purging, 7882
oncolytic effects
Hsp70i and, 8361
p53 activity and, 5941
*RIZ1* gene therapy, colorectal cancer, 1796
transgene expression enhancement by FR901228, 6328
truncated XPA protein-expressing, 764
**Adenovirus-directed enzyme prodrug therapy**
rCE and CPT-11, neuroblastoma purging, 5083
**Adipocytes**
differentiation, malignant breast epithelial cells, 2250
**Adoptive transfer**
self-tumor transgene, 3077

**Adozelesin**
DNA replication effects, kinase mutants, 3787
**β-Adrenoceptor antagonists**
NE-induced cell migration blockade, SW 480 colon cancer cells, 2866
**Adrenocortical tumors**
sporadic
prognosis, 6762
**Adrenomedullin**
expression, hormone-independent prostate cancer, 1196
**Adriamycin**
AN-9 interactions, 8194
nuclear transport mechanism, 2467
**Adriamycin-proteasome complex**
nuclear translocation, 2467
**AF17**
colorectal carcinogenesis, 6345
**African-American women**
breast cancer risk, 3326
**Age**
and amifostine effects, rats, 6423
**Age-related methylation**
CpG islands, ulcerative colitis, 3573
**Aggressiveness**
BEHAV/brevican and, glioma, 7056
**Ah receptor**
NMT-2 mRNA induction, 8534
**AIDS-related lymphoma**
children
PBMC SDF-1 mRNA levels, 5028
**Akt**
Akt/PKB pathway
activation
estrogen, ER-negative breast cancer, 8390
glioblastoma multiforme, 6674
KSHV-GPCR, 2641
activity
non-small cell lung cancer, 3986
ovarian cancer cells, 1862
and COX-2 mRNA stability, 2670
hypoxia-induced PDGFR/PI3K/Akt/GSK-3 cascade, 2429
IGF-IR-Akt pathway
inhibition by NEP, 3294
upregulation, pancreatic cancer, 589
overexpression and overactivation, thyroid carcinoma, 6105
PI3K/Akt pathway
downregulation by PKC412, 8203
hypoxia-induced PDGFR/PI3K/Akt/GSK-3 cascade, 2429
methylseleninic acid effects, 7171
nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis, 2194
regulatory ERα interactions, breast cancer, 5985
PI3-kinase-Akt signaling inhibitors
ETV6-NTRK3 transformation blockade, 8909
UVB COX-2 induction, 4329
**Akt1**
and MMP-2 activation, mouse mammary epithelial cells, 7647
**Akt2**
regulatory ERα interactions, breast cancer, 5985
**Aldehyde dehydrogenase 6**
retinoic acid production, breast epithelim, 7065
**Aldo-keto reductase**
induction, human colon cells, 6112
**Alkylators**
bone marrow toxicity
enhancement and protection, 7868
**$O^6$-Alkylguanine DNA alkyltransferase**
activity reduction by NNKOAc, 5757
**Allelic deletions:** *See* **Deletions**
**Allelic imbalance**
*APC2* localization and, 7978
**Allelotyping**
gallbladder carcinoma, 3795
nonfunctional pancreatic endocrine tumors, 285
**17-Allylamino-17-demethoxygeldanamycin**
apoptosis induction, 4003
and differentiation, breast cancer, 2945
***S*-Allylmercaptocysteine**
antiproliferative effects, colon cancer, 725
**α-irradiation**
LNCaP spheroid effects, 2008
**α-radioimmunotherapy**
locoregional
$^{213}$Bi-labeled MAb, 2804
**Alternate reading frame**
growth inhibition, 3145
MIP-2 INK4a/ARF transgenic mice
melanoma induction, 8150
***ALT1* gene**
identification, chronic lymphocytic leukemia, 6640
**Aluminum (III) phthalocyanine tetrasulfonate**
targeting, mAb, 1970
**Amifostine**
age-dependent effects, rats, 6423
**5-Aminolevulinic acid**
photodynamic therapy, human tumor xenografts, 5824
**2-Amino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine**
intestinal tumorigenesis
perinatal susceptibility, 8689
**Amplified in breast cancer *AIB1***
and *BRCA1*- and *BRCA2*-associated breast cancer risk, 5420
and estrogen-dependent cyclin D1 expression, 3858
overexpression, breast cancer, 903
**AN-9:** *See* **Pivaloyloxymethyl butyrate**
**Anaplastic astrocytoma**
conversion to glioblastoma multiforme by Akt pathway activation, 6674
genetic subroups, 7683
**Anaplastic lymphoma kinase**
nucleophosmin/ALK-mediated transformation
STAT5 role, 6517
nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis
PI3K-Akt pathway, 2194
**Anchorage**
global gene expression effects, mammary carcinoma, 1334
**Androgen**
activity, malignant prostatic epithelial cells, 5038
apoptosis blockade, prostate cancer, 5611
prostate cancer, transgenic rats, 4693
receptor
activation by glucocorticoids, LNCaP cells, 8712
*AR* gene
amplification and overexpression, prostate cancer, 3550
and breast cancer, 5869
coactivators, recurrent prostate cancer, 4315
expression, prostate cancer, 1919
expression, prostate cancer epithelium and stroma
prognostic value, 423
growth regulation restoration, prostate cancer, 7310
and ovarian cancer susceptibility, case series, 908
partial
coexpression with PSAP, gene therapy, 1276
p21$^{WAF1}$ silencing
and apoptosis, prostate cancer, 7544
stabilization, recurrent prostate cancer, 2892
transcriptional inhibition by SMAD3, 2112
**Anemia**
correction
and cyclophosphamide cytotoxicity, rat tumors, 1358
**Aneuploidization**
breast cancer, 1214
**Angiogenesis**
inhibition
BMS-275291, murine models, 8480
combination docetaxel and anti-VEGF mAb or 2-methoxyestradiol, 3369
combination phenylbutyrate and 13-*cis* retinoic acid, prostate cancer, 1477
DC101, glioma, 6624
DMXAA, 1517
motuporamines, 6788
*RB2/p130*, 462
SCH221153, 2232
soluble recombinant endostatin from *E. coli*, 478
TIMP-2, mammary tumors, 3450
inhibitors
multiple, pancreatic cancer, 7298
markers
circulating endothelial cells, lymphoma, 4341
modulation by VEGF and bFGF, melanoma, 7282
promotion by PAI-1, 5587
promotion by VEGF isoforms, 8569
and prostate cancer, 2736
Sp1 activity and, pancreatic adenocarcinoma, 4143
stimulation by autotaxin, 6938
stimulation by pyruvic acid, 3290
surrogate markers, liver metastasis, 7048
tumor
angiopoietin-1 and angiopoietin-2 effects, colon cancer, 1255
Bcl-2 upregulation and, 2183
Flt-1 tyrosine kinase, 1207
HOXB7, 6532
modulation by FGF2 expression, 309
regulation by ORP150, 4206
tumor vascularity and, 2907
VEGF isoform functions, 8569
**Angiogenin**
Ang-CD30L, CD30-positive lymphoma treatment, 8737
**Angiopoietin-1**
tumor growth and angiogenesis effects, colon cancer, 1255
**Angiopoietin-2**
expression, glioma, 6248
gastric carcinoma, 2145
**Angiostatin**
gene transfer, Kaposi's sarcoma, 5441
**Annexin II**
loss of expression, prostate cancer, 6331
**Anogenital cancer**
HPV 16 and 18 L1 serology, 1934
**Anoikis**
caspase-dependent
induction by methyl selenium, prostate cancer, 3062

induction
Adv-mediated caspase-8 gene transfer, gastric carcinoma, 7009
ovarian cancer, 4837
melanoma, 1707
TRAIL role, mammary carcinoma, 1334
tumor cell resistance
tyrosine kinases and, lung adenocarcinoma, 2439
**Anorexia**
prostanoid-related
brain cytokine and, 4707
**Ansamycin**
and differentiation, breast cancer, 2945
**Anthracyclines**
cell signaling, 2558
**Antiangiogenic therapy**
endoglin-targeted, skin/SCID mouse chimeras, 7846
**Antibodies:** *See also* **Monoclonal antibodies**
anti-EGFR
combined with TNF-α, solid tumors, 1045
resistance, 5090
anti-huAb A33 Ig responses, colon cancer, 6851
anti-PSMA J591
$^{213}$Bi-labeled, LNCaP spheroid effects, 2008
antitumor VH-CDR3, 1555
anti-VEGF sFV
targeting, tumor endothelium, 3653
autoantibodies
protein gene product 9.5, lung cancer, 7908
4–1BB
antitumor effects, 2031
bifunctional anti-VEGFRs diabody
VEGFR inhibition, 7002
bispecific
restricted CD95 triggering, 1846
bispecific anti-*MUC-1* DF3xH22
antibody-dependent cellular phagocytosis, breast cancer, 4061
$G_{D3}$ ganglioside targeting, melanoma, 4474
HPV, anogenital cancer, 1934
human IgM
neuroblastoma eradication, 2968
$^{131}$I-anti-CD45
immunosuppressive effects, murine HSCT models, 5126
microarrays
differentiation, leukemia immunophenotyping, 4483
taxane-antibody conjugates
specific targeting, 694
**Antibody-dependent cellular phagocytosis**
mediation by MAb DF3 and BsAb DF3xH22, breast cancer, 4061
**Anticancer agents**
sensitization
*E1A*, Ewing's sarcoma, 3394
tumor cell, 1645
**Antiestrogens**
GW5638
growth inhibition, breast cancer, 2917
**Antigen**
carbohydrate, clustered
expression, colonic adenocarcinoma, 950
carcinoembryonic
-expressing cells, targeted killing by retrovirus, 370
peritoneal micrometastasis detection, gastric cancer, 5570
scFv antibody, targeted CEA-expressing cell kill by retrovirus, 370
chimeric Flt3-ligand DNA vaccine, tumor immunotherapy, 1080
glioma-associated
cytokine-assisted SEREX and, 2625
HLA
class II polymorphisms, and gastric cancer, 2684
vulval neoplasia, 192
HLA-A*0201
CTL epitopes
Ep-CAM, 4761
CTL epitopes, Ep-CAM, 4761
MAGE-A1 HLA-A*0201 epitope, identification by mass spectrometry, 4072
-restricted T cells
melanoma antigen, identification by immunoselected tumor cell lines, 1089
HLA-A2.1-restricted T antigen-specific CTLs, 873
HLA-G
expression, renal cell carcinoma, 6838
lymph node targeting, 8110
melanoma-associated
cloning, immunoselected tumor cell lines, 1089
gene-modified dendritic cells
by-passing CD4+ T cells, 8787
Melan-A-specific repertoire, melanoma, 2047
melanoma-associated gp100
CTL and T helper epitopes, 7577
melanoma-associated *MAGE*
gene family overview, 5544
melanoma-associated MAGE-A3
promiscuous T helper epitope, 4773
melanoma-associated MAGE-A10
heterogenous CTL response, 5850
melanoma-associated *MAGE-E1*
expression, glioma, 4809
MHC class I processing alterations, melanoma, 8647
multiple adenocarcinoma-associated
FGF-5, identification, 5511
mutated lung cancer
CTL response, 3718
presentation
direct
effector CTL induction, 1107
Retrogen strategy, 197
prostate stem cell
expression, prostate cancer, 3256
self-antigen
adoptive immunotherapy, 3077
-specific immune responses
vaccination strategies, synergy, 4497
squamous cell carcinoma
antisense, tumor growth inhibition, 1776
SV40 large T antigen
HLA-A2.1-restricted specific CTLs, 873
*mlt 1* silence by methylation, transgenic mice liver tumors, 1144
T-antigen
cell adhesion, breast and prostate cancer, 4851
expression, central nervous system tumors, 4287
tumor
Csk, carcinoma, 1415
NY-BR-1, breast cancer, 2055
P-glycoprotein, 8100
retroviral, endogenous immunization, 7920
serological identification of tumor antigens by cDNA expression cloning melanoma antigen isolation, 7900
tumor rejection
MRP-3, 6459
**Antigenicity**
sarcoma-associated chromosomal translocation fusion proteins, 6868
**Antigen-presenting cells**
regional lymph node
enrichment by recombinant, 206
**Antioxidants**
etoposide effects, HL-60 cells, 7777
**Antisense**
cyclin D1
growth inhibition, rat hepatoma, 4779
heparanase expression inhibition, 7855
oligodeoxynucleotide
midkine, rectal carcinoma, 8486
squamous cell carcinoma antigen
tumor growth inhibition, 1776
**Antitumor immunity**
enhancement by intranodal dendritic cells, 641
IgE-driven, 5517
and IL-18, 3735
induction via intratumoral tetra-costimulator protein transfer, 8127
laser immunotherapy, 459
T cell-dependent
secondary lymphoid tissue chemokine-mediated, 2062
**Antivascular therapy**
tumor
ultrasound monitoring, 2974
**Antiviral phosphonated nucleoside analogs**
growth inhibition, nasopharyngeal carcinoma, 7875
**Antizyme**
transgenic
expression, mouse skin, 6073
**Ape1/ref-1**
protective effects against bleomcyin and radiation, germ cell tumors, 2220
***Apex* gene**
*Apex*$^{+/-}$ mouse model
oxidative stress, 5552
**APO-1:** *See* **Fas**
**Apo-2 ligand**
Apo-2L/TRAIL-induced apoptosis
enhancement by paclitaxel, prostate cancer, 759
**Apoptosis:** *See also* **Anoikis**
Apo-2L/TRAIL-induced
enhancement by paclitaxel, prostate cancer, 759
blockade by androgen, prostate cancer, 5611
c-Myc
mediation by Bin1, 3151
DNA damage-induced
p53 target *APAF-1*, 6660
doxorubicin and, cardiomyocytes, 2335
early melanoma
dendritic cell maturation blockade, 8218
early metastatic inefficiency, 333
endothelial
stimulation by VEGF receptor, 8629
Fas-mediated
inhibition by FLIP and bcl-2, neuroblastoma, 4864
gastric epithelial cell
and *cagA+ H. pylori*, 1406
helenalin-induced, 5817
ibandronate effects, breast cancer metastasis to bone, 4418
-inducing MAb
metastasis marker binding, 5741
induction
17AAG, 4003
adenovirus-mediated Bax overexpression, prostate cancer, 186
CEP1612, lung adenocarcinoma, 1280
ceramide analogues, metastatic colon cancer, 1233

dietary indoles and isothiocyanates, cruciferous vegetable
colon cells, 6120
*FHIT* expression, pancreatic cancer, 4827
5-FU, mouse thymocytes, 243
geldanamycin, 1799
HMGA1 overexpression, rat thyroid, 4583
iNOS inhibition, melanoma, 318
iron chelation, neuroblastoma, 1073
IsoGb4, 5741
MM11453, 4723
9-nitrocamptothecin, 7148
NSAIDs, esophageal cancer, 4879
resveratrol, 1604
SU9516, colon carcinoma, 6170
TRAIL, anticancer drug sensitization, 1645
triterpenoid saponins, 5486
UCN-01 and MEK inhibitors, 5106
verteporfin, mediation by adenine nucleotide translocator, 1260
inhibition
FLIP and bcl-2, neuroblastoma, 4864
TCDD, MCF-10A cells, 3314
intestinal goblet cells, mouse, 3472
leukemia
loaded dendritic cells, 2386
and lung cancer susceptibility, 7819
mediation by $G_{D2}$, small cell lung cancer, 4244
*MLL* translocations, 4550
NO-induced
and FTI, breast cancer, 4701
HIF-1 and IRF-1 interactions, 3682
nuclear FAK aggregation, glioblastoma, 4978
p53 and, murine tumors, 327
p53 expression and, retinoblastoma, 3157
photosensitization-induced, 7495
p38 MAPK-dependent
leukemia, 6290
tyrphostin AG825 and, prostate cancer, 7408
polyamine analogue signaling, SK-MEL-28 melanoma cells, 6437
proapoptotic peptide, solid tumor treatment, 7709
$p21^{waf-1}$ expression and, retinoblastoma, 3157
$p21^{WAF1}$ silencing androgen receptor and, prostate cancer, 7544
regulation by redox
NF-κB, 2656
resistance
catalase overexpression, 2766
resveratrol-induced, acute lymphoblastic leukemia, 4731
RRM-induced
JNK/p38 MAP kinase activation, 8504
selenium-induced
and stress kinases, oral carcinoma, 7479
selenium redox effects, prostate cancer, 7071
sulindac sulfide-induced, colon and prostate cancer, 6918
tamoxifen-mediated
promotion by p53 inactivation by E6, mammary epithelial cells, 616
TNF-α pro- and antiapoptotic signals, prostate cancer LNCaP cells, 2713
TRAIL-induced
caspase-8 requirement, 1138
glioma, 1162
inhibition by XIAP, melanoma, 7339
tumor-pulsed dendritic cells, 8105
vinblastine-induced
AP-1 role, 4450
potentiation, ML-1 cells, 1533
vitamin E succinate-induced, breast cancer, 6569
X-linked inhibitor XIAP
activity, ovarian cancer cells, 1862
**Apoptosis protease-activating factor *Apaf-1***
downstream of Rb roles, 8395
p53 target, DNA damage-induced apoptosis, 6660
**1-β-d-Arabinofuranosylcytosine**
analogue DMDC
cell differentiation, acute promyelocytic leukemia, 178
duanorubicin cross-resistance, HL60 cells, 172
**Arginase**
macrophage
tumor cell growth regulation, 1100
**Aromatase**
C/EBPβ-mediated upregulation, malignant breast epithelial cells, 2328
overexpression, breast tissue, 1910
promoter I.3 activity
downregulation by SnaH, breast tissue, 1338
**Arsenic trioxide**
tumor growth inhibition, prostate cancer, 5432
**Aryl hydrocarbon receptor**
modulation by dibenzoylmethane, 3919
**6-Aryl-pyrido[2,3-*d*] pyrimidine:** *See* **PD0166285**
**Arzoxifene**
chemoprevention, breast cancer, 8412
**Aspirin**
lifetime
neoplasia suppression, mice, 7060
**Astrocytes**
genetically modified
intracranial tumor formation, 4956
**Astrocytoma**
anaplastic
conversion to glioblastoma multiforme by Akt pathway activation, 6674
genetic subroups, 7683
isotype-specific Ras•GTP levels, 4425
transgenic mouse model, 3826
**Ataxia telangiectasia**
oxidative stress, 1849
**Ataxia telangiectasia mutated protein**
*ATM* gene mutations
germline, breast cancer, 7608
*ATM* heterozygotes
radiation oncogenesis, 5710
*Atm* knock-in mice
variant phenotype, 4561
**Ataxia telangiectasia mutated protein (ATM)-related protein gene *ATR***
mutations, gastric tumors, 7727
**ATP-binding cassette transporter BCRP/MXR/ABCP**
*ABCP* gene mutations
substrate specificity alteration, 6635
indolocarbazole resistance, 2827
**Atrophy**
proliferative inflammatory
prostate
COX-2 upregulation, 8617
**Autoantibodies**
protein gene product 9.5, lung cancer, 7908
**Autophagy**
beclin 1 nuclear export signal, 3443
radiation response, cancer cells, 439
**Autotaxin**
angiogenesis stimulation, 6938
**Avian poxvirus**
avipox-CEA/B7–1-infected dendritic cells
T-cell activation, 7568
recombinant
GM-CSF-expressing, immunoadjuvant activity, 206
***AXIN1***
deletions, sporadic medulloblastoma, 7039
**5-Aza-2′-deoxycytidine**
combined with trichostatin A
ER-α induction, breast cancer, 7025
**Azoxymethane**
activation
CYP2E1 null status, 8435

**B**

**B7–1**
avipox-CEA/B7–1-infected dendritic cells
T-cell activation, 7568
soluble
tumor immune gene therapy, 153
**B7.1**
combined with 5,6-dimethylxanthenone-4-acetic acid, cancer immunotherapy, 1948
**Barrett's esophagus**
malignant transformation
genomic alterations, 3164
$p16^{INK4a}$, 8284
**BARX2**
suppressor function, ovarian cancer, 6977
**Base excision repair proteins**
protection against thioTEPA-induced toxicity, hematopoietic cell, 5116
**Basement membrane**
subendothelial
laminin 8 and 10, neoplastic lymphocyte interactions, 339
**Batimastat**
liver metastasis promotion, 1272
***Bax***
adenovirus-mediated overexpression, prostate cancer, 186
tumorigenesis promotion, *p53*-deficient mice, 659
**4–1BB antibodies**
antitumor effects, 2031
**B16 cells**
MHC class I deficiencies, 1095
**Bcl-2**
apoptosis inhibition, neuroblastoma, 4864
deregulation, lymphoma, 5202
and hepatocarcinogenesis, 594
*K14/bcl-2* transgenic mice
carcinogenesis, 3619
upregulation
E2F1, glioma, 6693
and tumor angiogenesis, endothelial cells, 2183
**Bcl-2/adenovirus EIB 19kD-interacting protein 3**
expression, tumors, 6669
***Bcl-6***
translocations, long-distance PCR-based assays, 7363
**Bcl-$X_L$**
overexpression, prostate cancer, 1699
**BCNU:** *See* **1,3-bis(2-Chloroethyl)-1-nitrosourea**
**BCR(64–413)**
growth inhibition and cell death induction, chronic myelogenous leukemia, 138
**Bcr-Abl**
and cyclin D2 expression, lymphoblasts, 8005
geldanamycin and, 1799
leukemogenesis
enhancement by Crkl, *BCR/ABL* P190 transgenic mice, 1398
and Ph chromosome-positive leukemogene-

sis, 2343
survival effects
Mdm2 requirement, 7635
**Beclin 1**
nuclear export signal
autophagy and tumor suppression, 3443
**Benign colorectal tumors**
genes expressed, 6996
**Benign prostatic hyperplasia**
gene expression profiling, 4683
**Benzo(*a*)pyrene diol epoxide**
DNA adducts, lung cancer, 1445
p53 mutations, nontumorous human lung, 6350
sensitivity
modulation by *GSTM1* and *GSTT1*, breast cancer, 8465
**Biliary tract cancer**
β-catenin mutations, 3406
ErbB-2 transgenic mice, 6971
**Bin1**
c-Myc apoptosis mediation, 3151
**Biomarkers**
modulation by chemopreventives, smoke-exposed rats, 2472
risk-stratification model, non-small cell lung cancer, 2500
**Bioreductive enzymes**
mitomycin C resistance reversal, Chinese hamster ovary cells, 7770
**1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylamino)carbonylhydrazine**
antineoplastic activity, 3033
**Bismuth-213**
-labeled MAb, locoregional α-radioimmunotherapy, 2804
**Bisphosphonate**
growth inhibition, prostate cancer, 2602
**Black raspberries**
esophageal tumorigenesis chemoprevention, 6112
**Black tea**
tissue fat and UVB skin carcinogenesis inhibition, 5002
**Bladder cancer**
aberrant promoter methylation profile, 8659
adenoviral gene expression
l-plastin, 4405
β- and γ-catenin alterations, 7101
cyclin E nucleoplasm-nucleolar shuttling disruption, 1220
epigenetic patterns, 5875
HER1 ligands, prognostic value, 6227
invasive
gene expression patterns, 2492
karyotypes, multivariate analyses, 8241
multifocal, cytogenetic analysis, 355
*NAT1* and *NAT2* polymorphisms and, 5051
RAF1 and FGFR1 copy number alterations, 4514
*RASSF1A* epigenetic inactivation, 6688
superficial
*FGFR3* mutation, 1265
gene expression patterns, 2492
transitional cell
IFN-α signaling, 2261
TSU-Pr1 and JCA-1 cell derivations, 6340
**Bladder epithelium**
*p53* mutations, Chernobyl accident, 6964
**Bladder tumorigenesis**
inhibition by exisulind, rat, 3961
**Bleomycin**
resistance by Ape1/ref-1, germ cell tumors, 2220
**Blood, peripheral**
mononuclear cells
SDF-1 mRNA levels, AIDS-related lymphoma children, 5028
**Blood-borne cells**
CEA mRNA
RT-PCR, colorectal cancer, 2523
**Blood clotting regulators**
dysregulation by tumor hypoxia, 795, 7697
**Blood group antigen binding adhesin BabA2**
*H. pylori*, chronic gastric inflammation, 1903
**Blood-spinal cord barrier**
radiation-induced breakdown
hypoxia, 3348
**Blood vessels**
tumor
selective thrombosis, mice, 711
**B lymphocytes**
leukemia, acute lymphoblastic
clonal variation, 5268
*MLL* partial nontandem duplication, 59
leukemia, chronic lymphocytic
13q14 *CLLD6, CLLD7, CLLD8* genes, cloning and characterization, 2870
lymphoma
cytokine gene expression, 1285
lymphoma, non-Hodgkin's
STAT3 inhibition by rituximab, 5137
responses
HER-2/*neu*-expressing tumor rejection requirement, 880
**B lymphoproliferative disorders**
antitumor VH-CDR3 antibodies, 1555
***BMI-1* gene**
amplification and overexpression, hematological malignancies, 2409
**BMS-214662**
antitumor activity, 7507
**BMS-275291**
angiogenesis and metastasis inhibition, murine models, 8480
**BN 80915**
colon cancer potency, 2961
**BNCT:** *See* **Boron neutron capture therapy**
**BNIP3:** *See* **Bcl-2/adenovirus E1B 19kD-interacting protein 3**
**Bob-1**
deficiency, Hodgkin and Reed Sternberg cells, 2080
**Bone**
breast cancer metastasis
ibandronate effects, 4418
induction by cortactin overexpression, 6906
metastasis
inhibition by osteoprotegerin, mouse models, 4432
prostate cancer metastasis
NOD/SCID-hu mouse model, 2177
systemic replication-competent Ad-OC-E1a gene therapy, 6012
**Bone cancer**
advanced
pain, osteoprotegerin relief, 4038
**Bone marrow**
alkylator toxicity
enhancement and protection, 7868
breast cancer metastasis
erbB2 overexpression, prognostic value, 1890
multiple myeloma binding
mediation by CD44v10, 2862
transplantation
GM-CSF tumor cell vaccine, 162
**Bone marrow-derived dendritic cells**
combined with chemotherapy, murine tumors, 7530
**Bone marrow tumors**
purging
HSV, breast cancer, 3009
midkine promoter-based replicative adenovirus, 7882
**Borderline ovarian tumors**
serous
K-*ras* and *p53* mutations, 7264
**Boron**
delivery by boronophenylalanine, hamster cheek pouch oral cancer model, 8775
**Boron-10**
quantitative ion imaging, brain tumors, 8179
**Boron neutron capture therapy**
oral cancer, hamster cheek pouch model, 8638, 8775
**Boronophenylalanine**
boron delivery, hamster cheek pouch oral cancer model, 8775
**BPDE:** *See* **Benzo(*a*)pyrene diol epoxide**
**BRaf**
heterodimerization, 3595
**Brain**
cytokine, prostanoid-related anorexia, 4707
malignant lymphoma entry routes, mouse, 5242
**Brain enriched hyaluronan binding (BEHAB)/brevican**
and aggressiveness, glioma, 7056
**Brain tumors**
convection-enhanced drug delivery
diffusion-weighted MRI monitoring, 4971
human neurotropic virus and, 4287
IL-4 receptors, 8058
malignant
DMBTI, digestive tract cancer, 8880
HuR expression, 2154
methionine dependence, athymic mice, 4017
PNET/medulloblastoma
CCI-779 antitumor activity, 1527
quantitative boron ion imaging, 8179
VEGF regulation by $pO_2$ and pH, 6020
$^{65}$-Zn imaging, rat, 5065
***BRCA1***
breast cancer risk
modulation by *AIB1*, 5420
-deficient cells
DNA double-strand break rejoining, 270
DNA repair, mitomycin-C resistance, and chromosome stability restoration, 4842
γ-tubulin-binding domain, identification, 7713
mutations
and induced micronucleus frequencies, 5948
-related breast cancer
*TP53* mutations, 4092
***BRCA2***
breast cancer risk
modulation by *AIB1*, 5420
-deficient cells
DNA double-strand break rejoining, 270
mutation carriers
chromosome 9p23–24 instability, 5179
protein depletion
UV-induced, 2838
-related breast cancer
*TP53* mutations, 4092
**Breast**
aromatase overexpression, 1910
aromatase promoter I.3 activity downregulation by SnaH, 1338
epithelial cells
invasion regulation by heregulin, 400
malignant
adipocyte differentiation, 2250
C/EBPβ-mediated aromatase upregulation, 2328
retinoic acid production by ALDH6, 7065
ribozyme cleavage of telomerase mRNA, 3053

stromal-epithelial interactions, *in vitro* model, 1320
**Breast cancer**
advanced
therapy response, VEGF levels and, 5415
thymidine kinase and thymidylate synthase, 1421
VEGF levels, and therapy response, 5415
aggressive
gene expression profiles, 5168
AIB1 overexpression, 903
antibody-dependent cellular phagocytosis
mediation by MAb DF3 and BsAb DF3xH22, 4061
apoptosis
inhibition by TCDD, MCF-10A cells, 3314
TRAIL-mediated, enhancement by trastuzumab, 4892
*AR* gene and, 5869
*ATM* mutations, germline, 7608
$\beta_1$ integrin-mediated collagen IV adhesion
PKC role, 2445
bone marrow purging by HSV, 3009
*BRCA1/2*-related
*TP53* mutations, 4092
*CCN* expression, 8917
*CDH13* methylation, 4556
cell adhesion
T antigen, 4851
cell proliferation and migration
IL-6 effects, 383
chemoprevention by arzoxifene, 8412
chromosome 17q22–23 amplicon, structural analysis, 4951
chromosome 17q12 amplification, 8235
chromosome 16q loss of heterozygosity, 1171
collagenase-3 expression, 7091
combination radioimmunotherapy and topotecan, 2996
CPMT effects, 7488
cyclin D2 expression loss
promoter hypermethylation and, 2782
*CYP17* and, 785
CYP regulation by dioxin and pesticides, 3942
differentiation
ansamycin and, 2945
DNA binding proteins, 1362
DNA hypermethylation, 8375
DNA repair defects, 3627
doxorubicin sensitization
caspase 3 reconstitution-mediated, 348
ductal
collagenase-3 expression, 7091
ER-$\alpha$ induction by 5-aza-dC and TSA, 7025
*ERBB2* amplicon, 8235
erbB2 overexpression, prognostic value, 1890
ER-negative
Akt activation by estrogen, 8390
IGF-IR, 6747
ER-positive
*CGA* overexpression, 1652
HER2 amplification and hormonal antiproliferative effects, 8452
ER status
associated gene expression patterns, 5979
estrogen-dependent
growth stimulation by soy protein, 5045
estrogen nuclear signaling via MAP kinase, 6360
etoposide sensitization
caspase 3 reconstitution-mediated, 348
Fas upregulation by IL-12, 4066
*FHIT* methylation and expression loss, 3581
galectin-3 release by fetuin, 1869
gene amplification and aneuploidization, 1214
*GIRK1* expression, 582
glypican-1 overexpression, 5562
growth
FGF-8b effects, 4229
IL-6 effects, 383
NGF-induced
inhibition by tamoxifen, 3002
*uPA* role, 532
growth inhibition
dendritic cells, 228
maspin, 6945
tamoxifen, 3002
*WWOX*, 8068
*HER-2/neu* and *topo IIA* amplification, 5345
HGF/SF-treated
altered gene expression patterns, 8022
*HSD17B1* and, 785
17$\beta$-HSD expression, 8448
*hSRBC* inactivation, 7943
IGF activity regulation by ER$\alpha$, MCF-7 cells, 5771
IKK and CK2 kinase activities, 3810
inflammatory
E-cadherin/$\alpha$,$\beta$-catenin axis, 5231
endothelial formation, 445
invasion
FGF-8b effects, 4229
inhibition by PAR1-$G_i$ signaling, 5933
*KAI1/CD82* expression, 5284
*mdm2* mRNA splicing, 3212
locally advanced
*TP53* alterations and doxorubicin resistance, 2505
MAGE-A gene expression pattern, 6682
medullary ductal
humoral immune response, 7889
Met activity, *in vivo* molecular imaging, 4873
metastasis
gap junctional intercellular communication and, 1765
hematogenous, detection, 8845
impeding loss of heterozygosity, *MTA1* gene, 3578
inhibition by maspin, 6945
*KAI1/CD82* expression, 5284
*TRAIL-R1* and *TRAIL-R2* mutations, 4942
metastasis to bone
ibandronate effects, 4418
induction by cortactin overexpression, 6906
metastasis to bone marrow
erbB2 overexpression, prognostic value, 1890
metastasis to lymph node
*GIRK1* expression, 582
mitoxantrone resistance, MCF-7 cells, 5461
MRI-guided focused ultrasound surgery, 8441
mtDNA mutations, 7623
multidrug resistance by IL-6, 8851
mutagen sensitivity modulation by *GSTM1* and *GSTT1*, 8465
mutant E-cadherin
Wnt signaling, 278
nerve growth factor receptor expression, prognostic value, 4337
neuropeptide Y receptors, 4636
NO-induced apoptosis
and FTI, 4701
NY-BR-1 tumor antigen, 2055
paclitaxel resistance
IRF9-mediated, 6540
phospholipid metabolite levels, 7536
PI3K/AKT2–ER$\alpha$ interactions, 5985
*p53* mutation, 2256
postmenopausal
Fasladex *vs* tamoxifen short-term biological effects, 6739
pretargeted immunoscintigraphy with PET, 3712
progression
*p53* mutation frequency, 8317
serial analysis of gene expression, 5697
proviral structure, identification, 1754
*RASSF1A* hypermethylation, 3105
recurrent
*TGFBR2* mutations, 482
regulation by Rad and Nm23, 2062
retroviral sequences, 1754
risk
*BRCA1*- and *BRCA2*-associated, modulation by *AIB1*, 5420
dietary folate intake and, Shanghai, 7136
ethnic differences, 3326
germline *HER-2/neu* mutations and, 8393
*Prkdc* polymorphism and, 1820
scirrhous
caveolin-1 mutations, 2361
14–3–3$\sigma$ downregulation, 76
single nucleotide instability, 7739
suberoylanilide hydroxamic acid and differentiation, 8492
survival
*GSTM1* and *GSTT1* and, 7130
susceptibility
multigenic model, 785
*SYK* hypermethylation, 5558
*T$\beta$RII* expression induction by MS-275, 931
tubulin detyrosination, 5024
VEGF autocrine survival function, 5736
VEGF expression, 2256
VEGF expression regulation by p53, 6952
VEGF upregulation by heregulin-$\beta$1, 1727
vitamin D prooxidant activity, 1432
*WT1* expression, 921
**Breast cancer metastasis suppressor *Brms1***
and mammary tumor metastatic progression, 8866
**Breast cancer resistance protein**
BCRP/MXR/ABCP
indolocarbazole resistance, 2827
and camptothecin resistance, colon carcinoma, 6034
intracellular localization, normal tissue, 3458
*MXR/BCRP/ABCP* gene mutations
substrate specificity alteration, 6635
**Breast fibroadenoma**
genetic abnormalities absence, 7955
**Breast tumors**
NES1/kallikrein 10 methylation, 8014
**Brevican**
BEHAV/brevican
and aggressiveness, glioma, 7056
**Bronchial lavage**
genomic instability, lung cancer, 1624
**Bronchoalveolar cell carcinoma**
secondary lymphoid organ chemokine antitumor response, spontaneous murine, 6406
**Bystander effects**
*TRAIL* gene, 3330

**C**

**Cables**
cell growth inhibition, colon and squamous cancer, 7325
**Cachexia**
melanocortins and, 1432
skeletal muscle protein catabolism by eicosapentaenoic acid, 3604

**Cadherin 6**
inhibition by BARX2, ovarian cancer, 6977
**E-Cadherin**
mutations
$^{213}$Bi-labeled MAb, locoregional α-radioimmunotherapy, 2804
Wnt signaling, breast cancer, 278
substrate-induced downregulation, pancreatic cancer, 3508
truncation and inactivation, prostate cancer, 489
**E-Cadherin/α,β-catenin axis**
inflammatory breast cancer, 5231
**H-Cadherin**
*CDH13*
methylation, breast and lung cancer, 4556
**N-Cadherin**
melanoma role, 3819
**Cadmium**
malignant transformation, prostate epithelial cells, 455
**Caffeine**
tissue fat and UVB skin carcinogenesis inhibition, 5002
**Calponin h1 deficiency**
metastases, mice, 7627
**Calu-3 cells**
ouabain-induced multidrug resistance, 1693
**Camptothecin**
analogue BN 80915
colon cancer potency, 2961
cytotoxicity
mismatch repair and, colorectal cancer, 6555
resistance
BCRP-associated, colon carcinoma, 6034
NB-506 antiproliferative activity, 504
R364H top1 mutation, prostate cancer, 1964
7-substituted ST1481, antitumor activity and pharmacological profile, 7189
**Canarypox virus**
recombinant
GM-CSF-expressing, immunoadjuvant activity, 206
**Cancer:** *See also* ***specific cells, sites, types***
advanced
T-cell inhibition by activated granulocytes, 4756
cell cycling
normal cell protection, 4301
cell profiling, protein microarray, 7585
coagulopathy
tumor hypoxia and, 795, 7697
EPO and EPOR expression, 3561
fractals and, 8347
gene therapy
adeno-associated virus, 6313
genetic instability, 428
immunosuppression
metalloproteinase, 237
immunotherapy
DNA vaccines, 3698
EGP-2 transgenic mice tumor model, 4105
invasive
cell migration promotion by focal adhesion kinase, 7079
local recurrence inhibition by sFlt-1 fibroblasts, 7840
molecular classification by gene expression signatures, 7388
*MRE11* gene alterations, 23
plasma DNA fragments
origin, 1659
prevention
Twentieth International Symposium of the Sapporo Cancer Seminar Foundation, meeting report, 2788
radiation
autophagy and acidic vesicle response, 439
*RIZ1* hypermethylation, 8094
telomerase-specific T cells, 8366
**Cannabinoid receptor $CB_2$**
glioma growth inhibition, 5784
**CAR:** *See* **Coxsackievirus and adenovirus receptor**
**Carbohydrate antigens**
clustered, colonic adenocarcinoma, 950
**Carbon-11**
-labeled DACA and DACA analogues, biodistribution and metabolism, 2935
**Carbonic anhydrase-9**
cervical cancer, 8924
expression
head and neck squamous cell carcinoma, 5262
and hypoxia, locally advanced cervical cancer, 6394
non-small cell lung cancer, 7992
**m-Carboxycinnamic acid bis-hydroxamide**
growth inhibition, neuroblastoma, 3591
**Carboxylesterase**
expression
MYC-mediated, 3045
rabbit liver rCE, adenoviral
and CPT-11, VDEPT, neuroblastoma purging, 5083
CPT-11 sensitization, 5078
**Carcinoembryonic antigen**
avipox-CEA/B7–1-infected dendritic cells
T-cell activation, 7568
blood-borne
RT-PCR, colorectal cancer, 2523
colon cancer metastasis role, 2732
mutations
and liver metastasis, colorectal cancer, 2822
peritoneal micrometastasis detection, gastric cancer, 5570
scFv antibody
targeted CEA-expressing cell kill by retrovirus, 370
suicide gene therapy of CD/5-FC
enhanced by Cre/loxP, gastric carcinoma treatment, 6158
targeted killing by retrovirus, 370
**Carcinogen-DNA adducts**
and lung cancer risk, 6708
**Carcinogenesis**
chemical
sensitization by LMP-1, transgenic mice, 6730
dimethylbenzanthracene-induced, *Gadd45a*-null mice, 2487
hormonal
human prostatic epithelial model, 6064
*K14/bcl-2* transgenic mice, 3619
PAI-2 overexpression and, transgenic mice, 970
reversal by lipoxygenase modulation, 6307
**Carcinoid tumor**
gastrointestinal
β-catenin mutations, 6656
**Cardiomyocytes**
apoptosis
doxorubicin and, 2335
**Cardiotoxicity**
doxorubicin
inhibition by metallothionein, mouse, 3382
mitochondrial dysfunction, 771
**β-Carotene**
supplemental
preventive effects, second head and neck cancer, 1457
**Casein kinase II:** *See* **CK2**
**Caspase**
anoikis
induction by methyl selenium, prostate cancer, 3062
inducible, prostate cancer treatment, 2562
inhibition
γδ T cell functional maintenance, lymphoma, 3092
**Caspase 1**
expression loss, prostate cancer, 1227
**Caspase 3**
activation by lysosomal enzymes, P39 cells, 2878
expression loss, prostate cancer, 1227
reconstitution-mediated doxorubicin and etoposide sensitization, MCF-7 breast cancer, 348
**Caspase 6**
hTERT promoter/rev-caspase-6 construct gene therapy, malignant glioma, 5796
**Caspase 8**
activation by sulindac sulfide, colon and prostate cancer, 6918
activation by TRAIL
anticancer drug sensitization, 1645
expression loss, TRAIL-resistant neuroblastoma, 1314
gene transfer
Adv-mediated
anoikis induction, gastric cancer, 7009
TRAIL-induced apoptosis requirement, 1138
**Caspase 9**
inducible, prostate cancer therapy, 6795
**Catalase**
expression, lung cancer, 8578
gene promoter regulation, hydrogen peroxide-resistant HP100 cells, 5885
overexpression, apoptosis resistance, 2766
**(+)-Catechin**
tumor and FAK-p-Y397 inhibition, 118
**Catechol estrogens**
metabolism
COMT and, 6716
**Catechol-*O*-methyltransferase**
and catechol estrogen metabolism, 6716
effects, breast cancer, 7488
***β*-Catenin**
activation, hepatocarcinogenesis, 2085
alterations, bladder cancer, 7101
deregulation, ovarian endometrioid adenocarcinoma, 8247
epithelial cell polarity restoration, colorectal cancer, 2751
exon 3 mutations, gallbladder adenoma, 19
expression, colon tumorigenesis, 8085
hepatomegaly, transgenic mice, 3245
inhibition
growth inhibition, colon cancer, 6563
laminin γ2 regulation, colorectal cancer, 8089
localization modulation by sphingolipids, 6723
mutations
biliary tract cancer, 3406
gastrointestinal carcinoid tumor, 6656
point, solid-pseudopapillary neoplasms, 8401
premalignant crypts, rat colon carcinogenesis, 1874, 7699
proliferating colonocyte expression, 2899
stabilized
colonic epithelial cell immortalization, 2097
TCF signaling

and colonic epithelial cell differentiation, 3465
hyperactive, targeting, colon cancer, 4445
tyrosine phosphorylation
inhibition by geldanamycin, 1671
**γ-Catenin**
alterations, bladder cancer, 7101
**Cathepsin B**
intracellular
and cancer cell invasiveness, 3493
**Caveolin-1**
effects, prostate cancer, 4386
mutations, scirrhous breast cancer, 2361
secretion, prostate cancer, 3882
**CBHA:** *See* **m-Carboxycinnamic acid bis-hydroxamide**
**CCAAT/enhancer binding protein β**
aromatase upregulation, malignant breast epithelial cells, 2328
**CCAAT/enhancer binding protein β-liver-enriched inhibitory protein**
mammary epithelial cell proliferation, 261
**C-cell carcinoma**
NF-κB activity, 4526
**CCI-779**
antitumor activity, PNET/medulloblastoma, 1527
***CCN* genes**
expression, breast cancer, 8917
**CCTC-binding factor**
cell growth inhibition, 6002
**CD4**
CD4+CD25+ T cells
regulatory, early-stage non-small cell lung cancer and late-stage ovarian cancer, 4766
T cells
by-passing, 8787
**CD8**
T cells
clonal expansion, 6860
prognostic value, esophageal carcinoma, 3932
proliferative activity, renal cell carcinoma, 5132
**CD25**
CD4+CD25+ T cells
regulatory, early-stage non-small cell lung cancer and late-stage ovarian cancer, 4766
**CD26**
doxorubicin-induced arrest effects, 7204
**CD30**
ligand
Ang-CD30L, CD30-positive lymphoma treatment, 8737
lymphoma
Ang-CD30L treatment, 8737
**CD34**
dendritic cells
melanoma immunity, 6451
**CD40**
coexpression with CD40L, cutaneous T-cell lymphoma, 452
ligand
coexpression with CD40, cutaneous T-cell lymphoma, 452
rhuCD40L
combined with cisplatin, ovarian tumors, 7556
**CD44**
-targeted liposomes, 2592
variant
chemotherapeutic protection, colon cancer, 5275
**CD44v10**
multiple myeloma homing, 2862
**CD45**
$^{131}$I-anti-CD45 antibody
immunosuppressive effects, murine HSCT models, 5126
**CD64:** *See* **FcγRI**
**CD80:** *See* **B7–1**
**CD82**
expression
breast cancer invasion and metastasis, 5284
NF-κB–dependent, lung cancer, 673
**CD89:** *See* **FcαRI**
**CD95:** *See* **Fas**
**CD147/EMMPRIN**
MMP-1 and MMP-2 production interactions, 2276
**CD437**
cross-resistance, paclitaxel-resistant ovarian carcinoma, 7552
resistance, respiration-deficient cells, 6698
**cdc2**
MMR-mediated phosphorylation, 8290
**Cdc25A phosphatase**
inhibition by novel vitamin K analogs, 7211
**CDC25B**
and radiation-induced $G_2$-M arrest, esophageal cancer, 3188
**Cell adhesion**
regulation by Ets-1, glioma, 7985
T antigen, breast and prostate cancer, 4851
**Cell adhesion molecule**
epithelial
CTL epitopes, 4761
**Cell-cell interactions**
steel c-Kit and, cervical cancer and leukemia, 6281
**Cell cycle**
arrest
doxorubicin-induced
CD26/DPPIV effects, 7204
$G_1$, PTEN-induced
$p27^{KIP1}$ requirement, 2105
$G_1$, rapamycin-induced, 3373
$G_1$, tetraploid
induction by $p21^{WAF1}$, colon cancer, 7660
$G_2$, MMR-mediated, 8290
$G_2$-M, radiation-induced, CDC25B and, 3188
induction by PTEN, endometrial carcinoma, 4569
S-phase
UCN-01 effects, 1065
base excision repair modulation by p53 and, 88
Chk2 activity, 4990
cyclin E intranuclear compartmentalization, 1220
fluoropyrimidine-mediated
hMLH1 role, 5193
5-FU antitumor effects, colorectal cancer, 1029
$G_2$ checkpoint
abrogator PD0166285
radiosensitization, 8211
temozolomide-treated glioma, 5843
$G_2$ delay
and lung cancer susceptibility, 7819
p53-regulated checkpoint
p53R2 role, 8256
regulatory responses to polyamine depletion, melanoma, 7754
selenium redox effects, prostate cancer, 7071
S-phase alterations
silica-induced, 1791
**Cell death:** *See also* **Apoptosis**
CEA-expressing cells
targeted by retrovirus, 370
fluoropyrimidine-mediated
hMLH1 role, 5193
induction by BCR(64–413), chronic myelogenous leukemia, 138
mitochondrial cytochrome *c* expression and, 1038
radiation-induced
MnSOD protection against, hepatocellular carcinoma, 5382
stromelysin-3 deficiency, 2189
tumor
macrophages and, 7240
**Cell differentiation**
adipocyte, malignant breast epithelial cells, 2250
ansamycin and, breast cancer, 2945
araC analogue DMDC, acute promyelocytic leukemia, 178
Chk2 activity, 4990
colonic epithelial cell
β-catenin-TCF signaling and, 3465
dendritic cell
tumor-induced blockade, prevention by IL-4, 3096
granulocytic
ATRA metabolite-induced, NB4 promyelocytic leukemia cells, 700
HDAC-targeted treatment, acute myeloid leukemia, 2
inhibitor of differentiation/DNA binding Id-1 overexpression, early-stage cervical cancer, 5703
myelomonocytic, *myc*-dependent MLL-ENL, 6480
phenylacetate
PPARγ-mediated, neuroblastoma, 3998
redifferentiation
cystemustine-induced, melanoma murine model, 2294
suberoylanilide hydroxamic acid and, breast cancer, 8492
TGF-β1-induced transdifferentiation, pancreatic cancer, 4222
**Cell growth:** *See also* **Tumor growth**
arrest
PTEN-induced, $p27^{KIP1}$ requirement, 2105
CD8+ T cells, renal cell carcinoma, 5132
clonal model, 1879
colonocyte
β-catenin expression, 2899
enhancement by $G_{D2}$, small cell lung cancer, 4244
induction by IGF-1, melanoma, 7318
induction by LMP-1, epithelial cells, 6730
inhibition
*S*-allylmercaptocysteine, colon cancer, 725
antisense cyclin D1, rat hepatoma, 4779
BCR(64–413), chronic myelogenous leukemia, 138
bisphosphonate, prostate cancer, 2602
cables, colon and squamous cancer, 7325
CAR, colon cancer, 6592
β-catenin inhibition, colon cancer, 6563
$CB_2$ receptor, glioma, 5784
CCTC-binding factor, 6002
DC101, glioma, 6624
EB1089, LNCaP tumors, 4294
GW5638, breast cancer, 2917
25-hydroxyvitamin $D_3$, prostate cancer, 2852
IL-6, T47D breast cancer cells, 383
IRF-1, hepatocellular carcinoma Hepa1–6 cells, 2609
NB-506, camptothecin resistance, 504
NK4, pancreatic cancer, 7518

novel indolinone Kit inhibitors, small cell lung cancer, 3660
PEX, glioma, 8730
phosphorylated prolactin, prostate cancer, 6098
RGD-tachyplesin, 2434
15S-HETE, prostate cancer, 497
STAT3B-induced soluble factors, 3276
tamoxifen, breast cancer, 3002
TGF-$\beta$, Smad4-mutant colon adenoma, 256
triterpenoid saponins, 5486
vitamin D
mediation by p21, prostate cancer, 7122
low-dose x-rays, diploid cells, 5396
mammary epithelial cells
C/EBP$\beta$-LIP, 261
NGF-induced
inhibition by tamoxifen, breast cancer, 3002
novel suppressor gene, hepatocellular carcinoma, 7383
regulation
hormonal, ovarian surface epithelial cells, 6768
macrophage arginase, 1100
Rad and Nm23, breast cancer, 2062
redox
NF-$\kappa$B, 2656
restoration by androgen receptor, prostate cancer, 7310
retinoid receptors and, lung cancer, 556
**Cell killing**
chimeric tumor suppressor 1, glioma, 5833
cisplatin
*SKY1* effects, *S cerevisiae,* 6982
H-3Glu$_2$ peptide, prostate tumors, 6783
**Cell migration**
chemokines and, epithelial cancer, 4961
endothelial
regulation by RUNX2, 4994
increase by IL-6, T47D breast cancer cells, 383
NE-induced, SW 480 colon cancer cells, 2866
promotion by focal adhesion kinase, invasive carcinoma, 7079
radiation effects, glioma, 2744
regulation by Ets-1, glioma, 7985
**Cell proliferation:** *See* **Cell growth**
**Cell surface tumor endothelial markers**
conservation, mice and humans, 6649
**Cell survival**
autocrine VEGF function, breast cancer, 5736
IGF-IR-Akt pathway
inhibition by NEP, 3294
promotion by Akt/PKB, non-small cell lung cancer, 3986
promotion by KSHV-GPCR, 2641
**Cell transformation**
chimeric ETV6-NTRK3
blockade by signaling inhibitors, 8909
c-Myc downregulation effects, 1178
EGF-induced
inhibition by [6]-gingerol, 850
EWS/Fli-1 COOH terminus requirement, 5311
HPV16-mediated
EGF receptor, 3837
inhibition by [6]-gingerol, 850
inhibition by noni glycosides, 5749
malignant
cadmium-induced, prostate epithelial cells, 455
genomic alterations, Barrett's esophagus, 3164
prostatic epithelial cells, 8135
nucleophosmin/anaplastic lymphoma kinase-mediated
STAT5 role, 6517
p65/NF-$\kappa$B-dependent, 4160
prostatic epithelial cells
androgen activity, 5038
Raf-induced
IL-1 requirement, 602
RET-induced
NF-$\kappa$B requirement, 4526
thyroid
ETS-1 and ETS-2 induction requirement, 2267
**Cell transmembrane pH gradient**
chlorambucil efficacy *in vivo* and, 4740
**Cellular morphology**
VHL protein function, 4184
**Central nervous system**
radioresponse to irradiation
TNF signaling and, 8859
**Central nervous system lymphoma**
*p14$^{ARF}$* and *p16$^{INK4a}$* alterations, 6335
**Central nervous system tumors**
JC virus, 4287
pediatric subtypes
microsatellite instability, 2124
T-antigen expression, 4287
**Centrosome abnormalities**
defects, prostate cancer, 2212
HPV-16 E7 and, 2356
**CEP1612**
apoptosis induction and tumor growth inhibition, lung adenocarcinoma, 1280
**Ceramidase**
inhibition, colon cancer, 1233
**Ceramide analogues**
apoptosis induction and tumor growth prevention, metastatic colon cancer, 1233
**Ceramide synthase**
activation by 4-HPR, neuroblastoma, 5102
***c-erbB-2*:** *See* **HER-2/*neu***
**Cervical cancer**
advanced
*FHIT* expression, 4382
CA-9 endogenous marker, 8924
cell density-dependent growth
steel factor and, 6281
chromosome 6p25 and 6p21.3 tumor suppressor sites, identification, 2119
early-stage
Id-1 overexpression, prognostic value, 5703
hypoxia
HIF-1$\alpha$ marker, 7394
interstitial fluid pressure, prognostic value, 6400
locally advanced
CA IX expression and hypoxia, 6394
risk factors, 608
**Checkpoint kinase**
Chk1
Finnish Li-Fraumeni syndrome families, 5718
mutations, gastric tumors, 7727
Chk2
cell cycle, quiescence, and differentiation, 4990
destabilization by missense mutation, 8062
Finnish Li-Fraumeni syndrome families, 5718
mutations, lung cancer, 5362
yeast
mutations
adozelesin DNA replication effects, 3787
**Chemical carcinogenesis**
sensitization by LMP-1, transgenic mice, 6730
**Chemical exposure**
transplacental
and MLL$^{+ve}$ infant leukemia, 2542
**Chemokines**
and cell migration, epithelial cancer, 4961
dendritic cells secreting
extranodal tumor reactive T-cell priming, 8794
Fas-induced expression, glioma, 3084
gene therapy
combined with targeted IL-2, murine colon carcinoma, 8498
**Chemoprevention**
arzoxifene, breast cancer, 8412
GGMSC activity, 2923
lasofoxifene, rat mammary tumors, 8683
lunasin property, 7473
NSAID
metabolic enzymes and, colon adenoma, 3566
*p*-XSe-SG, colon cancer, 3647
raspberries, esophageal tumorigenesis, 6112
**Chemopreventive agents**
biomarker modulation, smoke-exposed rats, 2472
**Chemosensitivity**
CPT-11
augmentation by PS-341, 3535
prediction by cDNA microarray analysis, 6474
reduction by transgenic antizyme expression, mouse skin, 6073
**Chemotherapy**
CD44 variant, colon cancer, 5275
combined with bone marrow-derived dendritic cells, murine tumors, 7530
delivery
detection by MR, solid tumors, 3039
lasofoxifene, rat mammary tumors, 8683
low-dose
combined with PEX, glioma, 7501
metastatic potential and, 2857
MMP-7 protection against, 577
mortality
reduction by GLP-2, 687
resistance
promotion by Akt/PKB, non-small cell lung cancer, 3986
response
thymidine kinase and thymidylate synthase and, advanced breast cancer, 1421
specific targeting, 694
vaccine synergy, HER-2/*neu* tolerized mice, 3689
**Chernobyl accident**
*p53* mutations, 6964
**Childhood central nervous system tumors**
subtypes
microsatellite instability, 2124
**Childhood germ cell tumors**
multipoint imprinting analysis, 7268
**Childhood leukemia, acute lymphoblastic**
*NBS1* mutations, 3570
T-cell
thioredoxin expression, 7333
*TEL-AML1*-positive, RQ-RT-PCR, 2517
**Childhood lymphoma, AIDS-related**
PBMC SDF-1 mRNA levels, 5028
**Childhood malignant glioma**
p53 mutations, 7404
**Childhood renal cell carcinoma**
papillary
*RCC17/TFE3* fusion gene, 4130
**Childhood solid tumors**
dendritic cell vaccination, 8513

midkine promoter-based replicative adenovirus treatment, 7882
**Chimeric tumor suppressor 1**
cell kill, glioma, 5833
**China**
prostate cancer risk
VDR polymorphisms, IGFs and, 4333
Singapore
breast cancer risk, Chinese women, 3326
**Chinese hamster ovary cells**
mitomycin C resistance
reversal by bioreductive enzyme overexpression, 7770
mutation frequency, 50
**Chinese women**
breast cancer risk, Singapore, 3326
**Chlorambucil**
efficacy *in vivo*
and cell pH gradient, 4740
**Chlorin$_{e6}$ polymer**
photosensitizer conjugates
pegylated
tumor targeting, 7155
**Chlorins**
phototoxicity, mechanistic study, 717
**8-Chloro-adenosine**
mechanism of action, multiple myeloma, 5474
**8-Chloro-cAMP**
mechanism of action, multiple myeloma, 5474
**1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea:** *See* **Lomustine**
**1,3-bis(2-Chloroethyl)-1-nitrosourea**
sensitization
p53 inactivation, glioma, 4155
single-quantum- and triple-quantum-filtered $^{23}$Na and $^{31}$P NMR and, 9L glioma, 2002
**Choline**
$^{18}$F-labeled
PET findings, prostate cancer, 110
**Choline compounds**
increase, malignant human prostate cells, 3599
**Chromosome 3**
partial deletions, uveal melanoma, 3439
**Chromosome 5**
allelic deletions, ovarian tumors, 4169
**Chromosome 6**
allelic deletions, ovarian tumors, 4169
**Chromosome 3p**
novel tumor suppressor gene FOXP1, 8820
**Chromosome 3p21**
loss of heterozygosity
tobacco smoke-induced DNA damage and smoking age of initiation and, 612
**Chromosome 3p21.3**
*RASSF1A* gene
epigenetic inactivation, clear cell and papillary renal cell carcinoma, 7277
**Chromosome 3p25**
copy number alterations, bladder cancer, 4514
**Chromosome 6p21.3**
tumor suppressor sites, cervical cancer, 2119
**Chromosome 6p25**
tumor suppressor sites, cervical cancer, 2119
**Chromosome 8p12**
copy number alterations, bladder cancer, 4514
**Chromosome 9p**
loss of heterozygosity
multiple loci, melanoma, 1154
**Chromosome 9p21**
loss of heterozygosity, non-small cell lung cancer from smokers, 2092
tumor suppressor genes
inactivation, neuroendocrine gastroenteropancreatic tumors, 5905
**Chromosome 9p23–24**
instability, *BRCA2* mutation carriers, 5179
**Chromosome 17p13.3**
novel growth suppressor gene, hepatocellular carcinoma, 7383
**Chromosome 10p14–p15**
senescence gene locus, 7118
**Chromosome 3q**
amplification, head and neck squamous cell carcinoma, 4506
**Chromosome 3q26**
novel candidate oncogene, ovarian cancer, 3806
**Chromosome 9q34**
gain, early insulinoma, 5186
**Chromosome 11q22**
*cIAP1* amplification, esophageal squamous cell carcinoma, 6629
**Chromosome 13q14**
*CLLD6, CLLD7, CLLD8,* cloning and characterization, 2870
tumor suppressor locus characterization, chronic lymphocytic leukemia, 6640
**Chromosome 16q**
loss of heterozygosity, breast cancer, 1171
**Chromosome 17q12**
amplification, breast cancer, 8235
**Chromosome 17q22–23**
amplicon
structural analysis, breast cancer, 4951
**Chromosomes**
alterations
breast cancer, 1214
colorectal cancer, 8274
early head and neck squamous cell carcinoma, 4122
lung adenocarcinoma, 1309
aneuploidy, prostate carcinogenesis, 8143
stability
restoration, *BRCA1,* 4842
translocation
sarcoma-associated
fusion proteins, antigenicity, 6868
translocation t(11;14) junctions
T-nucleotide additions, mantle cell lymphoma, 1629
translocation t(7;12)(;36↔3)
*HLXB9* and *ETV6* fusion, infant acute myeloid leukemia, 5374
translocation t(11;14)(q23↖4)
*MLL*-human *gephyrin* fusion gene, acute monoblastic leukemia, 2665
**CI1033**
combined with SN-38 and topotecan, 739
***cIAP1***
amplification, esophageal squamous cell carcinoma, 6629
**Cidofovir**
antitumor activity, 5057
growth inhibition, nasopharyngeal carcinoma, 7875
**Cirrhosis**
liver
LYVE-1 downregulation, 8079
**Cisplatin**
cell kill
*SKY1* effects, *S cerevisiae,* 6982
combined with rhuCD40L
antitumor effects, ovarian tumors, 7556
resistance
human HMG1 gene expression regulation, 1592
induction by *SRPK1* inactivation, ovarian cancer, 6982
sensitization by truncated XPA-expressing adenovirus, 764
**c-Jun NH$_2$-terminal kinase**
activation
RRM-induced apoptosis, 8504
VES-induced apoptosis, breast cancer, 6569
methylseleninic acid effects, 7171
silica-induced activation, 1791
vinblastine-induced apoptosis, 4450
**c-Jun NH$_2$-terminal kinase-2**
skin tumorigenesis, mice, 3908
**CK2**
activity, breast cancer, 3810
***c*-kinase**
human *hSRBC*
inactivation, breast and lung cancer, 7943
**c-Kit**
aberrant
protective effects, colon carcinoma, 2200
cell-cell interactions mediated by, cervical cancer and leukemia, 6281
**Claudin-3**
expression, prostate cancer, 7878
**Claudin-4**
expression, prostate cancer, 7878
**Clear cell carcinoma**
renal
cytogenetic findings, prognostic impact, 7731
*RASSF1A* 3p21.3 gene inactivation, 7277
**CLL:** *See* **Leukemia, chronic lymphocytic**
***CLLD6***
cloning and characterization, 2870
***CLLD7***
cloning and characterization, 2870
***CLLD8***
cloning and characterization, 2870
**Clonal expansion**
CD8 T cells, 6860
initial, acute lymphoblastic leukemia, 8547
**Clonal growth**
model, 1879
**Clonal variation**
B-lineage acute lymphoblastic leukemia, 5268
**Cloning**
human polyamine oxidase, 5370
immunoselected tumor cell lines
antigen, 1089
**Clonotype mapping**
tetramer-guided, melanoma, 493
**Cloudman S91 cells**
anoikis and metastatic potential, 1707
**c-*mos***
expression, non-small cell lung cancer, 538
**c-Myc**
apoptosis mediation by Bin1, 3151
deregulation, lymphoma, 5202
downregulation
Ras and Raf transformation effects, 1178
p53 interactions
and 5-FU sensitivity, colon cancer, 4910
***CNTN2*: *See TAX-1***
**Coagulopathy**
carcinoma-induced
tumor hypoxia and, 795, 7697
**Coding for glycoprotein hormone α subunit *(CGA)***
overexpression, ER-positive breast cancer, 1652
**Colitis**
inhibition by PPAR ligands, 2424
**Collagenase-3**
expression, breast cancer, 7091
**Collagenase-4**
small inhibitors, targeted cancer therapy,

3978
**Collagen I**
E-cadherin expression downregulation, pancreatic cancer, 3508
degradation by oral squamous cell carcinoma, 6264
**Collagen III**
E-cadherin expression downregulation, pancreatic cancer, 3508
**Collagen IV**
$\beta_1$ integrin-mediated adhesion
PKC role, breast cancer, 2445
**Collagen XVIII**
expression, hepatocellular carcinoma, 45
**Colon**
aberrant crypt foci
$\beta$-catenin expression, 8085
dysplastic
and tumorigenesis, *Min*/+ mouse, 5010
inhibition by PPAR ligands, 2424
iNOS expression, 419
AKR induction, 6112
cytochrome P450 induction, 6112
epithelial cells
differentiation
$\beta$-catenin-TCF signaling and, 3465
immortalization by stabilized $\beta$-catenin, 2097
$\gamma$-glutamylcysteine synthetase induction, 6112
invasion
spatial model, 81
mucosa
methylation, 6991
NQO induction, 6112
**Colon adenocarcinoma**
clustered carbohydrate antigen expression, 950
fatty acid CoA ligase 4 upregulation, 8429
MUC2 *O*-glycosylation by *N*-acetylgalactosaminyltransferase-3, 950
TCR$\beta^{-/-}$ p53$^{-/-}$ mice, 2390
**Colon adenoma**
risk
NSAID chemoprevention and, 3566
Smad4-mutant
growth inhibition by TGF-$\beta$, 256
**Colon cancer**
aberrant c-kit protective effects, 2200
angiopoietin-1 and angiopoietin-2 effects, colon cancer, 1255
APC-mutated
mammalian two-hybrid system, 854
apoptosis induction by SU9516, 6170
BN 80915 potency, 2961
camptothecin resistance
BCRP-associated, 6034
CD44 variant chemotherapy, 5275
cell line kinetics
NO-releasing NSAIDs and, 3285
cell migration
NE-induced, SW 480 cells, 2866
ceramidase inhibition, 1233
chemoprevention by *p*-XSe-SG, 3647
combination chemokine gene therapy and targeted IL-2, murine, 8498
death receptor 5 and caspase 8 activation by sulindac sulfide, 6918
ER$\beta$ expression, 632
5-FU sensitivity
c-myc/p53 interactions and, 4910
gene expression profiles, 3124
growth inhibition
*S*-allylmercaptocysteine, 725
cables, 7325
CAR, 6592
$\beta$-catenin inhibition, 6563
16K hPRL, 7356
$G_1$ tetraploid arrest
induction by p21$^{WAF1}$, 7660
hyperactive $\beta$-catenin/T-cell factor pathway targeting, 4445
initiation
stem cell overproduction, 8408
metastasis
apoptosis induction and tumor growth prevention by ceramide analogues, 1233
carcinoembryonic antigen role, 2732
metastasis to liver
SU6668 and, 1464
microsatellite instability
sex differences, 126
molecular genetics, IL-2$^{null}$ $\times$ $\beta_2$M$^{null}$ mice, 6912
nonpolypotic
*MSH6* and *MSH3* mutations, 1619
risk
*Apc(B1822V)* and, 1000
serum methylated *hMLH1*, 900
UDP-Gal transporter expression, 4620
**Colon carcinogenesis**
DNA-dependent protein kinase expression, 8381
early
PKC $\beta$II levels, 1375
premalignant lesions, rat, 1874, 7699
**Colonocytes**
proliferating
$\beta$-catenin expression, 2899
**Colon tumorigenesis**
$\beta$-catenin expression, 8085
dysplastic aberrant crypt foci and, *Min*/+ mouse, 5010
iNOS expression, 419
modulation by dietary fatty acids, 1927
**Colon tumors**
PI3K p85$\alpha$ subunit oncogene, 7426
VEGF regulation by Wnt and K-ras, 6050
**Colorectal adenocarcinoma**
gene expression profiles, 3124
Id helix-loop-helix protein expression, 8803
**Colorectal adenoma**
gene expression profiles, 3124
mEH and, 2381
risk factors, 2381
**Colorectal cancer**
advanced
XPD polymorphism and, 8654
age-associated risk
*NAT2* mutations and, 1265
camptothecin cytotoxicity
mismatch repair and, 6555
combination radioimmunotherapy and combrestatin A-4 3-*O*-phosphate, 4716
early
low-level microsatellite instability frequency, 7743
*ENC1* upregulation, 7722
epithelial cell polarity
restoration by TCF4, 2744
etoposide cytotoxicity
mismatch repair and, 6555
*FGFR2* and *FGFR3* mutations, 3541
5-FU antitumor effects, dual, 1029
hereditary nonpolyposis
*cyclin D1*, 6042
exon skipping by nonsense *MLH1* mutations, 7020
microsatellite instability, 896
mismatch repair defects, 7369
MLH1 expression, 2813
MSH2 and MSH6 expression, 2813
mutators and, 7369
screening, microsatellite markers, 4545
*hPMS1* and *hPMS2*, 7798
immunotherapy, mouse model, 8520
intrachromosomal genomic instability, 8274
laminin $\gamma$2 regulation by $\beta$-catenin, 8089
malignant
genes expressed, 6996
metastasis
protoporphyrin IX, 991
metastasis to liver
CEA mutations and, 2822
microsatellite instability, low-level
*MGMT* methylation and, 827
Msh2 and *FHIT* expression, 7379
oxidative stress and frameshift mutations, 7444
protoporphyrin IX, 991
RT-PCR for blood CEA mRNA, 2523
stem cell factor-induced
survival and invasion, 2200
ST6GalNAc-II overexpression, 4605
T$\beta$R-I(6A) polymorphism, Macedonian patients, 8351
Thomsen-Friedenreich glycotype, 4605
tumor markers, identification with cDNA microarray, 7792
tumor suppressor gene therapy
*RIZ1*, 1796
**Colorectal carcinogenesis**
AF17, 6345
genes expression alterations, 3544
microsatellite instability, 896
**Colorectal tumorigenesis**
early
genetic instability, 818
**Colorectal tumors**
benign
genes expressed, 6996
genetic pathways, 2676
**Combrestatin A-4 3-*O*-phosphate**
combined with radioimmunotherapy, colorectal xenografts, 4716
**Combrestatin A-4 phosphate**
tumor vascular permeability and response, 6811
tumor vascular shut-down, 6413
**Comparative genomic hybridization**
ovarian cancer analysis, 5895
**Complementary-determining region 3**
variable immunoglobulin heavy chain antitumor VH-CDR3 antibodies, 1555
**Complementary DNA**
microarrays
chemoresistance analysis, 5505
chemotherapy sensitivity prediction, 6474
colorectal cancer tumor marker identification, 7792
molecular profiling, squamous cell carcinoma, 4797
osteosarcoma metastasis evaluation, 3750
ovarian cancer analysis, 5895
radiation response assessment, head and neck squamous cell carcinoma, 2376
serological identification of tumor antigens by cDNA expression cloning
melanoma antigen isolation, 7900
**Constitutive photomorphogenesis 9 signalosome**
and VEGF production, 8416
**Convection-enhanced drug delivery**
diffusion-weighted MRI monitoring, brain tumor, 4971
**Core 2 $\beta$1,6-*N*-acetylglucosaminyltransferase**
expression, lung adenocarcinoma, 2226
**Cortactin**
metastasis induction, breast cancer, 6906
**Costimulators**
hyperexpression, dendritic cells, 3725

intratumoral protein transfer, 8127
**Coxsackievirus and adenovirus receptor**
deficiency
and replicating adenovirus potency, 813
growth-inhibitory effects, colon cancer, 6592
**CpG dinucleotides**
methylated
mutations, 7110
**CPT-11:** *See* **Irinotecan**
**Crabtree effects**
absence, low pH-adapted melanoma, 5630
**cRaf-BRaf**
heterodimerization, 3595
**Cre/loxP system**
-enhanced CEA-specific suicide gene therapy of CD/5-FC, gastric carcinoma treatment, 6158
**cRel**
antiproliferative and antiapoptotic effects, 2656
**Crkl**
leukemogenesis enhancement, *BCR/ABL* P190 transgenic mice, 1398
**Cruciferous vegetables**
dietary indoles and isothiocyanates
apoptosis induction and protective effects, colon cells, 6120
**Csk**
tumor antigen, carcinoma, 1415
***CTCF***
binding site methylation, Wilms' tumor, 4947
**CTGF**
levels, breast cancer, 8917
**Cullin**
ROC-cullin ligases
E2F1 ubiquitination, 1347
**Curcumin**
metabolites, 1058
**Cutaneous fatty acid-binding protein**
metastasis induction, 4357
VEGF upregulation, 4357
**Cutaneous lymphoma**
T-cell
CD40/CD40L coexpression, 452
**Cutaneous melanoma**
malignant
invasiveness
*MMP-1* gene polymorphism and, 1296
Ski overexpression, 8074
**CV706**
combined with radiotherapy, antitumor effects, 5453
phase I trial, prostate cancer treatment, 7464
**CV787**
synergy with paclitaxel and docetaxel, 517
**CV890**
combined with doxorubicin, liver tumors, 6428
**CXCL9:** *See* **MIG**
**Cyclic AMP**
inducible cAMP early repressor
expression, prostate cancer, 6055
**Cyclic AMP response element binding protein**
p300/CREB-binding protein
hHR23A interactions, 64
**Cyclic hydroxamic-acid containing peptide 31**
antitumor activity, 4459
**Cyclin B1**
tetraploidy regulation, 6487
**Cyclin D1**
antisense
growth inhibition, rat hepatoma, 4779
cdk4 binding site, Rb C domain, 2885
ErbB2/*neu* kinase-mediated modulation, 6583
expression, estrogen-dependent
*AIB1* and, 3858
hepatocyte replication promotion, 8564
hereditary nonpolyposis colorectal cancer, 6042
overexpression, chronic
and hepatocellular carcinoma, transgenic mice, 5389
**Cyclin D2**
expression
BCR-ABL activity and, lymphoblasts, 8005
testicular germ cell tumors, 4214
expression loss
promoter hypermethylation and, breast cancer, 2782
**Cyclin-dependent kinase 2**
expression, testicular germ cell tumors, 4214
-selective inhibitor SU9516
apoptosis induction, colon carcinoma, 6170
**Cyclin-dependent kinase 4**
cyclin D1 binding site, Rb C domain, 2885
expression, testicular germ cell tumors, 4214
**Cyclin-dependent kinase inhibitors**
inactivation, neuroendocrine gastroenteropancreatic tumors, 5905
**Cyclin-dependent kinase N2A**
*CDKN2A*
gene loss, sequential oral epithelial dysplasia and carcinoma, 2371
homozygous deletion, neuroblastoma, 679
**Cyclin E**
expression, testicular germ cell tumors, 4214
intranuclear compartmentalization, 1220
nucleoplasm-nucleolar shuttling disruption, bladder cancer, 1220
risk-stratification model, non-small cell lung cancer, 2500
and survival, early stage non-small cell lung cancer, 647
**Cyclooxygenase 1**
inhibitors, mismatch repair-deficient mice, 6131
**Cyclooxygenase 2**
brain, prostanoid-related anorexia, 4707
expression
malignant melanoma, 303
ovarian tumors and macrophages, 7305
prognostic value, glioma, 4375
prostate cancer, 2720
rat tongue carcinogenesis, 1451
induction by UVB
Akt and GSK-3$\beta$ roles, 4329
inhibitors
mismatch repair-deficient mice, 6131
rofecoxib
intestinal polyposis chemoprevention, *Apc*$^{\Delta}$*716* mouse, 1733
methylation
gastric carcinoma, 4628
gastric epithelial cells, 2399
mRNA stability
Akt/PKB and, 2670
upregulation, proliferative inflammatory prostate atrophy, 8617
**Cyclophosphamide**
cytotoxicity
anemia correction and, rat tumors, 1358
early response, monitoring, 7747
polymer-based delivery
and rRp450, 864
scheduling
and CYP/CYP reductase gene therapy, 4437
vaccine synergy, HER-2/*neu* tolerized mice, 3689
**CYR61**
levels, breast cancer, 8917
**Cystemustine**
redifferentiation and protective effects, melanoma murine model, 2294
**Cytochrome *c***
mitochondrial expression
and cell death, 1038
**Cytochrome P450**
CYP1A1
expression inhibition by dibenzoylmethane, 3919
regulation by dioxin and pesticides, breast cancer, 3942
CYP1A2
expression inhibition by dibenzoylmethane, 3919
CYP1B1
expression inhibition by dibenzoylmethane, 3919
mutations, head and neck squamous cell carcinoma, 4398
regulation by dioxin and pesticides, breast cancer, 3942
selective inhibition, 8164
*CYP2B1*
rRp450, CPA-polymer and, 864
*CYP2C9*
and NSAID chemoprevention, colon adenoma, 3566
CYP2E1
null status, azoxymethane and methylazoxymethanol activation, 8435
induction, human colon cells, 6112
**Cytochrome P450c17$\alpha$**
*CYP17*
and breast cancer, 785
genotype analysis, endometrial cancer and estrogen replacement therapy, 848
polymorphism, and endometrial cancer risk, 3955
**Cytochrome P450/cytochrome P450 reductase**
gene therapy
cyclophosphamide scheduling and, 4437
**Cytogenetic analysis**
clear cell renal cell carcinoma findings, prognostic impact, 7731
multifocal bladder cancer, 355
**Cytokines**
-assisted SEREX
tumor growth inhibition, rat 9L glioma, 2625
brain, prostanoid-related anorexia, 4707
and electroporation, tumor therapy, 3281
gene expression, B-cell lymphoma, 1285
**Cytosine deaminase/5-fluorocytosine**
CEA-specific suicide gene therapy
enhanced by Cre/loxP, gastric carcinoma treatment, 6158
**Cytosine deaminase suicide gene *CD* therapy**
repeated gene transfer, 14
**Cytotoxicity**
camptothecin
mismatch repair and, colorectal cancer, 6555
combination selective retinoid ligands and Taxol, 8703
cyclophosphamide
anemia correction and, rat tumors, 1358
etoposide
mismatch repair and, colorectal cancer, 6555
ganciclovir-induced
$\beta$-pol protection against, 7399
*N*-OH-PhIP
GSTP1 and, 103

TopI-mediated
MNNG, 53
tumor
nitric oxide, inhibition by macrophage arginase, 1100
**Cytotoxic therapy**
*p53* mutations, neuroblastoma, 8
**Cytotoxic T lymphocytes**
α-actinin-4 mutated peptide-reactive, non-small cell lung cancer, 4078
EBV-specific responses, Hodgkin's disease, 6219
effector
induction, direct antigen presentation, 1107
epitopes
Ep-CAM, 4761
γδ T cell functions
maintenance by caspase blockade, lymphoma, 3092
gp100 epitopes, 7577
heterogenous
MAGE-A10 response, 5850
HLA-A2.1-restricted T antigen-specific, 873
MAGE-$A10_{254-262}$-specific, melanoma, 509
Melan-A-specific
PS-SCL recognition, 5153
mutated lung cancer antigen response, 3718
survivin response, cancer, 869
telomerase-specific, cancer, 8366
tumor-specific response, renal cell carcinoma, 3240

**D**

**D-24851**
antitumoral effects, 392
**DACA:** *See* ***N*-[2-(Dimethylamino)ethyl]acridine-4-carboxamide**
**DC101**
angiogenesis and growth inhibition, glioma, 6624
combined with radiation therapy, tumor xenografts, 39
**Deacetylase**
HDAC inhibitor-induced apoptosis enhancement, 1327
**Death-associated protein kinase**
promoter hypermethylation pattern, head and neck squamous cell carcinoma, 939
**Death receptor 4**
expression, Ewing's sarcoma, 2704
induction by paclitaxel, prostate cancer, 759
**Death receptor 5**
activation by sulindac sulfide, colon and prostate cancer, 6918
expression, Ewing's sarcoma, 2704
induction by paclitaxel, prostate cancer, 759
**Death receptors**
CD95 (APO-1/Fas)
restricted triggering, bispecific antibody, 1846
expression, prostate cancer, 7179
VEGF-triggered, 8629
**Decoy receptor 3**
expression, malignant glioma, 2759
**Dehydroepiandrosterone**
tumor progression inhibition, mammary cancer, 7449
**Deleted in malignant brain tumors DMBT1**
digestive tract cancer, 8880
**Deletions:** *See also* **Loss of heterozygosity**
*AXIN1*, sporadic medulloblastoma, 7039
chromosome 5, ovarian tumors, 4169
chromosome 6, ovarian tumors, 4169
hepatitis B virus X, hepatocellular carcinoma, 7803
partial
chromosome 3, uveal melanoma, 3439
*in utero* V(D)J recombinase-mediated, 3432
UVB-induced, murine epidermis, 3913
**4-Demethoxy-3′-deamino-3′-aziridinyl-4′-methylsulphonyl-daunorubicin**
anti-tumor activity, resistant tumors, 1991
pharmacological and toxicological aspects, 1983
**Dendritic cells**
apoptotic leukemia cell-loaded, 2386
Arg-Gly-Asp fiber-mutant Ad vector-transduced
vaccine efficacy, 7913
avipox-CEA/B7–1-infected
T-cell activation, 7568
bone marrow-derived
combined with chemotherapy, murine tumors, 7530
CD34-DCs
melanoma immunity, 6451
chemokine-secreting
extranodal tumor reactive T-cell priming, 8794
costimulatory molecule hyperexpression, 3725
and DNA vaccine potency, 3704
growth inhibition, breast cancer, 228
inhibition by neuroblastoma-derived gangliosides, 363
intranodal, 641
maturational blockade by early apoptotic melanoma, 8218
melanoma antigen gene-modified
by-passing CD4+ T cells, 8787
pancreatic cancer, 6445
peptide-pulsed, malignant glioma vaccination, 842
renal cell carcinoma RNA-transfected, tumor vaccine, 3388
Retrogen strategy, 197
TRP2-transduced
and IFNα-induced immunity, melanoma, 8643
tumor-induced blockade
prevention by IL-4, 3096
tumor-pulsed
necrotic *versus* apoptotic, 8105
vaccination, pediatric solid tumor patients, 8513
vaccines
combined with IL-12, hepatocellular carcinoma immunotherapy, 7563
keyhole limpet hemocyanin and, 2618
**Dendropoiesis**
inhibition by neuroblastoma-derived gangliosides, 363
**1-(2-Deoxy-2-methylene-β-D-*erythro*-pentofuranosyl)cytidine**
cell differentiation, acute promyelocytic leukemia, 178
**Dermatofibrosarcoma protuberans**
inhibition by STI571, 5778
**Desmoplasia**
induction by TGF-β1, pancreatic cancer, 550
**DF3**
antibody-dependent cellular phagocytosis, breast cancer, 4061
**DF3xH22**
antibody-dependent cellular phagocytosis, breast cancer, 4061
**Dialysis**
tumor microdialysis
urea recovery marker, 7964
**Diaminobutane-Am64-(1B4M-Gd)$_{64}$**
dynamic micro-MRI, liver micrometastasis, 4966
**Dibenzoylmethane**
CYP1A1, CYP1A2, and CYP1B1 expression inhibition, 3919
**Dietary fat**
*Apc(B1822V)* and, 1000
**Dietary fatty acids**
colon tumorigenesis modulation, 1927
**Dietary folate**
and breast cancer risk, Shanghai, 7136
**Dietary genistein**
prostate cancer prevention, mice, 6777
**Dietary modulation**
*Apc*-initiated tumors, 565
low-iron
and 8-OHdG, chronic hepatitis C, 8697
**Differential display**
molecular profiling, squamous cell carcinoma, 4797
**Differentiation antibody microarray**
leukemia immunophenotyping, 4483
**2′,2′-Difluoro-2′-deoxycytidine:** *See* **Gemcitabine**
**2-Difluoromethylornithine**
tumor progression inhibition, mammary cancer, 7449
**Digestive tract cancer**
DMBT1 role, 8880
**Dihydrodiol dehydrogenase**
overexpression, non-small cell lung cancer, 2727
**Dihydrofolate reductase**
mutations
methotrexate pharmacokinetics, mice, 1522
**1α,25-Dihydroxyvitamin $D_3$**
growth inhibitory effects
mediation by p21, prostate cancer, 7122
***N*-[2-(Dimethylamino)ethyl]acridine-4-carboxamide**
$^{11}$C-labeled, biodistribution and metabolism, 2935
**Dimethylbenzanthracene**
carcinogenesis, *Gadd45a*-null mice, 2487
**5,6-Dimethylxanthenone-4-acetic acid**
angiogenesis inhibition, 1517
combined with B7.1-mediated immunotherapy, 1948
**Dioxin**
Ah receptor
NMT-2 mRNA induction, 8534
CYP regulation, breast cancer, 3942
Mad2 inhibition by, 5707
**Dipeptidyl peptidase IV**
doxorubicin-induced arrest effects, 7204
**Diploid cells**
proliferation and MAPK activation by low-dose x-rays, 5396
**DMDC:** *See* **1-(2-Deoxy-2-methylene-β-D-*erythro*-pentofuranosyl)cytidine**
**DNA**
CpG islands
CpG-ODN, antimetastatic effects, 5523
hypermethylation
*PRB* inactivation and, endometrial cancer, 97
reversal by procainamide, prostate cancer, 8611
methylation
age-related, ulcerative colitis, 3573
histology-specific, non-small cell lung cancer, 3419
mutations, 7110
pancreatic cancer, 8540
premalignant gastric cancer, 2847
hypermethylation, breast cancer, 8375
inhibitor of differentiation/DNA binding Id-1
overexpression, early-stage cervical cancer, 5703

metastasis-inducing
Tcf-4 binding, 5619
methylation
Nm23-H1 and, 2320
mitochondrial
alterations, human tumors, 7015
mutations
breast cancer, 7623
pancreatic cancer, 1299
somatic, hepatocarcinogenesis, 1843
somatic, ovarian cancer, 5998
*OGG1* gene, mouse, 5378
replication
adozelesin effects, kinase mutants, 3787
inhibition by tirapazamine, 5425
vaccination
naked
antitumor VH-CDR3 antibodies, 1555
vaccines
cancer immunotherapy, 3698
chimeric Flt3-ligand, tumor immunotherapy, 1080
potency
dendritic cells and, 3704
**DNA adducts**
BPDE-induced, lung cancer, 1445
carcinogen
and lung cancer risk, 6708
*N*-OH-PhIP
GSTP1 and, 103
**DNA affinity immunoblotting,** 5402
**DNA binding proteins**
breast cancer, 1362
**DNA damage**
apoptosis
p53 target *APAF-1,* 6660
DNA-PK and p53 sensor complex, 8723
double-strand breaks
end-joining, genomic rearrangements, 3886
marked defects, SCID/RAD54$^{-/-}$ cells, 2649
rejoining, BRCA2-deficient cells, 270
fragments
plasma
origin, cancer, 1659
ganciclovir-induced
$\beta$-pol protection against, 7399
NF-$\kappa$B activation, HeLa cells, 7785
protection against
dietary indoles and isothiocyanates, cruciferous vegetable
colon cells, 6120
radical-induced
and prostate cancer, 6025
tobacco smoke-induced
chromosome 3p21 loss, lung cancer, 612
UV-induced
Hupki mice, 8158
**DNA-dependent protein kinase**
catalytic subunit
gene amplification and, rodent cells, 4520
*Prkdc* polymorphism, and breast cancer risk, 1820
expression, colon carcinogenesis, 8381
p53 DNA damage sensor complex, 8723
**DNA polymerase $\beta$**
protection against ganciclovir, 7399
**DNA polymerase $\kappa$**
overexpression, lung cancer, 5366
**DNA repair**
base excision
inhibition by nitric oxide, 6388
modulation by p53, 88
defects, breast cancer, 3627
double-strand break rejoining, BRCA2-deficient cells, 270
error-prone chromosome repair
marked defects, SCID/RAD54$^{-/-}$ cells, 2649
*Gadd45a*-null mice, 2487
mismatch
camptothecin and etoposide cytotoxicity, colorectal cancer, 6555
cdc2 phosphorylation and $G_2$ arrest, 8290
defects
hereditary nonpolyposis colorectal cancer, 7369
prostate cancer, 4112
deficiency
COX inhibitors, mice, 6131
ionizing radiation mutagenesis, mice, 3775
mononucleotide repeat variability, 3801
p53 interactions, colon cancer, 1508
modulation by p21waf1cip1, p53-deficient cells, 3781
nucleotide excision
modulation by XPD polymorphisms, lung cancer, 1354
p33$^{ING1}$-mediated, 4974
restoration, *BRCA1,* 4842
**DNA topoisomerase**
inhibitors
sensitization
ribozyme cleavage of telomerase mRNA, breast epithelial cells, 3053
**DNA topoisomerase I**
degradation
ubiquitin/26S proteasome-mediated, 5926
NB-506 antiproliferative activity, camptothecin resistance, 504
R364H mutation, CPT-resistant prostate cancer, 1964
trapping by $O^6$-MG, 53
**DNA topoisomerase IIA**
*topo IIA* amplification, breast cancer, 5345
**Docetaxel**
combined with anti-VEGF mAb or 2-methoxyestradiol, antiangiogenic therapy, 3369
combined with doxorubicin, mammary adenocarcinoma chemotherapy, 1996
synergy with CV787, 517
**Doppler ultrasound**
tumor antivascular therapy monitoring, 2974
**Dormancy**
tumor cell
promotion by primary tumor, 5575
**DOTA:** *See* **1,4,7,10-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-Lys$^8$-vasotocin**
**Doxorubicin**
cardiac mitochondrial dysfunction, 771
and cardiomyocyte apoptosis, 2335
cardiotoxicity
inhibition by metallothionein, mouse, 3382
cell cycle arrest
CD26/DPPIV effects, 7204
clinical levels
iPLA$_2$ inhibition, 4024
combined with CV890, liver tumors, 6428
combined with docetaxel, mammary adenocarcinoma chemotherapy, 1996
extracellularly tumor-activated prodrug, 2843
and iron regulatory proteins, 8422
liposome-encapsulated
CD44-targeted, 2592
resistance
*TP53* alterations and, locally advanced breast cancer, 2505
sensitivity
enhancement by flavopiridol, Rb-deficient sarcoma, 2579
sensitization
caspase 3 reconstitution-mediated, MCF-7 breast cancer, 348
toxicity
age-dependent amifostine effects, rats, 6423
vaccine synergy, HER-2/*neu* tolerized mice, 3689
**Drug delivery**
convection-enhanced
diffusion-weighted MRI monitoring, brain tumor, 4971
**Drug resistance:** *See also* **Multidrug resistance**
anti-EGFR antibodies, 5090
cDNA array analysis, 5505
cross-resistance
ara-C and daunorubicin, HL-60 cells, 172
p53 and, neuroblastoma, 6185
p73$\alpha$ overexpression and, ovarian cancer, 935
PNU-159548 anti-tumor activity, 1991
**Drug sensitization**
*E1A,* Ewing's sarcoma, 3394
tumor cell, 1645
**Duanorubicin**
ara-C cross-resistance, HL60 cells, 172
**DU-145 cells**
caspase-dependent anoikis induction by methyl selenium, 3062
**Ductal adenocarcinoma**
pancreatic
microsatellite instability, features, 3139
**Ductal carcinoma**
mammary
collagenase-3 expression, 7091
hormone-responsive cells, murine, 293
medullary
humoral immune response, 7889
**Dysplasia**
aberrant crypt foci
and tumorigenesis, *Min*/+ mouse colon tumorigenesis, 5010
oral epithelial
*CDKN2A* gene loss, 2371

**E**

**E1A**
anticancer drug sensitization, Ewing's sarcoma cells, 3394
IκB degradation inhibition, 7413
**E1a**
replication-competent Ad-OC-E1a
systemic gene therapy, prostate cancer bone metastasis, 6012
**EB1089**
growth inhibition, LNCaP tumors, 4294
**Ectodermal-neural cortex 1 *(ENC1)* gene**
upregulation, colorectal cancer, 7722
**E2F1**
Bcl-2 upregulation, glioma, 6693
cancer therapy role, pancreatic cancer, 7052
ubiquitination by mutliple ROC-cullin ligases, 1347
**EF-2 kinase/Hsp90 protein complex**
geldanamycin effects, 4010
**EIB**
Bcl2/adenovirus EIB 19kD-interacting protein 3
expression, tumors, 6669
**Eicosapentaenoic acid**
skeletal muscle protein catabolism, cancer cachexia, 3604
***ELAC2/HPC* gene**
hereditary and sporadic prostate cancer,

Finland, 6038
hereditary prostate cancer, 6494
loss of heterozygosity, prostate cancer, 8651
polymorphisms, prostate cancer, 4982
**Elastin-like polypeptide**
thermally targeted
cellular uptake, 7163
thermal targeting, solid tumors, 1548
**Electroporation**
*Il-12* gene therapy, hepatocellular carcinoma, 1005
tumor therapy with cytokines and, 3281
**Electrospray ionization mass spectrometry**
*p53* mutation detection, hepatocellular carcinoma, 33
**ELP:** *See* **Elastin-like polypeptide**
**Embryogenesis**
trichostatin A effects, mouse, 1247
**Embryoid bodies**
α5-integrin-null, 5255
**End-joining deficiency**
gemcitabine, 1585
**Endocrine tumors, pancreatic**
nonfunctional
allelotype, 285
small
genetic alterations, 5186
**Endoglin**
anti-endoglin mAbs
antiangiogenic therapy, skin/SCID mouse chimeras, 7846
-targeted antiangiogenic therapy, skin/SCID mouse chimeras, 7846
**Endometrial adenocarcinoma**
resveratrol properties, 6137
**Endometrial cancer**
cell cycle arrest induction by PTEN, 4569
estrogen receptor methylation, 3262
gene amplification, rat, 8263
*PRB* inactivation and CpG hypermethylation, 97
PTEN-expressing
gene expression profiles, 3741
risk
*CYP17* polymorphism and, 3955
and estrogen replacement therapy, *CYP17* genotype analysis, 848
**Endometrial precancer**
latent, molecular identification, 4311
**Endometrioid adenocarcinoma**
ovarian
β-catenin deregulation, 8247
**Endometrioid cancer**
progesterone receptors A and B, 4576
**Endostatin**
intraperitoneal, mouse xenograft tumor model, 7669
intratumoral
vascular growth inhibition, murine mammary carcinoma, 526
intravital microscopic study, 6830
polymorphism
and prostatic adenocarcinoma, 7375
soluble recombinant, *E. coli*
antitumor effects, 478
uPA modulation
and focal adhesions, endothelial cells, 6511
**Endothelial cells**
apoptosis stimulation by VEGF receptor, 8629
Bcl-2 upregulation
and tumor angiogenesis, 2183
circulating
angiogenesis marker, lymphoma, 4341
endostatin-induced uPA modulation and focal adhesions, 6511
migration regulation by RUNX2, 4994
mitogenesis
methylseleninic acid effects, 7171
survival promotion by KSHV-GPCR, 2641
**Endothelin-1**
tumor proteinase and invasiveness induction, ovarian cancer, 8340
**Endothelium**
cell adhesion
T antigen, breast and prostate cancer, 4851
formation, inflammatory breast cancer, 445
tumor
anti-VEGF sFV targeting, 3653
**Environment**
gene interactions
Twentieth International Symposium of the Sapporo Cancer Seminar Foundation, meeting report, 2788
**Enzymes:** *See also* ***specific enzymes***
bioreductive
mitomycin C resistance reversal, Chinese hamster ovary cells, 7770
lysosomal
caspase-3 activation, P39 cells, 2878
**EphA2**
overexpression, mammary tumorigenesis, 2301
**Epidermal growth factor**
cell transformation
inhibition by [6]-gingerol, 850
receptor
anti-EGFR therapy
combined with TNF-α, solid tumors, 1045
resistance, 5090
HPV16-mediated transformation, 3837
immunophotodiagnosis and photoimmunotherapy, oral precancer, 4490
inhibitors
HER2 blockade, breast cancer, 8887
novel dual ErbB-2/EGFR tyrosine kinase inhibitor, characterization, 7196
mutations
ΔEGFR, anti-ΔEGFR 806, growth inhibition, 5355
ΔEGFR-expressing glioblastoma, mAb treatment, 5349
and p53, glioblastoma, 1122
RXR-selective modulation, head and neck squamous cell carcinoma, 5919
signaling
activated ERK1/2 and, head and neck squamous cell carcinoma, 6500
signaling-inactive
ligand binding, 5790
-targeted oncolytic adenovirus, 6377
**Epidermal squamous cell carcinoma**
inhibition by suprabasal α3β1 integrin expression, transgenic mouse model, 5248
**Epidermis**
UVB-induced deletions, murine, 3913
**Epidermoid carcinoma**
streptococcal antitumor glycoprotein effects, 6151
**Epigenetic patterns**
bladder cancer, 5875
**Epithelial cancer**
cell migration
chemokines and, 4961
**Epithelial cell adhesion molecule**
CTL epitopes, 4761
**Epithelial cell kinase**
vasculogenic mimicry, 3250
**Epithelial cells**
breast
invasion, regulation by heregulin, 400
malignant, adipocyte differentiation, 2250
malignant, C/EBPβ-mediated aromatase upregulation, 2328
ribozyme cleavage of telomerase mRNA, 3053
stromal interactions, *in vitro* model, 1320
colonic
differentiation, β-catenin-TCF signaling and, 3465
immortalization by stabilized β-catenin, 2097
gastric
apoptosis, and *cagA+ H. pylori*, 1406
COX-2 methylation, 2399
intestinal
ERK/MAP kinase regulation by kinase suppressor of Ras, 963
survival
*Ras* kinase suppressor and, 8668
mammary
Akt1 and MMP-2 activation, mouse, 7647
human, immortalization by *ZNF217*, 1250
proliferation, C/EBPβ-LIP, 261
tamoxifen-mediated apoptosis promotion by p53 inactivation by E6, 616
ovarian
hTERT promoter regulation, 5529
ovarian surface
growth
hormonal regulation, 6768
polarity
restoration by TCF4, colorectal cancer, 2744
proliferation
induction by LMP-1, 6730
prostate
TMPRSS2 protease cleavage and secretion, 1686
prostatic
androgen activity, malignant transformation, 5038
malignant transformation, 8135
**Epithelial dysplasia**
oral
*CDKN2A* gene loss, 2371
**Epithelial glycoprotein 2**
transgenic mice tumor model, 4105
**Epithelium**
bladder
*p53* mutations, Chernobyl accident, 6964
breast
retinoic acid production by ALDH6, 7065
malignant
AR expression, prognostic value, prostate cancer, 423
prostate
*PSDR1* expression, 1611
stroma interactions, meeting report, 3844
**Epoxide hydrolase**
microsomal
and colorectal adenoma risk, 2381
**Epstein-Barr virus**
-specific T-cell responses, Hodgkin's disease, 6219
**erbB-1:** *See* **HER-1**
**erbB-2:** *See* **HER-2/*neu***
**ErbB3**
inhibition by p85-sErbB3, 4467
**erbB-4/HER-4**
expression, ovarian cancer, 2169
**ERG**
TLS/ERG fusion protein
YB-1 functional interference, 3586
**ERR family receptors**
pS2 regulation, 6755
**Erythroid cells**
maturation

Lyn kinase activity, 2453
**Erythroleukemia**
Lyn kinase activity, 2453
**Erythropoietin**
anemia-induced cyclophosphamide cytotoxicity reduction, rat tumors, 1358
expression, cancer, 3561
receptor
expression, cancer, 3561
***Escherichia coli***
soluble recombinant endostatin, antitumor effects, 478
**Esophageal adenocarcinoma**
hypermethylation, 3410
progression
epigenetic patterns, 3410
**Esophageal cancer**
adenoviral *FHIT* transduction, 1578
apoptosis induction by NSAIDs, 4879
CD8+ T cells, prognostic value, 3932
early
HIF-1a and HIF-2a expression, 1830
radiation-induced $G_2$-M arrest
CDC25B and, 3188
radiosensitivity
*HDGF* and, 5714
risk
*MTHFR* polymorphisms and, 3272
squamous cell carcinoma
*cIAP1* amplification, 6629
genetic progression and heterogeneity, 4098
*ING1* genetic alterations, 4345
p53 mutations, northern Iran, 3119
**Esophageal tumorigenesis**
chemoprevention by raspberries, 6112
**Esophagus, Barrett's**
malignant transformation
genomic alterations, 3164
*p16*$^{INK4a}$, 8284
**17β-Estradiol**
breast cancer tumor growth stimulation by soy protein, 5045
**Estrogen**
Akt activation, ER-negative breast cancer, 8390
breast cancer tumor growth stimulation by soy protein, 5045
cyclin D1 expression
*AIB1* and, 3858
effects
hormone-responsive murine mammary ductal carcinoma cells, 293
metabolism
COMT and, 6716
ethnic differences, 3326
molecular classification, 6619
nuclear signaling by MAP kinase, breast cancer, 6360
prostate imprinting
mediation by ERα, 6089
receptor
associated gene expression patterns, breast cancer, 5979
*CGA* overexpression, breast cancer, 1652
expression, prostate cancer, 1919
HER2 amplification and hormonal antiproliferative effects, breast cancer, 8452
methylation, endometrial cancer, 3262
quantification by DNA affinity immunoblotting, 5402
silencing and reactivation by SERMs, 3632
receptor α
estrogen prostate imprinting mediation, 6089
expression modulation, intestinal tumorigenesis, 2547
IGF activity control, MCF-7 cells, 5771
induction by 5-aza-dC and TSA, breast cancer, 7025
receptor β
expression
colon cancer, 632
modulation, intestinal tumorigenesis, 2547
proliferative preinvasive mammary tumors, 2537
expression loss, prostate cancer, 5331
replacement therapy
endometrial cancer and, *CYP17* genotype analysis, 848
**Estrogen-fatty acid esters**
mammary-selective hormone functions, 5764
**Ethnic differences**
estrogen metabolism, 3326
and genetic pathways, malignant glioma, 3949
**7-Ethyl-10-hydroxycamptothecin**
combined with CI1033, 739
***N*-Ethylmaleimide-sensitive factor attachment protein receptors**
soluble SNAREs
expression, small cell lung cancer, 2138
**Etoposide**
cytotoxicity
mismatch repair and, colorectal cancer, 6555
pro-/antioxidant effects, HL-60 cells, 7777
sensitization
caspase 3 reconstitution-mediated, MCF-7 breast cancer, 348
**Ets-1**
activity, thyroid carcinogenesis, 2267
cell adhesion and migration regulation, glioma, 7985
**Ets-2**
activity, thyroid carcinogenesis, 2267
**Ets variant gene 6 *(ETV6/TEL)***
chimeric ETV6-NTRK3
transformation blockade by signaling inhibitors, 8909
FGFR3 fusion, peripheral T cell lymphoma, 8371
*HLXB9* fusion, t(7;12)(;36↔3) infant acute myeloid leukemia, 5374
*PAX5* fusion, acute lymphoblastic leukemia, 4666
**Ewing's sarcoma**
anticancer drug sensitization by *E1A*, 3394
death receptors 4 and 5 expression, 2704
EWS
protein loss, Ewing tumor, 5992
transcriptional activation, 2690
EWS/Fli-1
COOH terminus, transformation requirement, 5311
YB-1 functional interference, 3586
TRAIL sensitivity, 2704
**Ewing tumors**
EWS protein loss, 5992
**Excision repair gene cross complementation group**
*ERCC1*-deficient Chinese hamster ovary cells
mutation frequency, 50
**Exisulind**
urinary bladder tumorigenesis inhibition, rat, 3961
**Extracellular leaflet**
substrate concentration
P-glycoprotein and, 7763
**Extracellular matrix**
urothelial cell interactions
genes involved, 1678
**Extracellular matrix metalloproteinase inducer**
MMP-1 and MMP-2 production interactions, 2276
**Extracellular matrix proteins**
tumor cell adhesion
inhibition by synthetic peptides, 3308
**Extracellular signal-regulated kinase/mitogen-activated protein kinase**
activation
low-dose x-rays, diploid cells, 5396
VES-induced apoptosis, breast cancer, 6569
methylseleninic acid effects, 7171
phosphorylation, prostate cancer, 6060
p38 signaling
apoptosis, leukemia, 6290
methylseleninic acid effects, 7171
regulation by kinase suppressor of Ras, intestinal epithelial cells, 963
resveratrol p53 activation mediation, 1604
selenium-induced apoptosis and, oral carcinoma, 7479
and vinblastine-induced apoptosis, ML-1 cells, 1533
**Extracellular signal-regulated kinase 1/2**
activated
and EGFR/TGFα signaling, head and neck squamous cell carcinoma, 6500
phosphorylation
inhibition by sulindac metabolites, 1541
**Eyes**
malignant lymphoma entry routes, mouse, 5242

**F**

**Familial adenomatous polyposis**
*APC* mutations and microsatellite instability, 7616
**Familial prostate cancer**
*HPC2/ELAC2* loss of heterozygosity, 8651
novel human cell culture model, 5969
**Families**
hereditary nonpolyposis colorectal cancer
exon skipping by nonsense *MLH1* mutations, 7020
**Farnesyltransferase inhibitors**
antitumor effects
isotype-specific Ras•GTP levels and, astrocytomas, 4425
BMS-214662, antitumor activity, 7507
combined with GGTIs, preclinical evaluation, 8758
L744,832
hypoxia reduction, 2289
and NO-induced apoptosis, breast cancer, 4701
R115777, antitumor effects, 131
SCH66336
P-glycoprotein inhibition, 7525
**Fas**
apoptosis
induction by 5-FU, mouse thymocytes, 243
induction by 9-nitrocamptothecin, 7148
inhibition by FLIP and bcl-2, neuroblastoma, 4864
chemokine expression, glioma, 3084
gene mutations, thyroid lymphoma, 1382
regulation by *Par*-4, 7255
restricted triggering
bispecific antibodies, 1846
transcriptional profiling, 433
upregulation by IL-12, osteosarcoma and breast cancer cells, 4066

**Faslodex:** *See* **7α-[9-(4,4,5,5,5,5-Pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17β-diol**
**Fat**
dietary
*Apc(B1822V)* and, 1000
tissue
decrease by tea/caffeine, 5002
**Fatty acid-binding protein**
cutaneous
metastasis induction, 4357
VEGF upregulation, 4357
**Fatty acids**
CoA ligase 4 upregulation, colon adenocarcinoma, 8429
dietary
colon tumorigenesis modulation, 1927
estrogen-fatty acid esters
mammary-selective hormone functions, 5764
n-3
tumor growth inhibition, 1386
**Fatty acid synthase inhibitors**
growth inhibition, 1493
**F-box protein**
human
expression, oral squamous cell carcinoma, 7044
**FcαRI**
tumor cell lysis enhancement, 4055
**FcγRI**
tumor cell lysis enhancement, 4055
**α-Fetoprotein**
immunity
plasmid prime-boost adenovirus vaccination, hepatocellular carcinoma, 8782
**Fetuin**
galectin-3 release, breast cancer, 1869
**Fibroadenoma**
breast
genetic abnormalities absence, 7955
**Fibroblast growth factor**
basic bFGF
angiogenesis modulation, melanoma, 7282
urine levels, prostate cancer, 2533
novel oncogenic, 3131
receptor
and tumor growth, glioma, 1717
receptor 1
copy number alterations, bladder cancer, 4514
syndecan-1 complex, 5295
receptor 2
*FGFR2* mutations, gastric and colorectal cancer, 3541
receptor 3
*ETV6* fusion, peripheral T cell lymphoma, 8371
*FGFR3* mutations, gastric and colorectal cancer, 3541
mutations, superficial bladder cancer, 1265
and tumor growth, glioma, 1717
**Fibroblast growth factor 2**
expression
tetracycline-dependent, 309
tumor formation
inhibition by cidofovir, 5057
**Fibroblast growth factor 5**
overexpression, adenocarcinoma, 5511
**Fibroblast growth factor 8b**
invasion and tumor growth effects, MCF-7 breast cancer cells, 4229
**Fibroblastic tumors**
molecular characteristics, 3171
**Fibroblasts**
DNA repair defects, breast cancer, 3627
HeLa ′ fibroblast hybrids
genes differentially expressed, 4536
placenta growth factor induction by hypoxia, 2696
prostate
prostate cancer-derived TGF-β1 and versican levels, 926
sFlt-1
local cancer recurrence inhibition, 7840
telomerase-immortalized
microsatellite mutations, 8405
**Fibronectin**
ED-B domain
tissue factor delivery, solid tumor infarction mediation, mice, 711
**Fibrosarcoma**
cyclophosphamide therapy
early response, monitoring, 7747
**Fibrosis**
inflammatory breast cancer, 445
**Finland**
hereditary prostate cancer
*ELAC2/HPC2* gene, 6038
Li-Fraumeni syndrome families
*p53, CHK2,* and *CHK1* genes, 5718
**Flavopiridol**
antileukemic synergy with phorbol 12-myristate 13-acetate, myeloid leukemia, 2583
doxorubicin sensitivity enhancement, Rb-deficient sarcoma, 2579
**Fli-1**
EWS/Fli-1 fusion protein
COOH terminus, transformation requirement, 5311
YB-1 functional interference, 3586
**FLICE inhibitor protein**
apoptosis inhibition, neuroblastoma, 4864
**Flk-1**
inhibition
radioresistance reversal by, 2413
**Fluorescence *in situ* hybridization**
spectral, oncology assay, 831
**Fluorine-18**
5-[$^{18}$F]FdUrd
PET tracer, *in vivo* evaluation, 3853
-labeled choline
PET imaging, prostate cancer, 110
-labeled RGD-containing glycopeptide
$\alpha_v\beta_3$ integrin expression imaging, 1781
**5-Fluorocytosine**
bioactivation
HSV-1 oncolysis and, 5447
combined with *CD,* gene therapy
repeated gene transfer, 14
**Fluorodeoxyuridine**
combined with radio-IdUrd imaging, glioblastoma, 7971
**5-Fluorodeoxyuridine**
resistance
thymidylate synthase Arg$^{50}$ loop mutants, 666
**5-[$^{18}$F]Fluoro-2′-deoxyuridine**
PET tracer, *in vivo* evaluation, 3853
**Fluoropyrimidine**
hMLH1 response, 5193
**5-Fluorouracil**
apoptosis induction, mouse thymocytes, 243
dual antitumor effects, colorectal cancer, 1029
extraction by tumor and liver, gastrointestinal cancer, 4937
sensitivity
c-myc/p53 interactions and, colon cancer, 4910
**Fms-like tyrosine kinase Flt1**
pathological angiogenesis, 1207
soluble sFlt-1 fibroblasts
local cancer recurrence inhibition, 7840
**Fms-like tyrosine kinase Flt3**
*FLT3$^{ITD/-}$*
adult acute myeloid leukemia with normal karyotypes, 7233
ligand
chimeric DNA vaccine, tumor immunotherapy, 1080
coadministered with *p53,* genetic immunization, 8227
**Focal adhesion kinase**
activation
inhibition by (+)-catechin, 118
and anti-invasive strategies, glioma, 5688
cell migration promotion, invasive carcinoma, 7079
gene dosage effects, mouse skin carcinogenesis, 8385
nuclear aggregation, apoptotic glioblastoma, 4978
**Focal adhesion kinase-p-Y397**
inhibition by (+)-catechin, 118
**Focal adhesions**
endostatin, endothelial cells, 6511
**Folate**
dietary intake
and breast cancer risk, Shanghai, 7136
endogenous
modulation, and TSI therapeutic efficacy, 3675
transport by MRP3 and MRP1, 7225
**Formamidopyrimidine DNA glycosylase**
expression
protection against thioTEPA-induced toxicity, hematopoietic cell, 5116
**14–3–3σ**
downregulation, breast cancer, 76
**14–3–3 proteins**
p53 association, 7030
**Fowlpox virus**
recombinant
GM-CSF-expressing, immunoadjuvant activity, 206
**FOXP1**
novel chromosome 3p tumor suppressor gene, 8820
**FR901228**
adenovirus transgene expression enhancement, 6328
***fra-1***
expression
silica-induced, 1791
**Fractals,** 8347
**Fragile histidine triad *(FHIT)* gene**
adenoviral transduction, esophageal cancer, 1578
alterations, idiopathic pulmonary fibrosis, 8527
expression
advanced cervical cancer, 4382
colorectal carcinoma, 7379
prognostic value, tongue cancer, 837
tumor development delay, pancreatic cancer, 4827
loss of heterozygosity, renal cell carcinoma, 4815
methylation
and expression loss, lung and breast cancer, 3581
**Fusion genes**
*ETV6* to FGFR3, peripheral T cell lymphoma, 8371
*HLXB9* and *ETV6,* t(7;12)(;36↔3) infant acute myeloid leukemia, 5374
*RCC17/TFE3,* childhood papillary renal cell carcinoma, 4130
**Fusion proteins**
ETV6-NTRK3

blockade by signaling inhibitors, 8909
EWS/Fli-1
COOH terminus, transformation requirement, 5311
YB-1 functional interference, 3586
RANK.Fc
hypercalcemia blockade, humoral hypercalcemia of malignancy, 2572
sarcoma translocation, antigenicity, 6868
TLS/ERG
YB-1 functional interference, 3586
**Fv antibody**
anti-VEGF sFV
targeting, tumor endothelium, 3653
recombinant immunotoxin portion
isoelectric point lowering, 5070
single-chain molecules
high affinity and tumor localization and penetration, 4750

**G**

***gadd45***
promoter Oct-1
ultraviolet response, 1187
***Gadd45a***
*Gadd45a*-null mice
DNA repair and mutations, 2487
**Gadolinium**
DAB-Am64-(1B4M-Gd)$_{64}$
dynamic micro-MRI, liver micrometastasis, 4966
**Gadolinium neutron capture therapy**
glioblastoma, 4272
**Galectin-3**
intracellular
release by fetuin, breast cancer, 1869
**Gallbladder adenoma**
$\beta$-catenin exon 3 mutations, 19
**Gallbladder carcinoma**
allelotyping, 3795
**Ganciclovir**
$\beta$-pol protection against, 7399
**Ganglioside $G_{D2}$**
small cell lung cancer, 4244
**Ganglioside $G_{D3}$**
antibody targeting, melanoma xenografts, 4474
**Gangliosides**
neuroblastoma
dendritic cell inhibition, 363
**Gap junctional intercellular communication**
and breast cancer metastatic potential, 1765
**Garlic**
anticancer GGMSC
chemopreventive activity, 2923
**Gastric adenocarcinoma**
*RASSF1A* inactivation, 7034
**Gastric cancer**
angiopoietin-2, 2145
anoikis induction by Adv-mediated caspase-8 gene transfer, 7009
CEA-specific suicide gene therapy of CD/5-FC enhanced by Cre/loxP, 6158
COX-2 methylation, 4628
diffuse-type
locoregional $\alpha$-radioimmunotherapy, $^{213}$Bi-labeled MAb, 2804
*FGFR2* and *FGFR3* mutations, 3541
HLA class II polymorphisms and, 2684
micrometastasis
peritoneal, detection by EGFP and CEA, 5570
premalignant
CpG island methylation, 2847
scirrhous
metastasis, gene expression profiles, 889
**Gastric cells**
epithelial
apoptosis
and *cagA+ H. pylori*, 1406
COX-2 methylation, 2399
turnover
and *cagA+ H. pylori*, 1406
**Gastric inflammation**
chronic
*H. pylori* BabA2, 1903
**Gastric tumors**
*ATR* and *CHK1* mutations, 7727
GRP78 induction by chronic hypoxia, 8322
**Gastroenteropancreatic tumors**
neuroendocrine
CDK inhibitor inactivation, 5905
**Gastrointestinal cancer**
5-FU extraction by tumor and liver, 4937
*hRAD50* frameshift mutations, 36
**Gastrointestinal carcinoid tumor**
$\beta$-catenin mutations, 6656
**Gastrointestinal stromal tumors**
KIT activation, 8118
*KIT* mutations, 8624
**GCS:** *See* **$\gamma$-Glutamylcysteine synthetase**
**GDNF:** *See* **Glial cell line-derived neurotrophic factor**
**Gelatinase inhibitors**
small
targeted cancer therapy, 3978
**Geldanamycin**
apoptosis induction, 1799
$\beta$-catenin tyrosine phosphorylation inhibition, 1671
Bcr-Abl levels and, 1799
EF-2 kinase/Hsp90 protein complex effects, 4010
glioblastoma inhibition, 4010
**Gemcitabine**
end-joining deficiency and radiosensitization, 1585
**Gender differences**
*in utero* V(D)J recombinase-mediated deletions, 3432
**Gene amplifications**
breast cancer, 1214
and DNA-PK$_{cs}$, 4520
endometrial cancer, rat, 8263
Ori and MAR plasmids, 6987
**Gene expression**
chromosomal aneuploidy effects, prostate carcinogenesis, 8143
global analysis, lung cancer invasion, 5223
hepatocellular carcinoma, genome-wide analysis, 2129
overexpression, prostate cancer, 5857
patterns
bladder cancer, 2492
ER-associated, breast cancer, 5979
HGF/SF-treated breast cancer, 8022
metastatic phenotype, rodent and human tumors, 1569
profiles
aggressive breast cancer, 5168
benign prostatic hyperplasia, 4683
colon cancer profiles, 3124
gastrointestinal stromal tumors with *KIT* mutations, 8624
metastatic scirrhous gastric cancer, 889
oligodendroglioma, 1825
prostate cancer, 4683, 5974
PTEN-expressing endometrial cancer, 3741
serial analysis, breast cancer progression, 5697
signatures
molecular classification of human carcinomas, 7388
**Gene polymorphisms**
endostatin
and prostatic adenocarcinoma, 7375
*GSTM1*
and non-small cell lung cancer, 8718
and survival, breast cancer, 7130
*GSTT1*
and survival, breast cancer, 7130
*MMP-1*
and cutaneous malignant melanoma invasiveness, 1296
*NAT1* and *NAT2*
and bladder cancer, 5051
*p53* codon 72
and cervical cancer, 608
and non-small cell lung cancer, 8718
single nucleotide
MMP-1 promoter
and lung cancer susceptibility, 7825
*XPC*
and head and neck squamous cell carcinoma risk, 3321
*XPD*
advanced colorectal cancer, 8654
functional significance, 7430
nucleotide excision repair modulation, lung cancer, 1354
**Gene promoters**
aberrant methylation, non-small cell lung cancer, 249
**Genes**
alterations
colorectal carcinogenesis, 3544
small endocrine pancreatic tumors, 5186
benign and malignant colorectal tumors, 6996
coordinately upregulated, ovarian cancer, 3869
differentially expressed
HeLa ′ fibroblast hybrids, 4536
prostate cancer, serial analysis of gene expression, 4283
environment interaction
Twentieth International Symposium of the Sapporo Cancer Seminar Foundation, meeting report, 2788
hypermethylation, human cancer profile, 3225
invasion-specific, pancreatic cancer, 1833
microarrays
laminin 8 overexpression analysis, glioma, 5601
senescence
chromosome 10p14–p15 locus, 7118
silica-induced proto-oncogenes, 1791
urothelial cell-matrix interactions, 1678
**Gene therapy**
adeno-associated virus, cancer, 6313
adenoviral Ad.IFN-$\beta$ gene therapy, mesothelioma, 6201
chemokine
combined with targeted IL-2, murine colon carcinoma, 8498
combined with immune therapy, glioma, 8769
CYP/CYP reductase
cyclophosphamide scheduling and, 4437
electroporation-mediated
*IL-12*, hepatocellular carcinoma, 1005
hepatocellular carcinoma targeting, 3016
hTERT promoter/rev-caspase-6 construct, malignant glioma, 5796
protease-enhanced, glioblastoma, 1805
rAdMET-SeMET, 6805
suicide
*CD*
repeated gene transfer, 14
CEA-specific of CD/5-FC
enhanced by Cre/loxP, gastric carcinoma treatment, 6158

PSAP and ARf, prostate cancer, 1276
systemic replication-competent Ad-OC-E1a, prostate cancer bone metastasis, 6012
thyroglobulin promoter and TTF-1, thyroid cancer, 3640
TK- and VGF-mutant vaccinia virus, 8751
tumor immune
sB7–1, 153
tumor suppressor
*RIZ1*, colorectal cancer, 1796
**Genetic instability**
cancer cells, 428
early colorectal tumorigenesis, 818
**Gene transfer**
Adv-mediated caspase-8
anoikis induction, gastric cancer, 7009
angiostatin, Kaposi's sarcoma, 5441
repeated, *CD* suicide gene therapy, 14
viral vectors, 5336
**Genistein**
dietary
prostate cancer prevention, mice, 6777
uterine adenocarcinoma, mice, 4325
**Genome-wide analysis**
hepatocellular carcinoma gene expression, 2129
**Genome-wide hypomethylation**
hepatocellular carcinogenesis, 4238
**Genomic alterations**
Barrett's esophagus, 3164
rearrangements, DNA end-joining, 3886
**Genomic instability**
bronchial lavage, lung cancer, 1624
chromosome 9p23–24, *BRCA2* mutation carriers, 5179
intrachromosomal, colorectal cancer, 8274
-null human tumor cells, 8838
**Genotoxicity**
toremifene, 3925
**Genotoxic stress**
base excision repair modulation by p53, 88
**Genotype-phenotype association**
soft-tissue tumors, model, 3171
***gephyrin* gene**
*MLL*-human *gephyrin* fusion gene, acute monoblastic leukemia, 2665
**Geranylgeranyl:protein transferase inhibitors**
combined with FTIs, preclinical evaluation, 8758
**Germ cell tumors**
bleomycin and radiation therapy resistance by Ape1/ref-1, 2220
pediatric
multipoint imprinting analysis, 7268
**Gestational age**
*in utero* V(D)J recombinase-mediated deletions, 3432
**GGMSC:** *See* **γ-Glutamyl-*Se*-methylselenocysteine**
**[6]-Gingerol**
cell transformation and AP-1 inhibition, 850
**Glial cell line-derived neurotrophic factor**
overexpression, seminomatous tumors, 3267
**Glioblastoma**
anaplastic astrocytoma conversion by Akt pathway activation, 6674
apoptosis
nuclear FAK aggregation, 4978
ΔEGFR-expressing
mAb treatment, 5349
EGFR and p53, 1122
gadolinium neutron capture therapy, 4272
inhibition by geldanamycin, 4010
invasion
*P311* gene, laser capture microdissection, 4190
protease-enhanced gene therapy, 1805
radio-IdUrd imaging after FdUrd, 7971
temozolomide-treated
p53 effects, 1957
**Glioma**
aggressiveness
BEHAB/brevican and, Lewis rats, 7056
angiogenesis inhibition by PEX, 8730
angiopoietin-2 expression, 6248
anti-invasive strategies
FAK and, 5688
Bcl-2 upregulation by E2F1, 6693
BCNU chemotherapy and single-quantum- and triple-quantum-filtered $^{23}$Na and $^{31}$P NMR, 2002
BCNU sensitization by p53 inactivation, 4155
cell adhesion regulation by Ets-1, 7985
cell kill by CTS1, 5833
cell migration regulation by Ets-1, 7985
cell motility
radiation effects, 2744
combinatory immune gene therapy, 8769
COX-2 expression, prognostic value, 4375
Fas-induced chemokine expression, 3084
formation, genetically tractable model, 3556
glycolytic activity, rat, 5595
growth inhibition
$CB_2$ receptor, 5784
combination low-dose chemotherapy and PEX, 7501
cytokine-assisted SEREX, rat 9L glioma, 2625
PEX, 8730
α2,6-sialylation, 6822
invasion inhibition by PEX, 8730
laminin 8 overexpression, gene microarray analysis, 5601
*MAGE-E1* expression, 4809
malignant
childhood
p53 mutations, 7404
decoy receptor 3 expression, 2759
dendritic cell vaccination, 842
gene therapy, hTERT promoter/rev-caspase-6 construct, 5796
genetic pathways, ethnicity and, 3949
IL-13Rα tumor-asociated protein, 5660
replicating HSV1-tk adenovirus treatment, 8743
*TAX-1* expression, 2162
TRAIL-induced apoptosis, 1162
molecular profiles, 6885
$pH_E$ and metabolite mapping, rat, 6524
PKC signaling, 4612
temozolomide-treated
$G_2$ checkpoint role, 5843
p53 effects, 1957
transgenic mouse model
astrocytoma, 3826
tumor growth
FGF/FGFR and, 1717
**Glioma-associated antigens**
cytokine-assisted SEREX and, 2625
**Gliomagenesis**
genetically modified astrocytes, 4956
**Glucagon-like peptide 2**
chemotherapy-associated mortality reduction, 687
**Glucocorticoids**
LNCaP androgen receptor activation, 8712
receptor splice variant, hematological malignancy, 3937
**Glucose-regulated protein 78**
induction by chronic hypoxia, gastric tumor, 8322
**γ-Glutamylcysteine synthetase**
induction, human colon cells, 6112
regulation by Nrf2, 3299
**γ-Glutamyl hydrolase**
overexpression
methotrexate resistance effects, 4599
**γ-Glutamyl-*Se*-methylselenocysteine**
chemopreventive activity, 2923
**Glutathione**
*p*-XSC conjugate *p*-XSe-SG
chemoprevention, colon cancer, 3647
**Glutathione *S*-transferase**
regulation by Nrf2, 3299
**Glutathione *S*-transferase μ**
*GSTM1*
mutagen sensitivity modulation, breast cancer, 8465
polymorphisms
and non-small cell lung cancer, 8718
and survival, breast cancer, 7130
*GSTM3*
and colorectal adenoma risk, 2381
**Glutathione *S*-transferase π**
*GSTP1*
CpG island hypermethylation reversal by procainamide, prostate cancer, 8611
expression reactivation by procainamide, prostate cancer, 8611
inhibition by methylation, prostate cancer, 4820
and *N*-OH-PhIP cytotoxicity and DNA adduct formation, 103
**Glutathione *S*-transferase τ**
*GSTT1*
mutagen sensitivity modulation, breast cancer, 8465
polymorphisms
and survival, breast cancer, 7130
**Glycogen synthase kinase 3**
inactivation
hypoxia-induced PDGFR/PI3K/Akt/GSK-3 cascade, 2429
**Glycogen synthase kinase 3β**
UVB COX-2 induction, 4329
**Glycolytic rate**
rat glioma, 5595
tumor oxygenation effects, murine mammary carcinoma, 5318
**Glycophosphatidylinositol defects**
and *Mutator* phenotypes, cancer, 654
**Glycoprotein**
streptococcal antitumor
effects, epidermoid carcinoma, 6151
**Glycoprotein hormones**
α subunit, coding for (*CGA* gene)
overexpression, ER-positive breast cancer, 1652
**Glycosides**
noni
AP-1 and cell transformation inhibition, 5749
**Glycotype**
Thomsen-Friedenreich, colorectal cancer, 4605
**Glypican-1**
overexpression, breast cancer, 5562
**Goblet cells**
intestinal
apoptosis, mouse, 3472
**gp100**
CTL and T helper epitopes, 7577
polyimmunization with TRP-2, 859
**G protein**
Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor
cell survival promotion, 2641
**G-protein inwardly rectifying potassium channel 1 *(GIRK1)***
expression, breast cancer, 582

**Graft-*versus*-host disease**
murine suicidal lymphocyte model, 3355
**Granulocyte-macrophage colony-stimulating factor**
avipox-GM-CSF, immunoadjuvant activity, 206
and skin carcinogenesis susceptibility, 2311
tumor cell vaccine, bone marrow transplantation, 162
whole-cell vaccines, HER-2/*neu* tolerized mice, 3689
**Granulocytes**
activated
T-cell inhibition, advanced cancer, 4756
differentiation
ATRA metabolite-induced, NB4 promyelocytic leukemia cells, 700
**Green fluorescent protein**
enhanced
peritoneal micrometastasis detection, gastric cancer, 5570
reporter, hypoxia, 4784
**Green tea**
tissue fat and UVB skin carcinogenesis inhibition, 5002
**GTPase**
transmembrane, non-small cell lung cancer, 8873
**GW5638**
growth inhibition, breast cancer, 2917

**H**

**8H9**
novel solid tumor target, 4048
**Halichondrin B**
synthetic analogues, anticancer activities, 1013
**HDMX proteins**
expression, tumor cells, 1839
**Head and neck cancer**
second
supplemental $\beta$-carotene effects, 1457
**Head and neck squamous cell carcinoma**
activated ERK1/2 and EGFR/TGF$\alpha$ signaling, 6500
carbonic anhydrase IX expression, 5262
chromosome 3q amplification, 4506
*CYP1B1* mutations, 4398
early disease
chromosomal alterations, 4122
EGFR signaling
RXR-selective modulation, 5919
IL-8 and VEGF expression, 5911
IL-13 toxin, antitumor activity, 6194
molecular cytogenetic characterization, 4506
*p16, MGMT,* and *DAP-K* promoter hypermethylation patterns, 939
p53 mutations, 4398
radiation response, cDNA array assessment, 2376
risk
*XPC* polymorphism and, 3321
tumor plasma DNA, 8595
**Heat-activated transgene expression**
prostate cancer, 1113
**Heat shock protein 70**
Hsp70i
and replicative adenovirus oncolytic effects, 8361
peptide complexes
antimelanoma T cell activation, 222
**Heat shock protein 90**
EF-2 kinase/Hsp90 protein complex
geldanamycin effects, 4010
inhibition by ansamycin
and differentiation, breast cancer, 2945
**HeLa cells**
HeLa ′ fibroblast hybrids
genes differentially expressed, 4536
killing by staurosporine, 2459
NF-$\kappa$B activation by DNA damage, 7785
radiosensitization and inhibition of NF-$\kappa$B by p38, 7689
**Helenalin**
apoptosis, 5817
***Helicobacter pylori***
blood group antigen binding adhesin BabA2, chronic gastric inflammation, 1903
*cagA+*
gastric cell turnover and, 1406
membrane protein 1, 6356
**Helper T lymphocytes**
gp100 epitopes, 7577
promiscuous epitope for MAGE-A3, 4773
prostatic acid phosphatase epitopes, identification, 5161
**Hemagglutinating virus of Japan-liposome**
gene transfer
repeated, *CD* suicide gene therapy, 14
**Hematological malignancy**
*BMI-1* amplification and overexpression, 2409
glucocorticoid receptor splice variant, 3937
MUC1 expression, 6846
**Hematopoietic cells**
Bcr-Abl and IL-3 survival effects
Mdm2 requirement, 7635
CD34+ cell-related enhanced tumor growth, non-Hodgkin's lymphoma, 7654
thioTEPA-induced toxicity
BER protection against, 5116
**Hematopoietic progenitor cells**
NF-$\kappa$B activation
VEGF effects, 2015
**Hematopoietic stem cell transplants**
radioimmunotherapy, murine models, 5126
**Hepa1–6 cells**
growth inhibition by IRF-1, 2609
**Heparanase**
expression
antisense-mediated inhibition, 7855
pancreatic cancer, 4655
**Hepatitis B virus X**
mutations, hepatocellular carcinoma, 7803
**Hepatitis C**
chronic
8-OHdG normalization by phlebotomy and low-iron diet, 8697
**Hepatitis C virus**
oxidative stress and, mouse model, 4365
**Hepatocarcinogenesis**
Bcl-2 and, 594
$\beta$-catenin activation, transgenic mouse models, 2085
genome-wide hypomethylation, 4238
HCV-associated
oxidative stress, mouse model, 4365
mtDNA somatic mutations, 1843
TGF-$\beta$ RII gene-dosage effects, 6665
**Hepatocellular carcinoma**
chronic cyclin D1 overexpression and, transgenic mice, 5389
collagen XVIII expression, 45
combination CV890 and doxorubicin, 6428
gene expression, genome-wide analysis, 2129
gene therapy targeting, 3016
growth inhibition
IRF-1, 2609
hepatitis B virus X mutation effects, 7803
*IL-12* electroporation-mediated gene therapy, 1005
immunotherapy
combination IL-12 and dendritic cell-based vaccines, mouose, 7563
liver-enriched transcription factors, 3176
LYVE-1 downregulation, 8079
novel growth suppressor gene, 7383
plasmid prime-adenovirus boost vaccination, 8782
*p53* mutations
detection by electrospray ionization mass spectrometry, 33
radiation-induced cell death
MnSOD protection against, 5382
RXR$\alpha$ phosphorylation, 7675
**Hepatocyte growth factor**
altered gene expression patterns, breast cancer, 8022
MEK and PI3K activation, 5911
transcriptional targets, 5861
**Hepatocytes**
curcumin metabolites, 1058
replication promotion by cyclin D1, 8564
**Hepatoma**
growth inhibition
antisense cyclin D1, rat, 4779
**Hepatoma-derived growth factor**
and radiosensitivity, esophageal cancer, 5714
**Hepatomegaly**
$\beta$-catenin-induced, transgenic mice, 3245
**Hepsin**
expression, prostate cancer, 5692
**HER-1/*erb*B1**
ligands
prognostic value, bladder cancer, 6227
**HER-2/*neu* (*erb*B2)**
amplicon, breast cancer, 8235
amplification
breast cancer, 5345
and hormonal antiproliferative effects, ER-positive breast cancer, 8452
anti-HER2 trastuzumab
HER2 shedding inhibition, 4744
TRAIL-mediated apoptosis enhancement, breast and ovarian cancer, 4892
biliary tract cancer, transgenic mice, 6971
blockade by EGFR tyrosine kinase inhibitors, breast cancer, 8887
-driven sigaling and tumor growth inhibition by ZD1839, 7184
expression
and doxorubicin resistance, locally advanced breast cancer, 2505
rejection, B- and T-cell response requirement, 880
mammary carcinogenesis
minimal IL-12 antitumor treatment, BALB/c transgenic mice, 2809
mutations
germline
and breast cancer risk, 8393
novel dual ErbB-2/EGFR tyrosine kinase inhibitor, characterization, 7196
overexpression
breast cancer, 1890
ovarian cancer, 2420
$p27^{Kip1}$ and cyclin D1 modulation, 6583
shedding
inhibition by trastuzumab, 4744
**HER-3/erbB-3**
inhibition by p85-sErbB3, 4467
**HER-4/erbB-4**
expression, ovarian cancer, 2169
**Herceptin:** *See* **Trastuzumab**
**Hereditary nonpolyposis colorectal cancer**
*cyclin D1,* 6042
exon skipping by nonsense *MLH1* mutations, 7020
microsatellite instability, 896
mismatch repair defects, 7369
MLH1 expression, 2813

MSH2 and MSH6 expression, 2813
mutators and, 7369
screening
microsatellite markers, 4545
**Hereditary prostate cancer**
*HPC/ELAC2*, 6494
**Heregulin**
colon cell invasiveness model, 81
ErbB3 activation
inhibition by p85-sErbB3, 4467
uPA system regulation, 400
**Heregulin-β1**
VEGF upregulation, breast cancer, 1727
**Herpes simplex virus**
bone marrow breast cancer purging, 3009
replication-competent vector
sarcoma targeting, 3969
sB7–1 tumor immune gene therapy, 153
type 1 mutant vectors
PET-based transgene expression imaging, 2983
**Herpes simplex virus 1**
infection
and oropharyngeal cancer risk, 8459
oncolysis
and 5-FC bioactivation, 5447
**Herpes simplex virus 1-thymidine kinase**
mutations, 3022
replicating HSV1-tk adenovirus, malignant glioma treatment, 8743
**Herpesvirus**
KS-associated
G protein-coupled receptor, cell survival promotion, 2641
**H-3Glu$_3$ peptide**
cell killing, prostate tumors, 6783
**High mobility group HMG1**
gene expression regulation, cisplatin-resistant cancer cells, 1592
**High mobility group HMGA1**
overexpression
apoptosis induction, rat thyroid, 4583
**Histone deacetylase**
inhibition by trichostatin A
effects, mouse embryogenesis, 1247
inhibitor MS-275
*TβRII* expression induction, breast cancer, 931
inhibitors
apoptosis enhancement by deacetylase, 1327
-targeted treatment
differentation, acute myeloid leukemia, 2
**Histone deacetylation**
TGF-β unresponsiveness due to, lung cancer, 8331
**HL-60 cells**
ara-C and daunorubicin cross-resistance, 172
pro-/antioxidant etoposide effects, 7777
***HLXB9***
*ETV6* fusion, t(7;12)(;36↔3) infant acute myeloid leukemia, 5374
**Hodgkin and Reed Sternberg cells**
Oct-2 and Bob-1 deficiency, 2080
**Hodgkin's disease**
EBV-specific T-cell responses, 6219
**Homeobox HOXB7**
tumor-associated neoangiogenesis, 6532
**Homoplasmy**
genetic drift, pancreatic cancer, 1299
**Hormonal carcinogenesis**
human prostatic epithelial model, 6064
**Hormone-responsive cells**
murine mammary ductal carcinoma, 293
**Hormones:** ***See also specific hormones***
antiproliferative effects
HER2 amplification and, ER-positive breast cancer, 8452
mammary-selective
estrogen-fatty acid ester functions, 5764
***HPC/ELAC2* gene**
hereditary and sporadic prostate cancer, Finland, 6038
hereditary prostate cancer, 6494
loss of heterozygosity, prostate cancer, 8651
polymorphisms, prostate cancer, 4982
**HP100 cells**
catalase gene promoter regulation, 5885
**HTLs:** ***See* Helper T lymphocytes**
**Human antibody A33**
anti-huAb A33 Ig responses, colon cancer, 6851
**Human double minute 2 protein**
overexpression, melanoma, 7642
**Human epidermal growth factor receptor 1:** ***See* HER-1**
**Human epidermal growth factor receptor 2:** ***See* HER-2/*neu***
**Human epidermal growth factor receptor 4:** ***See* HER-4/erbB-4**
**Human lymphocyte antigen**
class II
polymorphisms, and gastric cancer, 2684
vulval neoplasia, 192
**Human lymphocyte antigen-A2.1**
-restricted T antigen-specific CTLs, 873
**Human lymphocyte antigen-A*0201**
CTL epitopes
Ep-CAM, 4761
MAGE-A1 HLA-A*0201 epitope, identification by mass spectrometry, 4072
-restricted T cells
melanoma antigen, identification by immunoselected tumor cell iines, 1089
**Human lymphocyte antigen-G**
expression, renal cell carcinoma, 6838
**Human neurotropic virus**
and brain tumors, 4287
**Human papillomavirus**
vulval neoplasia, 192
**Human papillomavirus 16**
E6
genotype
and cervical cancer, 608
p53 inactivation
tamoxifen-mediated apoptosis promotion, mammary epithelial cells, 616
transformation
EGF receptor, 3837
E7
and centrosome abnormalities, 2356
replicon particles
tumor eradication, 7861
transformation
EGF receptor, 3837
infection
and lung cancer, nonsmoking Taiwanese women, 2799
serology, anogenital cancer, 1934
**Human papillomavirus 18**
*E7*
tetrasomy induction, keratinocytes, 4858
infection
and lung cancer, nonsmoking Taiwanese women, 2799
serology, anogenital cancer, 1934
**Human T cell lymphotrophic virus type 1 carriers**
adult T-cell leukemia/lymphoma
TNF-α polymorphism, 3770
**Humoral hypercalcemia of malignancy**
hypercalcemia blockade by RANK.Fc, 2572
**Humoral immune responses**
medullary ductal breast cancer, 7889
**HuR**
expression, malignant brain tumors, 2154
**Hyaluronan-binding complexes**
metastatin
tumor growth inhibition, 1022
**Hyaluronan synthase 3**
and tumor growth, prostate cancer, 5207
**Hydrogen peroxide**
generation by nickel, 8051
resistance
catalase gene promoter regulation, 5885
**2-Hydroxyamino-1-methyl-6-phenylimidazo[4,5-*b*]pyridine**
cytotoxicity and DNA adduct formation
GSTP1 protection, 103
**8-Hydroxy-2′-deoxyguanosine**
normalization by phlebotomy and low iron diet, chronic hepatitis C, 8697
**15S-Hydroxyeicosatetraenoic acid**
growth inhibition, prostate cancer, 497
PPARγ activation, prostate cancer, 497
**3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors**
anti-invasive effects, pancreatic cancer, 4885
***N*-(4-Hydroxyphenyl)retinamide**
serine palmitoyltransferase and ceramide synthase activation, neuroblastoma, 5102
**1-[3-Hydroxy-2-(phosphonylmethoxy)-propyl]cytosine**
growth inhibition, nasopharyngeal carcinoma, 7875
**7-Hydroxystaurosporine**
MEK inhibitor interactions
apoptosis induction, 5106
S-phase-arrested cell effects, 1065
**17β-Hydroxysteroid dehydrogenase**
expression, breast cancer, 8448
*HSD17B1*
and breast cancer, 785
**25-Hydroxyvitamin D$_3$**
antiproliferative activity, prostate cancer, 2852
**Hypercalcemia**
blockade by RANK.Fc, humoral hypercalcemia of malignancy, 2572
**Hypergastrinemia**
and adenoma progression, APC$^{Min-/+}$ mouse model, 625
**Hypermethylation**
CpG island
*PRB* inactivation and, endometrial cancer, 97
reversal by procainamide, prostate cancer, 8611
esophageal adenocarcinoma, 3410
human cancer profile, 3225
*O$^6$-MGMT* promoter
and *p53* transition mutations, 4689
*RASSF1A*, nasopharyngeal carcinoma, 3877
*SYK*, breast cancer, 5558
uveal melanoma, 5303
**Hyperplasia**
hepatic
noncirrhotic fatty liver, 5016
**Hyperplasia, benign prostatic**
gene expression profiling, 4683
**Hypertension**
tumoral interstitial
reduction by PDGF inhibition, 2929
**Hyperthermia**
local
elastin-like polypeptide targeting, solid tumors, 1548
nanoparticle extravasation effects, 3027
**Hypomethylation**
genome-wide
hepatocellular carcinogenesis, 4238
**Hypoxia**
acute

and metastasis, KHT murine tumors, 8903
BNIP3 and NIX induction, tumors, 6669
CA-9 and
cervical cancer, 8924
locally advanced cervical cancer, 6394
chronic
GRP78 induction, gastric tumors, 8322
green fluorescent protein reporter, 4784
HIF-1α marker, cervical cancer, 7394
PDGFR/PI3K/Akt/GSK-3 cascade, 2429
placenta growth factor induction, fibroblasts, 2696
radiation-induced blood-spinal cord barrier breakdown, 3348
reduction by L744,832, 2289
tumor
blood clotting regulator dysregulation, 795, 7697
tumor vascularity and, 2907
VEGF-B and VEGF-C expression regulation, renal cell carcinoma, 3206
VEGF regulation, brain tumors, 6020
**Hypoxia-induced mutagenicity,** 7603
**Hypoxia-inducible factor 1**
and BNIP3 and NIX expression, tumors, 6669
IRF-1 interactions, 3682
**Hypoxia-inducible factor 1α**
activation, renal cell carcinoma, 5215
expression
early esophageal cancer, 1830
oropharyngeal cancer radiotherapy, 2911
pancreatic cancer, 6548
ras and VHL effects, 7349
hypoxia marker, cervical cancer, 7394
VEGF upregulation, 5731
VHL interactions, 4136
**Hypoxia-inducible factor 2α**
expression
early esophageal cancer, 1830
ras and VHL effects, 7349

I

**Ibandronate**
apoptotic effects, breast cancer metastasis to bone, 4418
**ICER:** *See* **Inducible cAMP early repressor**
**ICI 182,780:** *See* **7α-[9-(4,4,5,5,5-Pentafluoropentylsulfinyl)-nonyl]estra-1,3,5,(10)-triene-3,17β-diol**
**Id helix-loop-helix proteins**
expression, colorectal adenocarcinoma, 8803
Id1 upregulation, early melanoma, 6008
**Idiotype**
lymphoma-derived immunoglobulin
MHC class I binding, lymphoma, 5145
**IKK kinase**
activity, breast cancer, 3810
**Imaging:** *See also* ***specific modalities***
molecular
Met activity, *in vivo*, 4873
$^{65}$-Zn, rat brain tumors, 5065
**3-[1-(3*H*-Imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one:** *See* **SU9516**
**Immortalization**
human mammary epithelial cells
*ZNF217*, 1250
**Immune responses**
antigen-specific
vaccination strategies, synergy, 4497
B- and T-cell
HER-2/*neu*-expressing tumor rejection requirement, 880
humoral, medullary ductal breast cancer, 7889
**Immunity**
anti-melanoma, 8647
IFNα-induced, 8643
immunogenic lung metastasis persistence, mice, 215
antitumor
IFN-γ role, 3399
IgE-driven, 5517
and IL-18, 3735
induction via intratumoral tetra-costimulator protein transfer, 8127
laser immunotherapy, 459
sB7–1 gene therapy, 153
CD34-DCs, metastatic melanoma, 6451
α-fetoprotein-specific
plasmid prime-boost adenovirus vaccination, hepatocellular carcinoma, 8782
IFNα-induced, melanoma, 8643
**Immunization**
antitumor
intranodal dendritic cells, 641
endogenous retroviral tumor antigen, 7920
genetic
wild-type *p53* coadministered with Flt3L, 8227
melanoma antigen gene-modified dendritic cells
by-passing CD4+ T cells, 8787
polyimmunization with gp100 and TRP-2, 859
**Immunoassays**
SELDI
serum PSMA quantitation, 6029
**Immunoblotting**
DNA affinity, 5402
**Immunocytokines**
MHC class I expression and, adenocarcinoma, 1500
**Immunodeficiency, severe combined**
SCID/RAD54$^{-/-}$ cells
marked defects, 2649
*scid* thymocytes
TCRβ gene rearrangements, 6382
**Immunoglobulin**
fusion proteins
RANK.Fc
hypercalcemia blockade, humoral hypercalcemia of malignancy, 2572
heavy chain
variable
antitumor VH-CDR3 antibodies, 1555
lymphoma-derived idiotype
MHC class I binding, 5145
**Immunoglobulin E**
antitumor immunity, 5517
**Immunoglobulin M**
human antibodies
neuroblastoma eradication, 2968
**Immunophenotyping**
differentiation antibody microarray, leukemia, 4483
**Immunophotodiagnosis**
EGFR-targeted, oral precancer, 4490
**Immunoscintigraphy**
pretargeted
combined with PET, breast cancer, 3712
**Immunosorption**
serum F-PSA precursor forms, prostate cancer, 957
**Immunosuppression**
cancer-mediated
metalloproteinase, 237
$^{131}$I-anti-CD45 antibody, murine HSCT models, 5126
**Immunotherapy**
adoptive
self-tumor transgene, 3077
B7.1-mediated
combined with 5,6-dimethylxanthenone-4-acetic acid, 1948
cancer
DNA vaccines, 3698
EGP-2 transgenic mice tumor model, 4105
colorectal cancer, mouse model, 8520
combination IL-12 and dendritic cell-based vaccines, hepatocellular carcinoma, 7563
combined with gene therapy, glioma, 8769
laser
antitumor immunity, 459
Third International Dresden Symposium on Immunotherapy of Cancer, meeting report, 3524
tumor
chimeric Flt3-ligand DNA vaccine, 1080
**Immunotoxins**
Ang-CD30L, CD30-positive lymphoma treatment, 8737
recombinant
improvement by Fv portion isoelectric point lowering, 5070
**Imprinting analysis**
multipoint
pediatric germ cell tumors, 7268
**Indanocine**
resistance, leukemia, 7248
**Indium-111**
-labeled DOTA-LVT
oxytocin receptor-positive tumors, 4393
**Indium-135**
$^{131}$I-anti-CD45 antibody
immunosuppressive effects, murine HSCT models, 5126
**Indoles**
dietary, cruciferous vegetable
apoptosis induction and protective effects, colon cells, 6120
**Indolinone tyrosine kinase inhibitors**
novel
growth inhibition, small cell lung cancer, 3660
**Indolocarbazoles**
resistance by BCRP/MXR/ABCP, 2827
**Inducible cAMP early repressor**
expression, prostate cancer, 6055
**Infant leukemia**
MLL$^{+ve}$
transplacental exposure and, 2542
**Infant leukemia, acute myeloid**
t(7;12)(;36↔3)
*HLXB9* and *ETV6* fusion, 5374
**Infarction**
solid tumor
mediation by targeted tissue factor delivery to fibronectin ED-B domain, mice, 711
**Infection**
HPV 16/18 infection
and lung cancer, nonsmoking Taiwanese women, 2799
HSV-1
and oropharyngeal cancer risk, 8459
**Inflammation**
gastric, chronic
*H. pylori* BabA2, 1903
**Inflammatory atrophy**
proliferative
prostate
COX-2 upregulation, 8617
**Inflammatory breast cancer**
E-cadherin/α.β-catenin axis, 5231
endothelial formation, 445
**Influenza A virus**
oncolytic, 8188

*ING1*
genetic alterations, esophageal squamous cell carcinoma, 4345
**Inhibitor of differentiation/DNA binding Id-1**
overexpression, early-stage cervical cancer, 5703
**Inhibitor of kinase/alternate reading frame**
MIP-2 INK4a/ARF transgenic mice
melanoma induction, 8150
**Inhibitor of nuclear factor-κB (IκB)**
activity
and nuclear factor-κB activation, melanoma, 4901
degradation
inhibition by E1A, 7413
**Instabilotyping**
coding region microsatellite instability, 6046
**Insulin-like growth factor**
binding protein 2, tumorigenesis, 8601
and prostate cancer risk, China, 4333
regulation by ERα, MCF-7 cells, 5771
**Insulin-like growth factor I**
expression, androgen-independent prostate cancer, 6276
melanoma survival and growth induction, 7318
receptor
ER-negative breast cancer, 6747
expression, androgen-independent prostate cancer, 6276
IGF-IR-Akt cell survival pathway
inhibition by NEP, 3294
upregulation by AKT, pancreatic cancer, 589
uPA upregulation, 1367
**Insulin-like growth factor II**
*IGF2* loss of imprinting, Wilms' tumor, 4947
**Insulinoma**
early
9Q34 gain, 5186
**Integrins**
α5
-null teratocarcinoma, 5255
$\beta_1$
collagen IV adhesion, PKC role, breast cancer, 2445
ICAM-1 expression downregulation, lung cancer, 2022
α3β1
suprabasal expression, squamous cell carcinoma inhibition, 5248
α6β4
epidermal, regulation by PKCδ, 4591
$\alpha_v\beta_3$
dual antagonist SCH221153, 2232
expression, noninvasive imaging, 1781
$\alpha_v\beta_5$
dual antagonist SCH221153, 2232
**Intercellular adhesion molecule-1**
expression
downregulation by $\beta_1$ integrin, lung cancer, 2022
soluble
tumor growth stimulation, 4253
**Interferon α**
melanoma immunity, 8643
signaling, transitional cell carcinoma, 2261
**Interferon β**
adenoviral Ad.IFN-β gene therapy, mesothelioma, 6201
NOS II gene and, pancreatic adenocarcinoma, 71
**Interferon γ**
thymidine phosphorylase induction, 469
tumor immunity role, 3399
**Interferon regulatory factor 1**
cell growth inhibition, hepatocellular carcinoma, 2609
HIF-1 interactions, 3682
**Interferon regulatory factor 9**
overexpression
paclitaxel resistance, breast cancer, 6540
**Interleukin 1**
Raf-induced cell transformation requirement, 602
**Interleukin 2**
IL-$2^{null}$ × $\beta_2M^{null}$ mice
colon cancer molecular genetics, 6912
intracerebral transplantation
combinatory immune gene therapy, glioma, 8769
synergy with IL-18, natural killer cells, 884
targeted therapy
combined with chemokine gene therapy, murine colon carcinoma, 8498
combined with oral melanoma vaccine, 6178
**Interleukin 3**
survival effects
Mdm2 requirement, 7635
**Interleukin 4**
receptors
expression, brain tumors, 8058
tumor-induced dendritic cell blockade prevention, 3096
**Interleukin 6**
multidrug resistance, breast cancer, 8851
proliferation and migration effects, T47D breast cancer cells, 383
**Interleukin 8**
expression, head and neck squamous cell carcinoma, 5911
stimulation by PTHrP, 2282
**Interleukin 12**
-activated lymphocytes
and tumor genetic programs, 3518
combined with dendritic cell-based vaccines, hepatocellular carcinoma immunotherapy, 7563
electroporation-mediated gene therapy, hepatocellular carcinoma, 1005
Fas upregulation, osteosarcoma and breast cancer cells, 4066
minimal antitumor treatment, HER-2/*neu* mammary carcinogenesis, 2809
**Interleukin 13**
receptor α
tumor-asociated protein, malignant glioma, 5660
toxin, antitumor activity, 6194
**Interleukin 18**
antitumor immunity and, 3735
synergy with IL-2, natural killer cells, 884
**Interspecific backcross mice**
epistatic interactions, 1305
**Interstitial fluid pressure**
cervical cancer, 6400
**Intestinal epithelial cells**
ERK/MAP kinase regulation by kinase suppressor of Ras, 963
survival
*Ras* kinase suppressor and, 8668
**Intestinal goblet cells**
apoptosis, mouse, 3472
**Intestinal neoplasia**
suppression by lifetime aspirin, mice, 7060
**Intestinal polyposis**
chemoprevention by rofecoxib, $Apc^{\Delta 716}$ mouse, 1733
inhibition by iNOS-selective inhibitors, $Apc^{Min/+}$ mice, 8357
**Intestinal tumorigenesis**
ERα and ERβ expression modulation, 2547
modulation by sphingolipids, 6723
PhIP-induced
perinatal susceptibility, 8689
**Intestinal tumors**
*Apc*-initiated
genetic/dietary modulation, 565
inhibition by (+)-catechin, 118
**Intestines**
sulindac response
$p21^{WAF1/cip1}$ and, 6297
**Intracranial tumors**
formation by genetically modified astrocytes, 4956
**Intraepithelial neoplasia**
pancreatic
molecular aberrations, 8830
vulval
photodynamic therapy response factors, 192
**Invasion**
anti-invasive strategies
FAK and, glioma, 5688
breast epithelial cells
regulation by heregulin, 400
cell migration promotion by focal adhesion kinase, 7079
colon cells, spatial model, 81
FGF-8b effects, MCF-7 breast cancer cells, 4229
global gene expression analysis, lung cancer, 5223
inhibition
HMG-CoA reductase inhibitors, pancreatic cancer, 4885
motuporamines, 6788
NK4, pancreatic cancer, 7518
PEX, glioma, 8730
VHL peptide β-domain, renal cell carcinoma, 1768
intracellular cathepsin B and, 3493
MMP-dependent
mediation by LPA, ovarian cancer, 3194
promotion by AKT, pancreatic cancer, 589
radiation effects, glioma, 2744
-specific genes, pancreatic cancer, 1833
stem cell factor-induced colorectal carcinoma, 2200
stimulation by ET-1, ovarian cancer, 8340
**Invasive bladder cancer**
gene expression patterns, 2492
**Invasive breast cancer**
FGF-8b effects, 4229
inhibition by PAR1-$G_i$ signaling, 5933
*KAI1/CD82* expression, 5284
*mdm2* mRNA splicing, 3212
**Invasive glioblastoma**
*P311* gene, laser capture microdissection, 4190
**Invasive melanoma**
cutaneous malignant
*MMP-1* gene polymorphism and, 1296
**Iododeoxyuridine**
radiolabeled
imaging after FdUrd, glioblastoma, 7971
**Ionizing radiation:** *See also* **Radiation**
CNS radioresponse
TNF signaling and, 8859
low-dose
cell proliferation and MAPK activation, diploid cells, 5396
mammary tumorigenesis, p53-deficient mice, 6577
and mitochondria, 3894
mutagenesis, MMR-deficient mice, 3775
ultraviolet
BRCA2 protein depletion, 2838
**Ion microscopy**
secondary ion mass spectrometry

quantitative boron-10 imaging, brain tumors, 8179
**Iran, northern**
esophageal squamous cell carcinoma
p53 mutations, 3119
**Iressa:** *See* **ZD1839**
**Irinotecan**
chemosensitivity
augmentation by PS-341, 3535
rCE and
VDEPT, neuroblastoma purging, 5083
sensitization
MYC-mediated, 3045
sensitization via adenoviral rCE, 5078
**Iron**
chelation
N-*myc* inhibition and apoptosis induction, neuroblastoma, 1073
low-iron diet
and 8-OHdG, chronic hepatitis C, 8697
protection against NO, tumor cells, 5289
regulatory proteins
doxorubicin and, 8422
**Isoglobotetraosylceramide**
apoptosis induction, 5741
**Isothiocyanates**
dietary, cruciferous vegetable
apoptosis induction and protective effects, colon cells, 6120
**2-(*p*-Isothiocyanatobenzyl)-6-methyl-diethylenetriamine-pentaacetic acid**
DAB-Am64-(1B4M-Gd)$_{64}$
dynamic micro-MRI, liver micrometastasis, 4966

**J**

**J591**
$^{213}$Bi-labeled, LNCaP spheroid effects, 2008
**J-107088**
resistance by BCRP/MXR/ABCP, 2827
**Japan-liposome hemagglutinating virus**
gene transfer
repeated, *CD* suicide gene therapy, 14
**JCA-1 cells**
bladder cancer derivation, 6340
**JC virus**
central nervous system tumors, 4287
**Jordan, V. Craig**
special recognition, 5954
**JunD**
menin binding, 916

**K**

***KAI1/CD82***
expression
breast cancer invasion and metastasis, 5284
NF-κB–dependent, lung cancer, 673
**Kallikrein**
*KLK9*
gene expression, ovarian cancer, 7811
*KLK14*
cloning and characterization, 3425
NES1/kallikrein 10
methylation, breast tumors, 8014
**Kaposi's sarcoma**
angiostatin gene transfer, 5441
growth inhibition by *N*-acetylcysteine, 8171
**Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor**
cell survival promotion, 2641
**Karyotype**
bladder cancer, multivariate analyses, 8241
pathways, transitional cell carcinoma, 8241
**Keratin 14**
*K14/bcl-2* transgenic mice
carcinogenesis, 3619
**Keratinocytes**
basal
PAI-2 overexpression, transgenic mice, 970
tetrasomy induction by HPV *E7*, 4858
**Keyhole limpet hemocyanin**
and dendritic cell-based tumor vaccine efficacy, 2618
**KHT murine tumors**
acute hypoxia and metastasis, 8903
**Ki-67**
risk-stratification model, non-small cell lung cancer, 2500
***KiSS1***
expression loss, melanoma, 7422
**Kit**
activation, gastrointestinal stromal tumors, 8118
mutations, gastrointestinal stromal tumors, 8624
novel inhibitors
growth inhibition, small cell lung cancer, 3660
**K-*ras***
mutations
lung tumors, 6679
serous borderline ovarian tumors and ovarian carcinoma, 7264
VEGF regulation, colonic neoplasia, 6050

**L**

**L744,832**
hypoxia reduction, 2289
**Laminin 5**
MMP-2 and MTI-MMP interactions, aggressive melanoma, 6322
**Laminin 8**
neoplastic lymphocyte interactions, 339
overexpression
gene microarray analysis, glioma, 5601
**Laminin 10**
neoplastic lymphocyte interactions, 339
**Laminin γ2**
regulation by β-catenin, colorectal cancer, 8089
**Large intestine:** *See* **Colon**
**Laser capture microdissection**
*P311* gene, glioblastoma invasion, 4190
**Laser immunotherapy**
antitumor immunity, 459
**Lasofoxifene**
chemopreventive and chemotherapeutic effects, rat mammary tumors, 8683
**Latent membrane protein-1**
tumor promotion, 6730
**Letters to the editor**
re: H. Akasaka, *et al., 60:* 2335–2341, 7363
re: O. J. Arola, *et al., 60:* 1789–1792, 2335
re: J. W. Baish and R. K. Jain, *60:* 3683–3688, 8347
re: S. E. Blutt, *et al., 60:* 779–782, 4294
re: P. P. Claudio *et al., 60:* 8–12, 5950
re: F. Coulet *et al., 60:* 707–709, 8595
re: N. C. Denko and A. J. Giaccia, *61:* 795–798, 7697
re: B. H. Joshi *et al., 60:* 1168–1172, 5660
re: W. Paile *et al., 60:* 1146, 6964
re: B. Pasche *et al., 58:* 2727–2732, 8351
re: A. Rothfuss *et al., 60:* 390–394, 5948
re: Y. Yamada *et al., 61:* 1874–1878, 7699
***LEU2* gene**
alternative splice variant *ALT1*, identification, 6640
**Leukemia**
apoptosis
loaded dendritic cells, 2386
p38 MAPK-dependent, 6290
cell density-dependent growth
steel factor and, 6281
human RFC protein, localization, 1941
immunophenotyping
differentiation antibody microarray, 4483
indanocine resistance, biochemical genetic analysis, 7248
infant
MLL$^{+ve}$, transplacental exposure and, 2542
β2-microglobulin antitumor effects, 4414
myeloid
antileukemic synergism between flavopiridol and PMA, 2583
24-oxo vitamin $D_3$ analogue metabolite effects, 3361
promyelocytic
ATRA metabolite-induced granulocytic differentiation, NB4 cells, 700
PML/RARα inhibition by peptide nucleic acid, acute promyelocytic leukemia, 5468
T-cell leukemia/lymphoma
HTLV-1 carriers
TNF-α polymorphism, 3770
testicular cell transplantation and, 706
thiopurine methyltransferase effects on thiopurines, 5810
troxacitabine uptake and resistance, 7217
vaccination
apoptotic leukemia cell-loaded dendritic cells, 2386
*Vinca* alkaloid resistance
microtubule alterations, 5803
**Leukemia, acute lymphoblastic**
apoptosis
resveratrol-induced, 4731
B-cell
clonal variation, 5268
*MLL* partial nontandem duplication, 59
childhood
*NBS1* mutations, 3570
*TEL-AML1*-positive, RQ-RT-PCR, 2517
initial clonal expansion origin, 8547
*PAX5-TEL* fusion, 4666
T-cell
childhood
thioredoxin expression, 7333
**Leukemia, acute monoblastic**
*MLL*-human *gephyrin* fusion gene, t(11;14)(q23↖4), 2665
**Leukemia, acute myeloid**
adult, with normal karyotypes
*FLT3*$^{ITD/-}$, 7233
differentiation by HDAC-targeted treatment, 2
infant
t(7;12)(;36↔3), *HLXB9* and *ETV6* fusion, 5374
proteolytic activity and STAT transcription, 1747
**Leukemia, acute promyelocytic**
cell differentiation by araC analogue DMDC, 178
PML/RARα inhibition by peptide nucleic acid, 5468
**Leukemia, chronic lymphocytic**
B-cell
13q14 *CLLD6, CLLD7, CLLD8* genes, cloning and characterization, 2870
chromosome 13q14 tumor suppressor locus characterization, 6640
**Leukemia, chronic myelogenous**
cell death induction by BCR(64–413), 138
growth inhibition by BCR(64–413), 138
**Leukemia, chronic myeloid**
*ABL* promoter methylation, 6931

**Leukemogenesis**
candidate *CLLD6, CLLD7, CLLD8* genes, cloning and characterization, 2870
enhancement by Crkl, *BCR/ABL* P190 transgenic mice, 1398
Ph chromosome-positive *BCR* gene and, 2343
**Li-Fraumeni-like syndrome**
*p53, CHK2,* and *CHK1* genes, Finnish families, 5718
**Li-Fraumeni syndrome**
missense mutation
CHK2 destabilization, 8062
*p53, CHK2,* and *CHK1* genes, Finnish families, 5718
p53 functional inactivation, 1741
**Liposomes**
CD44-targeted, 2592
lomustine, antitumor activity, 3669
**Lipoxygenase**
modulation
carcinogenesis reversal, 6307
**15-Lipoxygenase-1**
expressional restoration by NSAIDs, esophageal cancer, 4879
**Liver**
colon cancer metastasis
SU6668 and, 1464
colorectal cancer metastasis
CEA mutations and, 2822
5-FU extraction, gastrointestinal cancer, 4937
growth promotion by cyclin D1, 8564
hyperplasia, noncirrhotic fatty liver, 5016
metastasis
promotion by batimastat, 1272
surrogate angiogenesis markers, 7048
micrometastasis
dynamic micro-MRI with DAB-Am64-$(1B4M\text{-}Gd)_{64}$, 4966
noncirrhotic fatty
hyperplasia, 5016
preneoplastic foci, clonal growth model, 1879
rabbit carboxylesterase rCE, adenoviral and CPT-11, VDEPT, neuroblastoma purging, 5083
CPT-11 sensitization, 5078
steatosis
obesity-related, premalignancy, 5016
**Liver cirrhosis**
LYVE-1 downregulation, 8079
**Liver-enriched inhibitory protein**
C/EBP$\beta$-LIP
mammary epithelial cell proliferation, 261
**Liver-enriched transcription factors**
expression, hepatocellular carcinoma, 3176
**Liver tumors**
*mlt 1* silence by methylation, 1144
**LNCaP cells**
androgen receptor activation by glucocorticoids, 8712
TNF-$\alpha$ pro- and antiapoptotic signals, 2713
**LNCaP spheroids**
$\alpha$-irradiation effects, 2008
**LNCaP tumors**
growth inhibition by EB1089, 4294
**Local hyperthermia**
elastin-like polypeptide targeting, solid tumors, 1548
**Locoregional $\alpha$-radioimmunotherapy**
$^{213}$Bi-labeled MAb, 2804
**Lomustine**
liposomal, antitumor activity, 3669
**Loss of heterozygosity:** *See also* **Deletions**
chromosome 3p21
tobacco smoke-induced DNA damage and smoking age of initiation and, 612
chromosome 9p
multiple loci, melanoma, 1154
chromosome 16q, breast cancer, 1171
*FHIT,* renal cell carcinoma, 4815
*HPC/ELAC2* gene, prostate cancer, 8651
impeding breast cancer metastasis *MTA1* gene, 3578
pulmonary adenocarcinoma, 7950
radiation-induced, lymphoid cells, 1129
*VHL,* renal cell carcinoma, 4815
**Loss of imprinting**
*IGF2,* Wilms' tumor, 4947
**LPA:** *See* **Lysophosphatidic acid**
**Lunasin**
chemopreventive property, 7473
**Lung**
BPDE p53 mutations, nontumorous human, 6350
melanoma metastases, immunogenic persistence, immunized mice, 215
polycyclic aromatic hydrocarbons, 6367
**Lung adenocarcinoma**
chromosomal alterations, smokers and nonsmokers, 1309
core 2 $\beta$1,6-*N*-acetylglucosaminyltransferase expression, 2226
growth inhibition by CEP1612, nude mice, 1280
loss of heterozygosity, 7950
tumor cell anoikis resistance
tyrosine kinases and, 2439
**Lung cancer**
BPDE-induced DNA adducts, 1445
bronchial lavage genomic instability, 1624
*CDH13* methylation, 4556
cell proliferation
retinoid receptors and, 556
Chk2 mutant, functional analysis, 5362
chromosome 3p21 loss of heterozygosity
tobacco smoke-induced DNA damage and smoking age of initiation and, 612
combination suramin and paclitaxel, antitumor activity, 6145
early biomarker hnRNP B1, 1896
*FHIT* methylation and expression loss, 3581
HPV 16/18 infection and, nonsmoking Taiwanese women, 2799
*hSRBC* inactivation, 7943
ICAM-1 expression downregulation by $\beta_1$ integrin, 2022
invasion
global gene expression analysis, 5223
*KAI1/CD82* expression
NF-$\kappa$B–dependent, 673
MnSOD and catalase expression, 8578
mutated lung cancer antigen
CTL response, 3718
non-small cell
$\alpha$-actinin-4 mutated peptide-reactive CTLs, 4078
Akt/PKB activity, 3986
CA9 expression, 7992
chromosome 9p21 loss of heterozygosity, smokers, 2092
c-*mos* expression, 538
dihydrodiol dehydrogenase overexpression, 2727
early stage
cyclin E, prognostic value, 647
regulatory T cells, 4766
*GSTM1* polymorphisms and, 8718
histology-specific methylation by tobacco smoke exposure
$p16^{INK4A}$ and, 3419
hRad17 phosphorylation and overexpression, 7417
MGMT inactivation, 8113
$p14^{ARF}$ alterations, 5636
*p53* alterations, 5636
*p73* alterations, 5636
*p53* mutations, 8113
*p53* polymorphisms and, 8718
promoter methylation, 249
resected
polysialic acid expression, 1666
risk-stratification model, 2500
transmembrane GTPase, 8873
nucleotide excision repair modulation by XPD polymorphisms, 1354
ouabain-induced multidrug resistance, 1693
plasma circulating tumor DNA, 4675
plasma proteins, 778
*p53* mutations, ex-smoker women, 4350
Pol $\kappa$ overexpression, 5366
protein gene product 9.5 autoantibodies, 7908
risk
carcinogen-DNA adducts and, 6708
secondary lymphoid organ chemokine antitumor response, spontaneous murine model, 6406
small cell
apoptosis mediation by $G_{D2}$, 4244
cell proliferation enhancement by $G_{D2}$, 4244
growth inhibition by novel indolinone Kit inhibitors, 3660
Notch effects, 3200
SNAREs and VMATs, 2138
susceptibility
$G_2$ delay, apoptosis, and p53 response and, 7819
MMP-1 promoter single nucleotide polymorphism and, 7825
TGF-$\beta$ unresponsiveness, 8331
**Lung carcinogenesis**
early stage
S100A2 expression, 7999
MAGE activation, 7959
**Lung tumors**
*KRAS* mutations, 6679
mutation spectrum
and PAH exposure, 6679
*TP53* mutations, 6679
**LVT:** *See* **Lys$^8$-vasotocin**
**Lymphangiogenesis**
tumor
VEGF-C, 1786
**Lymphatic vessel endothelial hyaluronan receptor LYVE-1**
downregulation, liver cancer and cirrhosis, 8079
**Lymph nodes**
antigen targeting, 8110
regional
antigen-presenting cell enrichment by recombinant, 206
scirrhous gastric cancer metastasis
gene expression profiles, 889
**Lymphoblasts**
BCR-ABL activity and cyclin D2 expression, 8005
**Lymphocytes**
IL-12-activated
and tumor genetic programs, 3518
neoplastic
laminin 8 and 10 interactions, 339
suicide
GVHD control, murine model, 3355
**Lymphoid cells**
radiation-induced loss of heterozygosity, 1129
**Lymphoid tissue**
secondary lymphoid tissue chemokine

T cell-dependent antitumor immunity, 2062
**Lymphoma**
AIDS-related
children
PBMC SDF-1 mRNA levels, 5028
angiogenesis
circulating endothelial cell markers, 4341
B-cell
cytokine gene expression, 1285
*bcl-2* and c-*myc* deregulation, 5202
CD30-positive
Ang-CD30L treatment, 8737
CNS
$p14^{ARF}$ and $p16^{INK4a}$ alterations, 6335
γδ T cell functional maintenance by caspase blockade, 3092
malignant
entry routes, mouse brain and eyes, 5242
mantle cell
*BMI-1* amplification and overexpression, 2409
T-nucleotide additions, 1629
MHC class I-idiotypic peptide binding, 5145
T-cell
HTLV-1 carriers
TNF-α polymorphism, 3770
T-cell, cutaneous
CD40/CD40L coexpression, 452
T-cell, peripheral
*ETV6* to FGFR3 fusion, 8371
thyroid
*Fas* gene mutations, 1382
**Lymphoma, non-Hodgkin's**
B-cell
STAT3 inhibition by rituximab, 5137
tumor growth
CD34+ cell-related enhanced tumor growth, NOD/SCID mouse model, 7654
**Lymphomagenesis**
nucleophosmin/anaplastic lymphoma kinase-mediated
PI3K-Akt pathway, 2194
**Lymphovascular embolism**
E-cadherin/α.β-catenin axis and, inflammatory breast cancer, 5231
**Lyn**
kinase activity, erythroid cell maturation and erythroleukemia, 2453
**Lysophosphatidic acid**
MMP processing and invasion promotion, ovarian cancer, 3194
**Lysosomal enzymes**
caspase-3 activation, P39 cells, 2878
**$Lys^8$-vasotocin**
$^{111}$In-labeled DOTA-LVT
oxytocin receptor-positive tumors, 4393

**M**

**101M:** *See* **1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylamino)carbonylhydrazine**
**Macedonian patients**
colorectal cancer
TβR-I(6A) polymorphism, 8351
**Macrophage arginase**
tumor cell growth regulation, 1100
**Macrophage inflammatory protein 2**
INK4a/ARF transgenic mice
melanoma induction, 8150
**Macrophages**
tumor-associated
COX-2 and iNOS expression, ovarian tumors, 7305
tumor cell death orchestration, 7240
**Mad2**
inhibition by dioxin, 5707
**MAGI-2/ARIP1**
PTEN binding
regulation by phosphorylation sites, 4985
**Magnetic resonance imaging**
diffusion-weighted
convection-enhanced drug delivery monitoring, brain tumor, 4971
dynamic
tumor microcirculation assessment, rectal carcinoma, 2513
dynamic micro-MRI with DAB-Am64-$(1B4M\text{-}Gd)_{64}$, liver micrometastasis, 4966
ultrasound surgery, breast cancer, 8441
**Magnetic resonance pharmacoangiography**
chemotherapy delivery detection, solid tumors, 3039
**Major histocompatibility complex**
class I
antigen processing alterations, melanoma, 8647
deficiencies, B16 melanoma cells, 1095
expression, murine adenocarcinoma, 1500
idiotypic peptide binding, lymphoma, 5145
**Malignancy**
anoikis and, ovarian cancer, 4837
astrocytoma, transgenic mouse model, 3826
Barrett's esophagus
genomic alterations, 3164
brain tumors
DMBTI, digestive tract cancer, 8880
HuR expression, 2154
breast epithelial cells
adipocyte differentiation, 2250
C/EBPβ-mediated aromatase upregulation, 2328
cadmium-induced transformation, prostate epithelial cells, 455
cell transformation, prostatic epithelial cells, 8135
colorectal cancer
genes expressed, 6996
epithelium
AR expression, prostate cancer, 423
glioma
childhood
p53 mutations, 7404
decoy receptor 3 expression, 2759
dendritic cell vaccination, 842
gene therapy, hTERT promoter/rev-caspase-6 construct, 5796
genetic pathways
ethnicity and, 3949
IL-13Rα tumor-asociated protein, 5660
replicating HSV1-tk adenovirus treatment, 8743
*TAX-1* expression, 2162
TRAIL-induced apoptosis, 1162
hematological
*BMI-1* amplification and overexpression, 2409
glucocorticoid receptor splice variant, 3937
MUC1 expression, 6846
humoral hypercalcemia
hypercalcemia blockade by RANK.Fc, 2572
invasion-specific genes, 1833
lymphoma
entry routes, mouse brain and eyes, 5242
melanoma
COX-2 expression, 303
cutaneous
invasiveness, *MMP-1* gene polymorphism and, 1296
N-*ras* mutations, 4916
mesothelioma
methylation and SV40, 5727
*PPARγ gene mutations, 5307*
prostate cells, human
choline compound increase, 3599
prostatic epithelial cells
androgen activity, 5038
**Mammary adenocarcinoma**
docetaxel and doxorubicin chemotherapy, mouse, 1996
*MT1-MMP* overexpression, transgenic mice, 984
**Mammary carcinogenesis**
minimal IL-12 antitumor treatment, BALB/c transgenic mice, 2809
**Mammary carcinoma:** *See also* **Breast cancer**
anoikis
TRAIL role, 1334
ductal
hormone-responsive cells, murine, 293
gene expression
global anchorage effects, 1334
glycolytic rate
tumor oxygenation effects, murine, 5318
single nucleotide instability, rat, 2632
vascular growth inhibition by endostatin, murine, 526
**Mammary epithelial cells**
Akt1 and MMP-2 activation, mouse, 7647
apoptosis, tamoxifen-mediated
promotion by p53 inactivation by E6, 616
immortalization by *ZNF217*, 1250
proliferation
C/EBPβ-LIP, 261
**Mammary gland**
development
$p16^{INK4a}$, 8811
premalignant disease, transgenic *PyV-mT* mouse model, 8298
**Mammary gland-selective hormones**
estrogen-fatty acid ester functions, 5764
**Mammary neoplasia**
suppression by lifetime aspirin, mice, 7060
susceptibility, $Apc^{Min}/+$ mice, 3480
**Mammary tumorigenesis**
EphA2 overexpression, 2301
inhibition by TIMP-2, 3450
irradiated p53-deficient mice, 6577
stimulation by TIMP-4, 2365
**Mammary tumors**
inhibition by 2-difluoromethylornithine and dehydroepiandrosterone, 7449
lasofoxifene chemopreventive and chemotherapeutic effects, rat, 8683
metastatic progression
*Brms1* and, 8866
proliferative preinvasive
ERβ expression, 2537
resveratrol properties, 7456
**Manganese superoxide dismutase**
expression
lung cancer, 8578
multistage skin carcinogenesis model, 6082
protection against radiation-induced cell death, hepatocellular carcinoma, 5382
upregulation by cRel, 2656
**Mantle cell lymphoma**
*BMI-1* amplification and overexpression, 2409
T-nucleotide additions, 1629
**Mapping**
clonotype
tetramer-guided, melanoma, 493
$pH_E$ and metabolite, rat glioma, 6524
**Maspin**
endogenous

pericellular uPA inhibition, 8676
tumor growth and metastasis inhibition, breast cancer, 6945
**Mass spectrometry**
electrospray ionization
*p53* mutation detection, hepatocellular carcinoma, 33
MAGE-A1 HLA-A*0201 epitope identification, 4072
secondary ion
quantitative boron-10 imaging, brain tumors, 8179
serum F-PSA precursor forms, prostate cancer, 957
**Matrix metalloproteinase**
activation and invasion
mediation by LPA, ovarian cancer, 3194
membrane type-1
laminin 5 and MTI-MMP interactions, aggressive melanoma, 6322
and type I collagen degradation by oral squamous cell carcinoma, 6264
**Matrix metalloproteinase 1**
membrane-type
overexpression, mammary adenocarcinoma, 984
*MMP-1* polymorphism
and cutaneous malignant melanoma invasiveness, 1296
production
CD147/EMMPRIN interactions, 2276
promoter SNP
and lung cancer susceptibility, 7825
**Matrix metalloproteinase 2**
activation
Akt1 and, mouse mammary epithelial cells, 7647
laminin 5 and MTI-MMP interactions, aggressive melanoma, 6322
membrane-type 1
inhibition by testican 3 and N-Tes, 8896
natural fragment PEX
glioma inhibition, 8730
platelet aggregation by tumor cells, 376
production
CD147/EMMPRIN interactions, 2276
**Matrix metalloproteinase 7**
protective effects against anticancer chemotherapy, 577
**Matrix metalloproteinase 9**
production
PI3K activity, 1855
**Matrix metalloproteinase 13:** *See* **Collagenase-3**
**6-MCDF:** *See* **6-Methyl-1,3–8-trichlorodibenzofuran**
**MCF-7 cells**
CYP regulation by dioxin and pesticides, 3942
doxorubicin sensitization
caspase 3 reconstitution-mediated, 348
etoposide sensitization
caspase 3 reconstitution-mediated, 348
growth
FGF-8b effects, 4229
IGF activity regulation by ERα, 5771
mitoxantrone resistance, 5461
**MDA:** *See* **Melanocyte differentiation antigen**
**Meat consumption**
and colorectal adenoma risk, 2381
**Medullary ductal breast cancer**
humoral immune response, 7889
**Medulloblastoma**
*AXIN1* deletions, 7039
CCI-779 antitumor activity, 1527
*Ptc*$^{+/-}$*p53*$^{-/-}$ mice, 513
**Meeting reports**
Epithelial-Stromal Interactions Workshop, 3844
melanoma biology and progression, 4642
Third International Dresden Symposium on Immunotherapy of Cancer, 3524
Twentieth International Symposium of the Sapporo Cancer Seminar Foundation: Gene Environment Interaction and Cancer Prevention, 2788
**Melanocortins**
and cachexia, 1432
**Melanocyte differentiation antigen**
-reactive T cells, stage IV melanoma, 493
**Melanoma**
aggressive
laminin 5, MMP-2 and MT1-MMP interactions, 6322
angiogenesis modulation by VEGF and bFGF, 7282
antimelanoma T cells
activation by HSP70 peptide complexes, 222
apoptosis
induction by iNOS inhibition, 318
TRAIL-induced
inhibition by XIAP, 7339
biology and progression, meeting report, 4642
N-cadherin role, 3819
cell cycle regulatory responses to polyamine depletion, 7754
cell survival induction by IGF-1, 7318
chromosome 9p loss of heterozygosity, multiple loci, 1154
clonotype mapping, tetramer-guided, 493
cutaneous
Ski overexpression, 8074
cystemustine redifferentiation and protective effects, murine model, 2294
early
Id1 upregulation, 6008
early apoptotic
dendritic cell maturation blockade, 8218
$G_{D3}$ ganglioside antibody targeting, 4474
growth
induction by IGF-1, 7318
NOS II knockout mice, 3182
HDM2 protein overexpression, 7642
IκB activity and NF-κB activation, 4901
immune escape, 8647
immunity
IFNα-induced, 8643
immunogenic lung metastasis persistence, mice, 215
induction, MIP-2 INK4a/ARF transgenic mice, 8150
*KiSS1* expression loss, 7422
low pH-adapted, 5630
malignant
COX-2 expression, 303
cutaneous
invasiveness, *MMP-1* gene polymorphism and, 1296
N-*ras* mutations, 4916
Melan-A-specific repertoire, 2047
metastasis
immunity via CD34-DCs, 6451
metastasis to lung, immunogenic persistence, immunized mice, 215
metastatic potential
anoikis and, 1707
MHC class I antigen processing alterations, 8647
MHC class I deficiencies, B16 cells, 1095
PAX3 expression, 823
plasma microsatellite markers, prognostic value, 5723
polyamine analogue-treated
apoptotic signaling, SK-MEL-28 cells, 6437
stage IV
melanocyte differentiation antigen-reactive T cells, 493
survival
TGF-β1 and, 8306
TNF-α killing, absent TNF-α, 1050
TNF R1 chimeric, antitumor activity, 1050
uveal
chromosome 3 partial deletions, 3439
*p16*$^{INK4a}$ expression reduction, 5303
vaccine
oral
combined with targeted IL-2 therapy, 6178
xeroderma pigmentosum
*p53* mutations, 2480
**Melanoma-associated antigen**
activation, lung carcinogenesis, 7959
cloning, immunoselected tumor cell lines, 1089
gene family overview, 5544
gene-modified dendritic cells
by-passing CD4+ T cells, 8787
gp100
CTL and T helper epitopes, 7577
isolation by SEREX, 7900
MAGE-A
gene expression pattern, breast cancer, 6682
MAGE-A1
HLA-A*0201 epitope, identification by mass spectrometry, 4072
MAGE-A3
promiscuous T helper epitope, 4773
MAGE-A10
heterogenous CTL response, 5850
MAGE-A10$_{254-262}$
CTL responses, melanoma, 509
*MAGE-E1*
expression, glioma, 4809
Melan-A-specific CTLs
PS-SCL recognition, 5153
Melan-A-specific repertoire, melanoma, 2047
**Membrane-type matrix metalloproteinase 1**
overexpression, mammary adenocarcinoma, 984
**Membrane-type-1 matrix metalloproteinase**
laminin 5 and MMP-2 interactions, aggressive melanoma, 6322
and type I collagen degradation by oral squamous cell carcinoma, 6264
**Membrane-type 1 matrix metalloproteinase 2**
inhibition by testican 3 and N-Tes, 8896
**Menin**
JunD binding, 916
**Mesothelioma**
Ad.IFN-β gene therapy, 6201
malignant
methylation and SV40, 5727
ONYX-015 effects
modulation by p14$^{ARF}$, 5959
**Met**
activity, *in vivo* molecular imaging, 4873
**Metalloproteinase**
cancer-mediated immunosuppression, 237
**Metallothionein**
doxorubicin cardiotoxicity inhibition, mouse, 3382
**Metal transcription factor-1**
placenta growth factor induction by hypoxia, fibroblasts, 2696

**Metastasis**
acute hypoxia and, KHT murine tumors, 8903
bone
inhibition by osteoprotegerin, mouse models, 4432
breast cancer
gap junctional intercellular communication and, 1765
hematogenous, detection, 8845
impeding loss of heterozygosity, *MTA1* gene, 3578
inhibition by maspin, 6945
*KAI1/CD82* expression, 5284
*TRAIL-R1* and *TRAIL-R2* mutations, 4942
breast cancer to bone
ibandronate effects, 4418
induction by cortactin overexpression, 6906
breast cancer to bone marrow
erbB2 overexpression, prognostic value, 1890
breast cancer to lymph node
*GIRK1* expression, 582
calponin h1-deficient mice, 7627
colon cancer
apoptosis induction and tumor growth prevention by ceramide analogues, 1233
carcinoembryonic antigen role, 2732
colon cancer to liver
SU6668 and, 1464
colorectal cancer
protoporphyrin IX, 991
colorectal cancer to liver
CEA mutations and, 2822
hematogenous
breast cancer, detection, 8845
immunogeneic
melanoma to lung, persistence, immunized mice, 215
induction by C-FABP, 4357
inefficiency, early
apoptosis, 333
inhibition
BMS-275291, murine models, 8480
CpG-ODN, 5523
SSeCKS, prostate cancer, 5644
KHT murine tumors
acute hypoxia and, 8903
liver
promotion by batimastat, 1272
surrogate angiogenesis markers, 7048
mammary tumors
*Brms1* and, 8866
markers
apoptosis-inducing MAb binding, 5741
melanoma
immunity via CD34-DCs, 6451
micrometastasis
liver
dynamic micro-MRI with DAB-Am64-$(1B4M\text{-}Gd)_{64}$, 4966
peritoneal gastric cancer
detection by EGFP and CEA, 5570
neuroblastoma to bone
osteoclast formation, 1637
non-small cell lung cancer
cyclin E and, 647
osteosarcoma, cDNA microarray evaluation, 3750
pancreatic cancer
heparanase expression, 4655
inhibition by NK4, orthotopic mouse model, 7518
papilloma
induction TGF-$\beta$1, 7435
phenotype
gene expression patterns, rodent and human tumors, 1569
potential
chemotherapeutic contribution, 2857
melanoma, 1707
prostate cancer
inhibition by *MKK4*, 2833
prostate cancer to bone
NOD/SCID-hu mouse model, 2177
systemic replication-competent Ad-OC-E1a gene therapy, 6012
scirrhous gastric cancer
gene expression profiles, 889
squamous cell carcinoma
molecular profiling, 4797
PKC$\epsilon$ transgenic mice, 808
stimulation by radiation therapy, mice, 2207
tumor hypoxia and, 795, 7697
**Metastasis-associated differences**
gene expression, osteosarcoma, 3750
**Metastasis-inducing DNA**
Tcf-4 binding, 5619
**Metastatin**
tumor growth inhibition, 1022
**Methioninase**
rAdMET-SeMET gene therapy, 6805
**Methionine**
brain tumor dependence, athymic mice, 4017
**Methotrexate**
pharmacokinetics, mutant DHFR-expressing mice, 1522
resistance
GGH overexpression effects, 4599
transport by MRP3 and MRP1, 7225
**2-Methoxyestradiol**
combined with docetaxel, antiangiogenic therapy, 3369
**Methoxyisobutylisonitrile**
Tc-MIBI scintimammography
Pgp/MRP expression and, 1412
**Methylation:** *See also* **Hypermethylation**
aberrant promoter, bladder cancer, 8659
*CTCF* binding site, Wilms' tumor, 4947
*FHIT* gene
and expression loss, lung and breast cancer, 3581
*GSTP1* gene inhibition, prostate cancer, 4820
hypomethylation
genome-wide, hepatocellular carcinogenesis, 4238
*mlt 1* silence, liver tumors, 1144
and SV40, malignant mesothelioma, 5727
uveal melanoma, 5303
**Methylation-controlled J protein**
expression loss, ovarian cancer, 4258
**Methylazoxymethanol**
activation, CYP2E1 null status, 8435
**Methylenetetrahydrofolate reductase**
polymorphisms
and esophageal cancer risk, 3272
***O*$^6$-Methylguanine**
Top1 trapping, 53
***O*$^6$-Methylguanine DNA methyltransferase**
inactivation
and *p53* mutations, non-small cell lung cancer, 8113
methylation
and low-level microsatellite instability, colorectal cancer, 827
promoter hypermethylation
head and neck squamous cell carcinoma, 939
and *p53* transition mutations, 4689
***N*-Methyl-*N'*-nitro-*N*-nitrosoguanidine**
TopI-mediated cytotoxicity, 53
**Methylseleninic acid**
effects on endothelial mitogenesis and protein kinases, 7171
**Methyl selenium**
caspase-dependent anoikis induction, prostate cancer, 3062
**6-Methyl-1,3–8-trichlorodibenzofuran**
tamoxifen antitumorigenicity enhancement, 3902
**MIBI:** *See* **Methoxyisobutylisonitrile**
**Microarrays**
cDNA
colorectal cancer tumor marker identification, 7792
CpG island
DNA hypermethylation, breast cancer, 8375
oligonucleotide, glioma, 6885
protein
cancer cell profiling, 7585
**Microcirculation**
tumor
assessment by dynamic MRI, rectal carcinoma, 2513
**Microdialysis**
tumor
urea recovery marker, 7964
**$\beta_2$-Microglobulin**
antitumor effects, leukemia, 4414
IL-$2^{null} \times \beta_2M^{null}$ mice
colon cancer molecular genetics, 6912
**Micrometastasis**
liver
dynamic micro-MRI with DAB-Am64-$(1B4M\text{-}Gd)_{64}$, 4966
peritoneal gastric cancer
detection by EGFP and CEA, 5570
**Micronucleus frequencies**
*BRCA1* mutations and, 5948
**Microsatellite instability**
*APC* mutations and, familial adenomatous polyposis, 7616
coding region, instabilotyping, 6046
colorectal carcinogenesis, 896
gastrointestinal carcinoma
*hRAD50* frameshift mutations, 36
low-level
frequency, early colorectal cancer, 7743
*MGMT* methylation and, colorectal cancer, 827
ovarian cancer, 4371
oxidative stress and, 7444
pancreatic ductal adenocarcinoma, 3139
pediatric central nervous system tumor subtypes, 2124
sex differences, colon cancer, 126
**Microsatellites**
markers
hereditary nonpolyposis colorectal cancer screening, 4545
plasma, melanoma, 5723
mutations
somatic, normal tissue, 4541
TERT$^+$ cells, 8405
typing
tumor plasma DNA, head and neck squamous cell carcinoma, 8595
**Microscopy**
intravital
endostatin study, 6830
**Microtubule associated protein kinase**
estrogen nuclear signaling, breast cancer, 6360
TPA-induced, 4084
**Microtubules**
alterations
*Vinca* alkaloid resistance, leukemia, 5803

**Midkine**
antisense oligodeoxynucleotide, rectal carcinoma, 8486
**Midkine promoter-based replicative adenovirus**
pediatric solid tumor treatment and bone marrow tumor purging, 7882
**MIG**
chemokine gene therapy
combined with targeted IL-2, murine colon cancer, 8498
**Miller, James A.**
in memoriam, 3847
**Mismatch repair**
camptothecin and etoposide cytotoxicity, colorectal cancer, 6555
cdc2 phosphorylation and $G_2$ arrest, 8290
defects
hereditary nonpolyposis colorectal cancer, 7369
prostate cancer, 4112
deficiency
COX inhibitors, mice, 6131
ionizing radiation mutagenesis, mice, 3775
mononucleotide repeat variability, 3801
**Mitochondria**
aerobic tirapazamine exposure effects, 145
cytochrome *c* expression
and cell death, 1038
dysfunction
DOX-induced, heart, 771
human RFC protein
localization, leukemia, 1941
ionizing radiation and, 3894
*OGG1* gene, mouse, 5378
**Mitochondrial DNA**
alterations, human tumors, 7015
mutations
breast cancer, 7623
pancreatic cancer, 1299
somatic, hepatocarcinogenesis, 1843
somatic, ovarian cancer, 5998
**Mitochondrial permeability transition**
induction by staurosporine, 2459
**Mitochondrial respiration-deficiency**
CD437 resistance, 6698
**Mitogen-activated protein kinase:** *See* **Extracellular signal-regulated kinase**
**Mitogen-activated protein kinase kinase**
activation
HGF/SF-induced, 5911
inhibitors
UCN-01 interactions
apoptosis induction, 5106
**Mitogen-activated protein kinase kinase 4**
and histological pattern, advanced prostate cancer, 2833
**Mitogenesis**
endothelial
methylseleninic acid effects, 7171
**Mitomycin C**
resistance
restoration, *BRCA1*, 4842
reversal by bioreductive enzyme overexpression, Chinese hamster ovary cells, 7770
**Mitosis**
A-204197, antimitotic activity, 5480
**Mitotic recombination**
irradiated cells, 1129
**Mitoxantrone**
resistance
breast cancer MCF-7 cells, 5461
indolocarbazole resistance, 2827
**Mixed lineage leukemia *(MLL)* gene**
apoptosis-induced translocations, 4550
*MLL*-human *gephyrin* fusion gene
t(11;14)(q23↖4), acute monoblastic leukemia, 2665
MLL$^{+ve}$ infant leukemia
transplacental exposure and, 2542
partial nontandem duplication, B-cell acute lymphoblastic leukemia, 59
**ML-1 cells**
vinblastine-induced apoptosis potentiation, 1533
**MLL-ENL**
cooperation with *myc*, 6480
***mlt 1***
silence by methylation, liver tumors, 1144
**MM1143**
apoptosis induction, 4723
**MMR:** *See* **Mismatch repair**
**MNNG:** *See* ***N*-Methyl-*N'*-nitro-*N*-nitrosoguanidine**
**Molecular imaging**
Met activity, *in vivo*, 4873
**Monoclonal antibodies**
A33
anti-huAb A33 Ig responses, colon cancer, 6851
aluminum (III) phthalocyanine tetrasulfonate targeting, photodynamic therapy, 1970
anti-ΔEGFR 806
ΔEGFR-expressing glioblastoma treatment, 5349
growth inhibition, 5355
anti-endoglin
antiangiogenic therapy, skin/SCID mouse chimeras, 7846
anti-HER2 trastuzumab
HER2 shedding inhibition, 4744
TRAIL-mediated apoptosis enhancement, breast and ovarian cancer, 4892
anti-*MUC-1* DF3
antibody-dependent cellular phagocytosis, breast cancer, 4061
anti-VEGF
combined with docetaxel, antiangiogenic therapy, 3369
anti-VEGFR2 DC101
angiogenesis and growth inhibition, glioma, 6624
combined with radiation therapy, tumor xenografts, 39
apoptosis-inducing
metastasis marker binding, 5741
8H9, solid tumor target, 4048
**Mononuclear cells**
peripheral blood
SDF-1 mRNA levels, AIDS-related lymphoma children, 5028
**Mononucleotide repeat variability**
MMR-deficient cancers, 3801
***Morinda Citrifolia* (noni)**
glycosides
AP-1 and cell transformation inhibition, 5749
**Mortality**
chemotherapy-associated
reduction by GLP-2, 687
**Motuporamines**
invasion and angiogenesis inhibition, 6788
**Mouse double minute 2**
Bcr-Abl and IL-3 survival effects and, 7635
localization
*p14$^{ARF}$* methylation and, 2816
mRNA splicing, invasive breast cancer, 3212
p53 level modulation by p73, 1598
p73 nuclear aggregate induction, 6703
p53 subcellular distribution regulation, 6703
p73 subcellular distribution regulation, 6703
***MRE11* gene**
alterations, cancer, 23
**MS-275**
*TβRII* expression induction, breast cancer, 931
**Msh2 protein**
expression loss, colorectal carcinoma, 7379
**Mucins**
MUC1
anti-*MUC-1* MAb DF3, antibody-dependent cellular phagocytosis, 4061
bispecific anti-*MUC-1* DF3xH22, antibody-dependent cellular phagocytosis, 4061
expression, hematological malignancy, 6846
MUC2
*O*-glycosylation by *N*-acetylgalactosaminyltransferase-3, colonic adenocarcinoma, 950
promoter regulation by Sp transcription factor family, 570
**Mucosa**
methylation, 6991
**Multidrug resistance**
combination *mdr1a/1b*- and *mrp1*-deficient mice
pharmacological phenotype, 1469
D-24851 antitumoral effects, 392
IL-6, breast cancer, 8851
ouabain-induced, lung cancer, 1693
PNU-159548 anti-tumor activity, 1991
reversal
pervilleine A, 4030
XR9576, 749
**Multidrug resistance protein**
combination *mdr1a/1b*- and *mrp1*-deficient mice, pharmacological phenotype, 1469
expression
and Tc-MIB1 scintimammography, 1412
**Multidrug resistance protein 1**
methotrexate and folate transport, 7225
peptide transport, 2552
**Multidrug resistance protein 3**
methotrexate and folate transport, 7225
tumor rejection antigen, 6459
**Multi-molecular marker assay**
hematogenous metastatic breast cancer, 8845
**Multiple adenocarcinoma-associated antigen**
FGF-5, identification, 5511
**Multiple endocrine neoplasia**
type 2B
Ret phosphorylation, 1426
**Multiple myeloma**
8-chloro-cAMP and 8-chloro-adenosine mechanism of action, 5474
homing
CD44v10, 2862
PS-341 therapy, 3071
**Multipoint imprinting analysis**
pediatric germ cell tumors, 7268
**Mutagenesis**
ionizing radiation, MMR-deficient mice, 3775
**Mutagenicity**
hypoxia-induced, 7603
**Mutated lung cancer antigen**
CTL response, 3718
**Mutations:** *See also* **Deletions**
*Apc*
tumorigenesis and, *MSH* mutant *Apc$^{1638N}$* mice, 7934
*ATR*, gastric tumors, 7727
*BRCA1*
and induced micronucleus frequencies, 5948
*BRCA2*

chromosome 9p23–24 instability, 5179
E-cadherin
Wnt signaling, breast cancer, 278
carcinoembryonic antigen
and liver metastasis, colorectal cancer, 2822
β-catenin
biliary tract cancer, 3406
exon 3, gallbladder adenoma, 19
gastrointestinal carcinoid tumor, 6656
caveolin-1, scirrhous breast cancer, 2361
*CHK1*, gastric tumors, 7727
Chk2, lung cancer, 5362
CYP1B1, head and neck squamous cell carcinoma, 4398
dihydrofolate reductase
methotrexate pharmacokinetics, mice, 1522
EGFR
ΔEGFR-expressing glioblastoma, mAb treatment, 5349
*Fas*, thyroid lymphoma, 1382
*FGFR2*, gastric and colorectal cancer, 3541
*FGFR3*
gastric and colorectal cancer, 3541
superficial bladder cancer, 1265
frameshift
*hRAD50*, gastrointestinal carcinoma, 36
oxidative stress and, colorectal cancer, 7444
frequency, Chinese hamster ovary cells, 50
*Gadd45a*-null mice, 2487
germline
*APC* gene, familial adenomatous polyposis, 7616
*ATM* gene, breast cancer, 7608
*HER-2/neu*
and breast cancer risk, 8393
hepatitis B virus X, hepatocellular carcinoma, 7803
*hMSH2*, functional analysis, 7719
Hupki mice, 8158
*KIT*, gastrointestinal stromal tumors, 8624
K-*ras*
lung tumors, 6679
serous borderline ovarian tumors and ovarian carcinoma, 7264
lung tumor spectrum
and PAH exposure, 6679
methylated CpG dinucleotides, 7110
microsatellite, TERT$^{+}$ cells, 8405
missense
CHK2 destabilization, 8062
*MRE11*, cancer, 23
*MSH3*, nonpolypotic colon cancer, 1619
*MSH6*, nonpolypotic colon cancer, 1619
mtDNA, breast cancer, 7623
*MXR/BCRP/ABCP* gene
substrate specificity alteration, 6635
*NAT2*
age-associated cancer risk and, 1265
nonsense
*MLH1*
exon skipping, hereditary nonpolyposis colorectal cancer families, 7020
N-*ras*, malignant melanoma, 4916
p27, antitumor effects, 6163
*p53*
BPDE, nontumorous human lung, 6350
childhood malignant glioma, 7404
codon 72, cervical cancer, 608
cytotoxic therapy, neuroblastoma, 8
esophageal squamous cell carcinoma, northern Iran, 3119
frequency during tumor progression, breast cancer, 8317
head and neck squamous cell carcinoma, 4398
MGMT inactivation and, non-small cell lung cancer, 8113
plasma and tumor, detection by electrospray ionization mass spectrometry, hepatocellular carcinoma, 33
serous borderline ovarian tumors and ovarian carcinoma, 7264
point
β-catenin, solid-pseudopapillary neoplasms, 8401
*PPARγ, malignancy, 5307*
*RB2/p130*, nasopharyngeal carcinoma, 5950
Smad4-mutant colon adenoma
growth inhibition by TGF-β, 256
somatic microsatellite, normal tissue, 4541
somatic mtDNA
hepatocarcinogenesis, 1843
ovarian cancer, 5998
*TβR-I*, ovarian cancer, 4679
*TGFBR2*, recurrent breast cancer, 482
thymidine kinase, 3022
thymidylate synthase Arg$^{50}$ loop mutants
5-FdUR-resistant, 666
top1 R364H, camptothecin-resistant prostate cancer, 1964
*TP53*, lung tumors, 6679
*TRAIL-R1* and *TRAIL-R2*, metastatic breast cancer, 4942
yeast checkpoint kinase
adozelesin DNA replication effects, 3787
**Mutator phenotypes**
cancer, 3230
glycophosphatidylinositol defects and, cancer, 654
**Mutators**
and hereditary nonpolyposis colorectal cancer, 7369
**MutL homologue**
human *hMLH1*
fluoropyrimidine response, 5193
methylated, serum, colon cancer, 900
*MLH1*
expression, hereditary nonpolyposis colorectal cancer, 2813
nonsense mututation
exon skipping, hereditary nonpolyposis colorectal cancer families, 7020
oxidative stress response effects, 1392
5′ region hypermethylation, age-related, 6991
**MutS homologue**
human *hMSH2*
mutations, functional analysis, 7719
MSH2
expression, hereditary nonpolyposis colorectal cancer, 2813
*MSH3*
mutations, nonpolypotic colon cancer, 1619
*MSH6*
expression, hereditary nonpolyposis colorectal cancer, 2813
mutations, nonpolypotic colon cancer, 1619
mutant *Apc*$^{1638N}$ mice
tumorigenesis and *Apc* mutations, 7934
***MXR/BCRP/ABCP* gene**
mutations
substrate specificity alteration, 6635
***myc***
carboxylesterase expression and CPT-11 sensitization mediation, 3045
MLL-ENL cooperation, 6480
**Mycosis fungoides**
CD40/CD40L coexpression, 452
**Myelodysplastic syndrome**
caspase-3 activation by lysosomal enzymes, P39 cells, 2878
**Myeloma**
multiple
8-chloro-cAMP and 8-chloro-adenosine mechanism of action, 5474
homing, CD44v10, 2862
PS-341 therapy, 3071
**Myelomonocytic cell differentiation**
*myc*-dependent
MLL-ENL, 6480
**Myeloperoxidase**
pro-/antioxidant etoposide effects, HL-60 cells, 7777
**N-Myristoyltransferase 2**
Ah receptor-dependent induction, 8534

**N**

**NAD(P)H:quinone oxidoreductase**
induction, human colon cells, 6112
regulation by Nrf2, 3299
**Nanoparticles**
extravasation
hyperthermia effects, 3027
**Nasopharyngeal carcinoma**
growth inhibition by antiviral phosphonated nucleoside analogs, 7875
*RASSF1A* hypermethylation, 3877
*RB2/p130* mutations, 5950
**Natural killer cells**
IL-2 and IL-18 synergism, 884
**NB4 cells**
granulocytic differentiation
ATRA metabolite-induced, 700
**NB-506**
antiproliferative activity, camptothecin resistance, 504
resistance by BCRP/MXR/ABCP, 2827
splicing inhibition, 6876
**Necrosis**
central
inflammatory breast cancer, 445
photosensitization-induced, 7495
tumor-pulsed dendritic cells, 8105
**Neoangiogenesis**
tumor-associated
HOXB7, 6532
**Neoplasia**
colonic
VEGF regulation by Wnt and K-ras, 6050
colorectal
genetic pathways, 2676
intestinal
suppression by lifetime aspirin, mice, 7060
mammary
suppression by lifetime aspirin, mice, 7060
susceptibility, *Apc*$^{Min}$/+ mice, 3480
pancreatic intraepithelial
molecular aberrations, 8830
solid-pseudopapillary
pancreatic
β-catenin point mutations, 8401
somatic selection, 799
vulval
HLA and HPV, 192
vulval intraepithelial
photodynamic therapy response factors, 192
**Neoplastic lymphocytes**
laminin 8 and 10 interactions, 339
**Nerve growth factor**
cell proliferation
inhibition by tamoxifen, breast cancer, 3002
receptors
expression, breast cancer, 4337

**NES1:** *See* **Normal epithelial cell-specific-1 (NES1)/kallikrein 10**
**Neuroblastic cells**
neuroblastoma, 6892
**Neuroblastoma**
apoptosis induction by iron chelation, 1073
apoptosis inhibition by FLIP and bcl-2, 4864
*CDKN2A* homozygous deletion, 679
cytotoxic therapy
*p53* mutations, 8
differentiation by phenylacetate
PPARγ-mediated, 3998
eradication by human IgM antibodies, 2968
gangliosides
dendritic cell inhibition, 363
growth inhibition
CBHA and ATRA, 3591
neuroblastic cells, 6892
N-*myc* inhibition by iron chelation, 1073
osteoclast formation, 1637
p53 and drug resistance, 6185
Schwannian stromal cells, 6892
serine palmitoyltransferase and ceramide synthase activation by 4-HPR, 5102
TRAIL-resistant
caspase-8 expression loss, 1314
VDEPT purging, 5083
**Neuroendocrine carcinoma**
LPB-*Tag* transgenic mice, 2239
**Neuroendocrine gastroenteropancreatic tumors**
CDK inhibitor inactivation, 5905
**Neuropeptide Y**
receptors, breast cancer, 4636
**Neurotrophic factor**
glial cell line-derived
overexpression, seminomatous tumors, 3267
**Neurotrophin receptors**
chimeric ETV6-NTRK3
transformation blockade by signaling inhibitors, 8909
**Neurotropic virus**
human
and brain tumors, 4287
**Neutral endopeptidase**
IGF-IR-Akt cell survival pathway inhibition, 3294
**Neutron capture therapy**
gadolinium, glioblastoma, 4272
**NF-E2 p45-related factor 2**
NQO, glutathione *S*-transferase and GCS regulation, 3299
**Nickel**
NFAT activation and $H_2O_2$ generation, 8051
**Nijmegen breakage syndrome gene *(NBS1)***
mutations, childhood acute lymphoblastic leukemia, 3570
**Nimesulide**
chemopreventive effects, rat tongue carcinogenesis, 1451
**Nip3-like protein X**
expression, tumors, 6669
**Nitric oxide**
apoptosis
HIF-1 and IRF-1 interactions, 3682
potentiation by FTI, breast cancer, 4701
base excision repair inhibition, 6388
iron protection against, tumor cells, 5289
NSAIDs releasing
and colon cancer cell kinetics, 3285
platelet aggregation by tumor cells, 376
tumor cytotoxicity
inhibition by macrophage arginase, 1100
**Nitric oxide synthase**
inducible
expression, colon tumorigenesis, 419
expression, ovarian tumors and macrophages, 7305
inhibitors
intestinal polyposis inhibition, *Apc*$^{Min}$/+ mice, 8357
targeted CEA-expressing cell kill by retrovirus, 370
**Nitric-oxide synthase**
inducible
inhibition, melanoma apoptosis, 318
melanoma growth, NOS II knockout mice, 3182
NOS II gene
and IFN-β therapy, pancreatic adenocarcinoma, 71
**9-Nitrocamptothecin**
apoptosis induction, 7148
**Nitrogen**
ionizing radiation-induced mitochondria-dependent generation, 3894
**NIX:** *See* **Nip3-like protein X**
**NK4**
pancreatic cancer treatment, orthotopic mouse model, 7518
**Nm23**
breast cancer regulation, 2062
**Nm23-H1**
and DNA methylation, 2320
**N-*myc***
inhibition by iron chelation, neuroblastoma, 1073
**NNKOAc:** *See* **4-(Acetoxymethylnitrosamino)-1-(3-pyridyl)-1-butanone**
**Non-Hodgkin's lymphoma**
B-cell
STAT3 inhibition by rituximab, 5137
**Non-small cell lung cancer**
α-actinin-4 mutated peptide-reactive CTLs, 4078
Akt/PKB activity, 3986
CA9 expression, 7992
chromosome 9p21 loss of heterozygosity, smokers, 2092
c-*mos* expression, 538
dihydrodiol dehydrogenase overexpression, 2727
early stage
cyclin E, prognostic value, 647
regulatory T cells, 4766
*GSTM1* polymorphisms and, 8718
histology-specific methylation by tobacco smoke exposure
p16$^{INK4A}$ and, 3419
hRad17 phosphorylation and overexpression, 7417
MGMT inactivation, 8113
*p14*$^{ARF}$ alterations, 5636
*p53* alterations, 5636
*p73* alterations, 5636
*p53* mutations, 8113
*p53* polymorphisms and, 8718
promoter methylation, 249
resected
polysialic acid expression, 1666
risk-stratification model, 2500
transmembrane GTPase, 8873
**Nonsteroidal anti-inflammatory drugs**
apoptosis induction, esophageal cancer, 4879
chemoprevention
metabolic enzymes and, colon adenoma, 3566
NO-releasing
and colon cancer cell kinetics, 3285
**Norepinephrine**
SW 480 cell migration, 2866
**Normal epithelial cell-specific-1 (NES1)/kallikrein 10**
methylation, breast tumors, 8014
**Notch**
effects, small cell lung cancer, 3200
expression, prostate and prostate tumorigenesis, 7291
**NPP-2:** *See* **Autotaxin**
**N-*ras***
mutations, malignant melanoma, 4916
**Nrf2:** *See* **NF-E2 p45-related factor 2**
**NT2 cells**
bleomycin and radiation resistance by Ape1/ref-1, 2220
**Nuclear factor-κB**
activation
DNA damage, HeLa cells, 7785
IκB activity and, melanoma, 4901
oncogenic RET, 4526
VEGF effects, hematopoietic progenitor cells, 2015
activity, C-cell carcinoma, 4526
inhibition by p38, HeLa cells, 7689
inhibition by PS-341, 3535
*KAI1/CD82* expression, lung cancer, 673
ligand
receptor activator RANKL
osteoclast formation, neuroblastoma, 1637
p65/NF-κB-dependent transformation, 4160
proliferation and apoptosis redox control, 2656
receptor activator-IgG Fc fusion protein RANK.Fc
hypercalcemia blockade, humoral hypercalcemia of malignancy, 2572
**Nuclear factor of activated T cells**
activation by nickel, 8051
**Nuclear magnetic resonance**
single-quantum- and triple-quantum-filtered $^{23}$Na and $^{31}$P
BCNU effects, 9L glioma, 2002
**Nuclear matrix proteins**
profiles, breast cancer progression, 1362
**Nucleophosmin/anaplastic lymphoma kinase**
cell transformation
STAT5 role, 6517
lymphomagenesis
PI3K-Akt pathway, 2194
**Nucleoside analogs**
antiviral phosphonated
growth inhibition, nasopharyngeal carcinoma, 7875
**Nucleotide excision repair**
modulation by XPD polymorphisms, lung cancer, 1354
**Nucleotides**
T-nucleotide additions, mantle cell lymphoma, 1629
**NY-BR-1**
tumor antigen, breast cancer, 2055
**NY-ESO-1**
expression, transitional cell carcinoma, 4671

## O

**Obesity-related hepatic steatosis**
premalignant, 5016
**Obituaries**
Argyris, Thomas S., 8931
Gullino, Pietro M., 8930
Miller, James A., 3847
Weinhouse, Sidney, 8930
Weiss, Leonard L., 5663
**Oct-1**
*gadd45* activation by ultraviolet light, 1187
**Oct-2**
deficiency, Hodgkin and Reed Sternberg cells, 2080
**Ogg1**
human hOgg1

inhibition by nitric oxide, 6388
**Oligodendroglioma**
gene expression profiles, 1825
location-specific genetic changes, 6713
**Oligodeoxynucleotides**
antisense
midkine, rectal carcinoma, 8486
CpG-containing
antimetastatic effects, 5523
**Oligonucleotide microarray analysis**
glioma profiles, 6885
**Oncogenes**
amplification, breast cancer, 1214
novel candidate chromosome 3q26, ovarian cancer, 3806
silica-induced proto-oncogenes, 1791
**Oncogenesis**
radiation
*ATM* heterozygotes, 5710
**Oncology assay**
spectral FISH, 831
**Oncolysis**
poliovirus replicons, 8470
replicative adenovirus
Hsp70i and, 8361
**ONYX-015**
effects
modulation by $p14^{ARF}$, mesotheliomas, 5959
**Oral carcinoma**
boron neutron capture therapy, hamster cheek pouch model, 8638, 8775
*CDKN2A* gene loss, 2371
hamster cheek pouch model, BNCT studies, 8775
selenium-induced apoptosis and stress kinases, 7479
squamous cell
collagen type 1 degradation, 6264
S-phase kinase-interacting protein 2 expression, 7044
**Oral epithelial dysplasia**
*CDKN2A* gene loss, 2371
**Oral precancer**
EGFR-targeted immunophotodiagnosis and photoimmunotherapy, 4490
**Ornithine decarboxylase**
promoter
modified
MYC-regulated protein expression, 3045
reduction by transgenic antizyme expression, mouse skin, 6073
**Oropharyngeal cancer**
radiotherapy
HIF-1α expression, 2911
risk
HSV1 infection, 8459
**Orphan nuclear receptors**
ERR family
pS2 regulation, 6755
**Osteoblasts**
prostate cancer interactions, 5652, 6372
**Osteocalcin**
replication-competent Ad-OC-E1a
systemic gene therapy, prostate cancer bone metastasis, 6012
**Osteoclasts**
formation, neuroblastoma, 1637
**Osteolysis**
inhibition by osteoprotegerin, mouse models, 4432
**Osteopontin**
HGF-induced growth mediation, 5861
regulation by metastasis-inducing DNA, 5619
**Osteoprotegerin**
advanced bone cancer pain relief, 4038
bone metastasis inhibition, mouse models, 4432
**Osteosarcoma**
Fas upregulation by IL-12, 4066
gene expression
metastasis-associated differences, 3750
metastasis, cDNA microarray evaluation, 3750
**Ouabain**
multidrug resistance, lung cancer, 1693
**Ovarian cancer**
adenoviral gene expression
l-plastin, 4405
apoptosis
TRAIL-mediated, enhancement by trastuzumab, 4892
chlorin phototoxicity, mechanistic study, 717
chromosome 3q26 candidate oncogene, novel, 3806
cisplatin resistance induction by *SRPK1* inactivation, 6982
early- *versus* late-stage, 5895
erbB-4/HER-4 expression, 2169
gene upregulation, coordinate, 3869
HER-2 overexpression, 2420
inhibition by BARX2, 6977
invasion stimulation by ET-1, 8340
*KLK9* expression, 7811
K-*ras* and *p53* mutations, 7264
late-stage
regulatory T cells, 4766
LPA-mediated MMP activation and invasion, 3194
malignancy
anoikis and, 4837
MCJ expression loss, 4258
microarray and CGH analysis, 5895
microsatellite instability, 4371
paclitaxel resistance and RAR-γ, 7552
p73α overexpression and drug resistance, 935
susceptibility
androgen receptor and, case series, 908
*TβR-I* mutations, 4679
XIAP and Akt activity, 1862
**Ovarian endometrioid adenocarcinoma**
β-catenin deregulation, 8247
**Ovarian epithelial cells**
hTERT promoter regulation, 5529
**Ovarian-specific promoter 1**
identification, 1291
**Ovarian surface epithelial cells**
growth
hormonal regulation, 6768
**Ovarian tumors**
borderline
serous
K-*ras* and *p53* mutations, 7264
chromosome 5 allelic deletions, 4169
chromosome 6 allelic deletions, 4169
combination rhuCD40L and cisplatin, antitumor effects, 7556
COX-2 and iNOS expression, 7305
PI3K p85α subunit oncogene, 7426
**Oxidative stress**
*Apex*$^{+/-}$ mouse model, 5552
ataxia telangiectasia, 1849
and frameshift mutations, colorectal cancer, 7444
and hepatitis C virus, mouse model, 4365
and microsatellite instability, 7444
resistance
AP-1 activity, 3486
response
MLH1 effects, 1392
**Oxoguanine DNA glycosylase**
expression
protection against thioTEPA-induced toxicity, hematopoietic cell, 5116
*OGG1* gene, mouse mitochondria, 5378
**Oxygen**
tissue partial pressure ($pO_2$)
VEGF regulation, brain tumors, 6020
**Oxygenation**
tumor
and glycolytic rate, murine mammary carcinoma, 5318
vinblastine effects, 4266
**Oxygen-regulated protein 150**
tumor angiogenesis regulation, 4206
**Oxytocin**
receptor
tumors
radioligand, 4393

**P**

***$p14^{ARF}$***
alterations
non-small cell lung cancer, 5636
primary CNS lymphoma, 6335
methylation
and MDM2 localization, 2816
ONYX-015 effect modulation, mesotheliomas, 5959
***p16***
functional differences from p18, 3863
promoter hypermethylation pattern, head and neck squamous cell carcinoma, 939
***$p16^{INK4a}$***
alterations, primary CNS lymphoma, 6335
Barrett's esophagus, 8284
expression reduction, uveal melanoma, 5303
and histology-specific methylation
tobacco smoke exposure, non-small cell lung cancer, 3419
mammary development, 8811
**p18**
functional differences from p16, 3863
**p21**
ARF-induced growth inhibition, 3145
vitamin D growth inhibitory effects and, prostate cancer, 7122
***$p21^{WAF1/Cip1}$***
and apoptosis, retinoblastoma, 3157
-deficient mice
tumor susceptibility, 6234
DNA repair modulation, p53-deficient cells, 3781
and $G_1$ tetraploid arrest, colon cancer, 7660
induction by CEP1612, lung adenocarcinoma, 1280
overexpression, pancreatic intraepithelial neoplasia, 8830
silencing
androgen receptor
and apoptosis, prostate cancer, 7544
and sulindac intestinal cell response, 6297
**p27**
mutant
adenoviral, antitumor effects, 6163
**$p27^{Kip1}$**
ErbB2/*neu* kinase-mediated modulation, 6583
induction by CEP1612, lung adenocarcinoma, 1280
PTEN-induced growth arrest requirement, 2105
**$p33^{ING1}$**
DNA repair, 4974
**p38**
kinase
apoptosis, leukemia, 6290
resveratrol p53 activation mediation, 1604
MAPK activation, RRM-induced apoptosis,

8504
MAPK signaling
methylseleninic acid effects, 7171
radiosensitization and inhibition of NF-κB, HeLa cells, 7689
**p45**
NF-E2 p45-related factor 2
NQO, glutathione *S*-transferase and GCS regulation, 3299
***p53***
and aberrant *TSG101* transcripts, cancer cells, 486
activation
resveratrol-induced, 1604
activity
adenovirus replication and, 5941
alterations, non-small cell lung cancer, 5636
*APAF-1* target, DNA damage-induced apoptosis, 6660
and apoptosis
murine tumors, 327
retinoblastoma, 3157
base excision repair activity modulation, 88
cell cycle checkpoint regulation
p53R2 role, 8256
*CHK1*, Finnish Li-Fraumeni syndrome families, 5718
c-myc interactions
and 5-FU sensitivity, colon cancer, 4910
codon 72 polymorphism
and cervical cancer, 608
and non-small cell lung cancer, 8718
deficiency
DNA repair modulation by p21waf1cip1, 3781
mammary tumorigenesis, irradiated mice, 6577
p63 expression, mice, 6467
tumorigenesis promotion by *Bax*, 659
DNA-PK DNA damage sensor complex, 8723
and drug resistance, neuroblastoma, 6185
epidermal growth factor receptor and, glioblastoma, 1122
foci
and tumor risk, UV-exposed hairless mice, 977
functional inactivation, Li-Fraumeni syndrome, 1741
hotspot alterations, Hupki mice, 8158
Hupki (human p53 knock-in) mice
and p53 hotspot alterations, 8158
inactivation
BCNU sensitization, glioma, 4155
E6
tamoxifen-mediated apoptosis promotion, mammary epithelial cells, 616
levels
modulation by p73, 1598
mismatch repair interactions, colon cancer, 1508
mutations
BPDE, nontumorous human lung, 6350
Chernobyl accident, 6964
childhood malignant glioma, 7404
cytotoxic therapy, neuroblastoma, 8
esophageal squamous cell carcinoma, northern Iran, 3119
frequency during tumor progression, breast cancer, 8317
head and neck squamous cell carcinoma, 4398
lung cancer, ex-smoking women, 4350
MGMT inactivation and, non-small cell lung cancer, 8113
plasma and tumor, detection by electrospray ionization mass spectrometry, hepatocellular carcinoma, 33
serous borderline ovarian tumors and ovarian carcinoma, 7264
transition
$O^6$-*MGMT* promoter hypermethylation and, 4689
VEGF expression and, breast cancer, 2256
xeroderma pigmentosum melanoma, 2480
null Werner mice
tumorigenesis, 1816
14–3–3 protein association, 7030
*Ptc*$^{+/-}$*p53*$^{-/-}$ mice
medulloblastoma, 513
quantification by DNA affinity immunoblotting, 5402
regulation by hHR23A, 64
response
and lung cancer susceptibility, 7819
subcellular distribution regulation by MDM2, 6703
synthetic homologue CTS1
cell kill, glioma, 5833
TCR$\beta^{-/-}$ p53$^{-/-}$ mice
colon cancer, 2390
temozolomide-treated glioma effects, 1957
UPase gene expression downregulation, 6899
VPF/VEGF expression regulation, breast cancer, 6952
wild-type
coadministered with Flt3L genetic immunization, 8227
**p53R2**
p53-regulated cell cycle checkpoint role, 8256
**p63**
expression, p53-deficient mice, 6467
**p65**
p65/NF-κB-dependent transformation, 4160
**p73**
alterations, non-small cell lung cancer, 5636
cancer therapy role, pancreatic cancer, 7052
nuclear aggregates
induction by MDM2, 6703
p53 level modulation, 1598
subcellular distribution regulation by MDM2, 6703
**p73α**
overexpression
and drug resistance, ovarian cancer, 935
**p85-sErbB3**
heregulin-induced ErbB3 activation inhibition, 4467
**p85α**
PI3K oncogene, ovarian and colon tumors, 7426
***p130***
*Rb2/p130*, 4651
mutations, nasopharyngeal carcinoma, 5950
VEGF downregulation and angiogenic inhibition, 462
**p202**
antitumor activity, pancreatic cancer, 7142
**p300/cyclic AMP response element-binding protein**
hHR23A interactions
*p53* regulation, 64
***P311***
glioblastoma invasion gene, laser capture microdissection, 4190
**Paclitaxel**
Apo-2L/TRAIL-induced apoptosis enhancement, prostate cancer, 759
combined with suramin, lung metastases, 6145
resistance
IRF9-mediated, breast cancer, 6540
and RAR-γ, ovarian carcinoma, 7552
synergy with CV787, 517
vaccine synergy, HER-2/*neu* tolerized mice, 3689
**Pain**
advanced bone cancer
osteoprotegerin relief, 4038
**Pancreatic adenocarcinoma**
ductal
microsatellite instability, features, 3139
interferon β therapy
NOS II gene and, 71
Sp1 activity and angiogenesis, 4143
VEGF expression, 4143
**Pancreatic cancer**
E-cadherin expression
substrate-induced downregulation, 3508
CpG islands
methylated, isolation, 8540
dendritic cells, 6445
desmoplasia induction by TGF-β1, 550
heparanase expression, 4655
HIF-1α expression, 6548
IGF-IR expression
upregulation by AKT, 589
invasion
inhibition by HMG-CoA reductase inhibitors, 4885
invasion-specific genes, 1833
invasiveness
promotion by AKT, 589
mtDNA mutations and homoplasmy by genetic drift, 1299
mutliple angiogenesis inhibitors, 7298
NK4 treatment, orthotopic mouse model, 7518
p202 antitumor activity, 7142
PSCA overexpression, 4320
T-cell recognition, 2038
TGF-β1-induced transdifferentiation, 4222
TGF-β RII gene expression
Sp1 requirement, 6239
therapy
E2F1/p73 role, 7052
Think Tank White Paper, 4923
tumor development
delay by *FHIT* expression, 4827
**Pancreatic neoplasia**
intraepithelial
molecular aberrations, 8830
solid-pseudopapillary
β-catenin point mutations, 8401
**Pancreatic tumors**
endocrine
nonfunctional
allelotype, 285
small
genetic alterations, 5186
**Papillary renal cell carcinoma**
childhood
*RCC17/TFE3* fusion gene, 4130
*RASSF1A* 3p21.3 gene inactivation, 7277
**Papilloma**
FAK gene dosage effects, mouse skin carcinogenesis, 8385
metastasis induction by TGF-β1, 7435
PAI-2 overexpression and, transgenic mice, 970
**Parathyroid hormone-related protein**
IL-8 stimulation, 2282
**Partial pressure of oxygen in tissue ($pO_2$)**
VEGF regulation, brain tumors, 6020
***patched***
*Ptc*$^{+/-}$*p53*$^{-/-}$ mice
medulloblastoma, 513
**PAX3**
expression, melanoma, 823

*PAX5*
*TEL* fusion, acute lymphoblastic leukemia, 4666
**P39 cells**
caspase-3 activation by lysosomal enzymes, 2878
**PD0166285**
radiosensitization, 8211
**Pediatric central nervous system tumors**
subtypes
microsatellite instability, 2124
**Pediatric germ cell tumors**
multipoint imprinting analysis, 7268
**Pediatric solid tumors**
dendritic cell vaccination, 8513
midkine promoter-based replicative adenovirus treatment, 7882
**7α-[9-(4,4,5,5,5-Pentafluoropentylsulfinyl)-nonyl]estra-1,3,5, (10)-triene-3,17β-diol**
short-term biological effects, postmenopausal breast cancer, 6739
**Peptide nucleic acid**
PML/RARα inhibition, acute promyelocytic leukemia, 5468
**Peptides**
MRP1 transport, 2552
proapoptotic, solid tumor treatment, 7709
soybean lunasin, chemopreventive property, 7473
synthetic
tumor cell adhesion inhibition, 3308
**Peptidylglycine α-amidating monooxygenase**
hormone-independent prostate cancer, 1196
**Peripheral blood mononuclear cells**
SDF-1 mRNA levels, AIDS-related lymphoma children, 5028
**Peritoneal micrometastasis**
detection by EGFP and CEA, gastric cancer, 5570
**Peritoneum**
scirrhous gastric cancer metastasis
gene expression profiles, 889
**Peroxisome proliferator-activated receptor α**
ligand
colitis and aberrant crypt foci inhibition, 2424
**Peroxisome proliferator-activated receptor γ**
activation by 15S-HETE, prostate cancer, 497
ligand
colitis and aberrant crypt foci inhibition, 2424
phenylacetate cell differentiation, neuroblastoma, 3998
*PPARγ gene mutations, malignancy, 5307*
**Pervilleine A**
multidrug resistance reversal, 4030
**Pesticides**
CYP regulation, breast cancer, 3942
**PEX**
combined with low-dose chemotherapy, glioma, 7501
glioma inhibition, 8730
**P-glycoprotein**
expression
and Tc-MIBI scintimammography, 1412
and extracellular leaflet substrate concentration, 7763
inhibition by SCH66336, 7525
multidrug resistance
reversal by XR9576, 749
novel tumor-associated antigen, 8100
**pH**
cell transmembrane gradient
chlorambucil efficacy *in vivo* and, 4740
extracellular
mapping, rat glioma, 6524
low pH-adapted cells
respiration inhibition, 5630
VEGF regulation, brain tumors, 6020
**Phenotype**
genotype-phenotype association, soft-tissue tumors, 3171
metastatic
gene expression patterns, rodent and human tumors, 1569
mutator
cancer, 3230
glycophosphatidylinositol defects and, cancer, 654
variant, *Atm* knock-in mice, 4561
**Phenylacetate**
PPARγ-mediated cell differentiation, neuroblastoma, 3998
**Phenylbutyrate**
combined with 13-*cis* retinoic acid, prostate cancer, 1477
**1,4-Phenylene*bis*(methylene)selenocyanate**
glutathione conjugate *p*-XSe-SG
chemoprevention, colon cancer, 3647
**Philadelphia chromosome**
leukemogenesis
*BCR* gene and, 2343
**Phlebotomy**
and 8-OHdG, chronic hepatitis C, 8697
**Phorbol esters**
$PGE_2$ production
inhibition by curcumin metabolites, 1058
RasGRP3 modulation, 943
**Phorbol 12-myristate 13-acetate**
antileukemic synergy with flavopiridol, myeloid leukemia, 2583
**Phosphatidylinositol 3-kinase**
activity, MMP-9 production, 1855
HGF/SF-induced activation, 5911
p85α subunit oncogene, ovarian and colon tumors, 7426
PI3K/Akt pathway
downregulation by PKC412, 8203
hypoxia-induced PDGFR/PI3K/Akt/GSK-3 cascade, 2429
methylseleninic acid effects, 7171
nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis, 2194
regulatory ERα interactions, breast cancer, 5985
PI3-kinase-Akt signaling inhibitors
ETV6-NTRK3 transformation blockade, 8909
**Phospholipase $A_2$**
calcium-independent
inhibition by clinical doxorubicin levels, 4024
**Phospholipid metabolites**
levels, breast cancer, 7536
**Phosphonated nucleoside analogs**
antiviral
growth inhibition, nasopharyngeal carcinoma, 7875
**9-[2-(Phosphonomethoxy)ethyl]adenine**
growth inhibition, nasopharyngeal carcinoma, 7875
**Phosphorus-31**
single-quantum- and triple-quantum-filtered NMR
BCNU effects, 9L glioma, 2002
**Photodynamic therapy**
aluminum (III) phthalocyanine tetrasulfonate targeting, mAb, 1970
5-aminolevulinic acid and photofrin, human tumor xenografts, 5824
HIF-1a and HIF-2a and, esophageal cancer, 1830
response factors, vulval intraepithelial neoplasia, 192
**Photofrin**
photodynamic therapy, human tumor xenografts, 5824
**Photoimmunotherapy**
EGFR-targeted, oral precancer, 4490
**Photosensitization**
apoptosis *versus* necrosis, 7495
**Photosensitizer conjugates**
pegylated
tumor targeting, 7155
**Phototoxicity**
chlorins, mechanistic study, 717
**Pivaloyloxymethyl butyrate**
adriamycin interactions, 8194
**PKC412**
Akt pathway downregulation, 8203
radiosensitization mechanism, 732
**Placenta growth factor**
induction by hypoxia, fibroblasts, 2696
**Plasma**
circulating tumor DNA, lung cancer, 4675
DNA fragments
origin, cancer, 1659
microsatellite markers, melanoma, 5723
*p53* mutations
detection by electrospray ionization mass spectrometry, hepatocellular carcinoma, 33
proteins
smokers and lung cancer, 778
**Plasma membrane**
extracellular leaflet substrate concentration
P-glycoprotein and, 7763
**Plasmid prime-adenovirus**
boost vaccination, hepatocellular carcinoma, 8782
**Plasmids**
mammalian replication origin and matrix attachment region
gene amplification, 6987
**Plasminogen activator inhibitor 1**
angiogenesis promotion, 5587
regulation by redox, 5537
**Plasminogen activator inhibitor 2**
overexpression
and carcinogenesis, transgenic mice, 970
**L-Plastin**
adenoviral gene expression, ovarian and bladder cancer, 4405
**Platelet-derived endothelial growth factor**
induction by IFN-γ, 469
**Platelet-derived growth factor**
PI3K/Akt pathway
hypoxia activation
GSK-3 inactivation, 2429
receptors
inhibition
tumoral interstitial hypertension reduction, 2929
**Platelets**
tumor cell-induced aggregation
MMP-2 and NO, 376
**PMS**
human *hPMS1* and *hPMS2*, colorectal cancer, 7798
**PNU-159548:** *See* **4-Demethoxy-3′-deamino-3′-aziridinyl-4′-methylsulphonyl-daunorubicin**
**Poliovirus**
oncolytic replicons, 8470
**Poly(ADP-ribose) polymerase**
novel PARP1 inhibitors, cell-based yeast screen, 4175
novel PARP2 inhibitors, cell-based yeast screen, 4175

**Polyamine analogues**
apoptotic signaling, SK-MEL-28 melanoma cells, 6437
**Polyamine oxidase**
human, cloning, 5370
**Polyamines**
depletion
cell cycle regulatory responses, melanoma, 7754
**Polycyclic aromatic hydrocarbons**
exposure
lung tumor mutation spectrum and, 6679
lung tissue, 6367
**Polyimmunization**
gp100 and TRP-2, 859
**Polylmorphonuclear cells**
tumor cell lysis
enhancement by FcγRI and FcαRI, 4055
**Polymer**
CPA-polymer
and rRp450, 864
**Polymerase chain reaction**
long-distance assays
*BCL6* translocations, 7363
reverse transcription, nested
blood CEA mRNA, colorectal cancer, 2523
reverse transcription, real-time quantitative
steroid receptor expression, prostate cancer, 1919
*TEL-AML1*-positive childhood acute lymphoblastic leukemia, 2517
***Polyomavirus middle-T***
transgenic premalignant mammary disease mouse model, 8298
**Polypeptides**
elastin-like
thermally targeted
cellular uptake, 7163
**Polyposis**
intestinal
chemoprevention by rofecoxib, *Apc*$^{\Delta}$*716* mouse, 1733
**Polypropylenimine tetrahexacontaamine dendrimer-(1B4M-Gd)$_{64}$**
DAB-Am64-(1B4M-Gd)$_{64}$, 4966
**Polysialic acid**
expression, resected non-small cell lung cancer, 1666
**Polyunsaturated fatty acids**
n-3
tumor growth inhibition, 1386
**Positional scanning synthetic combinatorial peptide libraries**
recognition by Melan-A-specific CTLs, 5153
**Positron emission tomography**
combined with pretargeted immunoscintigraphy, breast cancer, 3712
[$^{18}$F]FdUrd tracer, *in vivo* evaluation, 3853
$^{18}$F-labeled choline
prostate cancer imaging, 110
transgene expression imaging, 2983
$\alpha_v\beta_3$ integrin expression imaging, 1781
**Precancer**
latent
endometrium, molecular identification, 4311
oral
EGFR-targeted immunophotodiagnosis and photoimmunotherapy, 4490
**Preinvasive mammary tumors**
proliferative
ERβ expression, 2537
**Premalignancy**
colon carcinogenesis, rat, 1874, 7699
gastric cancer
CpG island methylation, 2847
mammary disease
transgenic *PyV-mT* mouse model, 8298
obesity-related hepatic steatosis, 5016
**Preneoplastic foci**
clonal growth model, 1879
**Primitive neuroectodermal tumors/medulloblastoma**
CCI-779 antitumor activity, 1527
**Procainamide**
prostate cancer treatment, 8611
**Prodrugs**
adenovirus-directed enzyme prodrug therapy
rCE and CPT-11, neuroblastoma purging, 5083
doxorubicin
extracellularly tumor-activated, 2843
sulfonylhydrazine
101M, antineoplastic activity, 3033
**Progesterone**
receptor, prostate cancer, 1919
receptor A, endometrioid cancer, 4576
receptor B
endometrioid cancer, 4576
gene *PRB* inactivation
and CpG hypermethylation, endometrial cancer, 97
**Progestins**
effects
hormone-responsive murine mammary ductal carcinoma cells, 293
**Prolactin**
16K hPRL
tumor growth inhibition, colon cancer, 7356
phosphorylated
prostate cancer inhibition, 6098
**Proliferative preinvasive mammary tumors**
ERβ expression, 2537
**Proline oxidase**
reactive oxygen species generation, 1810
**Promoter I.3**
aromatase activity
downregulation by SnaH, breast tissue, 1338
**Prostaglandin $E_2$**
colon cell invasiveness model, 81
phorbol ester-induced production
inhibition by curcumin metabolites, 1058
**Prostanoid-related anorexia**
brain cytokine and, 4707
**Prostate**
atrophy, proliferative inflammatory
COX-2 upregulation, 8617
epithelial cells
hormonal carcinogenesis model, 6064
malignant transformation, 8135
androgen activity, 5038
cadmium-induced, 455
TMPRSS2 protease cleavage and secretion, 1686
epithelium
*PSDR1* expression, 1611
estrogen imprinting mediation by ERα, 6089
fibroblasts
prostate cancer-derived TGF-β1 and versican levels, 926
malignancy
choline compound increase, 3599
Notch expression, murine, 7291
**Prostate adenocarcinoma**
endostatin polymorphism and, 7375
LPB-*Tag* transgenic mice, 2239
**Prostate apoptosis response-4 (*Par*-4) gene**
Fas and FasL regulation, 7255
**Prostate cancer**
adenovirus-mediated Bax overexpression, 186
advanced
*MKK4* expression and histological pattern, 2833
*AIPC* expression, 2390
androgen-dependent, transgenic rats, 4693
androgen-independent
IGF-I and IGF-IR expression and, 6276
androgen receptor activation by glucocorticoids, LNCaP cells, 8712
angiogenesis and, 2736
annexin II expression loss, 6331
apoptosis
Apo-2L/TRAIL-induced, enhancement by paclitaxel, 759
blockade by androgen, 5611
apoptosis resistance
p21$^{WAF1}$ silencing androgen receptor and, 7544
*AR* gene amplification and overexpression, 3550
BCL-$X_L$ overexpression, 1699
E-cadherin truncation and inactivation, 489
camptothecin-resistant
R364H top1 mutation, 1964
caspase-8 activation by sulindac sulfide, 6918
caspase-dependent anoikis induction by methyl selenium, 3062
caspase-1 expression loss, 1227
caspase-3 expression loss, 1227
caveolin-1 effects, 4386
caveolin-1 secretion, 3882
cell adhesion
T antigen, 4851
centrosome defects, 2212
claudin expression, 7878
COX-2 expression and TNF-α responses, 2720
death receptor 5, 6918
death receptor expression, 7179
epithelium and stroma AR expression
prognostic value, 423
ER-β expression loss, 5331
familial
*HPC2/ELAC2* loss of heterozygosity, 8651
novel human cell culture model, 5969
gene expression profiling, 4683, 5974
genes differentially expressed, serial analysis of gene expression, 4283
genes overexpressed
identification, TRAMP mice, 5857
growth inhibition
arsenic trioxide, 5432
bisphosphonate, 2602
combination phenylbutyrate and 13-*cis* retinoic acid, 1477
EB1089, 4294
25-hydroxyvitamin $D_3$, 2852
15S-HETE, 497
vitamin D
mediation by p21, 7122
growth regulation
restoration by androgen receptor, 7310
*GSTP1* gene inhibition by methylation, 4820
heat-activated transgene expression, 1113
hepsin expression, 5692
hereditary
*HPC/ELAC2*, 6494
Finland, 6038
hormone-independent
adrenomedullin expression and peptidylglycine α-amidating monooxygenase, 1196
*HPC/ELAC2* loss of heterozygosity, 8651
*HPC/ELAC2* polymorphisms, 4982
iCaspase-9 therapy, 6795

ICER expression, 6055
inducible caspase treatment, 2562
inhibition by phosphorylated prolactin, 6098
kinase inhibitors and, 7408
locally recurrent
CV706 treatment, phase I trial, 7464
metastasis
inhibition by *MKK4*, 2833
inhibition by SSeCKS, 5644
metastasis to bone
NOD/SCID-hu mouse model, 2177
systemic replication-competent Ad-OC-E1a gene therapy, 6012
mismatch repair defects, 4112
mitogen-activated protein kinase phosphorylation, 6060
osteoblast interactions, 5652, 6372
PET imaging
$^{18}$F-labeled choline, 110
prevention by genistein, mice, 6777
procainamide treatment, 8611
PSCA expression, 3256
radical-induced DNA damage and, 6025
recurrent
androgen receptor coactivators, 4315
androgen receptor stabilization, 2892
risk
VDR polymorphisms, IGFs, and, 4333
selenium redox effects, 7071
serum F-PSA precursor forms, 957
serum truncated [-2]pPSA, 6958
steroid receptors, 1919
TARP expression effects, 8122
telomerase regulation, 4791
TGF-$\beta$1
stromal versican levels and, prostate fibroblasts, 926
TMPRSS2 protease cleavage and secretion, 1686
TNF-$\alpha$ pro- and antiapoptotic signals, 2713
TRAIL pathway member expression, 7179
*Trp-p8* upregulation, 3760
tumor growth
hyaluronan synthase 3 and, 5207
*uPA* gene amplification, 5340
VEGF and bFGF levels, 2533
**Prostate carcinogenesis**
chromosomal aneuploidy, 8143
**Prostate short-chain dehydrogenase reductase 1**
expression, prostate epithelium, 1611
**Prostate-specific antigen**
free, precursor forms
serum, prostate cancer, 957
promoter
coexpression with partial androgen receptor, gene therapy, 1276
PSA$^+$ CV787
synergy with paclitaxel and docetaxel, 517
-selective oncolytic adenovirus CV706
phase I trial, prostate cancer treatment, 7464
truncated [-2]pPSA
serum, prostate cancer, 6958
**Prostate-specific membrane antigen**
anti-PSMA J591 $\alpha$-irradiation
LNCaP spheroid effects, 2008
serum
SELDI immunoassay, 6029
**Prostate stem cell antigen**
expression, prostate cancer, 3256
overexpression
pancreatic cancer, 4320
transitional cell carcinoma, 4660
**Prostate tumorigenesis**
Notch expression, murine, 7291
**Prostate tumors**
cell killing by H-3Glu$_2$ peptide, 6783
**Prostatic acid phosphatase**
T helper epitopes, identification, 5161
**Prostatic hyperplasia, benign**
gene expression profiling, 4683
**Prostein**
identification and characterization, 1563
**Protease**
gene therapy enhancement, glioblastoma, 1805
**Protease-activated receptor-1**
$G_i$ signaling
breast cancer cell invasion inhibition, 5933
**Proteasome**
adriamycin-proteasome complex
nuclear translocation, 2467
**Proteasome inhibitor PS-341**
CPT-11 chemosensitivity augmentation, 3535
myeloma therapy, 3071
**Protein**
microarrays
cancer cell profiling, 7585
plasma
smokers and lung cancer, 778
transduction domains
synthetic, 474
**Proteinase**
stimulation by ET-1, ovarian cancer, 8340
**Protein gene product 9.5**
autoantibodies, lung cancer, 7908
**Protein kinase B**
Akt/PKB
activation by KSHV-GPCR, 2641
activity, non-small cell lung cancer, 3986
and COX-2 mRNA stability, 2670
**Protein kinase C**
$\beta_1$ integrin-mediated collagen IV adhesion, breast cancer, 2445
inhibitor PKC412
radiosensitization mechanism, 732
**Protein kinase C$\alpha$**
signaling, glioma, 4612
**Protein kinase C$\beta$II**
elevated levels, early colon carcinogenesis, 1375
**Protein kinase C$\delta$**
epidermal $\alpha 6\beta 4$ regulation, 4591
signaling, glioma, 4612
**Protein kinase C$\epsilon$**
transgenic mice
metastatic squamous cell carcinoma, 808
**Protein X**
Nip3-like
expression, tumors, 6669
**Proteolysis**
and STAT transcription, acute myeloid leukemia, 1747
**Proto-oncogenes**
silica-induced, 1791
**Protoporphyrin IX**
colorectal cancer, 991
**pS2**
regulation by ERR family, 6755
**PS-341**
myeloma therapy, 3071
***Pseudomonas* exotoxin A**
IL13-PE38QQR
antitumor activity, head and neck cancer, 6194
***PTEN***
cell cycle arrest, endometrial carcinoma, 4569
cell growth arrest
p27$^{KIP1}$ requirement, 2105
endometrial cancer
gene expression profiles, 3741
endometrial precancer
latent, 4311
MAGI-2 binding
regulation by phosphorylation sites, 4985
**Pulmonary adenocarcinoma:** *See* **Lung adenocarcinoma**
**Pulmonary fibrosis**
idiopathic
*FHIT* gene alterations, 8527
***N*-(Pyridin-4-yl)-[1-(4-chlorbenzyl)-indol-3-yl]-glyoxyl-amid:** *See* **D-24851**
**Pyruvic acid**
angiogenesis stimulation, 3290


**R**


**R115777**
antitumor effects, 131
**Rad**
breast cancer regulation, 2062
**Rad17**
human hRad17
phosphorylation and overexpression, non-small cell lung cancer, 7417
**Rad23**
human hHR23A
*p53* regulation, 64
***RAD50***
human *hRAD50*
frameshift mutations, gastrointestinal carcinoma, 36
**Rad54**
human hRAD54
SCID/RAD54$^{-/-}$ cells, defects, 2649
**Radiation**
$\alpha$-irradiation
LNCaP spheroid effects, 2008
autophagy and acidic vesicle response, cancer cells, 439
blood-spinal cord barrier breakdown
hypoxia, 3348
cell death
MnSOD protection against, hepatocellular carcinoma, 5382
glioma cell motility effects, 2744
$G_2$-M arrest
CDC25B and, esophageal cancer, 3188
ionizing
CNS radioresponse
TNF signaling and, 8859
low-dose
cell proliferation and MAPK activation, diploid cells, 5396
mammary tumorigenesis, p53-deficient mice, 6577
and mitochondria, 3894
mutagenesis, MMR-deficient mice, 3775
ultraviolet
BRCA2 protein depletion, 2838
loss of heterozygosity, lymphoid cells, 1129
metastatic growth stimulation, mice, 2207
mitotic recombination, 1129
oncogenesis
*ATM* heterozygotes, 5710
replication protein A phosphorylation, 8554
resistance
promotion by Akt/PKB, non-small cell lung cancer, 3986
Ras pathway, 4278
reversal by Flk-1 inhibition, 2413
response
cDNA array assessment, head and neck squamous cell carcinoma, 2376
**Radical-induced DNA damage**
and prostate cancer, 6025
**Radioimmunotherapy**
$\alpha$-radioimmunotherapy

locoregional
$^{213}$Bi-labeled MAb, 2804
combined with combrestatin A-4 3-*O*-phosphate, colorectal xenografts, 4716
combined with topotecan, breast cancer, 2996
murine HSCT models, 5126
**Radiosensitivity**
*HDGF* and, esophageal cancer, 5714
**Radiosensitization**
gemcitabine, 1585
p38, HeLa cells, 7689
PKC412, mechanism, 732
telomere length abnormalities, mammalian cells, 912
**Radiotherapy**
combined with anti-VEGFR2 mAb DC101, tumor xenografts, 39
combined with bleomycin
resistance by Ape1/ref-1, germ cell tumors, 2220
combined with CV706, antitumor effects, 5453
HIF-1a and HIF-2a and, esophageal cancer, 1830
HIF-1$\alpha$ expression, oropharyngeal cancer, 2911
**Raf**
transformation
c-Myc downregulation effects, 1178
IL-1 requirement, 602
**RAF1**
copy number alterations, bladder cancer, 4514
**Rapamycin**
$G_1$ arrest and cell response, 3373
***Ras***
active
cRaf-BRaf heterodimerization, 3595
HIF-1$\alpha$/2$\alpha$ and VEGF expression effects, 7349
kinase suppressor
and cell fate, 8668
ERK/MAP kinase regulation, intestinal epithelial cells, 963
radiation resistance pathway, 4278
Ras-Erk1/2 signaling inhibitors
ETV6-NTRK3 transformation blockade, 8909
risk-stratification model, non-small cell lung cancer, 2500
transformation
c-Myc downregulation effects, 1178
**Ras association domain family *RASSF1A***
hypermethylation
breast cancer, 3105
nasopharyngeal carcinoma, 3877
inactivation
bladder cancer, 6688
clear cell and papillary renal cell carcinoma, 7277
gastric adenocarcinoma, 7034
**RasGRP3**
modulation by phorbol esters, 943
**Ras•GTP**
isotype-specific levels, astrocytomas, 4425
**Raspberries**
esophageal tumorigenesis chemoprevention, 6112
**Reactive oxygen species**
generation by proline oxidase, 1810
ionizing radiation-induced mitochondria-dependent generation, 3894
**Receptors**
activator of NF-$\kappa$B Fc fusion protein RANK.Fc
hypercalcemia blockade, humoral hypercalcemia of malignancy, 2572
$\beta$-adrenoceptor antagonists
NE-induced cell migration blockade, SW 480 colon cancer cells, 2866
Ah
NMT-2 mRNA induction, 8534
androgen
activation by glucocorticoids, LNCaP cells, 8712
*AR* gene, and breast cancer, 5869
expression, prostate cancer, 1919
expression, prostate cancer epithelium and stroma, 423
growth regulation restoration, prostate cancer, 7310
and ovarian cancer susceptibility, case series, 908
partial, coexpression with PSAP, gene therapy, 1276
$p21^{WAF1}$ silencing
and apoptosis, prostate cancer, 7544
stabilization, recurrent prostate cancer, 2892
transcriptional inhibition by SMAD3, 2112
aryl hydrocarbon
modulation by dibenzoylmethane, 3919
cannabinoid $CB_2$
glioma growth inhibition, 5784
coxsackievirus and adenovirus
deficiency, and replicating adenovirus potency, 813
growth-inhibitory effects, colon cancer, 6592
death
CD95, restricted triggering by bispecific antibodies, 1846
expression, prostate cancer, 7179
VEGF-triggered, 8629
death 4
expression, Ewing's sarcoma, 2704
induction by paclitaxel, prostate cancer, 759
death 5
activation by sulindac sulfide, colon and prostate cancer, 6918
expression, Ewing's sarcoma, 2704
induction by paclitaxel, prostate cancer, 759
decoy 3
expression, malignant glioma, 2759
epidermal growth factor
activated ERK1/2 and, head and neck squamous cell carcinoma, 6500
anti-EGFR therapy, resistance, 5090
anti-EGFR therapy combined with TNF-$\alpha$, solid tumors, 1045
$\Delta$EGFR, anti-$\Delta$EGFR 806, growth inhibition, 5355
$\Delta$EGFR-expressing glioblastoma, mAb treatment, 5349
HPV16-mediated transformation, 3837
inhibitors
HER2 blockade, breast cancer, 8887
novel dual ErbB-2/EGFR tyrosine kinase inhibitor, characterization, 7196
and p53, glioblastoma, 1122
RXR-selective modulation, head and neck squamous cell carcinoma, 5919
signaling-inactive, ligand binding, 5790
-targeted oncolytic adenovirus, 6377
epidermal growth factor, human 1: *See* **HER-1**
epidermal growth factor, human 2: *See* **HER-2**
ErbB3
p85-sErbB3, heregulin-induced ErbB3 activation inhibition, 4467
estrogen
associated gene expression patterns, breast cancer, 5979
*CGA* overexpression, breast cancer, 1652
expression, prostate cancer, 1919
HER2 amplification and hormonal antiproliferative effects, breast cancer, 8452
quantification by DNA affinity immunoblotting, 5402
selective estrogen receptor modulators
arzoxifene, breast cancer chemoprevention, 8412
ER silencing and reactivation, 3632
personal perspective, 5683
silencing and reactivation by SERMs, 3632
estrogen $\alpha$
estrogen prostate imprinting mediation, 6089
IGF activity control, MCF-7 cells, 5771
modulation, intestinal tumorigenesis, 2547
estrogen $\beta$
expression, colon cancer, 632
expression, modulation, intestinal tumorigenesis, 2547
expression, proliferative preinvasive mammary tumors, 2537
expression loss, prostate cancer, 5331
fibroblast growth factor
and tumor growth, glioma, 1717
fibroblast growth factor 1
copy number alterations, bladder cancer, 4514
syndecan-1 complex, 5295
fibroblast growth factor 3
*ETV6* fusion, peripheral T cell lymphoma, 8371
mutations, superficial bladder cancer, 1265
glucocorticoid
splice variant, hematological malignancy, 3937
insulin-like growth factor I
Akt cell survival pathway, inhibition by NEP, 3294
ER-negative breast cancer, 6747
expression, androgen-independent prostate cancer, 6276
upregulation by AKT, pancreatic cancer, 589
interleukin 4
expression, brain tumors, 8058
interleukin 13 $\alpha$
tumor-asociated protein, malignant glioma, 5660
KSHV-GPCR
cell survival promotion, 2641
nerve growth factor
expression, breast cancer, 4337
neuropeptide Y
breast cancer, 4636
neurotrophin
chimeric ETV6-NTRK3 transformation blockade by signaling inhibitors, 8909
orphan nuclear
ERR family
pS2 regulation, 6755
oxytocin
tumors, radioligand, 4393
PAR1
$G_i$ signaling, breast cancer invasion inhibition, 5933
platelet-derived growth factor
hypoxia activation, GSK-3 inactivation, 2429

inhibition, tumoral interstitial hypertension reduction, 2929
PPAR-α ligand
colitis and aberrant crypt foci inhibition, 2424
PPAR-γ
activation by 15S-HETE, prostate cancer, 497
PPAR-γ ligand
colitis and aberrant crypt foci inhibition, 2424
progesterone
expression, prostate cancer, 1919
progesterone A, endometrioid cancer, 4576
progesterone B
endometrioid cancer, 4576
*PRB* inactivation, and CpG hypermethylation, endometrial cancer, 97
recombinant
T-cell activation, 1976
retinoic acid α
and cell proliferation, lung cancer, 556
retinoic acid γ
and cell proliferation, lung cancer, 556
paclitaxel resistance and, ovarian carcinoma, 7552
retinoid
and cell proliferation, lung cancer, 556
retinoid X
and cell proliferation, lung cancer, 556
EGFR modulation, head and neck squamous cell carcinoma, 5919
retinoid X α
phosphorylation, hepatocellular carcinoma, 7675
soluble SNAREs
expression, small cell lung cancer, 2138
steroid, prostate cancer, 1919
T-cell
MDA-reactive T-cell usage, stage IV melanoma, 493
TCRβ gene rearrangements, *scid* thymocytes, 6382
TCRβ$^{-/-}$ p53$^{-/-}$ mice, colon cancer, 2390
TGF-β type I
6(A) polymorphism, Macedonian colorectal cancer, 8351
TGF-β type I(6A)
colorectal cancer association, 8351
TGF-β type II
gene-dosage effects, hepatocellular carcinogenesis, 6665
gene expression
Sp1 requirement, pancreatic cancer, 6239
induction by MS-275, breast cancer, 931
mutations, recurrent breast cancer, 482
*TRAIL-R1* and *TRAIL-R2*
mutations, metastatic breast cancer, 4942
tumor necrosis factor
R1 chimeric, antitumor activity, melanoma, 1050
transcriptional profiling, 433
urokinase plasminogen activator
regulation by heregulin, 400
VEGF
bifunctional anti-VEGFRs diabody
VEGFR inhibition, 7002
endothelial apoptosis stimulation, 8629
inhibition by bifunctional diabody, 7002
VEGFR-1
pathological angiogenesis, 1207
VEGFR-2
anti-VEGFR2 mAb DC101, combined with radiation therapy, tumor xenografts, 39
vitamin D
polymorphisms, and prostate cancer risk, China, 4333
**Rectal carcinoma**
tumor microcirculation assessment by dynamic MRI, 2513
**Recurrence**
local
inhibition by sFlt-1 fibroblasts, 7840
**Redox**
PAI-1 regulation, 5537
proliferation and apoptosis control
NF-κB, 2656
selenium effects, prostate cancer, 7071
**Reduced folate carrier**
human
localization, leukemia, 1941
**ref-1:** *See* **Ape1/ref-1**
**Renal cell carcinoma**
CD8+ T cell proliferative activity, 5132
clear cell
cytogenetic findings, prognostic impact, 7731
*RASSF1A* 3p21.3 gene inactivation, 7277
growth inhibition by VHL peptide β-domain, 1768
HIF-1α activation, 5215
HLA-G expression, 6838
induction by streptozotocin, mouse, 6255
invasion
inhibition by VHL peptide β-domain, 1768
papillary
*RASSF1A* 3p21.3 gene inactivation, 7277
papillary, childhood
*RCC17/TFE3* fusion gene, 4130
*RCC17/TFE3* fusion gene, childhood papillary carcinoma, 4130
retinyl esters and vitamin A levels, 2774
RNA-transfected dendritic cells, tumor vaccine, 3388
specific T-cell response, 3240
tumor vaccine, generation, 7925
VEGF-B and VEGF-C expression, 3206
*VHL* and *FHIT* loss of heterozygosity, 4815
**RenCa cells**
telomerase inhibition, 5580
**Replication protein A**
radiation-induced phosphorylation, 8554
**Respiration**
inhibition, low pH-adapted cells, 5630
**Resveratrol**
apoptosis, acute lymphoblastic leukemia, 4731
cytostatic and antiestrogenic properties, endometrial adenocarcinoma, 6137
p53 activation and apoptosis induction, 1604
properties, mammary tumors, 7456
**RET**
oncogenic
NF-κB activation, 4526
**Retinoblastoma**
apoptosis
p53 and p21$^{waf-1}$ expression and, 3157
protein
C domain
cyclin D1/cdk4 binding site, 2885
deficiency
doxorubicin sensitivity, enhancement by flavopiridol, sarcoma, 2579
downstream Apaf-1 roles, 8395
protein *Rb2/p130*, 4651
mutations, nasopharyngeal carcinoma, 5950
VEGF downregulation and angiogenic inhibition, 462
Rb-interacting zinc finger *RIZ1*
tumor suppressor gene therapy, colorectal cancer, 1796
somatic growth regulation, mouse development, 3110
**Retinoic acid**
production by aldehyde dehydrogenase 6, breast epithelium, 7065
receptor α
and cell proliferation, lung cancer, 556
PML/RARα expression
inhibition by peptide nucleic acid, acute promyelocytic leukemia, 5468
receptor γ
and cell proliferation, lung cancer, 556
paclitaxel resistance and, ovarian carcinoma, 7552
signaling restoration by HDAC-targeted treatment, acute myeloid leukemia, 2
*Stra6* induction, 4197
**all-*trans*-Retinoic acid**
combined with CBHA
growth inhibition, neuroblastoma, 3591
metabolites
granulocytic differentiation, NB4 promyelocytic leukemia cells, 700
**13-*cis* Retinoic acid**
combined with phenylbutyrate, prostate cancer, 1477
**Retinoid ligands**
combined with Taxol, 8703
**Retinoid receptors**
and cell proliferation, lung cancer, 556
nuclear, skin squamous carcinogenesis, 4306
**Retinoid-related molecules**
apoptosis
JNK/p38 MAP kinase activation, 8504
**Retinoid X**
receptor
and cell proliferation, lung cancer, 556
EGFR modulation, head and neck squamous cell carcinoma, 5919
receptor α
phosphorylation, hepatocellular carcinoma, 7675
**Retinyl esters**
levels, renal cell carcinoma, 2774
**Retrogen strategy,** 197
**Retroviral tumor-associated antigens**
endogenous
immunization, 7920
**Retrovirus**
breast cancer sequences, 1754
scFv antibody to CEA
targeted CEA-expressing cell killing, 370
**Ret tyrosine 1062**
phosphorylation, MEN2B, 1426
**RGD-containing glycopeptide**
$^{18}$F-labeled
$\alpha_v\beta_3$ integrin expression imaging, 1781
**RGD-tachyplesin**
tumor growth inhibition, 2434
**Rhabdomyosarcoma**
adenovirus oncolysis, 2953
**Ribonucleoprotein B1**
heterogeneous nuclear
early lung cancer biomarker, 1896
**Ribozyme**
telomerase mRNA cleavage, breast epithelial cells, 3053
**RIF-1 tumors**
cyclophosphamide therapy
early response, monitoring, 7747
**Rituximab**
STAT3 inhibition, B-non-Hodgkin's lymphoma, 5137
***RIZ1***
hypermethylation, cancers, 8094
**ROC-cullin ligases**
E2F1 ubiquitination, 1347

**Rofecoxib**
intestinal polyposis chemoprevention, *Apc*$^{\Delta}$*716* mouse, 1733
**RRR-α-tocopheryl succinate:** *See* **Vitamin E succinate**
**Runt-related gene 2**
endothelial cell migration regulation, 4994

S

**S100A2**
expression, early stage lung carcinogenesis, 7999
***Saccharomyces cerevisiae***
cisplatin-induced cell kill
*SKY1* effects, 6982
**Saliva**
*p16, MGMT,* and *DAP-K* promoter hypermethylation patterns, head and neck squamous cell carcinoma, 939
**Sarcoma**
Ewing's
anticancer drug sensitization by *E1A,* 3394
death receptors 4 and 5 expression, 2704
EWS
protein loss, Ewing tumor, 5992
transcriptional activation, 2690
EWS/Fli-1
COOH terminus, transformation requirement, 5311
YB-1 functional interference, 3586
TRAIL sensitivity, 2704
Kaposi's
angiostatin gene transfer, 5441
growth inhibition by *N*-acetylcysteine, 8171
Rb-deficient
doxorubicin sensitivity, enhancement by flavopiridol, 2579
replication-competent HSV vector targeting, 3969
**Sarcoma-associated chromosomal translocations**
fusion proteins
tumor antigens, 6868
**SCH66336**
P-glycoprotein inhibition, 7525
**SCH221153**
angiogenesis and tumor growth inhibition, 2232
**Schwannian cells**
neuroblastoma, 6892
**Scintimammography**
Tc-MIBI
Pgp/MRP expression and, 1412
**Scirrhous breast cancer**
caveolin-1 mutations, 2361
**Scirrhous gastric cancer**
metastasis
gene expression profiles, 889
**Secondary ion mass spectrometry ion microscopy**
quantitative boron-10 imaging, brain tumors, 8179
**Secondary lymphoid organ chemokine**
antitumor response, spontaneous murine lung cancer model, 6406
**Secondary lymphoid tissue chemokine**
T cell-dependent antitumor immunity, 2062
**SELDI:** *See* **Surface-enhanced laser desorption/ionization**
**Selective estrogen receptor modulators**
arzoxifene
chemoprevention, breast cancer, 8412
estrogen receptor silencing and reactivation, 3632
personal perspective, 5683
**Selenium**
apoptosis
and stress kinases, oral carcinoma, 7479
redox effects, prostate cancer, 7071
**Selenomethioninase**
rAdMET-SeMET gene therapy, 6805
**Self-deleting suicide vectors,** 6925
**Self-tumor transgenes**
adoptive immunotherapy, 3077
**Seminomatous tumors**
GDNF-overexpressing mice, 3267
**Senescence gene**
chromosome 10p14–p15 locus, 7118
***Sep15***
gene polymorphisms, distribution and function, 2307
**SEREX:** *See* **Serological identification of tumor antigens by cDNA expression cloning**
**Serial analysis of gene expression**
breast cancer progression, 5697
genes differentially expressed, prostate cancer, 4283
**Serine/arginine-rich protein-specific kinase from budding yeast *SKY1***
cisplatin-induced cell kill, *S cerevisiae,* 6982
**Serine/arginine-rich protein-specific kinase *SRPK1***
inactivation
cisplatin resistance induction, ovarian cancer, 6982
**Serine palmitoyltransferase**
activation by 4-HPR, neuroblastoma, 5102
**Serological analysis of recombinant cDNA expression libraries**
cytokine-assisted SEREX
tumor growth inhibition, rat 9L glioma, 2625
**Serological identification of tumor antigens by cDNA expression cloning**
melanoma antigen isolation, 7900
**Serous borderline ovarian tumors**
K-*ras* and *p53* mutations, 7264
**Serum**
F-PSA precursor forms, prostate cancer, 957
methylated *hMLH1,* colon cancer, 900
PSMA, SELDI immunoassay, 6029
truncated [-2]pPSA, prostate cancer, 6958
**Serum deprivation response factor (*s*dr)-*r*elated gene product that *b*inds to *c*-kinase *(SRBC)***
human *hSRBC*
inactivation, breast and lung cancer, 7943
**Sex differences**
microsatellite instability, colon cancer, 126
**α2,6-Sialylation**
glioma formation inhibition, 6822
**Sialyltransferase CMP-sialic acid: Galβ1,3GalNAc-Rα6-sialyltransferase**
overexpression, colorectal cancer, 4605
**Signal transducers and activators of transcription**
STAT3
inhibition by rituximab, B-non-Hodgkin's lymphoma, 5137
STAT5, nucleophosmin/anaplastic lymphoma kinase transformation, 6517
STAT3B-induced soluble factors
growth inhibition, 3276
truncated
proteolytic activity and, acute myeloid leukemia, 1747
**Silica**
proto-oncogenes, 1791
**Simian virus 40 large T antigen**
HLA-A2.1-restricted specific CTLs, 873
methylation and, malignant mesothelioma, 5727
*mlt 1* silence by methylation, transgenic mice liver tumors, 1144
**SIMS:** *See* **Secondary ion mass spectrometry**
**Singapore Chinese women**
breast cancer risk, 3326
**Single nucleotide instability**
breast cancer, 7739
rat mammary carcinoma, 2632
**Single nucleotide polymorphisms**
MMP-1 promoter
and lung cancer susceptibility, 7825
**Skeletal muscle protein**
catabolism
eicosapentaenoic acid, cancer cachexia, 3604
**Ski**
overexpression, cutaneous melanoma, 8074
**Skin**
transgenic antizyme expression, mouse, 6073
**Skin carcinogenesis**
FAK gene dosage effects, mouse, 8385
MnSOD expression, multistage model, 6082
squamous
retinoid receptors, 4306
susceptibility
GM-CSF and, 2311
UVB-induced
inhibition by tea/caffeine, 5002
**Skin tumorigenesis**
JNK2-deficient mice, 3908
**Skin tumor modifier loci**
epistatic interactions, interspecific backcross mice, 1305
**SK-MEL-28 cells**
polyamine analogue apoptotic signaling, 6437
**SMAD3**
androgen receptor-mediated transcription inhibition, 2112
**Smad4**
-mutant colon adenoma
growth inhibition by TGF-β, 256
**Small cell lung cancer**
apoptosis mediation by $G_{D2}$, 4244
cell proliferation enhancement by $G_{D2}$, 4244
growth inhibition by novel indolinone Kit inhibitors, 3660
Notch effects, 3200
SNAREs and VMATs, 2138
**Smoke**
exposure
biomarkers and chemopreventives, rats, 2472
tobacco
exposure
$p16^{INK4A}$ and histology-specific methylation, non-small cell lung cancer, 3419
**Smokers**
chromosomal alterations, lung adenocarcinoma, 1309
**Smoking**
age of initiation
chromosome 3p21 loss, lung cancer, 612
chromosome 9p21 loss of heterozygosity, non-small cell lung cancer, 2092
and colorectal adenoma risk, 2381
lung cancer
*p53* mutations, ex-smoker women, 4350
plasma proteins, 778
**SN-38:** *See* **7-Ethyl-10-hydroxycamptothecin**
**Snail**
aromatase promoter I.3 activity downregulation, breast tissue, 1338
**Sodium-23**
single-quantum- and triple-quantum-filtered NMR

BCNU effects, 9L glioma, 2002
**Soft-tissue tumors**
genotype-phenotype association model, 3171
**Solid-pseudopapillary neoplasms**
pancreatic
$\beta$-catenin point mutations, 8401
**Solid tumors**
anti-EGFR and TNF-$\alpha$ therapy, 1045
chemotherapy delivery detection by MR, 3039
infarction
mediation by targeted tissue factor delivery to fibronectin ED-B domain, mice, 711
novel antibody target, 4048
pediatric
dendritic cell vaccination, 8513
midkine promoter-based replicative adenovirus treatment, 7882
proapoptotic peptide treatment, 7709
thermal targeting of elastin-like polypeptides, 1548
troxacitabine uptake and resistance, 7217
**Soluble factors**
STAT3B-induced
growth inhibition, 3276
**Soluble *N*-ethylmaleimide-sensitive factor attachment protein receptors**
expression, small cell lung cancer, 2138
**Somatic growth**
regulation by Rb, mouse development, 3110
**Somatic selection**
neoplastic development, 799
**Soybean peptide**
lunasin, chemopreventive property, 7473
**Soy protein**
and 17$\beta$-estradiol breast cancer tumor growth, 5045
**Sp**
*MUC2* promoter regulation, 570
**Sp1**
activity
and angiogenesis, pancreatic adenocarcinoma, 4143
TGF-$\beta$ RII gene expression and, pancreatic cancer, 6239
**Special recognition**
Jordan, V. Craig, 5954
**S-phase kinase-interacting protein 2**
expression, oral squamous cell carcinoma, 7044
**Sphingolipids**
$\beta$-catenin localization modulation, 6723
intestinal tumorigenesis modulation, 6723
**Spinal cord**
blood-spinal cord barrier
radiation-induced breakdown, hypoxia and, 3348
**Squamous carcinogenesis**
skin
retinoid receptors, 4306
**Squamous cell carcinoma**
epidermal
inhibition by suprabasal $\alpha3\beta1$ integrin expression, transgenic mouse model, 5248
esophageal
*cIAP1* amplification, 6629
genetic progression and heterogeneity, 4098
*ING1* genetic alterations, 4345
p53 mutations, northern Iran, 3119
growth inhibition
cables, 7325
head and neck
activated ERK1/2 and EGFR/TGF$\alpha$ signaling, 6500
carbonic anhydrase IX expression, 5262
chromosome 3q amplification, 4506
*CYP1B1* mutations, 4398
early, chromosomal alterations, 4122
EGFR signaling, RXR-selective modulation, 5919
IL-8 and VEGF expression, 5911
IL-13 toxin, antitumor activity, 6194
molecular cytogenetic characterization, 4506
*p16, MGMT,* and *DAP-K* promoter hypermethylation patterns, 939
p53 mutations, 4398
radiation response, cDNA array assessment, 2376
risk, *XPC* polymorphism and, 3321
tumor plasma DNA, 8595
metastatic, PKC$\epsilon$ transgenic mice, 808
molecular profiling, 4797
oral
collagen type 1 degradation, 6264
S-phase kinase-interacting protein 2 expression, 7044
**Squamous cell carcinoma antigen**
antisense
tumor growth inhibition, 1776
**Src kinase**
COOH-terminal Csk
tumor antigen, carcinoma, 1415
**SSeCKS**
metastasis inhibition, prostate cancer, 5644
**14–3–3$\sigma$**
downregulation, breast cancer, 76
**ST1481**
antitumor activity and pharmacological profile, 7189
**Staurosporine**
mitochondrial permeability transition induction, 2459
*N*-benzoylated
Akt survival pathway downregulation, 8203
**Steel factor**
and cell density-dependent growth, cervical cancer and leukemia, 6281
**Stem cell factor**
colorectal carcinoma
survival and invasion, 2200
**Stem cells**
hematopoietic
CD34+ cell-related enhanced tumor growth, non-Hodgkin's lymphoma, 7654
overproduction, colon cancer initiation, 8408
prostate stem cell antigen
expression, prostate cancer, 3256
**Steroid receptors**
prostate cancer, 1919
**ST6GalNAc-II:** *See* **Sialyltransferase CMP-sialic acid:Gal$\beta$1,3GalNAc-R$\alpha$6-sialyltransferase**
**STI571**
dermatofibrosarcoma inhibition, 5778
***Stra6***
induction by Wnt and retinoids, 4197
**Streptococcal antitumor glycoprotein**
effects, epidermoid carcinoma, 6151
**Streptozotocin**
renal cell carcinoma, mouse, 6255
**Stress**
genetic instability, cancer cells, 428
genotoxic
base excision repair modulation by p53, 88
oxidative
*Apex*$^{+/-}$ mouse model, 5552
ataxia telangiectasia, 1849
and frameshift mutations, colorectal cancer, 7444
and hepatitis C virus, mouse model, 4365
and microsatellite instability, 7444
MLH1 effects on response, 1392
**Stress kinases**
selenium-induced apoptosis and, oral carcinoma, 7479
**Stroma**
AR expression
prognostic value, prostate cancer, 423
breast
epithelial interactions, *in vitro* model, 1320
epithelial interactions, meeting report, 3844
neuroblastic and Schwannian cells, neuroblastoma, 6892
remodeling by TGF-$\beta$1, melanoma, 8306
versican levels
regulation by prostate cancer-derived TGF-$\beta$1, prostate fibroblasts, 926
**Stromal cell-derived factor-1**
mRNA levels
peripheral blood mononuclear cells, AIDS-related lymphoma children, 5028
**Stromal tumors**
gastrointestinal
KIT activation, 8118
*KIT* mutations, 8624
**Stromelysin-3**
novel cellular function, 2189
**SU6668**
and survival, colon cancer liver metastasis, 1464
**SU9516**
apoptosis induction, colon carcinoma, 6170
**Suberoylanilide hydroxamic acid**
and differentiation, breast cancer, 8492
**Suicide gene therapy**
*CD*
repeated gene transfer, 14
CEA-specific of CD/5-FC
enhanced by Cre/loxP, gastric carcinoma treatment, 6158
PSAP and ARf, prostate cancer, 1276
**Suicide lymphocytes**
GVHD control, murine model, 3355
**Suicide vectors**
self-deleting, 6925
**Sulfonylhydrazine prodrugs**
101M, antineoplastic activity, 3033
**Sulindac**
intestinal cell response
*p21*$^{WAF1/cip1}$ and, 6297
metabolites
ERK1/2 phosphorylation inhibition, 1541
**Sulindac sulfide**
combined with *S*-allylmercaptocysteine
antiproliferative effects, colon cancer, 725
death receptor 5 and caspase 8 activation, colon and prostate cancer, 6918
**Superficial bladder cancer**
gene expression patterns, 2492
**Superoxide dismutase**
manganese MnSOD
expression, multistage skin carcinogenesis model, 6082
**Suramin**
combined with paclitaxel, lung metastases, 6145
**Surface-enhanced laser desorption/ionization**
serum PSMA quantitation, 6029
**Surgery**
MRI-guided focused ultrasound, breast cancer, 8441
**Survivin**
CTL response, cancer, 869

immunogenicity, 5964
***SYK***
gene hypermethylation, breast cancer, 5558
**Synaptosomal-associated protein 25**
expression, small cell lung cancer, 2138
**Syndecan-1**
FGFR1 complex, 5295
**Synedecan-4**
tenascin-C functional interference, 8586
**Syntaxin1**
expression, small cell lung cancer, 2138
**Synthetic combinatorial peptide libraries**
positional scanning
recognition by Melan-A-specific CTLs, 5153
**Synthetic halichondrin B analogues**
anticancer activities, 1013
**Synthetic peptides**
tumor cell adhesion inhibition, 3308
**Synthetic p53 homologue CTS1**
cell kill, glioma, 5833
**Synthetic protein transduction domains,** 474

**T**

**Tachyplesin**
RGD-tachyplesin
tumor growth inhibition, 2434
**Taiwanese women**
nonsmoking
HPV 16/18 infection and lung cancer, 2799
**Tamoxifen**
antitumorigenicity
enhancement by 6-MCDF, 3902
apoptosis
promotion by p53 inactivation by E6, mammary epithelial cells, 616
NGF-induced proliferation inhibition, breast cancer, 3002
resistance
circumvention by GW5638, breast cancer, 2917
response
thymidine kinase and thymidylate synthase and, advanced breast cancer, 1421
short-term biological effects, postmenopausal breast cancer, 6739
**T antigen**
cell adhesion, breast and prostate cancer, 4851
expression, central nervous system tumors, 4287
HLA-A2.1-restricted specific CTLs, 873
*mlt 1* silence by methylation, transgenic mice liver tumors, 1144
**TARP:** *See* **T-cell receptor γ chain alternate reading frame protein**
**Taurolidine**
evaluation, 6816
***TAX-1***
expression, malignant glioma, 2162
**Taxanes**
antibody conjugates
specific targeting, 694
synergy with CV787, 517
**Taxol**
combined with selective retinoid ligands, 8703
convection-enhanced delivery
diffusion-weighted MRI monitoring, brain tumor, 4971
**TCDD:** *See* **2,3,7,8-Tetrachlorodibenzo-*p*-dioxin**
**T-cell factor**
β-catenin signaling
and colonic epithelial cell differentiation, 3465
hyperactive, targeting, colon cancer, 4445
**T-cell factor 4**
epithelial cell polarity restoration, colorectal cancer, 2744
metastasis-inducing DNA binding, 5619
**T-cell receptor γ chain alternate reading frame protein**
expression effects, prostate cancer, 8122
**T47D cells**
proliferation and migration
IL-6 effects, 383
**Tea**
tissue fat and UVB skin carcinogenesis inhibition, 5002
**Technetium-99m methoxyisobutylisonitrile scintimammography**
Pgp/MRP expression and, 1412
***TEL***
*PAX5* fusion, acute lymphoblastic leukemia, 4666
***TEL-AML1***
childhood acute lymphoblastic leukemia
RQ-RT-PCR, 2517
**Telomerase**
inhibition, murine RenCa cells, 5580
mRNA cleavage by ribozyme, breast epithelial cells, 3053
regulation, prostate cancer, 4791
-specific T cells, cancer, 8366
**Telomerase reverse transcriptase**
human *hTERT*
microsatellite mutations, 8405
mRNA levels
regulation, 7594
human *hTERT* promoter
regulation, ovarian epithelial cells, 5529
human hTERT promoter/rev-caspase-6 construct
gene therapy, malignant glioma, 5796
**Telomerase RNA gene**
human *hTERC*
promoter methylation, 27
**Telomeres**
length abnormalities, mammalian radiosensitive cells, 912
**Temozolomide**
$G_2$ checkpoint role, glioma treatment, 5843
p53 effects, glioblastoma treatment, 1957
TNP-470 interactions, 5491
**Tenascin-C**
synedecan-4 functional interference, 8586
**Teratocarcinoma**
α5-integrin-null, 5255
**N-Tes**
MT1-MMP inhibition, 8896
**Testican 3**
MT1-MMP inhibition, 8896
**Testicular cell transplantation**
and leukemia, 706
**Testicular germ cell tumors**
cyclins and CDKs, 4214
**1,4,7,10-Tetraazacyclododecane-*N,N',N'',N'''*-tetraacetic acid-Lys$^8$-vasotocin**
$^{111}$In-labeled, oxytocin receptor-positive tumors, 4393
**2,3,7,8-Tetrachlorodibenzo-*p*-dioxin**
apoptosis inhibition, MCF-10A cells, 3314
**Tetra-costimulators**
intratumoral protein transfer, 8127
**Tetracycline**
FGF2 expression and, 309
**12-*O*-Tetradecanoylphorbol-13-acetate**
AP-1 and MAP kinase activation, 4084
**Tetra-*O*-methyl nordihydroguaiaretic acid**
antitumor activity, 5499
**Tetraploid cells**
$G_1$ arrest
induction by $p21^{WAF1}$, colon cancer, 7660
**Tetraploidy**
regulation by cyclin B1, 6487
**Tetrasomy**
induction by HPV *E7*, keratinocytes, 4858
***TFE3***
*RCC17/TFE3* fusion gene, childhood papillary carcinoma, 4130
**Thermally targeted elastin-like polypeptides**
cellular uptake, 7163
**Thiazolidinediones**
translation initiation, 6213
**Think Tank**
White Paper, pancreatic cancer, 4923
**Thiopurine methyltransferase**
thiopurine effects, leukemia, 5810
**Thiopurines**
thiopurine methyltransferase effects, leukemia, 5810
**Thioredoxin**
expression, childhood T-cell acute lymphoblastic leukemia, 7333
**thioTEPA:** *See* ***N,N',N'''*-Triethylenethiophosphoramide**
**Thomsen-Friedenreich antigen**
cell adhesion, breast and prostate cancer, 4851
**Thomsen-Friedenreich glycotype**
colorectal cancer, 4605
**Thrombosis**
tumor blood vessel, mice, 711
**Thrombospondin-1 type 1 repeat proteins**
tumor growth inhibition, 7830
**Thymidine kinase**
advanced breast cancer, 1421
mutations, 3022
TK- and VGF-mutant vaccinia virus, gene therapy, 8751
**Thymidine phosphorylase**
induction by IFN-γ, 469
**Thymidines**
modulation, and TSI therapeutic efficacy, 3675
**Thymidylate synthase**
advanced breast cancer, 1421
5-FdUR-resistant $Arg^{50}$ loop mutants, 666
inhibitors
endogenous folates and thymidine and, 3675
resistance, cDNA array analysis, 5505
**Thymocytes**
apoptosis induction by 5-FU, mouse, 243
catalase-overexpressing
apoptosis resistance, 2766
*scid*
TCRβ gene rearrangements, 6382
**Thyroglobulin**
promoter
and TTF-1, thyroid cancer gene therapy, 3640
**Thyroid**
apoptosis induction by HMGA1 overexpression, rat, 4591
**Thyroid carcinogenesis**
ETS-1 and ETS-2 activity, 2267
**Thyroid carcinoma**
Akt overexpression and overactivation, 6105
gene therapy
thyroglobulin promoter and TTF-1, 3640
**Thyroid lymphoma**
*Fas* gene mutations, 1382
**Thyroid transcription factor 1**
and thyroglobulin promoter, thyroid cancer gene therapy, 3640
**Tin ethyl etiopurpurin I**
phototoxicity, mechanistic study, 717
**Tin octaethylbenzochlorin**
phototoxicity, mechanistic study, 717

**Tirapazamine**
aerobic exposure
mitochondrial effects, 145
DNA replication inhibition, 5425
**Tissue factor**
targeted delivery to fibronectin ED-B domain
solid tumor infarction mediation, mice, 711
**Tissue fat**
decrease by tea/caffeine, 5002
**Tissue inhibitor of metalloproteinase 2**
tumorigenesis and angiogenesis inhibition, mammary tumors, 3450
**Tissue inhibitor of metalloproteinase 4**
biochemical and cellular characterization, 3610
mammary tumorigenesis stimulation, 2365
**Tissue oxygenation**
and farnesyltransferase inhibitors, 2289
**Tissue oxygen partial pressure ($pO_2$)**
VEGF regulation, brain tumors, 6020
**T lymphocytes:** *See also* **Cytotoxic T lymphocytes**
activation
avipox-CEA/B7–1-infected dendritic cells, 7568
and costimulatory molecule hyperexpression, 3725
recombinant receptors, 1976
and tumor genetic programs, 3518
antimelanoma
activation by HSP70 peptide complexes, 222
antitumor immunity
secondary lymphoid tissue chemokine-mediated, 2062
CD4+
by-passing, 8787
CD8+
clonal expansion, 6860
prognostic value, esophageal carcinoma, 3932
proliferative activity, renal cell carcinoma, 5132
helper
gp100 epitopes, 7577
promiscuous epitope for MAGE-A3, 4773
prostatic acid phosphatase epitopes, identification, 5161
HLA-A*0201-restricted
melanoma antigen, identification by immunoselected tumor cell lines, 1089
inhibition by activated granulocytes, advanced cancer, 4756
leukemia, acute lymphoblastic
childhood
thioredoxin expression, 7333
leukemia/lymphoma, HTLV-1 carriers
TNF-α polymorphism, 3770
lymphoma, cutaneous
CD40/CD40L coexpression, 452
lymphoma, peripheral
*ETV6* to FGFR3 fusion, 8371
melanocyte differentiation antigen-reactive, stage IV melanoma, 493
pancreatic cancer cell recognition, 2038
receptor
MDA-reactive T-cell usage, stage IV melanoma, 493
TCRβ gene rearrangements, *scid* thymocytes, 6382
$TCR\beta^{-/-}$ $p53^{-/-}$ mice
colon cancer, 2390
receptor γ chain alternate reading frame protein
expression effects, prostate cancer, 8122
regulatory, early-stage non-small cell lung cancer and late-stage ovarian cancer, 4766
responses
extranodal priming, 8794
HER-2/*neu*-expressing tumor rejection requirement, 880
tumor-specific, renal cell carcinoma, 3240
type 1
genetic immunization with wild-type *p53* and Flt3L, 8227
**γδ T lymphocytes**
functional maintenance by caspase blockade, lymphoma, 3092
**TMPRSS2 protease**
catalytic cleavage and secretion, prostate cancer, 1686
**TNP-470**
temozolomide interactions, 5491
**Tobacco smoke**
exposure
$p16^{INK4A}$ and histology-specific methylation, non-small cell lung cancer, 3419
**Tongue cancer**
*FHIT* expression, prognostic value, 837
**Tongue carcinogenesis**
COX-2 expression, rat, 1451
**Topoisomerase inhibitors**
sensitization
ribozyme cleavage of telomerase mRNA, breast epithelial cells, 3053
**Topotecan**
combined with CI1033, 739
combined with radioimmunotherapy, breast cancer, 2996
**Toremifene**
genotoxicity, 3925
**Toxicity**
bone marrow
enhancement and protection, 7868
cyclophosphamide
anemia correction and, rat tumors, 1358
doxorubicin
age-dependent amifostine effects, rats, 6423
and cardiomyocyte apoptosis, 2335
inhibition by metallothionein, mouse, 3382
genotoxic stress
base excision repair modulation by p53, 88
NO tumor
inhibition by macrophage arginase, 1100
temozolomide-induced
$G_2$ checkpoint, glioma, 5843
thioTEPA
BER protection against, hematopoietic cells, 5116
toremifene genotoxicity, 3925
**Toxins**
IL-13, antitumor activity, 6194
***TP53***
alterations
and doxorubicin resistance, locally advanced breast cancer, 2505
mutations
*BRCA1/2*-related breast cancer, 4092
lung tumors, 6679
**TPA:** *See* **12-*O*-Tetradecanoylphorbol-13-acetate**
**Transcription**
androgen receptor-mediated
inhibition by SMAD3, 2112
HGF targets, 5861
**Transcriptional profiling**
TNF-R and Fas, 433
**Transcription factors:** *See also* ***specific factors***
liver-enriched
expression, hepatocellular carcinoma, 3176
Sp family
*MUC2* promoter regulation, 570
**Transforming growth factor α**
hepatocarcinogenesis
Bcl-2 and, 594
production
increase by TCDD, MCF-10A cells, 3314
signaling
activated ERK1/2 and, head and neck squamous cell carcinoma, 6500
**Transforming growth factor β**
androgen receptor cross-talk, 2112
growth inhibition, Smad4-mutant colon adenoma, 256
receptor type I
mutations, ovarian cancer, 4679
receptor type I(6A)
colorectal cancer association, 8351
Macedonian colorectal cancer, 8351
receptor type II
expression
induction by MS-275, breast cancer, 931
Sp1 requirement, pancreatic cancer, 6239
gene-dosage effects, hepatocellular carcinogenesis, 6665
mutations, recurrent breast cancer, 482
unresponsiveness, lung cancer, 8331
**Transforming growth factor β1**
desmoplasia, pancreatic cancer, 550
metastasis induction, papilloma, 7435
prostate cancer-derived
stromal versican levels and, prostate fibroblasts, 926
and survival, melanoma, 8306
transdifferentiation, pancreatic cancer, 4222
**Transgenes**
delivery
viral vectors, 5336
expression
PET-based imaging, 2983
heat-activated expression, prostate cancer, 1113
self-tumor
adoptive immunotherapy, 3077
**Transgenic adenocarcinoma mouse prostate mice**
genes overexpressed in prostate cancer, identification, 5857
**Transitional cell carcinoma**
bladder
IFN-α signaling, 2261
cytogenetic subgroups and karyotypic pathways, 8241
NY-ESO-1 expression, 4671
PSCA overexpression, 4660
**Translation**
initiation by thiazolidinediones, 6213
**Translocation liposarcoma protein TLS**
TLS/ERG fusion protein
YB-1 functional interference, 3586
**Transplacental chemical exposure**
and $MLL^{+ve}$ infant leukemia, 2542
**Transplantation**
bone marrow
GM-CSF tumor cell vaccine, 162
intracerebral IL-2-producing cells
combinatory immune gene therapy, glioma, 8769
testicular cell
and leukemia, 706

**Trastuzumab**
HER2 shedding inhibition, 4744
TRAIL-mediated apoptosis enhancement, breast and ovarian cancer, 4892
**Trichostatin A**
combined with 5-aza-dC
ER-α induction, breast cancer, 7025
embryogenesis effects, mouse, 1247
***N,N′,N′′*-Triethylenethiophosphoramide**
BER protection against, hematopoietic cells, 5116
**Triterpenoid saponins**
tumor cell proliferation inhibition, 5486
**Trousseau's syndrome**
tumor hypoxia and, 795, 7697
**Troxacitabine**
uptake and resistance, leukemic and solid tumor cells, 7217
**TRP-2**
polyimmunization with gp100, 859
***Trp-p8***
upregulation, prostate cancer, 3760
***TSG101***
aberrant transcripts
p53 and, cancer cells, 486
**TSU-PR1 cells**
bladder cancer derivation, 6340
**Tubulin**
detyrosination, breast cancer, 5024
**γ-Tubulin**
BRCA1 binding domain, identification, 7713
**Tumoral interstitial hypertension**
reduction by PDGF inhibition, 2929
**Tumor angiogenesis**
angiopoietin-1 and angiopoietin-2 effects, colon cancer, 1255
Bcl-2 upregulation and, 2183
Flt-1 tyrosine kinase, 1207
inhibition by TIMP-2, mammary tumors, 3450
modulation by FGF2 expression, 309
promotion by VEGF isoforms, 8569
regulation by ORP150, 4206
**Tumor antivascular therapy**
ultrasound monitoring, 2974
**Tumor-associated antigen**
Csk, carcinoma, 1415
P-glycoprotein, 8100
retroviral
endogenous
immunization, 7920
sarcoma translocation fusion protein, 6868
serological identification of tumor antigens by cDNA expression cloning
melanoma antigen isolation, 7900
**Tumor-associated macrophages**
COX-2 and iNOS expression, ovarian tumors, 7305
**Tumor-associated neoangiogenesis**
HOXB7, 6532
**Tumor cells**
adhesion inhibition by synthetic peptides, 3308
BRCA2-deficient
DNA double-strand break rejoining, 270
death
macrophages and, 7240
direct antigen presentation
effector CTL induction, 1107
dormancy promotion by primary tumor, 5575
genomic instability-null, 8838
HDMX protein expression, 1839
immunoselected lines
antigen cloning, 1089
iron protection against NO, 5289
lysis enhancement by FcγRI and FcαRI, 4055
MMP-7 protection against anticancer chemotherapy, 577
platelet aggregation
MMP-2 and NO, 376
resistance to anoikis
tyrosine kinases and, lung adenocarcinoma, 2439
**Tumor cell vaccines**
GM-CSF, bone marrow transplantation, 162
**Tumor endothelial markers**
cell surface
conservation, mice and humans, 6649
**Tumor endothelium**
anti-VEGF sFV targeting, 3653
**Tumor genetic programs**
activated T-LYs and, 3518
**Tumor growth**
angiopoietin-1 and angiopoietin-2 effects, colon cancer, 1255
CD34+ cell-related enhanced, non-Hodgkin's lymphoma, 7654
FGF-8b effects, MCF-7 breast cancer cells, 4229
FGF/FGFR and, glioma, 1717
HER2-driven
inhibition by ZD1839, 7184
hyaluronan synthase 3 and, prostate cancer, 5207
inhibition
*N*-acetylcysteine, Kaposi's sarcoma, 8171
alternative reading frame, 3145
anti-ΔEGFR mAb 806, 5355
antiviral phosphonated nucleoside analogs, 7875
arsenic trioxide, prostate cancer, 5432
CBHA and ATRA, neuroblastoma, 3591
CEP1612, lung adenocarcinoma, 1280
combination low-dose chemotherapy and PEX, glioma, 7501
combination phenylbutyrate and 13-*cis* retinoic acid, prostate cancer, 1477
cytokine-assisted SEREX, rat 9L glioma, 2625
dendritic cells, breast cancer, 228
EB1089, LNCaP tumors, 4294
fatty acid synthase inhibitors, 1493
16K hPRL, colon cancer, 7356
liposomal lomustine, rats, 3669
maspin, breast cancer, 6945
metastatin, 1022
n-3 fatty acids, 1386
RGD-tachyplesin, 2434
SCH221153, 2232
squamous cell carcinoma antigen antisense, 1776
STI571, dermatofibrosarcoma, 5778
TSP-1 type 1 repeat proteins, 7830
VHL peptide β-domain, renal cell carcinoma, 1768
*WWOX*, breast cancer, 8068
intralymphatic
promotion by VEGF-C, 1786
prevention
ceramide analogues, metastatic colon cancer, 1233
regulation by macrophage arginase, 1100
stimulation
17β-estradiol, breast cancer, 5045
radiation therapy, mice, 2207
sICAM-1, 4253
*uPA* role, breast cancer, 532
**Tumor hypoxia:** *See also* **Hypoxia**
blood clotting regulator dysregulation, 795, 7697
**Tumorigenesis**
and *Apc* mutations, *MSH* mutant $Apc^{1638N}$ mice, 7934
dysplastic aberrant crypt foci and, *Min*/+ mouse colon, 5010
inhibition
antisense oligodeoxynucleotide to midkine, rectal carcinoma, 8486
TIMP-2, mammary tumors, 3450
intestinal
ERα and ERβ expression modulation, 2547
p53-null Werner mice, 1816
promotion by *Bax, p53*-deficient mice, 659
**Tumor immune gene therapy**
sB7–1, 153
**Tumor immunity**
IFN-γ role, 3399
polyimmunization with gp100 and TRP-2, 859
**Tumor immunotherapy**
chimeric Flt3-ligand DNA vaccine, 1080
**Tumor lymphangiogenesis**
VEGF-C, 1786
**Tumor lysate-pulsed dendritic cells**
intranodal
immunization, 641
**Tumor microdialysis**
urea recovery marker, 7964
**Tumor necrosis factor**
receptor
R1 chimeric
antitumor activity, melanoma, 1050
transcriptional profiling, 433
signaling, CNS radioresponse, 8859
**Tumor necrosis factor-related apoptosis-inducing ligand**
anoikis role, mammary carcinoma, 1334
Apo-2L/TRAIL-induced apoptosis
enhancement by paclitaxel, prostate cancer, 759
apoptosis
caspase-8 requirement, 1138
enhancement by trastuzumab, breast and ovarian cancer, 4892
glioma, 1162
inhibition by XIAP, melanoma, 7339
caspase-8 activation and apoptosis
anticancer drug sensitization, 1645
receptor
*TRAIL-R1* and *TRAIL-R2* mutations, metastatic breast cancer, 4942
-resistant neuroblastoma
caspase-8 expression loss, 1314
sensitivity, Ewing's sarcoma, 2704
*TRAIL* gene
antitumor activity and bystander effect, 3330
**Tumor necrosis factor α**
combined with anti-EGFR therapy, solid tumors, 1045
COX-2 expression responses, prostate cancer, 2720
melanoma killing, absent TNF-α, 1050
polymorphism, adult T-cell leukemia/lymphoma and HTLV-1 carriers, 3770
pro- and antiapoptotic signals, prostate cancer LNCaP cells, 2713
**Tumor necrosis factor α-related apoptosis-inducing ligand**
pathway members
expression, prostate cancer, 7179
**Tumor-pulsed dendritic cells**
necrotic *versus* apoptotic, 8105
**Tumors**
apoptosis
p53 and, murine, 327
blood vessels
selective thrombosis, mice, 711

DNA
plasma, head and neck squamous cell carcinoma, 8595
DNA, circulating
plasma, lung cancer, 4675
intraperitoneal endostatin, mouse xenograft model, 7669
microcirculatory assessment by dynamic MRI, rectal carcinoma, 2513
mtDNA alterations, 7015
NO cytotoxicity
inhibition by macrophage arginase, 1100
oxygenation
and glycolytic rate, murine mammary carcinoma, 5318
vinblastine effects, 4266
oxytocin receptor-positive
radioligand, 4393
*p53* mutations
detection by electrospray ionization mass spectrometry, hepatocellular carcinoma, 33
risk
UV exposure
p53-positive foci and, hairless mice, 977
susceptiblity, $p21^{Waf1/Cip1}$-null mice, 6234
vasculature
and angiogenesis and hypoxia, 2907
CA4P permeability and response, 6811
shut-down by combrestatin A-4 phosphate, 6413
VEGF-C effects, 2404
**Tumor suppression**
beclin 1 nuclear export signal, 3443
**Tumor suppressor gene therapy**
*RIZ1*, colorectal cancer, 1796
**Tumor therapy**
cytokines and electroporation, 3281
**Tumor vaccines**
dendritic cell-based
keyhole limpet hemocyanin and, 2618
generation, renal cell carcinoma, 7925
renal cell carcinoma RNA-transfected dendritic cells, 3388
**Tyrosine kinases**
inhibitors
novel dual ErbB-2/EGFR, characterization, 7196
and tumor cell anoikis resistance, lung adenocarcinoma, 2439
**Tyrosine-related protein TRP2**
dendritic cells
and IFNα-induced immunity, melanoma, 8643
**Tyrphostin AG825**
kinase-dependent apoptosis and, prostate cancer, 7408

U

**Ubiquitin/26S proteasome**
TOP1 degradation, 5926
**UCN-01:** *See* **7-Hydroxystaurosporine**
**UDP-galactose transporter**
mRNA expression, colon cancer, 4620
**UDP-glucuronosyl transferase**
*UGT1A6*
and NSAID chemoprevention, colon adenoma, 3566
**Ulcerative colitis**
age-related CpG island methylation, 3573
**Ultrasound**
MRI-guided focused surgery, breast cancer, 8441
tumor antivascular therapy monitoring, 2974
**Ultraviolet B light**
COX-2 induction
Akt and GSK-3β roles, 4329
deletions, murine epidermis, 3913
skin carcinogenesis
inhibition by tea/caffeine, 5002
**Ultraviolet light**
BRCA2 protein depletion, 2838
DNA damage
Hupki mice, 8158
$p33^{ING1}$-mediated repair, 4974
exposure
p53-positive foci and tumor risk, hairless mice, 977
*gadd45* activation via Oct-1, 1187
mutation frequency, Chinese hamster ovary cells, 50
sensitization by truncated XPA-expressing adenovirus, 764
**United States women**
breast cancer risk, 3326
**Urea**
tumor microdialysis recovery marker, 7964
**Uridine phosphorylase**
gene expression downregulation by p53, 6899
**Urinary bladder tumorigenesis**
inhibition by exisulind, rat, 3961
**Urine**
bFGF levels, prostate cancer, 2533
VEGF levels, prostate cancer, 2533
**Urokinase**
*uPA* gene
amplification, prostate cancer, 5340
**Urokinase plasminogen activator**
breast cancer growth role, 532
modulation by endostatin, endothelial cells, 6511
pericellular
inhibition by endogenous maspin, 8676
regulation by heregulin, 400
upregulation by IGF-I, 1367
**Urothelial cells**
matrix interactions
genes involved, 1678
**Uterine adenocarcinoma**
genistein-induced, mice, 4325
**Uveal melanoma**
chromosome 3 partial deletions, 3439
$p16^{INK4a}$ expression reduction, 5303

V

**Vaccines**
apoptotic leukemia cell-loaded dendritic cells, 2386
Arg-Gly-Asp fiber-mutant Ad vector-transduced dendritic cells, efficacy, 7913
chemotherapy synergy, HER-2/*neu* tolerized mice, 3689
chimeric Flt3-ligand DNA vaccine, tumor immunotherapy, 1080
dendritic cell
combined with IL-12, hepatocellular carcinoma immunotherapy, 7563
keyhole limpet hemocyanin and, 2618
malignant glioma, 842
pediatric solid tumor patients, 8513
DNA
cancer immunotherapy, 3698
potency, dendritic cells and, 3704
DNA, naked
antitumor VH-CDR3 antibodies, 1555
oral
melanoma
combined with targeted IL-2 therapy, 6178
plasmid prime-adenovirus boost, hepatocellular carcinoma, 8782
synergy of strategies, 4497
tumor
GM-CSF, bone marrow transplantation, 162
renal cell carcinoma, generation, 7925
renal cell carcinoma RNA-transfected dendritic cells, 3388
**Vaccinia growth factor**
TK- and VGF-mutant vaccinia virus, gene therapy, 8751
**Vaccinia virus**
TK- and VGF-mutant, gene therapy, 8751
**Vascular attack**
5,6-dimethylxanthenone-4-acetic acid
combined with B7.1-mediated immunotherapy, 1948
**Vascular endothelial growth factor**
angiogenesis modulation, melanoma, 7282
anti-VEGF sFV
targeting, tumor endothelium, 3653
autocrine survival function, breast cancer, 5736
COP9 signalosome and, 8416
downregulation
*RB2/p130*, 462
TIMP-2, mammary tumors, 3450
expression
head and neck squamous cell carcinoma, 5911
pancreatic adenocarcinoma, 4143
and *p53* mutation, breast cancer, 2256
ras and VHL effects, 7349
regulation by p53, breast cancer, 6952
isoforms
function, angiogenesis, 8569
and NF-κB activation, hematopoietic progenitor cells, 2015
production, NOS II knockout mice, 3182
receptor
bifunctional anti-VEGFRs diabody VEGFR inhibition, 7002
endothelial apoptosis stimulation, 8629
inhibition by bifunctional diabody, 7002
receptor-1
pathological angiogenesis, 1207
receptor-2
anti-VEGFR2 mAb DC101
angiogenesis and growth inhibition, glioma, 6624
combined with radiation therapy, tumor xenografts, 39
receptor complex
targeting, antitumor vascular therapy, 3653
regulation
$pO_2$ and pH, brain tumors, 6020
Wnt and K-ras, colonic neoplasia, 6050
-triggered death receptor, 8629
tumor levels
and therapy response, advanced breast cancer, 5415
upregulation
C-FABP, 4357
heregulin-β1, breast cancer, 1727
HIF-1α-mediated, 5731
urine levels, prostate cancer, 2533
**Vascular endothelial growth factor B**
expression, renal cell carcinoma, 3206
**Vascular endothelial growth factor C**
expression, renal cell carcinoma, 3206
tumor effects, 2404
tumor lymphangiogenesis, 1786
**Vascular growth**
inhibition by endostatin, murine mammary carcinoma, 526
**Vascularity**
tumor
and angiogenesis and hypoxia, 2907

**Vascular permeability factor**
regulation by p53, breast cancer, 6952
**Vascular therapy**
antitumor
VEGF:receptor complex targeting, 3653
**Vasculogenic mimicry**
Eck/EphA2 role, 3250
**V(D)J recombinase**
-mediated deletions *in utero*, 3432
**Vegetables**
cruciferous
dietary indoles and isothiocyanates
apoptosis induction and protective effects, colon cells, 6120
**Venezuelan equine encephalitis replicon particles**
HPV 16 E7
tumor eradication, 7861
**Versican**
stromal levels
regulation by prostate cancer-derived TGF-$\beta$1, prostate fibroblasts, 926
**Verteporfin**
apoptosis induction
mediation by adenine nucleotide translocator, 1260
**Vesicles**
acidic
radiation response, cancer cells, 439
**Vesicular monoamine transporters**
expression, small cell lung cancer, 2138
**Vinblastine**
apoptosis
AP-1 role, 4450
potentiation, ML-1 cells, 1533
tumor oxygenation effects, 4266
***Vinca* alkaloids**
resistance
microtubule alterations, leukemia, 5803
**Vinculin**
assembly promotion by VHL, 4184
**Virus-directed enzyme prodrug therapy**
rCE and CPT-11, neuroblastoma purging, 5083
**Viruses:** *See also* ***specific viruses***
antitumor weapons, 3501
vectors
gene delivery, 5336
**Vitamin A**
levels, renal cell carcinoma, 2774
**Vitamin D**
growth inhibitory effects
mediation by p21, prostate cancer, 7122
prooxidant activity, breast cancer, 1432
receptor polymorphisms
and prostate cancer risk, China, 4333
**Vitamin $D_3$ analogues**
24-oxo metabolites
antileukemic effects, 3361
**Vitamin E succinate**
apoptosis, breast cancer, 6569
**Vitamin K**
novel analogs
Cdc25A phosphatase inhibition, 7211
**von Hippel-Lindau gene**
loss of heterozygosity, renal cell carcinoma, 4815
VEGF-B and VEGF-C expression regulation, renal cell carcinoma, 3206
**von Hippel-Lindau tumors**
*VHL* gene
HIF-1$\alpha$/2$\alpha$ and VEGF expression effects, 7349
VHL peptide $\beta$-domain
tumor growth and invasion inhibition, renal cell carcinoma, 1768
VHL protein
function, cellular morphology, 4184
HIF-1$\alpha$ interactions, 4136
**Vulval neoplasia**
HLA and HPV, 192
intraepithelial
photodynamic therapy response factors, 192

W

**Weiss, Leonard L.**
in memoriam, 5663
**Werner syndrome**
p53-null Werner mice
tumorigenesis, 1816
**Western-style diet**
and *Apc*-initiated tumors, 565
**White blood cells**
carcinogen-DNA adducts
and lung cancer risk, 6708
**White Paper**
Think Tank, pancreatic cancer, 4923
**White women**
breast cancer risk, 3326
**Wilms' tumor**
*CTCF* binding site methylation, 4947
*IGF2* loss of imprinting, 4947
*WT1* expression, breast cancer, 921
**WISP-1**
levels, breast cancer, 8917
**Wnt**
signaling, mutant E-cadherin breast cancer cells, 278
VEGF regulation, colonic neoplasia, 6050
**Wnt-1**
*Stra6* induction, 4197
**Women**
nonsmoking Taiwanese
HPV 16/18 infection and lung cancer, 2799
white
breast cancer risk, 3326
***WWOX***
growth inhibition, breast cancer, 8068

X

**Xenografts**
intraperitoneal endostatin, mouse tumor model, 7669
**Xeroderma pigmentosum A**
truncated protein
adenovirus expressing, 764
**Xeroderma pigmentosum C**
*XPC* polymorphism
and head and neck squamous cell carcinoma risk, 3321
**Xeroderma pigmentosum D**
*XPD* gene polymorphisms
advanced colorectal cancer, 8654
functional significance, 7430
nucleotide excision repair modulation, lung cancer, 1354
**Xeroderma pigmentosum melanoma**
*p53* mutations, 2480
**X-linked inhibitor of apoptosis protein**
activity, ovarian cancer cells, 1862
TRAIL-induced apoptosis inhibition, melanoma, 7339
**XR9576**
multidrug resistance reversal, 749
**X-rays**
low-dose
cell proliferation and MAPK activation, diploid cells, 5396

Y

**YB-1**
functional interference by TLS/ERG and EWS/Fli-1 fusion proteins, 3586
**Yeast checkpoint kinase**
mutations
adozelesin DNA replication effects, 3787
**Yeast Rad23 protein**
human hHR23A
*p53* regulation, 64
**Yeast screen**
cell-based
novel PARP/PARP2 inhibitors, 4175

Z

**ZD1839**
HER2 blockade, breast cancer, 8887
HER2-driven signaling and tumor growth inhibition, 7184
**Zinc (II) phthalocyanine**
photosensitization
apoptosis *versus* necrosis, 7495
**Zinc-65 imaging**
rat brain tumors, 5065
***ZNF217* gene**
HMEC immortalization, 1250